0001564590-21-024084.txt : 20210505 0001564590-21-024084.hdr.sgml : 20210505 20210505161908 ACCESSION NUMBER: 0001564590-21-024084 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210505 DATE AS OF CHANGE: 20210505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arcus Biosciences, Inc. CENTRAL INDEX KEY: 0001724521 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473898435 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38419 FILM NUMBER: 21893602 BUSINESS ADDRESS: STREET 1: 3928 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: (510) 694-6200 MAIL ADDRESS: STREET 1: 3928 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 10-Q 1 rcus-10q_20210331.htm 10-Q rcus-10q_20210331.htm
false Q1 0001724521 --12-31 rcus:CollaborationMember rcus:CollaborationMember P10Y true P5D P4Y P4Y P5Y rcus:CollaborationMember rcus:CollaborationMember 0001724521 2021-01-01 2021-03-31 xbrli:shares 0001724521 2021-04-30 iso4217:USD 0001724521 2021-03-31 0001724521 2020-12-31 iso4217:USD xbrli:shares 0001724521 2020-01-01 2020-03-31 0001724521 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001724521 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001724521 us-gaap:CommonStockMember 2019-12-31 0001724521 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001724521 us-gaap:RetainedEarningsMember 2019-12-31 0001724521 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001724521 2019-12-31 0001724521 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001724521 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001724521 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001724521 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001724521 us-gaap:CommonStockMember 2020-03-31 0001724521 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001724521 us-gaap:RetainedEarningsMember 2020-03-31 0001724521 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001724521 2020-03-31 0001724521 us-gaap:CommonStockMember 2020-12-31 0001724521 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001724521 us-gaap:RetainedEarningsMember 2020-12-31 0001724521 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001724521 us-gaap:CommonStockMember rcus:CommonStockPurchaseAgreementMember rcus:GileadSciencesIncMember 2021-01-01 2021-03-31 0001724521 us-gaap:AdditionalPaidInCapitalMember rcus:CommonStockPurchaseAgreementMember rcus:GileadSciencesIncMember 2021-01-01 2021-03-31 0001724521 rcus:CommonStockPurchaseAgreementMember rcus:GileadSciencesIncMember 2021-01-01 2021-03-31 0001724521 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001724521 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001724521 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001724521 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001724521 us-gaap:CommonStockMember 2021-03-31 0001724521 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001724521 us-gaap:RetainedEarningsMember 2021-03-31 0001724521 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001724521 rcus:GileadSciencesIncAndTaihoPharmaceuticalCoMember 2021-01-01 2021-03-31 rcus:Product 0001724521 rcus:CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember 2021-03-31 0001724521 2020-01-01 2020-12-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-03-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-03-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-03-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-03-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember rcus:CorporateSecuritiesAndCommercialPaperMember 2021-03-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember rcus:CorporateSecuritiesAndCommercialPaperMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-03-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember rcus:CorporateSecuritiesAndCommercialPaperMember 2020-12-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember rcus:CorporateSecuritiesAndCommercialPaperMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001724521 us-gaap:MoneyMarketFundsMember 2021-03-31 0001724521 us-gaap:USTreasurySecuritiesMember 2021-03-31 0001724521 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-03-31 0001724521 rcus:CorporateSecuritiesAndCommercialPaperMember 2021-03-31 0001724521 us-gaap:MoneyMarketFundsMember 2020-12-31 0001724521 us-gaap:USTreasurySecuritiesMember 2020-12-31 0001724521 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001724521 rcus:CorporateSecuritiesAndCommercialPaperMember 2020-12-31 0001724521 rcus:PACTPharmaMember us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001724521 us-gaap:SeriesAPreferredStockMember rcus:PACTPharmaMember 2016-01-01 2016-12-31 0001724521 rcus:PACTPharmaMember 2021-03-31 0001724521 rcus:PACTPharmaMember 2020-12-31 0001724521 rcus:PACTPharmaMember 2020-01-01 2020-03-31 0001724521 rcus:PACTPharmaMember srt:ScenarioPreviouslyReportedMember 2020-01-01 2020-03-31 0001724521 rcus:PACTPharmaMember 2021-01-01 2021-03-31 0001724521 rcus:PACTPharmaMember 2020-01-01 2021-03-31 0001724521 rcus:GileadSciencesIncAndTaihoPharmaceuticalCoMember rcus:CollaborationMember 2021-01-01 2021-03-31 0001724521 rcus:GileadSciencesIncAndTaihoPharmaceuticalCoMember rcus:CollaborationMember 2020-01-01 2020-03-31 0001724521 rcus:GileadSciencesIncAndTaihoPharmaceuticalCoMember us-gaap:LicenseAndServiceMember 2021-01-01 2021-03-31 0001724521 rcus:GileadSciencesIncAndTaihoPharmaceuticalCoMember us-gaap:LicenseAndServiceMember 2020-01-01 2020-03-31 0001724521 rcus:GileadAccessRightsMember 2021-01-01 2021-03-31 0001724521 rcus:TaihoCollaborationAgreementMember 2021-01-01 2021-03-31 0001724521 rcus:TaihoCollaborationAgreementMember 2020-01-01 2020-03-31 0001724521 rcus:OptionLicenseAndCollaborationAgreementMember rcus:GileadSciencesIncMember 2020-07-12 2020-07-13 0001724521 rcus:CommonStockPurchaseAgreementMember rcus:GileadSciencesIncMember 2020-07-12 2020-07-13 0001724521 rcus:CommonStockPurchaseAgreementMember rcus:GileadSciencesIncMember 2020-07-13 0001724521 rcus:OptionLicenseAndCollaborationAgreementMember rcus:GileadSciencesIncMember srt:MaximumMember 2020-07-13 0001724521 rcus:OptionLicenseAndCollaborationAgreementMember rcus:GileadSciencesIncMember srt:MinimumMember 2020-07-12 2020-07-13 0001724521 rcus:OptionLicenseAndCollaborationAgreementMember rcus:GileadSciencesIncMember srt:MaximumMember 2020-07-12 2020-07-13 xbrli:pure 0001724521 rcus:CommonStockPurchaseAgreementMember rcus:GileadSciencesIncMember 2021-01-01 2021-01-31 0001724521 rcus:CommonStockPurchaseAgreementMember rcus:GileadSciencesIncMember 2021-01-31 0001724521 rcus:GileadSciencesIncMember rcus:OptionLicenseAndCollaborationAgreementMember 2020-07-13 0001724521 rcus:GileadSciencesIncMember rcus:OptionLicenseAndCollaborationAgreementMember 2021-03-31 0001724521 rcus:GileadSciencesIncMember rcus:OptionLicenseAndCollaborationAgreementMember 2021-01-01 2021-03-31 0001724521 rcus:CommonStockPurchaseAgreementMember 2020-07-12 2020-07-13 0001724521 rcus:GileadSciencesIncMember rcus:OptionLicenseAndCollaborationAgreementMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2021-03-31 0001724521 rcus:GileadSciencesIncMember rcus:OptionLicenseAndCollaborationAgreementMember us-gaap:OtherNoncurrentAssetsMember 2021-03-31 0001724521 rcus:TaihoPharmaceuticalCoLtdMember rcus:OptionAndLicenseAgreementMember 2017-09-01 2017-09-30 0001724521 rcus:TaihoPharmaceuticalCoLtdMember rcus:OptionAndLicenseAgreementMember 2017-01-01 2017-12-31 0001724521 rcus:TaihoPharmaceuticalCoLtdMember rcus:OptionAndLicenseAgreementMember 2018-01-01 2018-12-31 0001724521 rcus:TaihoPharmaceuticalCoLtdMember rcus:OptionAndLicenseAgreementMember 2019-01-01 2019-12-31 rcus:Program 0001724521 rcus:TaihoPharmaceuticalCoLtdMember rcus:OptionAndLicenseAgreementMember srt:MinimumMember 2017-09-01 2017-09-30 0001724521 rcus:TaihoPharmaceuticalCoLtdMember rcus:OptionAndLicenseAgreementMember srt:MaximumMember 2017-09-01 2017-09-30 0001724521 rcus:TaihoPharmaceuticalCoLtdMember rcus:OptionAndLicenseAgreementMember srt:MaximumMember 2017-09-30 0001724521 rcus:TaihoPharmaceuticalCoLtdMember rcus:OptionAndLicenseAgreementMember 2021-01-01 2021-03-31 0001724521 rcus:WuXiBiologicsLicenseAgreementMember us-gaap:ResearchAndDevelopmentExpenseMember 2017-08-01 2021-03-31 0001724521 rcus:WuXiBiologicsLicenseAgreementMember srt:MaximumMember 2017-08-01 2017-08-31 0001724521 rcus:WuXiBiologicsLicenseAgreementMember 2021-01-01 2021-03-31 0001724521 rcus:WuXiBiologicsLicenseAgreementMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-12-01 2020-12-31 0001724521 rcus:WuXiBiologicsLicenseAgreementMember 2020-12-01 2020-12-31 0001724521 rcus:AbmunoLicenseAgreementMember 2021-01-01 2021-03-31 0001724521 rcus:GenentechMember 2021-01-01 2021-03-31 0001724521 rcus:GenentechMember 2020-01-01 2020-03-31 0001724521 rcus:StrataAgreementMember rcus:StrataOncologyIncMember 2019-04-30 0001724521 rcus:StrataAgreementMember rcus:StrataOncologyIncMember srt:MaximumMember 2019-04-30 0001724521 rcus:StrataAgreementMember rcus:StrataOncologyIncMember 2019-05-01 2021-03-31 0001724521 rcus:StrataAgreementMember rcus:StrataOncologyIncMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-05-01 2021-03-31 0001724521 rcus:StrataAgreementMember rcus:StrataOncologyIncMember 2019-04-30 2019-04-30 0001724521 rcus:StrataAgreementMember rcus:StrataOncologyIncMember us-gaap:RestrictedStockMember 2021-03-31 0001724521 rcus:StrataAgreementMember rcus:StrataOncologyIncMember us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0001724521 rcus:StrataAgreementMember rcus:StrataOncologyIncMember 2021-01-01 2021-03-31 0001724521 rcus:StrataAgreementMember rcus:StrataOncologyIncMember 2020-01-01 2020-03-31 0001724521 rcus:MayTwoThousandTwentyPublicOfferingMember 2020-06-01 2020-06-30 0001724521 rcus:MayTwoThousandTwentyPublicOfferingMember 2020-06-30 0001724521 rcus:BaseSharesMember 2020-06-01 2020-06-30 0001724521 rcus:UnderwritersOptionExerciseMember 2020-06-01 2020-06-30 0001724521 rcus:GileadSciencesIncMember rcus:CommonStockPurchaseAgreementMember 2021-02-01 2021-02-28 0001724521 rcus:GileadSciencesIncMember rcus:CommonStockPurchaseAgreementMember 2021-02-28 0001724521 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001724521 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001724521 us-gaap:StockCompensationPlanMember 2021-01-01 2021-03-31 0001724521 us-gaap:StockCompensationPlanMember 2020-01-01 2020-03-31 0001724521 rcus:UnvestedRestrictedStockIssuedAsPartOfCollaborationAgreementMember 2021-01-01 2021-03-31 0001724521 rcus:UnvestedRestrictedStockIssuedAsPartOfCollaborationAgreementMember 2020-01-01 2020-03-31 0001724521 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001724521 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001724521 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001724521 us-gaap:EmployeeStockMember 2021-01-01 2021-03-31 0001724521 us-gaap:StandbyLettersOfCreditMember 2021-03-31 0001724521 rcus:GileadSciencesIncMember 2021-03-31 0001724521 srt:MaximumMember rcus:GileadSciencesIncMember 2021-03-31 0001724521 rcus:GileadSciencesIncMember 2020-05-01 2020-05-31 0001724521 rcus:GileadSciencesIncMember rcus:CommonStockPurchaseAgreementMember 2020-07-12 2020-07-13 0001724521 rcus:GileadSciencesIncMember rcus:CommonStockPurchaseAgreementMember 2021-02-01 2021-02-28 0001724521 rcus:GileadSciencesIncMember rcus:CommonStockPurchaseAgreementMember 2021-01-01 2021-03-31 0001724521 rcus:OptionLicenseAndCollaborationAgreementMember rcus:GileadSciencesIncMember 2021-01-01 2021-03-31 0001724521 rcus:GileadSciencesIncMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001724521 rcus:CommonStockPurchaseAgreementMember rcus:GileadSciencesIncMember 2021-02-28 utr:sqft 0001724521 stpr:CA us-gaap:SubsequentEventMember 2021-04-30 0001724521 stpr:CA us-gaap:SubsequentEventMember 2021-04-01 2021-04-30

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____________to _______________

Commission File Number: 001-38419

 

Arcus Biosciences, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

47-3898435

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

3928 Point Eden Way

Hayward, CA 94545

 

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (510) 694-6200

 

Securities registered pursuant to Section 12(b) of the Act:

 

Titles of Each Class

 

Trading Symbol(s)

 

Name of Each Exchange on which Registered

Common Stock, Par Value $0.0001 Per Share

 

RCUS

 

The New York Stock Exchange

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

☐ 

  

Smaller reporting company

 

 

 

 

 

 

 

 

Emerging growth company

 

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

 

 

 

 

As of April 30, 2021, the registrant had 70,995,860 shares of common stock, $0.0001 par value per share, outstanding.

 

 

 


 

Table of Contents

 

 

 

Page

PART I.

FINANCIAL INFORMATION

 

Item 1.

Financial Statements

1

 

Condensed Consolidated Balance Sheets (unaudited)

1

 

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)

2

 

Condensed Consolidated Statements of Stockholders’ Equity (unaudited)

3

 

Condensed Consolidated Statements of Cash Flows (unaudited)

4

 

Notes to Condensed Consolidated Financial Statements (unaudited)

5

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

17

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

23

Item 4.

Controls and Procedures

23

PART II.

OTHER INFORMATION

 

Item 1.

Legal Proceedings

24

Item 1A.

Risk Factors

24

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

54

Item 3.

Defaults Upon Senior Securities

54

Item 4.

Mine Safety Disclosures

54

Item 5.

Other Information

54

Item 6.

Exhibits

55

SIGNATURES

56

 

 

 

 

 

i


 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

ARCUS BIOSCIENCES, INC.

Condensed Consolidated Balance Sheets

(unaudited)

(In thousands, except share and per share amounts)

 

 

 

March 31,

 

 

December 31,

 

 

 

2021

 

 

2020*

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

390,260

 

 

$

173,415

 

Short-term investments

 

 

436,666

 

 

 

555,231

 

Receivable from collaboration partners ($4,924 and $943 from a related party)

 

 

5,235

 

 

 

1,049

 

Accrued interest receivable

 

 

1,029

 

 

 

649

 

Prepaid expenses and other current assets

 

 

8,680

 

 

 

5,471

 

Total current assets

 

 

841,870

 

 

 

735,815

 

Long-term investments

 

 

57,986

 

 

 

6,440

 

Property and equipment, net

 

 

14,849

 

 

 

10,807

 

Right-of-use assets

 

 

12,243

 

 

 

12,781

 

Restricted cash

 

 

1,988

 

 

 

203

 

Other long-term assets

 

 

6,183

 

 

 

6,246

 

Total assets

 

$

935,119

 

 

$

772,292

 

LIABILITIES

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

24,544

 

 

$

15,682

 

Accrued research and development expenses

 

 

23,023

 

 

 

18,307

 

Other accrued liabilities

 

 

7,536

 

 

 

9,543

 

Deferred revenue, current ($67,571 and $67,571 to a related party)

 

 

74,571

 

 

 

74,571

 

Other current liabilities

 

 

2,381

 

 

 

3,566

 

Total current liabilities

 

 

132,055

 

 

 

121,669

 

Deferred revenue, noncurrent ($110,097 and $117,808 to a related party)

 

 

113,369

 

 

 

122,830

 

Operating lease liabilities, noncurrent

 

 

14,706

 

 

 

15,243

 

Other long-term liabilities ($9,703 and $9,703 to a related party)

 

 

10,199

 

 

 

10,246

 

Total liabilities

 

 

270,329

 

 

 

269,988

 

Commitments (Note 10)

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of March 31, 2021 and December 31, 2020; no shares issued and outstanding as of March 31, 2021 and December 31, 2020

 

 

-

 

 

 

-

 

Common stock, $0.0001 par value, 400,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 70,965,513 and 65,114,685 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively

 

 

7

 

 

 

6

 

Additional paid-in capital

 

 

1,065,562

 

 

 

830,438

 

Accumulated deficit

 

 

(400,777

)

 

 

(328,184

)

Accumulated other comprehensive (loss) income

 

 

(2

)

 

 

44

 

Total stockholders’ equity

 

 

664,790

 

 

 

502,304

 

Total liabilities and stockholders’ equity

 

$

935,119

 

 

$

772,292

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

*

The Condensed Consolidated Balance Sheet as of December 31, 2020 has been derived from the audited financial statements as of that date.

 

1


 

ARCUS BIOSCIENCES, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited)

(In thousands, except share and per share amounts)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2021

 

 

2020

 

Revenues:

 

 

 

 

 

 

 

 

Collaboration revenue ($7,711 and $0 from a related party)

 

$

9,461

 

 

$

1,750

 

Total collaboration and license revenues

 

 

9,461

 

 

 

1,750

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development (($4,924) and $0 from a related party)

 

 

66,387

 

 

 

23,142

 

General and administrative

 

 

15,821

 

 

 

7,008

 

Total operating expenses

 

 

82,208

 

 

 

30,150

 

Loss from operations

 

 

(72,747

)

 

 

(28,400

)

Non-operating income (expense):

 

 

 

 

 

 

 

 

Interest and other income, net

 

 

154

 

 

 

647

 

Gain on deemed sale from equity method investee

 

 

-

 

 

 

482

 

Share of loss from equity method investee

 

 

-

 

 

 

(482

)

Total non-operating income, net

 

 

154

 

 

 

647

 

Net loss

 

 

(72,593

)

 

 

(27,753

)

Other comprehensive income (loss)

 

 

(46

)

 

 

224

 

Comprehensive loss

 

$

(72,639

)

 

$

(27,529

)

Net loss per share, basic and diluted

 

$

(1.08

)

 

$

(0.63

)

Weighted-average number of shares used to

   compute basic and diluted net loss per share

 

 

67,082,161

 

 

 

44,282,607

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2


ARCUS BIOSCIENCES, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(unaudited)

(In thousands, except share amounts)

 

 

 

 

 

 

 

Common stock

 

 

Additional

Paid-In

 

 

Accumulated

 

 

Accumulated

Other

Comprehensive

 

 

Total

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Income (Loss)

 

 

Equity

 

Balance at December 31, 2019 *

 

 

44,212,195

 

 

$

4

 

 

$

369,100

 

 

$

(205,326

)

 

$

64

 

 

$

163,842

 

Issuance of common stock upon exercise of stock options

 

 

59,939

 

 

 

-

 

 

 

643

 

 

 

-

 

 

 

-

 

 

 

643

 

Vesting of early exercised stock options

 

 

77,388

 

 

 

-

 

 

 

220

 

 

 

-

 

 

 

-

 

 

 

220

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

3,462

 

 

 

-

 

 

 

-

 

 

 

3,462

 

Other comprehensive income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

224

 

 

 

224

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(27,753

)

 

 

-

 

 

 

(27,753

)

Balance at March 31, 2020

 

 

44,349,522

 

 

$

4

 

 

$

373,425

 

 

$

(233,079

)

 

$

288

 

 

$

140,638

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2020 *

 

 

63,691,901

 

 

$

6

 

 

$

830,438

 

 

$

(328,184

)

 

$

44

 

 

$

502,304

 

Issuance of common stock and rights to purchase additional shares in accordance with Amended and Restated Gilead Purchase Agreement, net of $55 offering costs

 

 

5,650,000

 

 

 

1

 

 

 

220,295

 

 

 

-

 

 

 

-

 

 

 

220,296

 

Issuance of common stock upon exercise of stock options

and vesting of restricted stock

 

 

200,828

 

 

 

-

 

 

 

1,885

 

 

 

-

 

 

 

-

 

 

 

1,885

 

Vesting of early exercised stock options

 

 

54,039

 

 

 

-

 

 

 

183

 

 

 

-

 

 

 

-

 

 

 

183

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

12,761

 

 

 

-

 

 

 

-

 

 

 

12,761

 

Other comprehensive loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(46

)

 

 

(46

)

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(72,593

)

 

 

-

 

 

 

(72,593

)

Balance at March 31, 2021

 

 

69,596,768

 

 

$

7

 

 

$

1,065,562

 

 

$

(400,777

)

 

$

(2

)

 

$

664,790

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

*

The balances as of December 31, 2020 and 2019 have been derived from the audited financial statements as of that date.

3


 

ARCUS BIOSCIENCES, INC.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(In thousands)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2021

 

 

2020

 

Cash flow from operating activities

 

 

 

 

 

 

 

 

Net loss

 

$

(72,593

)

 

$

(27,753

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

12,761

 

 

 

3,462

 

Depreciation and amortization

 

 

800

 

 

 

842

 

Amortization of right-of-use assets

 

 

538

 

 

 

144

 

Amortization of premiums on investments

 

 

506

 

 

 

(248

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Receivable from collaboration partners (($3,981) and $0 from a related party)

 

 

(4,186

)

 

 

(212

)

Prepaid expenses and other current assets

 

 

(4,568

)

 

 

(3,704

)

Other long-term assets

 

 

63

 

 

 

(91

)

Accounts payable

 

 

7,722

 

 

 

(2,342

)

Accrued research and development expenses

 

 

4,716

 

 

 

2,226

 

Other accrued liabilities

 

 

(2,007

)

 

 

(1,578

)

Deferred revenue (($7,711) and $0 to a related party)

 

 

(9,461

)

 

 

(1,750

)

Operating lease liabilities

 

 

(605

)

 

 

(273

)

Other long-term liabilities

 

 

(2

)

 

 

-

 

Net cash used in operating activities

 

 

(66,316

)

 

 

(31,277

)

Cash flow from investing activities

 

 

 

 

 

 

 

 

Purchases of short-term and long-term investments

 

 

(192,398

)

 

 

(8,885

)

Proceeds from maturities of short-term and long-term investments

 

 

251,365

 

 

 

49,150

 

Sales of short-term and long-term investments

 

 

7,500

 

 

 

-

 

Purchases of property and equipment

 

 

(3,641

)

 

 

(209

)

Net cash provided by investing activities

 

 

62,826

 

 

 

40,056

 

Cash flow from financing activities

 

 

 

 

 

 

 

 

Proceeds from issuance of common stock to related party

 

 

220,235

 

 

 

-

 

Proceeds from issuance of common stock pursuant to equity award plans

 

 

1,885

 

 

 

643

 

Repurchase of unvested shares of stock

 

 

-

 

 

 

(33

)

Net cash provided by financing activities

 

 

222,120

 

 

 

610

 

Net increase in cash and cash equivalents

 

 

218,630

 

 

 

9,389

 

Cash, cash equivalents and restricted cash at beginning of period

 

 

173,618

 

 

 

58,140

 

Cash, cash equivalents and restricted cash at end of period

 

$

392,248

 

 

$

67,529

 

 

 

 

 

 

 

 

 

 

Supplemental disclosures:

 

 

 

 

 

 

 

 

Cash paid for amounts included in measurement of lease liabilities

 

$

927

 

 

$

519

 

Non-cash investing and financing activities:

 

 

 

 

 

 

 

 

Unpaid portion of property and equipment purchases included in accounts payable and accrued liabilities

 

$

2,784

 

 

$

76

 

Vesting of early exercised stock options

 

$

183

 

 

$

220

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4


 

 

ARCUS BIOSCIENCES, INC.

Notes to Condensed Consolidated Financial Statements

Note 1. Organization

Description of Business

Arcus Biosciences, Inc. (the Company) is a clinical-stage biopharmaceutical company focused on creating best-in-class cancer therapies. The Company’s initial focus has been on well-characterized biological pathways with significant scientific data supporting their importance. Since its inception in 2015, the Company has built a robust and highly efficient drug discovery capability to create highly differentiated small molecules, which the Company is developing in combination with its in-licensed monoclonal antibodies through rationally designed, indication-specific clinical trial designs. The Company currently has five investigational products in clinical development: domvanalimab (formerly referred to as AB154), etrumadenant (formerly referred to as AB928), AB680, zimberelimab (formerly referred to as AB122), and AB308.

Liquidity and Capital Resources

As of March 31, 2021, the Company had cash and investments of $884.9 million, which are cash, cash equivalents, and investments in marketable securities, which the Company believes will be sufficient to fund its planned operations for a period of at least twelve months following the date of filing of this report.

Note 2. Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the Company’s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.

Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 or for any future period. The balance sheet as of December 31, 2020 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.

The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K filed with the SEC on February 25, 2021. There have been no significant changes to the Company’s significant accounting policies described in Note 2, Summary of Significant Accounting Policies, in Notes to Consolidated Financial Statements in Item 8 of Part II of the Form 10-K.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Arcus Biosciences, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

5


 

Use of Estimates

The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as related disclosures of contingent assets and liabilities. Estimates were used to determine the standalone selling price of performance obligations and the timing of revenue recognition, the value of stock-based awards and other issuances, accruals for research and development costs, useful lives of long-lived assets, and uncertain tax positions. Actual results could differ materially from the Company’s estimates.

Cash Equivalents and Investments

Cash equivalents include marketable securities having an original maturity of three months or less at the time of purchase. Short-term investments have maturities of greater than three months and up to twelve months at the time of purchase. Long-term investments have maturities greater than 12 months at the time of purchase. Collectively, cash equivalents, short-term and long-term investments are considered available-for-sale and are recorded at fair value. Unrealized gains and losses are recorded in accumulated other comprehensive income (loss). Realized gains and losses are included in interest and other income, net in the condensed consolidated statements of operations and comprehensive income or loss. The basis on which the cost of a security that is sold or an amount that is reclassified out of accumulated other comprehensive income or loss into earnings is determined using the specific identification method.

Reconciliation of Cash, Cash Equivalents, and Restricted Cash as Reported in Condensed Consolidated Statements of Cash Flows

Restricted cash at March 31, 2021 and 2020 represents cash balances held as security in connection with the Company’s facility lease agreements. The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the condensed consolidated balance sheets to the total shown in the condensed consolidated statements of cash flows (in thousands):

 

 

March 31,

 

 

 

2021

 

 

2020

 

Cash and cash equivalents

 

$

390,260

 

 

$

67,326

 

Restricted cash

 

 

1,988

 

 

 

203

 

Cash, cash equivalents and restricted cash

 

 

392,248

 

 

$

67,529

 

 

Concentration of Credit Risk

Cash equivalents, short-term and long-term investments are financial instruments that potentially subject the Company to concentrations of credit risk. The Company invests in money market funds, treasury bills and notes, government bonds, commercial paper and corporate notes. The Company limits its credit risk associated with cash equivalents, short-term and long-term investments by placing them with banks and institutions it believes are credit worthy and in highly rated investments.

Leases and Rent Expense

The Company recognizes a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. The Company determines whether an arrangement is or contains a lease at contract inception. Operating leases are included in operating lease right-of-use assets, other current liabilities, and operating lease liabilities, noncurrent in our condensed consolidated balance sheets at March 31, 2021 and December 31, 2020. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date. The incremental borrowing rate represents the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company considers a lease term to be the noncancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.

The Company elected to not apply the recognition requirements of the new leasing standard to short-term leases with terms of 12 months or less which do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. For short-term leases, lease payments are recognized as operating expenses on a straight-line basis over the lease term.

6


 

 

Note 3. Fair Value Measurements

Financial assets and liabilities are recorded at fair value. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.

During the periods presented, the Company has not changed the manner in which it values assets and liabilities that are measured at fair value. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy as of March 31, 2021 and December 31, 2020. The following tables set forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):

 

 

 

March 31, 2021

 

 

 

Total

 

 

Level 1

(Quoted Prices in

Active Markets For

Identical Assets)

 

 

Level 2

(Significant Other

Observable

Remaining Inputs)

 

 

Level 3

(Significant Other

Unobservable

Remaining Inputs)

 

Money market funds

 

$

362,762

 

 

$

362,762

 

 

$

-

 

 

$

-

 

U.S. treasury securities

 

 

206,460

 

 

 

-

 

 

 

206,460

 

 

 

-

 

U.S. government agency securities

 

 

5,002

 

 

 

-

 

 

 

5,002

 

 

 

-

 

Corporate securities and commercial paper

 

 

310,688

 

 

 

-

 

 

 

310,688

 

 

 

-

 

Total assets measured at fair value

 

$

884,912

 

 

$

362,762

 

 

$

522,150

 

 

$

-

 

 

 

 

December 31, 2020

 

 

 

Total

 

 

Level 1

(Quoted Prices in

Active Markets For

Identical Assets)

 

 

Level 2

(Significant Other

Observable

Remaining Inputs)

 

 

Level 3

(Significant Other

Unobservable

Remaining Inputs)

 

Money market funds

 

$

146,468

 

 

$

146,468

 

 

$

-

 

 

$

-

 

U.S. treasury securities

 

 

301,112

 

 

 

-

 

 

 

301,112

 

 

 

-

 

U.S. government agency obligations

 

 

25,001

 

 

 

-

 

 

 

25,001

 

 

 

-

 

Corporate securities and commercial paper

 

 

262,505

 

 

 

-

 

 

 

262,505

 

 

 

-

 

Total assets measured at fair value

 

$

735,086

 

 

$

146,468

 

 

$

588,618

 

 

$

-

 

 

Classified as (with contractual maturities):

 

 

March 31, 2021

 

 

December 31, 2020

 

Cash and cash equivalents

 

$

390,260

 

 

$

173,415

 

Short-term investments (due within one year)

 

 

436,666

 

 

 

555,231

 

Long-term investments (due between one and two years)

 

 

57,986

 

 

 

6,440

 

Total cash, cash equivalents and investments in marketable securities

 

$

884,912

 

 

$

735,086

 

 

7


 

 

Investments in marketable securities are classified as available-for-sale. At March 31, 2021 and December 31, 2020, the balance in the Company’s accumulated other comprehensive income comprised activity related to the Company’s available-for-sale marketable securities. There were immaterial realized gains or losses recognized on the sale or maturity of available-for-sale marketable securities as of March 31, 2021 and December 31, 2020, and as a result, the Company did not reclassify any amounts out of accumulated other comprehensive income for the periods then ended. The Company has a limited number of available-for-sale marketable securities in loss positions as of March 31, 2021, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized cost for the investment at maturity. The fair value and amortized cost of investments in marketable securities by major security type as of March 31, 2021 and December 31, 2020 are presented in the tables that follow (in thousands):

 

 

 

Amortized

Cost

 

 

Unrealized

Gain

 

 

Unrealized

Loss

 

 

Fair

Value

 

As of March 31, 2021:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

362,762

 

 

$

-

 

 

$

-

 

 

$

362,762

 

U.S. treasury securities

 

 

206,422

 

 

 

40

 

 

 

(2

)

 

 

206,460

 

U.S. government agency securities

 

 

5,000

 

 

 

2

 

 

 

-

 

 

 

5,002

 

Corporate securities and commercial paper

 

 

310,730

 

 

 

14

 

 

 

(56

)

 

 

310,688

 

Total

 

$

884,914

 

 

$

56

 

 

$

(58

)

 

$

884,912

 

 

 

 

Amortized

Cost

 

 

Unrealized

Gain

 

 

Unrealized

Loss

 

 

Fair

Value

 

As of December 31, 2020:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

146,468

 

 

$

-

 

 

$

-

 

 

$

146,468

 

U.S. treasury securities

 

 

301,075

 

 

 

38

 

 

 

(1

)

 

 

301,112

 

U.S. government agency obligations

 

 

24,997

 

 

 

4

 

 

 

-

 

 

 

25,001

 

Corporate securities and commercial paper

 

 

262,502

 

 

 

15

 

 

 

(12

)

 

 

262,505

 

Total

 

$

735,042

 

 

$

57

 

 

$

(13

)

 

$

735,086

 

 

 

Note 4. Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

 

 

 

As of March 31, 2021

 

 

As of December 31, 2020

 

Accrued personnel expenses

 

$

7,128

 

 

$

8,632

 

Professional fees

 

 

67

 

 

 

295

 

Other

 

 

341

 

 

 

616

 

Total

 

$

7,536

 

 

$

9,543

 

 

 

Note 5. Equity Investment in PACT Pharma

The Company owns approximately 3.6 million shares of common stock, 1.0 million shares of Series A preferred stock, and warrants to purchase additional stock of PACT Pharma, Inc. (PACT Pharma), a clinical-stage biopharmaceutical company focused on pioneering individualized, non-viral precision genome engineered, tumor-specific T cell therapies for the treatment of patients with solid tumors. This interest in PACT Pharma is accounted for as an equity method investment, and as a result the Company records its share of PACT Pharma’s operating results in interest and other income, net, in its condensed consolidated statements of operations and comprehensive loss. The investment balance was zero at March 31, 2021 and December 31, 2020. Since the Company has no obligation to provide cash financing to PACT Pharma, the Company is not required to record losses beyond the carrying amount of the investment.

In January and June 2020, PACT Pharma issued shares in its Series C and Series C-1 preferred stock financings. The Company did not participate in these financings. The decrease in the Company’s equity ownership percentage and increase in PACT Pharma’s estimated fair value per share resulted in gains on dilution totaling $1.3 million during the three months ended March 31, 2020. After applying $0.8 million in losses accumulated in prior periods when the equity investment balance was zero, the Company recorded a gain of $0.5 million for the three months ended March 31, 2020. There was no similar gain on dilution in the quarter ended March 31, 2021. For the three months ended March 31, 2021, the Company accounted for its $0.8 million share of PACT Pharma’s losses as unrecognized equity method losses.

8


 

The Company’s share of PACT Pharma’s losses for the three months ended March 31, 2021 and 2020 exceeded gains for the same periods. The Company recorded zero and $0.5 million for its share of PACT Pharma’s operating losses for the three months ended March 31, 2021 and 2020, respectively. The unrecognized equity method losses in excess of the Company’s investment was $2.1 million as of March 31, 2021.

At March 31, 2021 and December 31, 2020, the Company determined the fair value of the warrants to be insignificant to the condensed consolidated financial statements.

Note 6. License and Collaboration Agreements

The following table summarizes the revenues for the three months ended March 31, 2021 and 2020 received as a result of the Company’s collaboration agreements with Gilead Sciences, Inc. (Gilead) and Taiho Pharmaceutical Co., Ltd. (Taiho):

 

 

 

Three Months Ended March 31,

 

 

 

 

2021

 

 

2020

 

Collaboration revenue

 

 

$

9,461

 

 

$

1,750

 

Total collaboration and license revenue

 

 

$

9,461

 

 

$

1,750

 

 

The following table summarizes details of revenues for the three months ended March 31, 2021 and 2020 by collaboration and by category of revenue:

 

 

 

Three Months Ended March 31,

 

Revenues recognized:

Over time

Point in time

2021

 

 

2020

 

Gilead access rights related to the Company's research

   and development pipeline

*

 

$

7,711

 

 

$

-

 

Taiho collaboration agreement

*

 

 

1,750

 

 

 

1,750

 

Total collaboration and license revenue

 

 

$

9,461

 

 

$

1,750

 

The Company recognized the following revenue as a result of changes in the deferred revenue balance during the period below (in thousands):

 

Three Months Ended March 31,

 

Revenue recognized in the period from:

2021

 

2020

 

Amounts included in deferred revenue at the beginning of the period

$

9,461

 

$

1,750

 

Performance obligations satisfied in previous period

 

-

 

 

-

 

 

Gilead Sciences, Inc.

On May 27, 2020, the Company entered into an Option, License and Collaboration Agreement (Gilead Collaboration Agreement), Common Stock Purchase Agreement (the Stock Purchase Agreement), and Investor Rights Agreement, (collectively, the Gilead Agreements), each with Gilead Sciences, Inc. (Gilead). The transaction closed on July 13, 2020 following expiration of the antitrust waiting period. Upon closing, Gilead made an upfront payment of $175 million pursuant to the Gilead Collaboration Agreement, and made an equity investment of approximately $200 million in the Company by purchasing 5,963,029 shares of Arcus common stock at a per share price of $33.54 pursuant to the Stock Purchase Agreement. Pursuant to the Investor Rights Agreement, the Company appointed Gilead’s designees, Merdad Parsey, M.D., Ph.D. and Michael Quigley, Ph.D., to the Company’s Board of Directors. See Note 11 for further discussion of the agreements with Gilead.

Pursuant to the terms of the Gilead Collaboration Agreement, Gilead has an exclusive license to develop and commercialize zimberelimab in certain markets and obtained exclusive options to acquire an exclusive license to develop and commercialize all of the Company’s current and future clinical programs during the 10-year collaboration term, contingent upon Gilead’s access rights payments of up to $400 million and, for those programs that enter clinical development prior to the end of the collaboration term, for up to an additional three years thereafter. Gilead may exercise its option, on a program-by-program basis, upon payment of an option fee that ranges from $200 million to $275 million per program for the Company’s clinical programs in existence at the date of the agreement, and $150 million per program for all other programs that enter clinical development thereafter should Gilead elect to exercise its options.

9


 

Upon Gilead’s exercise of its option to a program, the two companies will co-develop and equally share global development costs, subject to certain opt-out rights of the Company, and expense caps on the Company’s spending and related subsequent adjustments. For each optioned program, provided the Company has not exercised its opt-out rights, the Company has an option to co-promote in the United States with equal sharing of related profits and losses. Gilead has the right to exclusively commercialize any optioned programs outside of the U.S., subject to the rights of the Company’s existing partners to any territories, and Gilead will pay to the Company tiered royalties as a percentage of revenues ranging from the high teens to the low twenties. Gilead will further provide ongoing research and development support in the form of research and development pipeline access rights payments of up to $400 million over the collaboration term.

Pursuant to the Stock Purchase Agreement and the Investor Rights Agreement, Gilead has the right, at its option, to purchase additional shares from the Company, up to a maximum of 35% of the Company’s then-outstanding voting common stock, from time to time over a five year period from closing of the initial transaction, at a purchase price equal to the greater of a 20% premium to market (based on a trailing five-day average closing price) at the time Gilead exercises such option, and the $33.54 initial purchase price. Based on the value of the Company’s common stock at the contract closing, the right to purchase additional shares had no value. In January 2021, the Company and Gilead entered into an Amended and Restated Common Stock Purchase Agreement, which amended and restated in its entirety the Common Stock Purchase Agreement, pursuant to which Gilead purchased 5,650,000 shares of the Company’s common stock at a purchase price of $39.00 per share for total gross proceeds of $220.4 million. All other terms of the original Stock Purchase Agreement remain unchanged. The Investor Rights Agreement also includes a three-year standstill and a two-year lockup and provides Gilead with registration rights commencing at the end of the lockup period, pro rata participation rights in certain future financings and the right to designate two individuals to be appointed to the Company’s Board of Directors.

The Company’s assessment of the transaction price included an analysis of amounts it expected to receive, which at contract inception consisted of the upfront cash payment of $175.0 million due upon contract closing in July 2020, the $100.0 million payment related to the research and development access rights due in 2022, and the $90.6 million premium resulting from Gilead’s purchase of common stock. All payments to date have been made by Gilead as they became due and payable so given this successful collection history, the Company considers the entire $365.6 million outlined above to be the initial transaction price.

The Company evaluated the Gilead Agreements under ASC 606 and determined that the performance obligations at the contract inception consisted of the following:

Zimberelimab license

Effective on closing, Gilead obtained an exclusive license to zimberelimab. The standalone selling price of this license was determined using a discounted cash flow method. The Company recognized the full revenues associated with this performance obligation on the date the transaction closed.

Etrumadenant option

Gilead has the right to exercise an option for exclusive rights to etrumadenant, the Company’s adenosine receptor program, in exchange for an option payment of $250.0 million, that expires after a proscribed period following the Company’s achievement of certain development milestones. The Company calculated the standalone selling price of this program using a discounted cash flow method and concluded that it exceeded the price of the option, creating a material right and a distinct performance obligation. If the option is exercised, the performance obligations associated with the option will be identified and the Company will determine the accounting for the option’s transaction price. If the option is allowed to lapse after development milestones trigger the start of the opt-in period, the Company will recognize any deferred revenue allocated to the option at the time of the lapse.

At March 31, 2021, the Company had $127.0 million of deferred revenue on its condensed consolidated balance sheets related to this performance obligation. The Company has evaluated the program’s status as of the balance sheet date and believes that some or all of the revenue associated with the opt-in will be recognized within the minimum four-year term of the Gilead Collaboration Agreement.

Domvanalimab option

Gilead has the right to exercise an option for exclusive rights to domvanalimab, the Company’s anti-TIGIT monoclonal antibody, in exchange for an option payment of $275.0 million, that expires after a proscribed period following the Company’s achievement of certain development milestones. The Company calculated the standalone selling price of this program using a discounted cash flow method and concluded that it exceeded the price of the option, creating a material right and a distinct performance obligation. If the option is exercised, the performance obligations associated with the option will be identified and will determine the accounting for the option’s transaction price. If the option is allowed to lapse after development milestones trigger the start of the opt-in period, the Company will recognize any deferred revenue allocated to the option at the time of the lapse.

At March 31, 2021, the Company had $36.7 million of deferred revenue on its condensed consolidated balance sheets related to this performance obligation. The Company has evaluated the program’s status and believes that revenue associated with the opt-in will be recognized within one year.

Access rights related to the Company’s research and development pipeline

10


 

Gilead receives exclusive access to the Company’s current programs as well as the future programs for a period of ten years, contingent upon Gilead’s payment of $400 million, with the first payment of $100 million in 2022, and an additional $100 million payment due at Gilead’s option on each of the fourth, sixth, and eighth anniversaries of the agreement. The standalone selling price of this ongoing research and development pipeline access was determined using an expected cost-plus margin approach. The Company evaluated its rights and obligations in the Gilead Collaboration Agreement and determined that Gilead is contractually obligated to make the $100 million payment due in 2022 resulting in a minimum term of four years for this performance obligation. As a result, the amount was included in the transaction price. The Company uses a time-elapsed input method to measure progress toward satisfying this obligation, which is the method the Company believes most faithfully depicts the Company’s performance in transferring the promised services during the time period in which Gilead has access to the Company’s research and development pipeline. Accordingly, the revenue allocated to the performance obligation is being recognized using this input method over the minimum four-year period. The Company further determined that Gilead is not obligated to pay the remaining $300 million due over the remainder of the term. Failure to pay the non-obligatory payments will result in Gilead’s loss of certain rights to access and obtain licenses to the programs arising from the Company’s research and development pipeline.

At March 31, 2021, the Company had $114.0 million of deferred revenue on its consolidated balance sheets related to this performance obligation, classified between current and noncurrent based on the amortization of the revenue.

Development and commercialization services for zimberelimab monotherapy

In conjunction with the license, the Company determined there existed a separate obligation to perform further development and commercialization services for Gilead. The standalone selling price of this obligation was determined using an expected cost-plus margin approach. This obligation includes a 50/50 share of the costs associated with all future development and commercialization of zimberelimab as a monotherapy. The portion of the transaction price allocated to this performance obligation has been allocated in accordance with the total costs forecast for the development and commercialization of zimberelimab as a monotherapy. The Company will recognize the amounts allocated to these services as the performance obligation is satisfied. Any additional payments received from or payments made to Gilead for the 50/50 cost share will be recognized as a reduction or an increase to R&D expense, respectively.

At March 31, 2021, the Company had $9.7 million of contract liabilities on its consolidated balance sheets related to this performance obligation. The Company has evaluated the program’s status and believes that revenue associated with these services will be recognized over the full term of the contract. As of March 31, 2021, no revenue had been recognized from this performance obligation.

Gilead was also granted option rights to programs not yet in development. These programs were not determined to be performance obligations at contract inception, as there are no identified programs, revenues, or costs to compare against the option price.

Prepaid expenses

The Company incurred $7.3 million in expenses to obtain the contract, which consisted of consultant and legal fees that were directly connected to the successful completion of the Gilead Agreements. The Company determined that $1.9 million of these expenses were related to the Stock Purchase Agreement and recorded them as offering costs. The Company allocated the remaining expenses between the various performance obligations, to be recognized when the underlying revenue is recognized. The portion allocated to the delivery of zimberelimab was recognized immediately, and the portion allocated to the remaining performance obligations will be recognized with timing consistent with the associated performance obligation. During the three months ended March 31, 2021, the Company recognized $0.1 million in expense from the amortization of these assets. At March 31, 2021, the Company had $4.1 million in prepaid expenses from costs to obtain the Gilead Agreements, of which $1.0 million was recorded in prepaid expenses and other current assets and $3.1 million was recorded in other long-term assets.

 

Taiho Pharmaceutical Co., Ltd

In September 2017, the Company and Taiho entered into an option and license agreement (the Taiho Agreement) to collaborate on the potential development and commercialization of certain investigational products from the Company’s portfolio in Japan and certain other territories in Asia (excluding China) (the Taiho Territory). The Taiho Agreement provides Taiho with exclusive options, over a five-year period (the Option Period), to obtain an exclusive development and commercialization license to clinical stage investigational products from the Company’s programs (each, an Arcus Program).

In consideration for the exclusive options and other rights contained in the Taiho Agreement, Taiho agreed to make non-refundable, non-creditable cash payments to the Company totaling $35.0 million, of which the Company received $25.0 million during 2017. An additional $5.0 million was received in 2018 and the remaining $5.0 million was received in 2019. 

In the event that the Company has not initiated IND enabling studies for at least five Arcus Programs prior to the expiration of the Option Period, Taiho may elect to extend the Option Period, up to a maximum of seven years, subject to an extension fee. For each option that Taiho elects to exercise, it will be obligated to make an option exercise payment of between $3.0 million to $15.0 million, depending on the development stage of the applicable Arcus Program for which the option is exercised. In addition, the Taiho Agreement provides that the Company is eligible to receive additional clinical and regulatory milestones totaling up to $130.0 million

11


 

per Arcus Program, and it will be eligible to receive contingent payments of up to $145.0 million per Arcus Program associated with the achievement of specified levels of Taiho net sales in the Taiho Territory.

In addition, the Company will receive royalties ranging from high single-digits to mid-teens on net sales of licensed products in the Taiho Territory. Royalties will be payable on a licensed product-by-licensed product and country-by-country basis during the period of time commencing on the first commercial sale of a licensed product in a country and ending upon the later of: (a) ten (10) years from the date of first commercial sale of such licensed product in such country; and (b) expiration of the last-to-expire valid claim of the Company’s patents covering the manufacture, use or sale or exploitation of such licensed product in such country (the Royalty Term).

The Company determined that the identified performance obligations, which include the combined performance obligation of the research and development services and the obligation to participate on the joint steering committee, are satisfied over time. The Company uses a time-elapsed input method to measure progress toward satisfying its performance obligation, which is the method the Company believes most faithfully depicts the Company’s performance in transferring the promised services during the time period in which Taiho has access to the Company’s research and development activities. Accordingly, the transaction price of $35.0 million is being recognized using this input method over the estimated performance period of five years.

Based on the nature of the clinical and regulatory milestones, such as the regulatory approvals which are not within the Company’s control, the Company will not consider achievement of such milestones to be probable until the uncertainty associated with the milestones has been resolved. When it is probable that a significant reversal of revenue will not occur, the milestone payment will be added to the transaction price, which will then be allocated to each performance obligation, on a relative standalone selling price basis, for which the Company recognizes revenue. As of March 31, 2021, no clinical or regulatory milestones had been achieved under the Taiho Agreement.

The Company also considers the contingent payments due from Taiho upon the achievement of specified sales volumes to be similar to royalty payments. The Company considers the license to be the predominant item to which the royalties relate. The Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). As of March 31, 2021, no sales milestone or royalty revenue has been recognized.

The Taiho Agreement shall remain in effect until expiry of all Royalty Terms for the licensed products, in each case subject to certain exceptions.

WuXi Biologics License Agreements

The Company entered into a license agreement (the WuXi PD-1 Agreement) with WuXi Biologics in August 2017, as subsequently amended, in which it obtained an exclusive license to develop, use, manufacture, and commercialize products including an anti-PD-1 antibody worldwide except for Greater China and Thailand. From the inception of the WuXi PD-1 Agreement through March 31, 2021, the Company has made upfront and milestone payments of $41.0 million and incurred sub-license fees of $11.3 million. These payments were recorded as research and development expense, as the products had not reached technological feasibility and did not have an alternative future use. The WuXi PD-1 Agreement also provides for clinical and regulatory milestone payments, commercialization milestone payments of up to $375.0 million, and tiered royalty payments to be made to WuXi Biologics that range from the high single-digits to low teens of net sales by the Company of licensed products.

The Company incurred $10.0 million in development milestone expense under the WuXi PD-1 Agreement during the three months ended March 31, 2021.

In December 2020, the Company entered into a separate license agreement (the WuXi CD-39 Agreement) with WuXi Biologics to develop anti-CD39 antibodies. Under the agreement, the Company was granted exclusive worldwide rights to anti-CD39 antibodies discovered under the collaboration and will be responsible for the further development and commercialization of those antibodies. From the inception of the WuXi CD-39 Agreement through March 31, 2021, the Company has paid $0.5 million in upfront payments which was recorded in research and development expense, as the products are still in research stage. The WuXi CD-39 Agreement provides for clinical and regulatory milestone payments totaling $16.5 million, and royalty payments in the low single digits of net sales by the Company of licensed products.

Abmuno License Agreement

In December 2016, the Company entered into a license agreement (the Abmuno Agreement) with Abmuno Therapeutics LLC (Abmuno) for a worldwide exclusive license to develop, use, manufacture, and commercialize products that include an anti-TIGIT antibody, including domvanalimab (formerly referred to as AB154). Under the Abmuno Agreement, the Company has made upfront and milestone payments totaling $14.6 million as of March 31, 2021. The Abmuno Agreement also provides for additional clinical, regulatory and commercialization milestone remaining payments of up to $93.0 million as of March 31, 2021.

12


 

The Company incurred $5.0 million in development milestone expense under the Abmuno Agreement during the three months ended March 31, 2021.

Genentech Collaboration Agreement

In December 2019, the Company and Genentech, through F. Hoffmann-La Roche Ltd (collectively, Genentech) entered into a Master Clinical Collaboration Agreement (the Genentech Agreement) pursuant to which the parties may conduct combination clinical studies involving Genentech’s monoclonal antibody, atezolizumab and the Company’s investigational products. Pursuant to the Genentech Agreement, the parties entered into Trial Supplements for the evaluation of etrumadenant and atezolizumab utilizing the MORPHEUS platform in two separate study indications: second and third line metastatic colorectal cancer and first line metastatic pancreatic cancer. The Company and Genentech will each supply their respective investigational products for use in the collaboration studies and will share a portion of the development costs under specific terms as set forth in the agreement. From the inception of the Agreement through March 31, 2021, the Company has incurred net expenses of $0.8 million.

For the three months ended March 31, 2021 and 2020, the Company incurred expenses pursuant to the Genentech Agreement of $0.3 million and zero, respectively. Net expenses related to this co-development agreement are recorded within research and development expenses.

Strata Collaboration Agreement

On April 30, 2019, the Company and Strata Oncology, Inc. (Strata) entered into a Co-Development and Collaboration Agreement (the Strata Agreement) to pursue a clinical development collaboration utilizing Strata’s precision drug development platform and proprietary biomarkers to evaluate zimberelimab, the Company’s clinical-stage anti-PD-1 antibody, in patients in a tumor-agnostic fashion.

 

Under the terms of the Strata Agreement, the parties will share a portion of development costs for the clinical collaboration under specified terms. Strata is eligible to receive $2.5 million upon the achievement of a development milestone, as well as regulatory and commercial milestones of up to $125.0 million and up to double-digit royalties on U.S. net sales of zimberelimab in the biomarker-identified indication. From the inception of the Agreement through March 31, 2021, the Company has made a milestone payment of $2.5 million and has incurred expenses of $3.3 million, of which $0.7 million had been reimbursed by Strata as development cost sharing. Net expenses related to this co-development agreement were recorded within research and development expenses.

As further consideration in connection with the Strata Agreement, the Company issued to Strata 1,257,651 restricted shares of its common stock with an initial measured fair value of $15.0 million, which are subject to vesting based upon the achievement of specified regulatory milestones within certain timelines. Expense relating to the restricted shares subject to these milestones is recognized if it is considered probable that the associated shares will vest. The probability of achievement is assessed at the end of each quarterly period. As of March 31, 2021, the Company determined that none of the restricted shares were probable of vesting and, as a result, no compensation expense related to the restricted shares has been recognized to date.

For the three months ended March 31, 2021 and 2020, the Company incurred expenses pursuant to the Strata Agreement of $0.6 million and $0.4 million, respectively. Of these expenses, $0.1 million have been reimbursed by Strata as development cost sharing for each of the three months ended March 31, 2021 and 2020. Net expenses related to this co-development agreement are recorded within research and development expenses.

AstraZeneca Agreement

On October 29, 2020 the Company announced a collaboration with AstraZeneca to evaluate domvanalimab, the Company’s investigational anti-TIGIT antibody, in combination with AstraZeneca’s Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer (NSCLC). Under the terms of the agreement, each company will retain existing rights to their respective molecules and any future commercial economics. AstraZeneca will conduct the trial, and each company will supply its respective anti-cancer agent to support the trial. Under the terms of the agreement and subject to the parties’ approval of a final budget for the clinical trial, the Company may be obligated to reimburse AstraZeneca for a portion of the costs incurred.

Consistent with the terms of the Gilead Collaboration Agreement, Gilead maintains an option to co-develop and co-commercialize domvanalimab. If Gilead exercises its option to domvanalimab, the trial from this AstraZeneca collaboration is expected to form part of the Arcus and Gilead joint development program and Arcus’s portion of the trial costs would be shared with Gilead.

For the three months ended March 31, 2021, the Company incurred immaterial expenses pursuant to the AstraZeneca Agreement. Expense from this co-development agreement are recorded within research and development expenses.

13


 

Note 7. Stockholders’ Equity

In June 2020, pursuant to a shelf registration statement on Form S-3 that was filed in May 2020, the Company issued 12,650,000 shares of its common stock at $27.50 per share in an underwritten public offering (the May 2020 Public Offering). The total number of shares sold consisted of 11,000,000 base shares and an additional 1,650,000 shares sold pursuant to the underwriters’ option exercise. Net proceeds from the May 2020 Public Offering were approximately $326.2 million after deducting underwriting discounts, commissions and other offering expenses.

In July 2020, the Company closed the Gilead Collaboration Agreement, Common Stock Purchase Agreement, and the Investor Rights Agreement, each signed with Gilead in May 2020. The transaction closed on July 13, 2020 following expiration of the antitrust waiting period. Upon closing, Gilead made an equity investment of approximately $200 million in the Company by purchasing 5,963,029 shares of Arcus common stock at a per share price of $33.54 pursuant to the Stock Purchase Agreement. Of the $200 million equity investment, approximately $90.6 million was determined to be a premium on the purchase of common stock and allocated to the performance obligations created by the Gilead Collaboration Agreement. See Note 6 in this Form 10-Q for further discussion of the agreements with Gilead. Net proceeds from Gilead’s equity investment were approximately $107.5 million after allocating the premium and deducting direct offering expenses of $1.9 million.

In February 2021, the Company closed the Amended and Restated Common Stock Purchase Agreement with Gilead, pursuant to which Gilead made an equity investment of approximately $220.4 million in the Company by purchasing 5,650,000 shares of the Company’s common stock at a per share price of $39.00.

Note 8. Stock-Based Compensation

 

The Company grants awards under its 2018 Equity Incentive Plan and the 2020 Inducement Plan. Total stock-based compensation expense was recognized in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Research and development

 

$

6,170

 

 

$

1,736

 

General and administrative

 

 

6,591

 

 

 

1,726

 

Total stock-based compensation

 

$

12,761

 

 

$

3,462

 

 

Note 9. Net Loss per Share

 

Basic net loss per share is calculated based on the weighted-average number of shares of the Company’s common stock during the period. Diluted net loss per share is calculated based on the weighted-average number of shares of the Company’s common stock and other dilutive securities outstanding during the period.

The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Numerator:

 

 

 

 

 

 

 

 

Net loss

 

$

(72,593

)

 

$

(27,753

)

Denominator:

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding

 

 

68,476,799

 

 

 

45,953,213

 

Less: weighted-average common shares subject to vesting

 

 

(1,394,638

)

 

 

(1,670,606

)

Weighted-average common shares used to compute basic and diluted net loss per share

 

 

67,082,161

 

 

 

44,282,607

 

Net loss per share: basic and diluted

 

$

(1.08

)

 

$

(0.63

)

14


 

 

 

The following outstanding potentially dilutive securities were excluded from the computation of diluted net loss per share because including them would have been antidilutive:

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Common stock options issued and outstanding

 

 

11,708,625

 

 

 

6,725,835

 

Unvested restricted common stock issued as part of

  collaboration agreement

 

 

1,257,651

 

 

 

1,257,651

 

Unvested early exercised common stock options

 

 

111,094

 

 

 

375,615

 

Unvested restricted stock units

 

 

1,532,162

 

 

 

-

 

Employee Stock Purchase Plan shares

 

 

96,591

 

 

 

-

 

Total

 

 

14,706,123

 

 

 

8,359,101

 

The Company also excluded the effect of Gilead’s right to purchase additional shares of the Company’s common stock from its calculation as these rights had no intrinsic value at March 31, 2021.

Note 10. Commitments

Standby Letters of Credit

The Company has standby letters of credit up to an aggregate of $2.0 million provided as collateral for its leases. The letters of credit are secured by $2.0 million in deposits classified as restricted cash on the Company’s condensed consolidated balance sheets. At March 31, 2021 the facilities were not drawn down.

 

Note 11. Related parties

Relationship and transactions with Gilead Sciences, Inc. (Gilead)

 

As of March 31, 2021, Gilead held approximately 19.5% of the Company’s outstanding common stock. These holdings resulted from Gilead’s participation in the May 2020 Public Offering as well as purchases of stock under the stock purchase agreements. In the May 2020 public offering, Gilead purchased 2,200,000 shares of common stock for an amount of $56.7 million, net of offering costs. Under the stock purchase agreements, Gilead purchased 5,963,029 and 5,650,000 shares in July 2020 and February 2021, respectively, for a total investment of $327.8 million, net of offering costs. Gilead has the right, at its option, to purchase up to a maximum of 35% of the Company’s then-outstanding voting common stock, from time to time over a five-year period from the closing of the initial transaction in July 2020. Gilead also has the right under the Investor Rights Agreement to designate two individuals to be appointed to the Company’s board of directors. Pursuant to the Investor Rights Agreement, the Company appointed the Gilead designees, Merdad Parsey, M.D., Ph.D. and Michael Quigley, Ph.D., to its board of directors, in July 2020 and January 2021, respectively. See Note 6 for further discussion of the agreements with Gilead.

 

At March 31, 2021, the Company had a $4.9 million cost sharing receivable recorded on the condensed consolidated balance sheets under receivable from collaboration partners, to be invoiced the following quarter. The Company also had $177.7 million in deferred revenue at March 31, 2021, of which $110.1 million represented the long-term portion of revenue allocated to performance obligations not expected to be completed within one year of the balance sheet date, which was recorded in deferred revenue, noncurrent on the condensed consolidated balance sheets. The Company also had $9.7 million in contract liabilities for future development and commercialization services which Gilead prepaid, all of which was recorded in other long-term liabilities on the consolidated balance sheets.

 

For the three months ended March 31, 2021, the Company recognized $7.7 million in revenue under the Gilead Collaboration Agreement. The Company also recognized a $4.9 million reduction in research and development expense, including $4.0 million of cost sharing reimbursement related to milestone expense, related to its cost-sharing provisions of the agreement.

 

The Company received a $175 million upfront payment from Gilead in connection with the Gilead Collaboration Agreement in July 2020 and identified $100 million in unconstrained consideration to be received in 2022. In addition, in July 2020 the Company received $200 million from Gilead in connection with the Stock Purchase Agreement, of which approximately $109.4 million represented the fair value of stock purchased at the transaction closing date with the remaining premium of $90.6 million allocated to the transaction price. In February 2021, the Company received $220.4 million from Gilead in connection with the purchase by Gilead of 5,650,000 shares of the Company’s common stock at a per share price of $39.00 pursuant to the amended and restated Stock Purchase Agreement.

 

15


 

 

Note 12. Subsequent event

 

In April 2021, the Company entered into a lease amendment that modifies rent schedules for its existing operating leases in Hayward, California, extends the terms of those leases, and adds 14,460 square feet of additional space in Hayward in a new operating lease expected to commence in 2022. Any extension periods defined under previous amendments are cancelled under the lease amendment and replaced by two options to extend the lease term for the entire Hayward premises for a period of eight years each. The amended leases will end at the same time as the Company’s lease of its building in Brisbane, expected to be no earlier than December 2031. The lease amendment includes approximately $43 million in additional undiscounted future minimum lease payments throughout the expected term and provides additional tenant improvement allowances totaling $5.8 million with options to increase the allowance by $10.9 million.

 

The lease amendment requires an additional $1.0 million in collateral for the operating leases in Hayward. In accordance with this requirement, the Company issued an additional $1.0 million letter of credit in April 2021.

 

 

16


 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and notes thereto in Part I, Item 1 of this Quarterly Report on Form 10-Q and with our audited consolidated financial statements and notes thereto for the year ended December 31, 2020, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2021. This discussion and other parts of this report contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations, and intentions. Further, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Our actual results could differ materially from those discussed in these forward-looking and other statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this report entitled “Risk Factors.”

Overview

We are a clinical-stage biopharmaceutical company focused on creating best-in-class cancer therapies. Our initial focus has been on well-characterized biological pathways with significant scientific data supporting their importance. We have built a robust and highly efficient drug discovery capability to create highly differentiated small molecules, which we have the ability to develop in combinations with our monoclonal antibodies through rationally designed, indication-specific clinical trial designs. Our vision is to create, develop and commercialize highly differentiated combination cancer therapies.

We currently have five investigational products in clinical development. In 2020, we entered into an Option, License and Collaboration Agreement (Gilead Collaboration Agreement) with Gilead Sciences, Inc. (Gilead), whereby Gilead obtained rights to zimberelimab and a time-limited exclusive option to all of our current and future programs during the 10-year collaboration term. For each program to which Gilead exercises their option, the parties will co-develop globally and co-commercialize in the U.S., subject to certain exceptions, and Gilead will have the right to commercialize the program outside of the United States, subject to the rights of our existing partners to certain territories. In 2017, we entered into an Option and License Agreement (Taiho Agreement) with Taiho Pharmaceutical Co., Ltd. (Taiho) pursuant to which Taiho has a time-limited option to exclusively license the development and commercialization rights to each of our programs for Japan and certain other territories in Asia (excluding China). To date, Taiho has exercised their option rights to our adenosine receptor antagonist program (including etrumadenant) and our anti-PD-1 program (including zimberelimab).

Domvanalimab (formerly referred to as AB154), our anti-TIGIT monoclonal antibody, is being evaluated in combination with zimberelimab with or without etrumadenant vs. zimberelimab monotherapy in ARC-7, our randomized Phase 2 trial in first-line metastatic PD-L150% non-small cell lung cancer. In February 2021, we initiated ARC-10, our first registrational trial evaluating domvanalimab in combination with zimberelimab and zimberelimab monotherapy vs. chemotherapy in this same setting.

Etrumadenant (formerly referred to as AB928), our small molecule dual A2a/A2b adenosine receptor antagonist, is being evaluated by us in several randomized or Phase 2 trials across major tumor types, including in our ARC-4, ARC-6, ARC-7, and ARC-9 studies, as well as in two randomized Phase 1b/2 trials being conducted by Genentech (the Morpheus trials).

AB680, our small-molecule CD73 inhibitor, is being evaluated in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer (ARC-8) as well as late-line metastatic prostate cancer (ARC-6).

Zimberelimab (formerly referred to as AB122), our anti-PD-1 monoclonal antibody, is the cornerstone of our combination strategy. We are currently evaluating zimberelimab, either alone or in combination with other agents across several tumor types, including non-small cell lung cancer in ARC-7, our Phase 2 trial, and ARC-10, our recently initiated registrational trial which is designed to support the approval of zimberelimab.

AB308, our Fc-enabled anti-TIGIT monoclonal antibody, is being evaluated in a dose escalation study designed to expeditiously identify an every three week and an every four week dose for AB308 in combination with zimberelimab. The dose escalation study will further evaluate the safety, pharmacokinetics and pharmacodynamics of AB308 in combination with zimberelimab.

Gilead Collaboration

On May 27, 2020, we entered into the Gilead Collaboration Agreement, a Common Stock Purchase Agreement (the Stock Purchase Agreement), and an Investor Rights Agreement, (collectively, the Gilead Agreements), each with Gilead. The transaction closed on July 13, 2020 following expiration of the antitrust waiting period. Upon closing, Gilead made an upfront payment of $175 million pursuant to the Gilead Collaboration Agreement, and Gilead made an equity investment of approximately $200 million in us by purchasing 5,963,029 shares of our common stock at a per share price of $33.54 pursuant to the Stock Purchase Agreement. Gilead made an additional equity investment in us of approximately $56.7 million, net of offering costs, by purchasing 2,200,000 shares of

17


 

our common stock at a per share price of $27.50 in our May 2020 Public Offering. Pursuant to the Investor Rights Agreement, we also appointed Gilead’s designees, Merdad Parsey, M.D., Ph.D. and Michael Quigley, Ph.D., to our Board of Directors.

Pursuant to the terms of the Gilead Collaboration Agreement, Gilead has an exclusive license to develop and commercialize zimberelimab in certain markets and obtained exclusive options to acquire an exclusive license to develop and commercialize all of our current and future clinical programs during the 10-year collaboration term, contingent upon Gilead’s payment of $400 million, with the first payment of $100 million in 2022 and an additional $100 million payment due at Gilead’s option on each of the fourth, sixth, and eighth anniversaries of the agreement. For those programs that enter clinical development prior to the end of the collaboration term, Gilead’s option rights will extend for up to an additional three years thereafter. Gilead may exercise its option, on a program-by-program basis, upon payment of an option fee that ranges from $200 million to $275 million per program for our clinical programs in existence at the date of the agreement, and $150 million per program for all other programs that enter clinical development thereafter. If Gilead exercises its option with respect to our TIGIT program, we are also eligible to receive up to $500 million in potential U.S. regulatory approval milestones with respect to domvanalimab.

Upon Gilead’s exercise of its option to a program, the two companies will co-develop and equally share global development costs, subject to certain of our opt-out rights, and expense caps on our spending and related subsequent adjustments. For each optioned program, provided we have not exercised our opt-out rights, we have an option to co-promote in the United States with equal sharing of related profits and losses. Gilead has the right to exclusively commercialize any optioned programs outside of the U.S., subject to the rights of our existing partners to any territories, and Gilead will pay to us tiered royalties as a percentage of revenues ranging from the high teens to the low twenties.

Pursuant to the Stock Purchase Agreement and the Investor Rights Agreement, Gilead has the right, at its option, to purchase additional shares from us, up to a maximum ownership of 35% of our then-outstanding voting common stock, from time to time over a five year period, at a purchase price equal to the greater of a 20% premium to market (based on a trailing five-day average closing price) at the time Gilead exercises such option, and the $33.54 initial purchase price. The Investor Rights Agreement also includes a three-year standstill and a two-year lockup and provides Gilead with registration rights commencing at the end of the lockup period, pro rata participation rights in certain future financings and the right to designate two individuals to be appointed to our Board of Directors.

On January 31, 2021, we and Gilead entered into an Amended and Restated Common Stock Purchase Agreement, which amended and restated in its entirety the Common Stock Purchase Agreement, pursuant to which Gilead purchased from us 5,650,000 shares of our common stock at a purchase price of $39.00 per share, for gross proceeds of $220.4 million. All other terms of the original Common Stock Purchase Agreement, including Gilead’s option to purchase additional shares from us, up to a maximum ownership of 35% of our then-outstanding common stock, remain unchanged.

COVID-19 Pandemic

The degree to which COVID-19 impacts our business operations, research and development programs and financial condition will depend on future developments, including the ultimate duration and/or severity of the outbreak, the impact of any resurgences and new strains that emerge, actions by government authorities to contain the spread of the virus, the timing, availability and effectiveness of any vaccines, and when and to what extent normal economic and operating conditions can resume. Our management continues to actively monitor this health crisis and its effects on our operations, key vendors and workforce.

We conduct our clinical trials in the U.S. and internationally in geographic regions that are impacted by COVID-19 to varying degrees. While we have seen relatively robust enrollment across our ongoing Arcus-sponsored studies, we expect to see volatility as local governments respond to resurgences and the emergence of new strains, each of which may result in the prolonged reinstitution, extension or enhancement of shelter-in-place measures. The American Cancer Society has also reported that the pandemic has led to declines in screening, diagnosis and treatment for cancer patients, which will impact the enrollment of patients in clinical trials targeting early stage cancers and retention of patients overall in our trials. Patient safety remains our paramount concern and we continue to collaborate with our existing and with new investigational sites to implement measures to minimize disruptions to patients and ensure continued access to treatment, in accordance with health authority guidance. We are unable to predict the ultimate impact of this pandemic on our ongoing and planned clinical programs.

With respect to manufacturing and supply, we believe we currently have sufficient drug supply for our ongoing clinical studies. Our third-party contract manufacturers continue to operate at or near normal levels and, at this time and subject to further COVID-19 implications, we do not anticipate any disruptions to our drug supply chain.

Our discovery programs are impacted by reduced operating capacity in our laboratories due to employee safety measures, such as social distancing requirements and shift work. This has slowed the pace of our discovery efforts, and our HIF-2α program is now expected to enter clinical development in the second half of 2021.

The full impact of the COVID-19 outbreak remains highly uncertain and subject to change. The safety, health and well-being of our employees remains a primary concern, and we instituted remote work arrangements for our office-based employees and regular

18


 

COVID-19 testing services for our laboratory-based employees in order to reduce the risk of exposure to COVID-19 among our employees. These actions have increased our operating costs, whjch together with the absence of any furlough or measures to reduce personnel costs despite reduced laboratory capacity, will have a negative impact on our operations and financial condition. We do not expect the forward impact will be material due to adjustments in operations that we have made. However, there are many uncertainties around the COVID pandemic and future developments, which are unpredictable, may result in a material, negative impact to our operations and financial condition.

Components of Operating Results

Collaboration and License Revenue

Our collaboration and license revenue consists of revenue recognized from the upfront and periodic payments received from Taiho and Gilead, for research and development services performed by us to develop our investigational products under the terms of our collaboration agreements, and from any option exercise payments.

Operating Expenses

Research and Development Expenses

Our research and development expenses consist of expenses incurred in connection with the research and development of our pipeline programs. These expenses include pre-clinical and clinical expenses, payroll and personnel expenses, including stock-based compensation for our employees, laboratory supplies, product licenses, consulting costs, contract research, and depreciation. Shared facility expenses are allocated to functional groups proportionally based on usage. Under certain collaboration agreements we agree to share research and development expenses with our partners or to reimburse our partners for qualified expenses. We expense both internal and external research and development costs as they are incurred. We record advance payments for services that will be used or rendered for future research and development activities as prepaid expenses and recognize them as an expense as the related services are performed.

We do not allocate our costs by investigational product, as a significant amount of research and development expenses include internal costs, such as payroll and other personnel expenses, and certain external costs that are not recorded at the investigational product level. In particular, with respect to internal costs, several of our departments support multiple research and development programs, and we do not allocate those costs by investigational product.

We expect our research and development expenses to increase substantially during the next few years due to our Gilead collaboration and as we seek to complete existing clinical trials and advance our programs into later-stage clinical trials, pursue regulatory approval for our investigational products, and advance other programs into the clinic. Later-stage clinical trials typically include a larger number of subjects, are of a longer duration and include more geographic regions. As we advance our clinical-stage programs and prepare to seek regulatory approval, we will also need to conduct certain validation activities with respect to our manufacturing processes for the investigational products in each program. Moreover, in order to maximize the potential of our collaboration with Gilead, we believe it will be important to grow our discovery capabilities and pipeline. As a result, we expect our preclinical, clinical, and contract manufacturing expenses to increase significantly relative to what we have incurred to date. The level of our future research and development investment will depend on a number of factors and uncertainties, including clinical outcomes from our ongoing clinical trials, whether our collaborators opt into any of our programs, the amount of opt-in and milestone payments we receive from our collaborators, and the breadth of any joint development program agreed to with Gilead for programs they opt into. In addition, under our license agreements with WuXi Biologics and Abmuno, and our co-development and collaboration agreements with Strata, and AstraZeneca, we may be required to pay additional clinical and regulatory milestone payments based on the development progress of our investigational products. Therefore, we are unable to predict the timing or the final cost to complete our clinical programs or validation of our manufacturing and supply processes and delays may occur due to numerous factors. Factors that could cause or contribute to delays or additional costs include, but are not limited to, those discussed in “Item 1A. Risk Factors.”

General and Administrative Expenses

General and administrative expenses consist principally of personnel-related costs including payroll and stock-based compensation for personnel in executive, finance, human resources, information technology, business and corporate development, and other administrative functions. Shared facility expenses are allocated to functional groups proportionally based on usage. Our general and administrative expenses also include professional fees for legal, consulting, and accounting services, rent and other facilities costs, fixed asset depreciation, and other general operating expenses not otherwise classified as research and development expenses.

19


 

We anticipate that our general and administrative expenses will increase substantially during the next few years as we support our growing research and development activities, including staff expansion, additional occupancy costs, and other costs associated with increased infrastructure needs.

Other Non-Operating Income, net

Other non-operating income, net consists primarily of interest earned on our investments in fixed-income marketable securities as well as activity related to our equity method investment in PACT Pharma, Inc (PACT Pharma). To date, gains have consisted of gains on dilution of our investment in PACT Pharma, typically occurring upon PACT Pharma’s new issuances of equity securities. Losses associated with the investment consist of our share of PACT Pharma’s net losses.

Critical Accounting Policies, Significant Judgments and Use of Estimates

Our condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported revenue and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies relating to revenue recognition, clinical trial accruals and stock-based compensation reflect the more significant estimates and assumptions used in the preparation of our condensed consolidated financial statements.

There have been no significant changes in our critical accounting policies and estimates during the three months ended March 31, 2021, as compared to the critical accounting policies and estimates disclosed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2020 and more fully described in Note 2 of the accompanying condensed consolidated financial statements.

Results of Operations

Three Months Ended March 31, 2021 and 2020

The following table summarizes our results of operations for the three months ended March 31, 2021 and 2020 (in thousands):

 

 

Three Months Ended March 31,

 

 

Change

 

 

 

2021

 

 

2020

 

 

$

 

 

%

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Collaboration revenue

 

 

9,461

 

 

 

1,750

 

 

 

7,711

 

 

*

 

Total collaboration and license revenue

 

 

9,461

 

 

 

1,750

 

 

 

7,711

 

 

*

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

66,387

 

 

 

23,142

 

 

 

43,245

 

 

 

187

%

General and administrative

 

 

15,821

 

 

 

7,008

 

 

 

8,813

 

 

 

126

%

Total operating expenses

 

 

82,208

 

 

 

30,150

 

 

 

52,058

 

 

 

173

%

Loss from operations

 

 

(72,747

)

 

 

(28,400

)

 

 

(44,347

)

 

 

156

%

Non-operating income, net

 

 

154

 

 

 

647

 

 

 

(493

)

 

 

-76

%

Net loss

 

$

(72,593

)

 

$

(27,753

)

 

$

(44,840

)

 

 

162

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*Not meaningful

Collaboration and License Revenue

Collaboration and license revenue increased $7.7 million, from $1.8 million for the three months ended March 31, 2020 to $9.5 million for the three months ended March 31, 2021. In the three months ended March 31, 2021, we recognized $7.7 million in collaboration revenues related to Gilead’s ongoing rights to access our intellectual property in accordance with the Gilead Collaboration Agreement, as well as $1.8 million under the Taiho Agreement. In the three months ended March 31, 2020, we recognized $1.8 million under the Taiho Agreement.

20


 

Research and Development Expenses

Research and development expenses increased $43.3 million, or 187%, from $23.1 million for the three months ended March 31, 2020 to $66.4 million for the three months ended March 31, 2021. The increase in research and development expenses included $15.0 million in development milestone expenses incurred, consisting of a $10.0 million milestone payment due to WuXi Biologics pertaining to zimberelimab and a $5.0 million milestone payment due to Abmuno pertaining to domvanalimab, with no similar expense in the same quarter in the prior year. There was also an increase of $10.5 million in employee compensation costs, approximately $4.4 million of which consists of non-cash stock-based compensation. This increase is driven by our growing headcount as well as our 2021 stock awards. Manufacturing costs and clinical costs for our ongoing studies increased $9.9 million and $9.0 million, respectively, as a result of the increased number of programs and clinical trials compared to the same quarter in the prior year. Office and facilities expense increased as we continued to grow. The overall increase in research and development expense is partially offset by a $4.9 million reimbursement by Gilead of certain applicable costs of developing zimberelimab, including $4.0 million of cost sharing reimbursement related to milestone expense incurred, in accordance with the Gilead Collaboration Agreement.

General and Administrative Expenses

General and administrative expenses increased $8.8 million, or 126%, from $7.0 million for the three months ended March 31, 2020 to $15.8 million for the three months ended March 31, 2021. The increase in general and administrative expenses was primarily due to $6.8 million in employee compensation costs, approximately $4.9 million of which consists of non-cash stock-based compensation. This increase is driven by our growing headcount as well as our 2021 stock awards. Additional increases in finance and legal expenses were largely driven by costs incurred to support our growth and ongoing compliance with public company requirements. We also incurred additional facilities expense due to our expanding headcount and office space.

Non-Operating Income, Net

Non-operating income, net decreased $0.4 million or 76%, from $0.6 million for the three months ended March 31, 2020 to $0.2 million for the three months ended March 31, 2021. The decrease was primarily due to lower interest income resulting from lower investment yields on our portfolio of marketable fixed-income securities during the quarter ended March 31, 2021 as compared to the same period in the prior year.

Liquidity and Capital Resources

To date, we have financed our operations primarily through net proceeds of approximately $677.1 million from equity offerings and proceeds of approximately $641.4 million from our collaboration and stock purchase agreements, including $220.4 million gross proceeds raised in February 2021 from the sale to Gilead of 5,650,000 shares of our common stock. As of March 31, 2021, we had $884.9 million of cash, cash equivalents, and investments in marketable securities, compared to $735.1 million as of December 31, 2020. Our cash and investments are held in a variety of interest-bearing instruments, including money market funds, U.S. government treasury obligations, U.S. government agency securities, and investments in corporate securities.

Based on our existing business plan, we believe that our existing cash, cash equivalents, and investments will be sufficient to fund our planned level of operations at least through 2023.

We may require additional capital to complete the development and any commercialization of our investigational products. Our future capital requirements will depend on many factors, including:

 

the scope, rate of progress and costs of clinical trials for our investigational products as well as drug discovery, preclinical development activities, and laboratory testing;

 

the number and scope of clinical programs we decide to pursue;

 

the scope and costs of manufacturing development and commercial manufacturing activities;

 

the timing and amount of expense related to our current and future clinical programs, subject to the rights of our existing partners, and the costs associated with our share of the global development plan for such programs;

 

the timing and amount of milestone payments we receive under the Taiho Agreement and Gilead Collaboration Agreement, and option fees under the Gilead Collaboration Agreement;

 

the extent to which we acquire or in-license other investigational products and technologies;

 

the cost, timing and outcome of regulatory review of our investigational products;

 

the cost and timing of establishing sales and marketing capabilities, if any of our investigational products receive marketing approval;

21


 

 

the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;

 

our ability to establish and maintain collaborations on favorable terms, if at all;

 

our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our investigational products;

 

the costs associated with being a public company; and

 

the cost associated with commercializing our investigational products, if they receive marketing approval.

If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to others rights to our investigational products in certain territories or indications that we would prefer to develop and commercialize ourselves.

See “Risk Factors” for additional risks associated with our substantial capital requirements.

Summary Condensed Consolidated Statement of Cash Flows

The following table sets forth the primary sources and uses of cash, cash equivalents and restricted cash for each of the periods presented below (in thousands):

 

 

 

Three Months Ended March 31,

 

Net cash (used in) provided by:

 

2021

 

 

2020

 

Operating activities

 

$

(66,316

)

 

$

(31,277

)

Investing activities

 

 

62,826

 

 

 

40,056

 

Financing activities

 

 

222,120

 

 

 

610

 

Net increase in cash, cash equivalents and restricted cash

 

$

218,630

 

 

$

9,389

 

Cash Used in Operating Activities

Net cash used in operating activities was $66.3 million for the three months ended March 31, 2021, as compared to $31.3 million for the same period in the prior year. The change in cash flow from operating activities is primarily due to the $44.8 million increase in our net loss to $72.6 million. The change in our net loss is primarily a result of our expanded clinical development activities and general and administrative costs incurred to support our operations. The overall increase in cash used is partially offset by year-over-year changes in non-cash items, including $9.3 million of increased expense from stock-based compensation, and changes in our asset and liability balances due to the timing of payments to or from our vendors and collaborators.

Cash Provided by Investing Activities

Cash provided by investing activities was a $62.8 million for the three months ended March 31, 2021 compared to $40.1 million for the same period in the prior year. The change in cash flow from investing activities was primarily due to net maturities of our investments in fixed-income marketable securities.

Cash Provided by Financing Activities

Cash provided by financing activities was $222.1 million for the three months ended March 31, 2021 compared to $0.6 million in the same period in the prior year. The increase in cash provided is primarily due to cash received from Gilead in February 2021 pursuant to the terms of the Amended and Restated Stock Purchase Agreement, as well as funds received during the three months ended March 31, 2021 for issuance of common stock pursuant to equity award plans.

Contractual Obligations and Commitments

There have been no material changes to our contractual obligations outside the ordinary course of business during the three months ended March 31, 2021, as compared to those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020.

22


 

Off-Balance Sheet Arrangements

Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates, exchange rates, or general market and economic conditions. Our market risks have not changed materially from those discussed in our Annual Report on Form 10-K filed with the SEC on February 25, 2021. We do not believe that inflation, interest rate changes, exchange rate fluctuations, or general market and economic conditions had a significant impact on our results of operations for any periods presented herein.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934 (Exchange Act) reports is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met.

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon, and as of the date of this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

23


 

PART II—OTHER INFORMATION

We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.

Item 1A. Risk Factors.

You should consider carefully the following risk factors, together with all the other information in this report, including our condensed consolidated financial statements and notes thereto, and in our other public filings with the SEC, including our Annual Report on Form 10-K filed with the SEC on February 25, 2021. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business.

Risk Factor Summary

 

The impact of the COVID-19 pandemic and related risks could have a material adverse impact on our research and development programs and financial condition.

 

We are an early-stage immuno-oncology company with a limited operating history. We have incurred annual net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We have never generated any revenue from product sales and may never be profitable.

 

We may need to obtain additional funding to finance our operations and complete the development and any commercialization of our investigational products. If we do not receive substantial opt-in, milestone or royalty payments from our existing collaboration agreements, or are unable to raise additional capital when needed, we may be forced to restrict our operations or delay, reduce or eliminate our product development programs.

 

We are early in our development efforts. If we are unable to develop, obtain regulatory approval for and commercialize our investigational products, or experience significant delays in doing so, our business will be materially harmed.

 

Clinical drug development is a lengthy, expensive and uncertain process. The results of preclinical studies and early clinical trials are not always predictive of future results. Any investigational product that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval.

 

Enrollment and retention of subjects in clinical trials is expensive and time consuming, can be made more difficult or rendered impossible by competing treatments, clinical trials of competing investigational products, and public health epidemics, each of which could result in significant delays and additional costs in our product development activities, or in the failure of such activities.

 

Serious adverse events, undesirable side effects or other unexpected properties of our investigational products may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our investigational products or limitations on the use of our investigational products or, if discovered following marketing approval, revocation of marketing authorizations or subsequent limitations on the use of our investigational products.

 

A key element of our strategy is the development of intra-portfolio combinations. If we are not successful in discovering, developing and commercializing investigational products that take advantage of different mechanisms of action to achieve superior outcomes relative to the use of single agents or other combination therapies, our ability to achieve our strategic objectives would be impaired.

 

Certain of our investigational products may require companion diagnostics in certain indications. Failure to successfully develop, validate and obtain regulatory clearance or approval for such tests could harm our product development strategy or prevent us from realizing the full commercial potential of our investigational products.

 

We have conducted, and continue to conduct, portions of our clinical trials outside the United States, and the FDA may not accept data from trials conducted in foreign locations.

 

We expect to depend on our collaboration with Gilead for the research, development, manufacture and commercialization of our investigational products. If this collaboration is not successful, our business could be adversely affected.

24


 

 

We rely on third parties to conduct our clinical trials, to manufacture and supply us with sufficient quantities of our investigational products, and to perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects.

 

Even if our investigational products are approved by the FDA, they may never be approved or commercialized outside the United States, which would limit our ability to realize their full market potential.

 

We are currently party to several in-license agreements under which we acquired rights to use, develop, manufacture and/or commercialize certain of our investigational products. If we breach our obligations under these agreements, we may be required to pay damages, lose our rights to these investigational products or both, which would adversely affect our business and prospects.

 

Our operating activities may be restricted by certain covenants in our license and other strategic agreements, which could limit our development and commercial opportunities.

 

If we are unable to obtain and maintain sufficient intellectual property protection for our investigational products, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.

 

We may need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.

 

We may become involved in lawsuits alleging that we have infringed the intellectual property rights of third parties or to protect or enforce our patents or other intellectual property, which litigation could be expensive, time consuming and adversely affect our ability to develop or commercialize our investigational products.

 

We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. If their investigational products are shown to be safer or more effective than ours, then our commercial opportunity will be reduced or eliminated.

 

The development and commercialization of zimberelimab may face strong competition from other anti-PD-1 antibodies that have already received marketing approval by larger companies with substantial resources and more experience developing, manufacturing and commercializing biologic compounds.

 

Our internal information technology systems, or those of our third-party CROs or other contractors or consultants, are subject to failure, security breaches, loss or leakage of data, and other disruptions, which could result in a material disruption of our investigational products’ development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to notification obligations, liability or reputational damage and otherwise adversely affecting our business.

 

Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.

 

Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict, and may have a significant adverse effect on our business and results of operations.

Risks Related to the Impact of COVID-19

The impact of the COVID-19 pandemic and related risks could have a material adverse impact on our research and development programs and financial condition.

The degree to which COVID-19 impacts our business operations, research and development programs and financial condition will depend on future developments, including the ultimate duration and/or severity of the outbreak, the impact of any resurgences and new strains that emerge, actions by government authorities to contain the spread of the virus, the timing, availability and effectiveness of any vaccines, and when and to what extent normal economic and operating conditions can resume. The American Cancer Society has reported that the pandemic has led to declines in screening, diagnosis and treatment for patients, which will adversely impact the enrollment of patients in clinical trials targeting early stage cancers and retention of patients overall in our trials. While we conduct our clinical trials in the U.S. and internationally in geographic regions that are impacted by COVID-19 to varying degrees, due to the foregoing factors, we are unable to predict the ultimate impact of this pandemic on our ongoing and planned clinical programs.

25


 

Our discovery programs are impacted by reduced operating capacity in our laboratories due to employee safety measures, such as social distancing requirements and shift work. This has slowed the pace of our discovery efforts, and our HIF-2α program is now expected to enter clinical development in the second half of 2021.

The full impact of the COVID-19 outbreak remains highly uncertain and subject to change. The safety, health and well-being of our employees remains a primary concerns, and we instituted remote work arrangements for our office-based employees and regular COVID-19 testing services for our laboratory-based employees in order to reduce the risk of exposure to COVID-19 among our employees. These actions have increased our operating costs, together with the absence of any furlough or measures to reduce personnel costs despite reduced laboratory capacity, will have an adverse impact on our financial condition.

In addition, the impact of the COVID-19 pandemic, including governmental and other actions to combat it such as the imposition of the shelter-in-place and other public health orders, may exacerbate the effects of the risks described below.

Risks Related to our Limited Operating History, Financial Position and Capital Requirements

We are an early-stage immuno-oncology company with a limited operating history. We have incurred annual net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We have never generated any revenue from product sales and may never be profitable.

We are an early-stage immuno-oncology company with a limited operating history that may make it difficult to evaluate the success of our business to date and to assess our future viability. All of our investigational products are in development, and none have been approved for commercial sale. We have never generated any revenue from product sales and have incurred net losses each year since we commenced operations. For the three months ended March 31, 2021 and the year ended December 31, 2020, our net losses were $72.6 million and $122.9 million, respectively. As of March 31, 2021, we had an accumulated deficit of $400.8 million. We expect that it will be several years, if ever, before we have an investigational product ready for commercialization. We expect to incur increasing levels of operating losses over the next several years and for the foreseeable future as we advance our investigational products. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ equity (deficit) and working capital.

To become and remain profitable, we must develop and eventually commercialize a product with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our investigational products, obtaining marketing approval for these investigational products, manufacturing, marketing and selling those products for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we succeed in commercializing one or more of our investigational products, we may never generate revenues that are significant or large enough to achieve profitability. In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis and we will continue to incur substantial research and development and other expenditures to develop and market additional investigational products. Our failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.

We may need to obtain additional funding to finance our operations and complete the development and any commercialization of our investigational products. If we do not receive substantial opt-in, milestone or royalty payments from our existing collaboration agreements, or are unable to raise additional capital when needed, we may be forced to restrict our operations or delay, reduce or eliminate our product development programs.

The development of biopharmaceutical investigational products is capital intensive. Since our inception, we have used substantial amounts of cash to fund our operations and expect our expenses to increase substantially during the next few years as our investigational products enter and advance through preclinical studies and clinical trials and we expand our clinical, regulatory, quality and manufacturing capabilities. In addition, if we obtain marketing approval for any of our investigational products, we expect to incur significant commercialization expenses related to marketing, sales, manufacturing and distribution.

As of March 31, 2021, we had $884.9 million of cash, cash equivalents and investments. While we believe that our cash position will be sufficient to fund our anticipated level of operations at least through 2023, our future capital requirements will depend on many factors, including:

 

the scope, rate of progress and costs of clinical trials for our investigational products as well as drug discovery, preclinical development activities, and laboratory testing;

 

the number and scope of clinical programs we decide to pursue;

 

the scope and costs of manufacturing development and commercial manufacturing activities;

26


 

 

 

the timing and number of programs Gilead exercises its option to obtain an exclusive license to our current and future clinical programs, subject to the rights of our existing partners, and the costs associated with our share of the global development plan for such optioned programs;

 

the timing and amount of milestone payments we receive from Taiho Pharmaceuticals Co., Ltd. (Taiho) under our option and license agreement (the Taiho Agreement) and the Gilead Collaboration Agreement, and option fees under the Gilead Collaboration Agreement;

 

the extent to which we acquire or in-license other investigational products and technologies;

 

the cost, timing and outcome of regulatory review of our investigational products;

 

the cost and timing of establishing sales and marketing capabilities, if any of our investigational products receive marketing approval;

 

the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;

 

our ability to establish and maintain collaborations on favorable terms, if at all;

 

our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our investigational products;

 

the costs associated with being a public company; and

 

the cost associated with commercializing our investigational products, if they receive marketing approval.

We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our investigational products. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts. In addition, if we are able to raise additional capital, raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or investigational products.

Risks Related to the Discovery and Development of our Investigational Products

We are early in our development efforts. If we are unable to develop, obtain regulatory approval for and commercialize our investigational products, or experience significant delays in doing so, our business will be materially harmed.

We have no products approved for sale and our most advanced investigational products only recently advanced into our first registrational trial. We may subsequently learn of certain information or data that the FDA may request, which may necessitate conducting additional preclinical studies or generating additional information at significant cost in terms of both time and expense, including under a clinical hold imposed on an investigational new drug application (IND). Even if we conducted the additional studies or generated the additional information requested, the FDA could disagree that we have satisfied their requirements, all of which will cause significant delays and expense to our programs.

To support the advancement of our clinical programs, we need to expand our clinical operations, quality and regulatory capabilities. In part because of our limited infrastructure, experience conducting clinical trials as a company and regulatory interactions, we cannot be certain that our clinical trials will be completed on time, that our planned clinical trials will be initiated on time, if at all, that our planned development programs would be acceptable to the FDA or other comparable foreign regulatory authorities, or that, if approval is obtained, such investigational products can be successfully commercialized.

Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on our ability to successfully complete the above activities and any other activities required for the successful development and eventual commercialization of one or more of our investigational products. The success of our investigational products will further depend on factors such as:

 

the success of our collaboration with Gilead;

 

successful completion of preclinical studies;

 

permission to proceed under regulatory applications for our planned clinical trials or future clinical trials;

 

successful enrollment in, and completion of, clinical trials;

 

receipt of marketing approvals from applicable regulatory authorities;

27


 

 

 

establishing manufacturing capabilities or arrangements with third party manufacturers for clinical supply and, if and when approved, for commercial supply;

 

establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in combination with others;

 

acceptance of our products, if and when approved, by patients, the medical community and third-party payors;

 

effectively competing with other therapies;

 

developing and implementing marketing and reimbursement strategies;

 

obtaining and maintaining third party coverage and adequate reimbursement;

 

obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity for our investigational products;

 

the ability to obtain clearance or approval of companion diagnostic tests, if required, on a timely basis, or at all; and

 

maintaining a continued acceptable safety profile of any product following approval.

If we do not achieve one or more of these factors in a timely manner, we could experience significant delays or an inability to successfully commercialize our investigational products, which would materially harm our business.

Clinical drug development is a lengthy, expensive and uncertain process. The results of preclinical studies and early clinical trials are not always predictive of future results. Any investigational product that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval.

The research and development of drugs and biological products is an extremely risky industry. Only a small percentage of investigational products that enter the development process ever receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of any investigational product, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our investigational products in humans. Clinical testing is expensive, can take many years to complete and its outcome is uncertain.

The results of preclinical and early clinical trials of our investigational products and other products with the same mechanism of action may not be predictive of the results of later-stage clinical trials. Clinical trial failure may result from a multitude of factors including flaws in study design, dose selection, placebo effect, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing. A number of companies in the biopharmaceutical industry have suffered setbacks in the advancement of clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. In addition, data obtained from clinical trials are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may further delay, limit or prevent marketing approval. In particular, results from uncontrolled trials, meaning trials in which there is no control group such as a placebo group, are inherently difficult to interpret. Clinical trials evaluating two or more investigational products in combination that have not yet been approved can compound these difficulties. As a key element of our strategy is the development of intra-portfolio combinations, our early clinical trials may test more than one investigational product in uncontrolled studies, such as our Phase 1/1b clinical trials for etrumadenant in which we evaluated etrumadenant in combination with zimberelimab. Furthermore, as more investigational products within a particular class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change.

We currently have five investigational products in clinical development and their risk of failure is high. We are unable to predict if these investigational products or any of our future investigational products that advance into clinical trials will prove safe or effective in humans or will obtain marketing approval. If we are unable to complete preclinical or clinical trials of current or future investigational products, due to safety concerns, or if the results of these trials are not satisfactory to convince regulatory authorities of their safety or efficacy, we will not be able to obtain marketing approval for commercialization. Even if we are able to obtain marketing approvals for any of our investigational products, those approvals may be for indications that are not as broad as desired or may contain other limitations that would adversely affect our ability to generate revenue from sales of those products. Moreover, if we are not able to differentiate our product against other approved products within the same class of drugs, or if any of the other circumstances described above occur, our business would be materially harmed and our ability to generate revenue from that class of drugs would be severely impaired.

Enrollment and retention of subjects in clinical trials is expensive and time consuming, can be made more difficult or rendered impossible by competing treatments, clinical trials of competing investigational products, and public health epidemics, each of

28


 

which could result in significant delays and additional costs in our product development activities, or in the failure of such activities.

We may encounter delays in enrolling, or be unable to enroll and maintain, a sufficient number of subjects to complete any of our clinical trials. Patient enrollment and retention in clinical trials is a significant factor in the timing of clinical trials and depends on many factors, including the size of the patient population required for analysis of the trial’s primary endpoints, the nature of the trial protocol, our ability to recruit clinical trial investigators with the appropriate competencies and experience, the existing body of safety and efficacy data with respect to the investigational product, the number and nature of competing products or investigational products and ongoing clinical trials of competing investigational products for the same indication, the proximity of subjects to clinical trial sites, the eligibility criteria for the clinical trial and our ability to obtain and maintain subject consents.

For example, enrollment of oncology subjects in our clinical trials evaluating zimberelimab may be hampered by nivolumab from Bristol-Myers Squibb and pembrolizumab from Merck, both of which are approved and on the market. Subjects may opt to be treated with an approved product rather than our anti-PD-1 antibody investigational product. In addition, Roche/Genentech have initiated Phase 3 trials with their anti-TIGIT antibody, which could reduce the number of clinical sites and subjects available for ARC-7, our Phase 2 trial evaluating combinations with domvanalimab (our anti-TIGIT antibody) and ARC-10, our Phase 3 trial evaluating zimberelimab monotherapy and zimberelimab plus domvanalimab combination therapy versus chemotherapy. Similarly, we are aware that AstraZeneca is conducting a broad clinical program with its A2aR antagonist in metastatic castration-resistant prostate cancer (mCRPC), and we may compete for clinical sites and enrollment in this patient population, which may adversely impact the rate of enrollment of the different cohorts of our Phase 2 platform trial evaluating combinations with etrumadenant in mCRPC.

Public health outbreaks, such as the COVID-19 pandemic, will also have an adverse impact our clinical trial operations. The limited resources available at investigational sites will limit their ability to initiate new studies, screen and enroll subjects, conduct and report all patient assessments and hinder their ability to collect all patients samples, which may impact our ability to assess the activity of our investigational products in a timely manner.

Furthermore, any negative results that we may report in clinical trials of our investigational products may make it difficult or impossible to recruit and retain subjects in other clinical trials of that same investigational product. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our investigational products. Failures in planned subject enrollment or retention may result in increased costs or program delays and could render further development impossible.

If we do not achieve our product development goals in the time frames we announce and expect, the commercialization of our investigational products may be delayed, our share price may decline and our commercial prospects may be adversely affected.

Drug development is inherently risky and uncertain. The actual timing of our development milestones can vary significantly compared to our estimates, in some cases for reasons beyond our control, for any number of reasons, including:

 

delays in completing IND-enabling preclinical studies or developing manufacturing processes and associated analytical methods that meet cGMP requirements;

 

the FDA placing a clinical trial on hold;

 

subjects failing to enroll or remain in our trial at the rate we expect;

 

subjects choosing an alternative treatment or other investigational products, or participating in competing clinical trials;

 

lack of adequate funding to continue our clinical trials;

 

subjects experiencing severe or unexpected drug-related adverse effects;

 

any interruptions or delays in the supply of our investigational products for our clinical trials;

 

a facility manufacturing any of our investigational products or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of good manufacturing practice (cGMP) regulations or other applicable requirements, or infections or cross-contaminations of investigational products in the manufacturing process;

 

any changes to our manufacturing process or product specifications that may be necessary or desired;

 

any failure or delay in reaching an agreement with contract research organizations (CROs) and clinical trial sites;

 

third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices (GCP) or regulatory requirements or other third parties not performing data collection or analysis in a timely or accurate manner;

29


 

 

third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other comparable foreign regulatory authorities for violations of applicable regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications;

 

one or more Institutional Review Boards (IRBs) refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing its approval of the trial;

 

changes in regulatory requirements and policies, which may require us to amend clinical trial protocols to comply with these changes and resubmit our clinical trial protocols to IRBs for reexamination; or

 

health crises and other epidemics, such as the COVID-19 pandemic, which has led to mandatory quarantines that has restricted the ability of trial sites to initiate new trials, screen patients for enrollment or treat enrolled patients, and has diverted clinical trial site resources away from the conduct of our clinical trials.

These and other factors may also lead to the suspension or termination of clinical trials, and ultimately the denial of regulatory approval of an investigational product. Any delays in achieving our development goals may allow our competitors to bring products to market before we do and adversely affect our commercial prospects and cause our stock price to decline.

Preliminary and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available.

From time to time, we publish preliminary or interim data from our clinical studies. Preliminary data remain subject to audit confirmation and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Interim data are also subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. As a result, preliminary and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data could significantly harm our business prospects.

Serious adverse events, undesirable side effects or other unexpected properties of our investigational products may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our investigational products or limitations on the use of our investigational products or, if discovered following marketing approval, revocation of marketing authorizations or subsequent limitations on the use of our investigational products.

To date, we have only tested our clinical-stage investigational products in a relatively small number of oncology subjects. As we continue our development of these investigational products and initiate clinical trials of our additional investigational products, serious adverse events, undesirable side effects or unexpected characteristics may emerge causing us to abandon these investigational products or limit their development to more narrow uses or subpopulations in which the serious adverse events, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Even if our investigational products initially show promise in these early clinical trials, the side effects of drugs are frequently only detectable after they are tested in large, Phase 3 clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. Sometimes, it can be difficult to determine if the serious adverse or unexpected side effects were caused by the investigational product or another factor, especially in oncology subjects who may suffer from other medical conditions and be taking other medications. If serious adverse or unexpected side effects are identified during development and are determined to be attributed to our investigational product, we may be required to develop a Risk Evaluation and Mitigation Strategy (REMS) to mitigate those serious safety risks, which could impose significant distribution and use restrictions on our products.

Drug-related side effects could also affect subject recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business prospects significantly.

In addition, if one or more of our investigational products receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:

 

regulatory authorities may withdraw approvals of such product;

 

regulatory authorities may require additional warnings on the label;

 

we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;

 

regulatory authorities may impose subsequent limitations on the use of the product;

 

we could be sued and held liable for harm caused to patients; and

 

our reputation may suffer.

30


 

 

Any of these events could prevent us from achieving or maintaining market acceptance of the particular investigational product, if approved, and could significantly harm our business, results of operations and prospects.

Adverse findings from clinical trials conducted by third parties investigating the same investigational products as us in different territories could adversely affect our development program.

Lack of efficacy, adverse events, undesirable side effects or other adverse findings may emerge in clinical trials conducted by third parties investigating the same investigational products as us in different territories. For example, we and Guangzhou Gloria Biosciences, Co. (Gloria Biosciences, formerly known as Harbin Gloria Pharmaceuticals Co. Ltd.) each licensed our rights to the same anti-PD-1 antibody (which we refer to as zimberelimab) from WuXi Biologics (Cayman) Inc. (WuXi Biologics). Gloria Biosciences refers to this antibody as GLS-010 and is conducting clinical trials with GLS-010 in China. We have no control over their clinical trials or development program, and adverse findings from the results or their conduct of clinical trials could adversely affect our development of zimberelimab or even the viability of zimberelimab as an investigational product. We may be required to report Gloria Biosciences’ adverse events or unexpected side effects to the FDA or comparable foreign regulatory authorities, which could, among other things, order us to cease further development of zimberelimab. We may face similar risks from any independent development conducted with our investigational products by Taiho and Gilead, following any exercise of their respective options to our programs.

A key element of our strategy is the development of intra-portfolio combinations. If we are not successful in discovering, developing and commercializing investigational products that take advantage of different mechanisms of action to achieve superior outcomes relative to the use of single agents or other combination therapies, our ability to achieve our strategic objectives would be impaired.

A key element of our strategy is to build a broad portfolio of investigational products that will allow for the development of intra-portfolio combinations. We believe that by developing or licensing these investigational products, we can control the combinations we pursue and, if and when approved, maximize the commercial potential of these combinations. However, these combinations have not been tested before and may fail to demonstrate synergistic activity against immunological targets, may fail to achieve superior outcomes relative to the use of single agents or other combination therapies, may exacerbate adverse events associated with one of the investigational products when used as monotherapy, or may fail to demonstrate sufficient safety or efficacy traits in clinical trials to enable us to complete those clinical trials or obtain marketing approval for the combination therapy. In addition, our early clinical trials may test more than one investigational product in uncontrolled studies, and it may be difficult to interpret the results of those uncontrolled trials.

We expect that our anti-PD-1 antibody, zimberelimab, will form the backbone of many of our intra-portfolio combinations. In the event that zimberelimab were to fail to demonstrate sufficient safety and efficacy, we would need to identify alternatives for accessing an anti-PD-1 antibody. In the event we are unable to do so or are unable to do so on commercially reasonable terms, our business and prospects would be materially harmed.

All of our investigational products are targeting mechanisms that other companies are pursuing as either monotherapy or combination products. As such, even if we are successful in developing combination therapies, competition from other investigational products in the same class which are either already approved or further along in development than ours may prevent us from realizing the commercial potential of our combination therapies and prevent us from achieving our strategic objectives.

Our intra-portfolio combination strategy relies on discovering, developing and commercializing highly differentiated small molecules. If we are not able to differentiate our small molecules from other products which are approved or in development, our business prospects would be materially adversely affected.

Our combination therapy strategy relies on discovering and developing differentiated small molecules with ideal pharmacologic properties for the targeted pathway to complement our antibody investigational products, which we believe will form the backbone of our combination therapies. We conduct in our laboratories those activities that we consider to be critical for creating a development candidate with optimal properties. These activities include medicinal chemistry, assay development, assessment of compound potency and selectivity, in vitro and in vivo pharmacokinetic profile evaluation, in vivo pharmacology and exploratory safety evaluation, among others. As such, we have invested heavily in these internal capabilities and over 75% of our current workforce is dedicated to research and development.

In addition, any small molecules we discover and design may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be medicines that will receive marketing approval and achieve market acceptance. If we are unable to identify suitable compounds with ideal pharmacological properties and which are differentiated from other investigational products in development for preclinical and clinical development, our business and prospects would be materially harmed.

31


 

Certain of our investigational products may require companion diagnostics in certain indications. Failure to successfully develop, validate and obtain regulatory clearance or approval for such tests could harm our product development strategy or prevent us from realizing the full commercial potential of our investigational products.

Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as a medical device and may require separate regulatory authorization prior to commercialization. Certain clinical trials that we are conducting, or may in the future conduct, include the use of a diagnostic test to help identify eligible patients. For example, we are conducting a clinical trial in collaboration with Strata Oncology (Strata) to evaluate zimberelimab in patients in a tumor-agnostic fashion utilizing Strata’s precision drug development platform and proprietary biomarkers. We also have significant efforts directed to identifying changes in various cells and proteins to understand their relationship, if any, to the clinical activity observed in our clinical trials and to assess if such cells and/or proteins could be used as predictive biomarkers to select for patients more likely to respond to our investigational products. However, we cannot be certain that we will be able to identify any such biomarkers, that such biomarkers will result in us identifying the appropriate patients for our investigational products or that we or any third party collaborators will be able to validate any diagnostic tests incorporating any predictive biomarkers we may identify.

We currently do not have any plans to develop diagnostic tests internally. We are therefore dependent on the sustained cooperation and effort of third-party collaborators in developing and, if our investigational products are approved for use only with an approved companion diagnostic test, obtaining approval and commercializing these tests. If these parties are unable to successfully develop companion diagnostics for these investigational products, or experience delays in doing so, the development of our investigational products may be adversely affected and we may not be able to obtain marketing authorization for these investigational products. Furthermore, our ability to market and sell, as well as the commercial success, of any of our investigational products that require a companion diagnostic will be tied to, and dependent upon, the receipt of required regulatory authorization and the continued ability of such third parties to make the companion diagnostic commercially available on reasonable terms in the relevant geographies. Any failure to develop, validate, obtain and maintain marketing authorization and supply for a companion diagnostic we need will harm our business prospects.

The design or our execution of our ongoing and future clinical trials may not support marketing approval.

The design or execution of a clinical trial can determine whether its results will support marketing approval, and flaws in the design or execution of a clinical trial may not become apparent until the clinical trial is well advanced. In some instances, there can be significant variability in safety or efficacy results between different trials with the same investigational product due to numerous factors, including differences in trial protocols, size and type of the patient populations, variable adherence to the dosing regimen or other protocol requirements and the rate of dropout among clinical trial participants. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and in determining when or whether marketing approval will be obtained for any of our investigational products. Our investigational products may not be approved even if they achieve their primary endpoints in any Phase 3 clinical trials or registrational trials we or our collaborators conduct. The FDA or comparable foreign regulatory authorities may disagree with our trial designs and our interpretation of data from preclinical studies or clinical trials. In addition, any of these regulatory authorities may change requirements for the approval of an investigational product even after reviewing and providing comments or advice on a protocol for a pivotal Phase 3 or registrational clinical trial that has the potential to result in FDA or other comparable foreign regulatory authorities’ approval. Any of these regulatory authorities may also approve an investigational product for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. Even if the FDA or comparable foreign regulatory authorities approve an investigational product, they may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our investigational products.

We have conducted, and continue to conduct, portions of our clinical trials outside the United States, and the FDA may not accept data from trials conducted in foreign locations.

We have conducted, and we expect to continue to conduct, portions of our clinical trials outside the United States. For example, ARC-10, our Phase 3 trial evaluating zimberelimab monotherapy and zimberelimab plus domvanalimab combination therapy versus chemotherapy, does not include any clinical sites in the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In general, the patient population for any clinical trials conducted outside the United States must be representative of the population for whom we intend to label the product in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. We cannot assure you that the FDA will accept data from trials conducted outside the United States. If the FDA does not accept the data from such clinical trials, we would likely need to conduct additional trials, which would be costly and time-consuming and delay or permanently halt our development of our investigational products.

32


 

Risks Related to Reliance on Third Parties, Manufacturing and Commercialization

We expect to depend on our collaboration with Gilead for the research, development, manufacture and commercialization of our investigational products. If this collaboration is not successful, our business could be adversely affected.

In May 2020, we entered into an option, license and collaboration agreement (the Gilead Collaboration Agreement) with Gilead Sciences, Inc. (Gilead) pursuant to which Gilead obtained an exclusive option to all of our current and future programs during the 10-year collaboration term contingent upon Gilead’s payment of up to $400.0 million. Upon Gilead’s exercise of its option to a program, the companies will co-develop and equally share global development costs, subject to certain opt-out rights for us, and expense caps on our spending and related subsequent adjustments. For each optioned program, provided we have not exercised our opt-out rights, we have an option to co-promote in the United States and share equally all associated profits and losses. Gilead has the right to exclusively commercialize any optioned programs outside of the U.S., subject to the rights of our existing partners to any territories, and will pay us tiered royalties as a percentage of revenues ranging from the high teens to the low twenties. In connection with the entering into of the Gilead Collaboration Agreement, we and Gilead also entered into a common stock purchase agreement and an investor rights agreement. Our agreements with Gilead pose a number of risks including, but not limited to, the following:

 

we may not be successful in this collaboration due to various factors, including our ability to demonstrate proof of concept in one or more clinical studies so that Gilead will exercise its option to these programs;

 

if our collaborations on research and development candidates do not result in the successful development and commercialization of products or if Gilead terminates the collaboration agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our investigational products could be delayed and we may need additional resources to develop our investigational products;

 

conflicts may arise between us and Gilead, such as conflicts regarding the combinations or indications to pursue or concerning the interpretation of clinical data, the commercial potential of any optioned investigational products, the interpretation of financial provisions or the ownership of intellectual property developed during the collaboration. Any such conflicts could slow or prevent the development or commercialization of our investigational products;

 

we will be heavily dependent on Gilead for its further development and commercialization of the investigational products from the programs that it opts into;

 

we have appointed two individuals designated by Gilead to our board of directors pursuant to the terms of the investor rights agreement, and Gilead owns approximately 19.5% of our outstanding common stock and will have the right (but not the obligation) to acquire additional shares from us up to an amount resulting in Gilead owning a total of 35% of our outstanding common stock and, as a result, may be able to exert significant influence over our company;

 

Gilead could independently develop, or develop with third parties, products that compete directly or indirectly with our investigational products if Gilead believes that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; and

 

because Gilead has an option to all of our programs, it will be difficult for us to enter into new collaborations.

We rely on third parties to conduct our clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects.

We do not have the ability to conduct all aspects of our preclinical testing or clinical trials ourselves. As a result, we are and expect to remain dependent on third parties to conduct our ongoing clinical trials and any future clinical trials of our investigational products. The timing of the initiation and completion of these trials will therefore be partially controlled by such third parties and may result in delays to our development programs. Specifically, we expect CROs, clinical investigators, and consultants to play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, we will not be able to control all aspects of their activities. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, Australian Therapeutic Goods Administration and comparable foreign regulatory authorities for all of our investigational products in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, clinical trial investigators and clinical trial sites. If we or any of our CROs or clinical trial sites fail to comply with applicable GCP requirements, the data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product

33


 

produced under cGMP regulations. Our failure to comply with these regulations may require us to stop and/or repeat clinical trials, which would delay the marketing approval process.

There is no guarantee that any such CROs, clinical trial investigators or other third parties on which we rely will devote adequate time and resources to our development activities or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, otherwise performs in a substandard manner, or terminates its engagement with us, the timelines for our development programs may be extended or delayed or our development activities may be suspended or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in such clinical trials unless we are able to transfer those subjects to another qualified clinical trial site, which may be difficult or impossible. In addition, clinical trial investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or comparable foreign regulatory authorities concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any marketing application we submit by the FDA or any comparable foreign regulatory authority. Any such delay or rejection could prevent us from commercializing our investigational products.

Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our investigational products and will not be able to, or may be delayed in our efforts to, successfully commercialize our products.

We contract with third parties for the manufacturing and supply of investigational products for use in preclinical testing and clinical trials, which supply may become limited or interrupted or may not be of satisfactory quality and quantity.

We do not have any manufacturing facilities. We produce in our laboratory relatively small quantities of compounds for evaluation in our research programs. We rely, and expect to continue to rely, on third parties for the manufacture of our investigational products for preclinical and clinical testing, as well as for commercial manufacture if any of our investigational products are approved. We currently have limited manufacturing arrangements and expect that each of our investigational products will only be covered by single source suppliers for the foreseeable future. In particular, we have an exclusive relationship with WuXi Biologics, located in China, for the manufacture of our investigational biologics, zimberelimab and domvanalimab. While we have not yet experienced any disruptions in the supply of our investigational products as a result of the COVID-19 health crisis, our reliance on limited manufacturing and supply relationships increases the risk that we will not have sufficient quantities of our investigational products or products, if approved, or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.

Furthermore, all entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers for our investigational products, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in clinical trials must be manufactured in accordance with cGMP requirements. These regulations govern manufacturing processes and procedures, including record keeping, and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants, or to inadvertent changes in the properties or stability of our investigational products that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of a New Drug Application (NDA) or Biologics License Application (BLA) on a timely basis and must adhere to the FDA’s Good Laboratory Practice regulations and cGMP regulations enforced by the FDA through its facilities inspection program. Comparable foreign regulatory authorities may require compliance with similar requirements. The facilities and quality systems of our third-party contractor manufacturers must pass a pre-approval inspection for compliance with the applicable regulations as a condition of marketing approval of our investigational products. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMP regulations.

In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on commercially reasonable terms, if at all. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. In some cases, the technical skills or technology required to manufacture our investigational products may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our investigational products. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new

34


 

manufacturer could negatively affect our ability to develop investigational products in a timely manner or within budget. Our or a third party’s failure to execute on our manufacturing requirements, to do so on commercially reasonable terms and comply with cGMP could adversely affect our business in a number of ways, including:

 

an inability to initiate or continue clinical trials of our investigational products under development;

 

delay in submitting regulatory applications, or receiving marketing approvals, for our investigational products;

 

loss of the cooperation of an existing or future collaborator, including option exercises by Taiho or Gilead under the Taiho Agreement or Gilead Collaboration Agreement, respectively;

 

subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities;

 

requirements to cease development or to recall batches of our investigational products; and

 

in the event of approval to market and commercialize our investigational products, an inability to meet commercial demands for our product or any other future investigational products.

We, or our third-party manufacturers, may be unable to successfully produce or scale-up manufacturing of our investigational products in sufficient quality and quantity, which would delay or prevent us and/or our third-party collaborators from conducting clinical trials and developing our investigational products.

We, or our third-party manufacturers, will need to manufacture and supply large quantities of our investigational products to support our clinical development plans. With respect to investigational products from optioned programs, we, or our third-party manufacturers, may need to produce additional quantities to support the scope of our joint clinical development program with Gilead, Gilead’s additional evaluations with its own proprietary products or Taiho’s independent clinical development plans. Furthermore, we are a party to various collaboration and supply arrangements, such as our clinical trial collaboration with Genentech to evaluate etrumadenant and atezolizumab utilizing the MORPHEUS platform. We, or our manufacturing partners, may be unable to successfully increase the manufacturing capacity for any of our investigational products in a timely or cost-effective manner, or at all, to support these collective needs. In addition, quality issues may arise during scale-up activities. If we or our manufacturing partners are unable to successfully produce or scale up the manufacture of our investigational products in sufficient quality and quantity, the development, testing and clinical trials of that investigational product may be delayed or become infeasible, and marketing approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business.

Changes in methods of investigational product manufacturing or formulation may result in additional costs or delay.

As investigational products progress through preclinical to late stage clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as the investigational product’s specifications, manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our investigational products to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our investigational products and jeopardize our ability to commercialize our investigational products and generate revenue.

The manufacture of biologics is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our investigational products for clinical trials or our products for patients, if approved, could be delayed or prevented.

Manufacturing biologics, especially in large quantities, is often complex and may require the use of innovative technologies to handle living cells. Each lot of an approved biologic must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing biologics requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at the facilities of our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. The use of biologically derived ingredients can also lead to allegations of harm, including infections or allergic reactions, or closure of product facilities due to possible contamination.

In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with good manufacturing

35


 

practices, lot consistency and timely availability of raw materials. Even if we obtain marketing approval for any of our investigational products, there is no assurance that our manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other comparable foreign regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential commercial launch of the product or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.

Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.

Because we rely on third parties to research and develop and to manufacture our investigational products, we must share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s independent discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.

In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with will likely expect to be granted rights to publish data arising out of such collaboration and any joint research and development programs may require us to share trade secrets under the terms of our research and development or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor’s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.

Our employees, clinical trial investigators, CROs, consultants, vendors, collaboration partners and any potential commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.

We are exposed to the risk of fraud or other misconduct by our employees, clinical trial investigators, CROs, consultants, vendors, collaboration partners and any potential commercial partners. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (i) FDA laws and regulations or those of comparable foreign regulatory authorities, including those laws that require the reporting of true, complete and accurate information, (ii) manufacturing standards, (iii) federal and state health and data privacy, security, fraud and abuse, government price reporting, transparency reporting requirements, and other healthcare laws and regulations in the United States and abroad, or (iv) laws that require the true, complete and accurate reporting of financial information or data. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, as well as a disclosure program and other applicable policies and procedures, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.

Even if we receive marketing approval, we may not be successful in commercializing our investigational products.

We have no sales, marketing or distribution capabilities or experience. If any of our investigational products ultimately obtains regulatory approval, we, whether alone or in collaboration with Gilead for programs that we commercialize together, may not be able to effectively or successfully market the product due to a number of factors, including:

 

the imposition by regulatory authorities of significant restrictions on a product’s indicated uses, marketing or distribution;

 

the imposition by regulatory authorities of costly and time-consuming post-approval studies, post-market surveillance or additional clinical trials;

 

our failure to establish sales and marketing capabilities;

36


 

 

 

the failure of our products to achieve the degree of market acceptance by physicians, patients, hospitals, cancer treatment centers, healthcare payors and others in the medical community necessary for commercial success;

 

unfavorable pricing regulations or third-party coverage and reimbursement policies;

 

inaccuracies in our estimates of the addressable patient population resulting in a smaller market opportunity than we believed.

If any of our investigational products for which we have or retain sales and marketing responsibilities are approved, we must either develop a sales and marketing organization, which would be expensive and time consuming, or outsource these functions to other third parties. We may be unable to recruit and retain adequate numbers of effective sales and marketing personnel, and if we enter into arrangements with third parties to perform sales, marketing and distribution services our product revenue or the profitability of these product revenue to us are likely to be lower than if we were to market and sell any medicines that we develop ourselves.

Our or our collaborators’ inability to successfully market and sell any of our investigational products, if approved, could have a material adverse effect on our business and our overall financial condition.

Even if we receive marketing approval for one or more of our investigational products, our commercial success is dependent on obtaining coverage and reimbursement approval for a product from a government or other third-party payor, which coverage may be delayed or may not be sufficient to cover our costs.

Our commercial success is dependent on obtaining coverage and reimbursement approval for a product from a government or other third-party payor, which is a time-consuming and costly process that could require us and any collaborators to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. There may be significant delays in obtaining such coverage and reimbursement for newly approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a product will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Obtaining reimbursement for our products may be particularly difficult because of the higher prices often associated with branded therapeutics and therapeutics administered under the supervision of a physician. Additionally, our collaborators, will be required to obtain coverage and reimbursement for any related companion diagnostics tests they develop separate and apart from the coverage and reimbursement we seek for our product candidates, once approved.

Reimbursement may also impact the demand for, and the price of, any product for which we obtain marketing approval. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with those medications. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement is critical to new product acceptance and we expect to experience pricing pressures in connection with the sale of any of our investigational products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes.

Our ability to obtain coverage and reimbursement approval for any of our investigational products, if approved, could have a material adverse effect on the demand for that investigational product, and on our business and our overall financial condition.

Even if our investigational products are approved by the FDA, they may never be approved or commercialized outside the United States, which would limit our ability to realize their full market potential.

In order to market any products outside the United States, we or our collaborators must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us or our collaborators and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our or our collaborators’ failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any investigational products approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we or our collaborators fail to comply with regulatory requirements in international markets or fail to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed.

37


 

Any investigational products for which we intend to seek approval as biologic products may face competition sooner than anticipated.

The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until twelve years from the date on which the reference product was first licensed. During this twelve-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The law is complex and is still being interpreted and implemented by the FDA. As a result, any such processes could have a material adverse effect on the future commercial prospects for our biological products.

Zimberelimab and domvanalimab are biological products and we may develop additional biological products in the future. We believe that any of our current and future investigational products approved as a biological product under a BLA should qualify for the twelve-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our investigational products to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, could be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors that are still developing.

Risks Related to our In-Licenses and Other Strategic Agreements

We are currently party to several in-license agreements under which we acquired rights to use, develop, manufacture and/or commercialize certain of our investigational products. If we breach our obligations under these agreements, we may be required to pay damages, lose our rights to these investigational products or both, which would adversely affect our business and prospects.

We rely, in part, on license and other strategic agreements, which subject us to various obligations, including diligence obligations with respect to development and commercialization activities, reporting and notification obligations, payment obligations for achievement of certain milestones and royalties on product sales, negative covenants and other material obligations. We may need to devote substantial time and attention to ensuring that we successfully integrate these transactions into our existing operations and are compliant with our obligations under these agreements, which may divert management’s time and attention away from our research and development programs or other day-to-day activities. If we fail to comply with the obligations under our license agreements or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and our licensors may have the right to terminate the license. If our license agreements are terminated, we may not be able to develop, manufacture, market or sell the products covered by our agreements and those being tested or approved in combination with such products. Such an occurrence could materially adversely affect the value of the investigational product being developed under any such agreement and any other investigational products being developed or tested in combination. For example, we intend to test many of our small-molecule investigational products with zimberelimab, which we in-licensed from WuXi Biologics. In the event we breach our license agreement with WuXi Biologics, and WuXi Biologics terminates our license agreement, we would be unable to test those combinations, or we would have to negotiate a new or reinstated agreement, which may not be available to us on equally favorable terms, or at all.

In addition, the agreements under which we license intellectual property or technology to or from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected investigational products.

If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant research program or investigational product and our business, financial condition, results of operations and prospects could suffer.

We may not realize the benefits of any acquisitions, in-license or other collaborations or strategic alliances that we enter into.

We have entered into in-license agreements with multiple licensors and option agreements to enable the development and commercialization of our investigational products worldwide. In the future, we may seek to enter into acquisitions or additional licensing arrangements with third parties to expand our pipeline or that we believe will complement or augment our development and commercialization efforts with respect to our investigational products and any future investigational products that we may develop. These transactions can entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our

38


 

business and diversion of our management’s time and attention in order to manage a collaboration or develop acquired products, investigational products or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. As a result, if we enter into in-license, acquisition or collaboration agreements, or strategic partnerships, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business.

We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction or such other benefits that led us to enter into the arrangement. For example, under the Gilead Collaboration Agreement, for each program Gilead exercises its option to, it will pay an option fee that ranges from $200 million to $275 million for our clinical programs in existence when we entered into the Gilead Collaboration Agreement, and $150 million per program for all other programs that enter clinical development. Furthermore, we and Gilead will equally share global development costs, as well as profits and losses for the United States, subject to certain opt-out rights for us, and expense caps on our spending and related subsequent adjustments. If Gilead does not exercise its option to develop a program, our capital requirements relating to that development program will significantly increase and we may need to seek a new partner in order to develop and commercialize our investigational products from that program. Failure to realize the benefits of any collaborations or strategic alliances may further cause us to curtail the development of an investigational product, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any planned sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we will need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our investigational products or bring them to market and generate product sales revenue, which would harm our business prospects, financial condition and results of operations.

We may wish to acquire rights to future assets through in-licensing or may attempt to form collaborations in the future with respect to our investigational products, but may not be able to do so, which may cause us to alter or delay our development and commercialization plans.

The development and potential commercialization of our investigational products may require substantial additional capital to fund expenses. Pursuant to the Gilead Collaboration Agreement, Gilead has an exclusive option to acquire an exclusive license to all of our current and future clinical programs during the 10-year collaboration term. Given the breadth of the collaboration, our ability to form new collaborations in the future will be limited. If Gilead declines to exercise its option to a program, we may need to enter into new collaborations for such programs with companies that have more resources and experience than us. We may not be successful in these efforts because third parties may not view our investigational products as having the requisite potential to demonstrate safety and efficacy. If and when we collaborate with a third party for development and commercialization of an investigational product, we can expect to relinquish some or all of the control over the future success of that investigational product to the third party. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. Those factors may include the following:

 

the design or results of clinical trials;

 

the likelihood of approval by the FDA or comparable foreign regulatory authorities;

 

the potential market for the investigational product;

 

the costs and complexities of manufacturing and delivering such investigational product to patients;

 

the potential of competing products;

 

the existence of uncertainty with respect to our ownership of technology or other rights, which can exist if there is a challenge to such ownership without regard to the merits of the challenge; and

 

industry and market conditions generally.

The collaborator may also consider alternative investigational products or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our investigational product. We may also be restricted under any license agreements from entering into agreements on certain terms or at all with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of

39


 

recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators and changes to the strategies of the combined company. As a result, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such investigational product, reduce or delay one or more of our other development programs, delay the potential commercialization or reduce the scope of any planned sales or marketing activities for such investigational product, or increase our expenditures and undertake development, manufacturing or commercialization activities at our own expense. If we elect to increase our expenditures to fund development, manufacturing or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our investigational products or bring them to market and generate product revenue.

Our operating activities may be restricted by certain covenants in our license and other strategic agreements, which could limit our development and commercial opportunities.

In connection with certain of our acquisitions, in-license or other collaborations or strategic alliances, we may agree to and be bound by negative covenants which may limit our development and commercial opportunities. For example, pursuant to our in-license of anti-PD-1 antibodies from WuXi Biologics, we made certain covenants to not commercialize any anti-PD-1 antibody licensed or obtained by us after the date of the license agreement with WuXi Biologics other than anti-PD-1 antibodies licensed from WuXi Biologics, subject to certain exceptions as set forth in our license agreement with WuXi Biologics. Furthermore, we agreed in our license agreement that WuXi Biologics would be our exclusive manufacturer of anti-PD-1 antibodies licensed thereunder until a certain number of years has elapsed following commercialization of such an anti-PD-1 antibody and that we would utilize WuXi Biologics as our exclusive provider of CMC development services for our biologic investigational products for five years from the date of our license agreement, subject to certain exceptions in each case. These exclusivity provisions may inhibit our development efforts, prevent us from forming strategic collaborations to develop and potentially commercialize any other anti-PD-1 antibody investigational products and may materially harm our business, financial condition, results of operations and prospects.

Risks Related to Intellectual Property

If we are unable to obtain and maintain sufficient intellectual property protection for our investigational products, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.

Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our investigational products and research programs. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel discoveries and technologies that are important to our business, however, we cannot predict:

 

if and when patents may issue based on our patent applications;

 

the scope of protection of any patent issuing based on our patent applications;

 

whether the claims of any patent issuing based on our patent applications will protect our investigational products and their intended uses or prevent others from commercializing competitive technologies or products;

 

whether or not third parties will find ways to invalidate or circumvent our patent rights;

 

whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; and/or

 

whether we will need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose.

Obtaining and enforcing patents is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications, or maintain and/or enforce patents that may issue based on our patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development results before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection.

We also cannot be certain that the claims in our pending patent applications directed to our investigational products and/or technologies will be considered patentable by the U.S. Patent and Trademark Office (USPTO) or by patent offices in foreign countries. One aspect of the determination of patentability of our inventions depends on the scope and content of the “prior art,” information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention.

40


 

There may be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim. Even if the patents do issue based on our patent applications, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, patents in our portfolio may not adequately exclude third parties from practicing relevant technology or prevent others from designing around our claims. If the breadth or strength of our intellectual property position with respect to our investigational products is threatened, it could dissuade companies from collaborating with us to develop and threaten our ability to commercialize our investigational products. In the event of litigation or administrative proceedings, we cannot be certain that the claims in any of our issued patents will be considered valid by courts in the United States or foreign countries.

We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third party patent which might adversely affect our ability to develop and market our products.

We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our investigational products in any jurisdiction.

The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent’s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third party patent or may incorrectly predict whether a third party’s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our investigational products. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.

In the future, we may need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.

From time to time we may be required to license technology from additional third parties to further develop or commercialize our investigational products. Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use or sell our investigational products, such licenses may not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license required to develop or commercialize any of our investigational products could cause us to abandon any related efforts, which could seriously harm our business and operations.

We may become involved in lawsuits alleging that we have infringed the intellectual property rights of third parties or to protect or enforce our patents or other intellectual property, which litigation could be expensive, time consuming and adversely affect our ability to develop or commercialize our investigational products.

The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our products candidates. Third parties may assert infringement claims against us based on existing or future intellectual property rights. For example, we are aware of certain patents owned or exclusively licensed by Bristol-Myers Squibb (BMS) having claims directed broadly to treating cancer with anti-PD-1 antibodies (the BMS Patents), which expire in 2023 and 2024. The BMS Patents have been and may in the future be the subject of litigation. If the validity of the BMS Patents is upheld following all such challenges, and if we receive regulatory approval for zimberelimab prior to expiration of the BMS Patents, then we may need to delay our commercialization of zimberelimab or we may need to obtain a license from BMS, which license may not be available on commercially reasonable terms, or at all. If we were sued for patent infringement, we would need to demonstrate that our investigational products, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. If we are found to infringe a third party’s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing investigational product or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing investigational product. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys’ fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our investigational products or force us to cease some of our business operations, which could materially harm our business.

41


 

In addition, we may find that competitors are infringing our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent’s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, we cannot assure you that we will have sufficient financial or other resources to defend or pursue such litigation, which typically last for years before they are concluded. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operations. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.

Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.

Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.

We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may become subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor.

While we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our investigational products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition.

We may not be able to protect our intellectual property rights throughout the world.

Patents are of national or regional effect, and filing, prosecuting and defending patents on all of our investigational products throughout the world would be prohibitively expensive. As such, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Further, the legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals or biologics,

42


 

which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. In addition, certain developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our investigational products.

As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. However, the patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation, resulting in court decisions, including Supreme Court decisions, that have increased uncertainties as to the ability to obtain and enforce patent rights in the future. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries could increase the uncertainties and costs. For example, in September 2011 the Leahy-Smith America Invents Act (the America Invents Act) was signed into law and included a number of significant changes to U.S. patent law as then existed. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. After March 2013, under the America Invents Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.

We may rely on trade secret and proprietary know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

In addition to seeking patents for some of our technology and investigational products, we may also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Elements of our investigational product, including processes for their preparation and manufacture, may involve proprietary know-how, information, or technology that is not covered by patents, and thus for these aspects we may consider trade secrets and know-how to be our primary intellectual property. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market.

Trade secrets and know-how can be difficult to protect. We require our employees to enter into written employment agreements containing provisions of confidentiality and obligations to assign to us any inventions generated in the course of their employment. We and any third parties with whom we share facilities enter into written agreements that include confidentiality and intellectual property obligations to protect each party’s property, potential trade secrets, proprietary know-how, and information. We further seek to protect our potential trade secrets, proprietary know-how, and information in part, by entering into non-disclosure and confidentiality agreements with parties who are given access to them, such as our corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be harmed.

43


 

We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.

We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our investigational products or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

Patent terms may be inadequate to protect our competitive position on our investigational products for an adequate amount of time.

Patent rights are of limited duration. Given the amount of time required for the development, testing and regulatory review of new investigational products, patents protecting such candidates might expire before or shortly after such investigational products are commercialized. Even if patents covering our investigational products are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic products. A patent term extension based on regulatory delay may be available in the United States. However, only a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the patent term extension does not extend to the full scope of the claim, but instead only to the scope of the product as approved. Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially.

Risks Related to our Business Operations

We expect to expand our research and development capabilities and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.

In order to maximize the potential of our Gilead Collaboration Agreement, we expect to significantly grow our discovery and clinical development capabilities. To support this growth, we will need to increase the number of employees in clinical operations, biostatistics and data management, quality, regulatory affairs and, if any of our investigational products receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must:

 

identify, recruit, integrate, maintain and motivate additional qualified personnel;

 

manage our development efforts effectively, including the initiation and conduct of clinical trials for our investigational products, both as monotherapy and in combination with other intra-portfolio investigational products; and

 

improve our operational, financial and management controls, reporting systems and procedures.

Our future financial performance and our ability to develop, manufacture and commercialize our investigational products will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert financial and other resources, and a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time, to managing these growth activities.

If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our investigational products and, accordingly, may not achieve our research, development and commercialization goals.

Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel.

Our industry has experienced a high rate of turnover in recent years. Our ability to compete in the highly competitive biopharmaceuticals industry depends upon our ability to attract, retain and motivate highly skilled and experienced personnel with scientific, medical, regulatory, manufacturing and management skills and experience. We conduct our operations in the San Francisco Bay Area, a region that is home to many other biopharmaceutical companies as well as many academic and research institutions,

44


 

resulting in fierce competition for qualified personnel. We may not be able to attract or retain qualified personnel in the future due to the intense competition for a limited number of qualified personnel among biopharmaceutical companies. Many of the other biopharmaceutical companies against which we compete have greater financial and other resources, different risk profiles and a longer history in the industry than we do. Our competitors may provide higher compensation, more diverse opportunities and/or better opportunities for career advancement. Any or all of these competing factors may limit our ability to continue to attract and retain high quality personnel, which could negatively affect our ability to successfully develop and commercialize our investigational products and to grow our business and operations as currently contemplated.

We are highly dependent on the services of our founders, Terry Rosen, Ph.D., who serves as our Chief Executive Officer, and Juan Jaen, Ph.D., who serves as our President.

We are highly dependent on the services of our founders, Terry Rosen, Ph.D., who serves as our Chief Executive Officer, and Juan Jaen, Ph.D., who serves as our President. Although we have entered into employment agreements with them, they are not for a specific term and each of them may terminate their employment with us at any time, though we are not aware of any present intention of either of these individuals to leave us.

Drs. Rosen and Jaen have significant experience identifying and developing biopharmaceuticals. We believe that their drug discovery and development experience, and overall biopharmaceutical company management experience, would be difficult to replace. However, the historical results, past performance and/or acquisitions of companies with which they were affiliated do not necessarily predict or guarantee similar results for our company. Further, Drs. Rosen and Jaen have certain other business and personal commitments outside of serving as the Chief Executive Officer and President of Arcus, including serving on the boards of other companies and foundations, which may result in diversion of their focus and attention on our company.

We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. If their investigational products are shown to be safer or more effective than ours, then our commercial opportunity will be reduced or eliminated.

We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer, which is highly competitive with rapidly changing standards of care. As such, our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop or that would render any products that we may develop obsolete or non-competitive. Our competitors also may obtain marketing approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.

Some of the other products in the same class as our investigational products have already been approved or are further along in development. With respect to our dual adenosine receptor antagonist, etrumadenant, we are aware that Incyte has initiated clinical development of a dual adenosine receptor antagonist and we are aware of clinical-stage selective adenosine A2aR antagonists being developed by other companies, including AstraZeneca, Corvus, CStone, iTeos Therapeutics and Novartis, and a clinical-stage selective adenosine A2bR antagonist being developed by Palobiofarma. For our small-molecule CD73 inhibitor, AB680, we are aware of several pharmaceutical companies developing antibodies against this target, including Akeso, AstraZeneca, Bristol-Myers Squibb, Corvus, Incyte, Novartis, Symphogen and Tracon/I-Mab, all of whom have advanced their CD73 antibodies into clinical development. Other pharmaceutical companies, such as Boehringer Ingelheim, Calithera, Merck and ORIC, have small-molecule programs against this target. Regarding our anti-PD-1 antibody, zimberelimab, multiple large pharmaceutical companies have already received regulatory approvals for their anti-PD-1/PD-L1 antibodies, including AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer in partnership with Merck KGaA, Regeneron in partnership with Sanofi Genzyme and Roche/Genentech, and there are also many other anti-PD-1 and anti-PD-L1 antibodies in clinical development. With respect to our anti-TIGIT antibody, domvanalimab, we are aware of several pharmaceutical companies developing antibodies against this target, including Agenus, Beigene, Bristol-Myers Squibb, Compugen, Roche/Genentech, Innovent, iTeos Therapeutics, Merck KGaA, Mereo and Seattle Genetics. To our knowledge, there are no approved anti-TIGIT antibodies and the most advanced agent is in Phase 3 development.

As more investigational products within a particular class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. Consequently, the results of our clinical trials for investigational products in those class will likely need to show a risk benefit profile that is competitive with or more favorable than those products and investigational products in order to obtain marketing approval or, if approved, a product label that is favorable for commercialization. If the risk benefit profile is not competitive with those products or investigational products, or if the approval of other agents for an indication or patient population significantly alters the standard of care with which we tested our investigational products, we may have developed a product that is not commercially viable, that we are not able to sell profitably or that is unable to achieve favorable pricing or reimbursement. In such circumstances, our future product revenue and financial condition would be materially and adversely affected.

45


 

Many of our competitors, such as large pharmaceutical and biotechnology companies like AstraZeneca, Bristol-Myers Squibb, Merck, Novartis and Roche/Genentech, have longer operating histories and significantly greater financial resources and expertise in research and development, manufacturing, preclinical studies, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and subject enrollment for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.

The key competitive factors affecting the success of all of our programs are likely to be their efficacy, safety, convenience, and availability of reimbursement. If we are not successful in developing, commercializing and achieving higher levels of reimbursement than our competitors, we will not be able to compete against them and our business would be materially harmed.

The development and commercialization of zimberelimab may face strong competition from other anti-PD-1 antibodies that have already received marketing approval by larger companies with substantial resources and more experience developing, manufacturing and commercializing biologic compounds.

As discussed above, some companies, such as AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer in partnership with Merck KGaA, Regeneron in partnership with Sanofi Genzyme and Roche/Genentech, have anti-PD-1/PD-L1 antibodies that are approved and on the market, and continue to develop and seek regulatory approval for their respective anti-PD-1/PD-L1 antibodies for additional oncology indications. For example, in June 2020, the U.S. FDA granted accelerated approval to Keytruda® (pembrolizumab) for the treatment of patients with solid tumors that have high tumor mutational burden. Many other companies are developing anti-PD-1/PD-L1 antibodies for various oncology indications that are further along in development than zimberelimab. This competitive environment could limit our development opportunities for zimberelimab or compromise our ability to successfully enroll our ongoing and future clinical trials with zimberelimab by limiting the availability of clinical trial investigators, sites and/or subjects which could slow, delay or limit the progress of zimberelimab’s development. As a result of these or other problems and risks, we may never receive marketing approval for zimberelimab, may not realize the full commercial potential of zimberelimab as monotherapy or in combination with our other investigational products, may never recoup our financial investment or may never generate significant value or revenue from this asset.

Our internal information technology systems, or those of our third-party CROs or other contractors or consultants, are subject to failure, security breaches, loss or leakage of data, and other disruptions, which could result in a material disruption of our investigational products’ development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to notification obligations, liability or reputational damage and otherwise adversely affecting our business.

We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information, including but not limited to intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the confidentiality, integrity and availability of such confidential information. We also have outsourced elements of our operations to third parties, and as a result we manage a number of third party contractors who have access to our confidential information.

Despite the implementation of security measures, given their size and complexity and the increasing amounts of confidential information that they maintain, our internal information technology systems and those of our third-party CROs and other contractors and consultants are vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), which may compromise our system infrastructure or lead to data leakage. We have experienced at least one intrusion into our computer systems, and, although our investigation indicates that it did not have a material adverse effect on our operations, there can be no assurance of a similar result in the future. The COVID-19 pandemic and our reliance on internet technology and the number of our employees who are working remotely may increase the opportunities for cybercriminals to exploit vulnerabilities. We cannot assure you that our data protection efforts and our investment in information technology will prevent other breakdowns, data leakages, breaches in our systems or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition. Furthermore, as the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication and intensity, and becoming increasingly difficult to detect. There can be no assurance that we and our third-party CROs and other contractors and consultants will be successful in detecting, preventing or fully recovering systems or data from all breakdowns, service interruptions, attacks or breaches of systems that could adversely affect our business and operations and/or result in the loss or disclosure of critical or sensitive data, which could result in financial, legal, business or reputational harm to us.

46


 

To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and reputational damage and the further development and commercialization of our drug candidates could be delayed. In addition, the loss of clinical trial data for our investigational products could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore, significant disruptions of our internal information technology systems or security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information, and personal information), which could result in financial, legal, business, and reputational harm to us. In particular, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.

Unfavorable global economic and trade conditions could adversely affect our business, financial condition or results of operations.

Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets and global trade. The current global economic conditions are highly volatile due to the COVID-19 pandemic and government restrictions on movement, which may lead to disruptions in the capital and credit markets and reduce our ability to raise additional capital when needed on acceptable terms, if at all. Furthermore, we conduct, and we expect to continue to conduct, portions of our clinical trials outside the United States, and unfavorable economic conditions resulting in the weakening of the U.S. dollar would make those clinical trials more costly to operate. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption.

Adverse trade conditions may further impact our operating results or financial condition by increasing the cost of our operations. For example, we have an exclusive relationship with WuXi Biologics, located in China, for the manufacture of zimberelimab and domvanalimab and for biologics CMC development and if tariffs are imposed on the investigational products they manufacture for us, such tariffs would have an adverse impact on our operating results and financial condition. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.

Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.

Our future profitability may depend, in part, on our ability to commercialize our investigational products in foreign markets for which we may rely on collaboration with third parties. We are not permitted to market or promote any of our investigational products before we receive marketing approval from the applicable regulatory authority in that foreign market, and we may never receive such marketing approval for any of our investigational products. To obtain marketing approval in many foreign countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our investigational products, and we cannot predict success in these jurisdictions. If we obtain approval of our investigational products and ultimately commercialize our investigational products in foreign markets, we would be subject to additional risks and uncertainties, including:

 

our customers’ ability to obtain reimbursement for our investigational products in foreign markets;

 

our inability to directly control commercial activities because we are relying on third parties;

 

the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements;

 

different medical practices and customs in foreign countries affecting acceptance in the marketplace;

 

import or export licensing requirements;

 

longer accounts receivable collection times;

 

longer lead times for shipping;

 

language barriers for technical training;

 

reduced protection of intellectual property rights in some foreign countries;

 

the existence of additional potentially relevant third-party intellectual property rights;

 

foreign currency exchange rate fluctuations; and

 

the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute.

47


 

 

Foreign sales of our investigational products could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs.

We or the third parties upon whom we depend may be adversely affected by earthquakes, fires or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.

Our headquarters and main research facility are located in the San Francisco Bay Area, which in the past has experienced severe earthquakes and fires. If these earthquakes, fires, other natural disasters, terrorism and similar unforeseen events beyond our control prevented us from using all or a significant portion of our headquarters or research facility, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. We do not have a disaster recovery or business continuity plan in place and may incur substantial expenses as a result of the absence or limited nature of our internal or third party service provider disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our ability to conduct our clinical trials, our development plans and business.

Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

We have incurred substantial losses during our history and our ability to generate profits in the future is uncertain. Unused net operating loss carryforwards (NOLs) for the tax year ended December 31, 2017 and prior tax years will carry forward to offset future taxable income, if any, until such unused NOLs expire. Unused NOLs generated after December 31, 2017, under current tax law will not expire and may be carried forward indefinitely, but the deductibility of such NOLs in tax years beginning after December 31, 2020 will be limited to 80% of current year taxable income in any given year. In addition, both our current and our future unused losses may be subject to limitation under Sections 382 and 383 of the Internal Revenue Code (IRC) of 1986, as amended, if we undergo an “ownership change,” generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period. We performed an analysis under IRC Section 382 and 383 through October 31, 2020 with respect to our net operating loss and credit carryforwards. We concluded that an ownership change, as defined under IRC Section 382, occurred in previous years. While we do not expect such ownership changes to result in the expiration of our net operating loss and credit carryforwards prior to utilization, we are subject to an annual limitation on the use of tax attributes. The limitation on our ability to use our net operating loss and credit carryforwards could reduce our ability to use a portion of our tax attributes to offset future taxable income, which could result in us being required to make material cash tax payments.

In addition, our sale of 5,650,000 shares of our common stock to Gilead in February 2021, as well as future equity issuances, may result in additional ownership changes. As a result, our ability to use all of our pre-change NOLs and other pre-change tax attributes (such as research tax credits) to offset our post-change income or taxes may be subject to limitations that could result in increased future tax liability to us. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, including a recent California franchise tax law change limiting the usability of California state NOLs to offset taxable income in taxable years beginning on or after January 1, 2020 and before January 1, 2023, which could accelerate or permanently increase state taxes owed. Therefore, even if we attain profitability, we may be unable to use all or a material portion of our NOLs and other tax attributes, which could adversely affect our future cash flows.

Risks Related to Our Industry

Product liability lawsuits against us could cause us to incur substantial liabilities and could limit our commercialization of any investigational products that we may develop.

We face an inherent risk of product liability exposure related to the testing of our investigational products in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our investigational products or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result in:

 

delay or termination of clinical trials;

 

decreased demand for any investigational products or products that we may develop;

 

injury to our reputation and significant negative media attention;

 

withdrawal of clinical trial subjects;

 

initiation of investigations by regulators;

 

significant costs to defend the related litigation and diversion of management’s time and our resources;

48


 

 

 

substantial monetary awards to study subjects or patients;

 

product recalls, withdrawals or labeling, marketing or promotional restrictions;

 

loss of revenue; and

 

the inability to commercialize any products that we may develop.

Although we maintain product liability insurance coverage, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as our investigational products advance through clinical trials and if we successfully commercialize any products. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.

Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.

We and any potential collaborators may be subject to federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security). In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the FTC Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH). Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA.

The legislative and regulatory landscape for privacy and data security continues to evolve, and we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data security in the United States, the EU and other jurisdictions. This increased focus on privacy and data security issues may negatively affect our operating results and our business. For example, the California Consumer Privacy Act of 2018 (CCPA), which took effect on January 1, 2020, gives California residents expanded rights to access and require deletion of their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. In addition, the CCPA authorizes private lawsuits to recover statutory damages for certain data breaches. While it exempts some data regulated by HIPAA and certain clinical trials data, the CCPA may increase our compliance costs and potential liability with respect to other personal information we collect about California residents. Some observers note that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business.

International data protection laws also apply to health-related and other personal data obtained outside the United States. In the European Union, Regulation (EU) 2016/679 (General Data Protection Regulation) took effect in May 2018 and imposes, in some cases, stricter obligations than data protection laws in the United States on the use of health-related and other personal data. These requirements include the obligation to appoint data protection officers in certain circumstances, rights for individuals to be “forgotten” and to data portability, and the obligation to make public notification of significant data breaches. Under the General Data Protection Regulation, data protection authorities can also impose administrative fines of up to 4% of our total worldwide turnover or up to €20 million (whichever is higher). In addition, the General Data Protection Regulation only permits the transfer of personal data outside the European Economic Area (EEA) to countries that offer a level of data protection deemed adequate by the European Commission, unless an approved data transfer mechanism is in place. One such mechanism was invalidated by the European Court of Justice, adding to the complexity of transferring personal data outside the EEA. The General Data Protection Regulation increases our responsibility and liability in relation to personal data that we process, and we must put in place additional mechanisms to ensure compliance with the new EU data protection rules.

Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals’ privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.

Our business operations expose us to broadly applicable fraud and abuse, transparency, government price reporting, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.

49


 

Our operations are subject, either directly or indirectly through our customers and third party payors, to various U.S. federal and state health care laws, including fraud and abuse, transparency and other healthcare laws and regulations, and similar laws in other jurisdictions in which we conduct our business. These laws may impact, among other things, our research and proposed sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers, physicians and other parties through which we market, sell and distribute our products for which we obtain marketing approval. The laws that may affect our ability to operate include, but are not limited to the federal Anti-Kickback Statute; federal civil and criminal false claims laws, such as the False Claims Act (FCA); HIPAA; federal and state consumer protection and unfair competition laws; the federal transparency requirements under the Physician Payments Sunshine Act; state and foreign law equivalents of each of these federal laws; and state and foreign laws that require pharmaceutical companies to implement compliance programs. Many of these laws are discussed in detail in “Item 1. Business” of our Annual Report on Form 10-K.

The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have continued their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be time-and resource-consuming and can divert management’s attention from the business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business.

Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. We have entered into consulting and advisory board arrangements with physicians and other healthcare providers, including some who could influence the use of our investigational products, if approved. Because of the complex and far-reaching nature of these laws, regulatory agencies may view these transactions as prohibited arrangements that must be restructured, or discontinued, or for which we could be subject to other significant civil, criminal and administrative penalties such as fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could substantially disrupt our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.

Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict, and may have a significant adverse effect on our business and results of operations.

In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of investigational products, restrict or regulate post-approval activities, and affect the ability to profitably sell investigational products for which marketing approval is obtained. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For additional detail regarding health care reform activities that may impact our business, see “Item 1. Business—Government Regulation—Healthcare Reform” in our Annual Report on Form 10-K.

We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.

U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations (collectively, Trade Laws) prohibit, among other things, companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase over time. We expect to rely on third parties for research, preclinical studies, and clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.

We, and the third parties with whom we share our facilities, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Each of our operations involve the use of hazardous and flammable materials, including chemicals and

50


 

biological and radioactive materials. Each of our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. We could be held liable for any resulting damages in the event of contamination or injury resulting from the use of hazardous materials by us or the third parties with whom we share our facilities, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.

Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research and development. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

Risks Related to Owning our Common Stock

The stock price of our common stock has been and may continue to be volatile or may decline regardless of our operating performance.

The market price of our common stock has fluctuated and may fluctuate significantly in response to numerous factors, many of which are beyond our control, including:

 

overall performance of the equity markets;

 

our operating performance and the performance of other similar companies;

 

results from our ongoing clinical trials and future clinical trials with our current and future investigational products or of our competitors;

 

changes in our projected operating results that we provide to the public, our failure to meet these projections or changes in recommendations by securities analysts that elect to follow our common stock;

 

regulatory, trade or legal developments in the United States and other countries, including changes in tariffs or other trade restrictions and the changes in the structure of healthcare payment systems;

 

the level of expenses related to future investigational products or clinical development programs;

 

our failure to achieve product development goals in the timeframe we announce;

 

announcements of acquisitions, strategic alliances or significant agreements by us or by our competitors;

 

recruitment or departure of key personnel;

 

the economy as a whole and market conditions in our industry;

 

trading activity by a limited number of stockholders who together beneficially own a majority of our outstanding common stock;

 

the size of our market float; and

 

any other factors discussed in this report.

In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many immuno-oncology companies. Stock prices of many immuno-oncology companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In the past, stockholders have filed securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and adversely affect our business.

The amount of our future losses is uncertain and our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.

Our quarterly and annual operating results may fluctuate significantly in the future due to a variety of factors, many of which are outside of our control and may be difficult to predict, including the following:

 

the timing and success or failure of clinical trials for our investigational products or competing investigational products, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;

51


 

 

our progress towards the achievement of any product development goals or milestones we announce, including any delays or failures which lead to the suspension or termination of any clinical trial or development program;

 

the timing and cost of, and level of investment in, research and development activities relating to our investigational products, which may change from time to time;

 

option fees received by us in connection with option exercises by Taiho and/or Gilead pursuant to their respective option agreements;

 

amounts payable by us in connection with the achievement of development, regulatory and commercial milestones under our in-license and other strategic agreements;

 

our ability to attract, hire and retain qualified personnel;

 

expenditures that we will or may incur to develop additional investigational products;

 

our ability to obtain marketing approval for our investigational products, and the timing and scope of any such approvals we may receive;

 

the changing and volatile U.S. and global economic environments; and

 

future accounting pronouncements or changes in our accounting policies.

The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.

The concentration of our stock ownership will likely limit our stockholders’ ability to influence corporate matters, including the ability to influence the outcome of director elections and other matters requiring stockholder approval.

Based upon shares outstanding as of March 31, 2021, our executive officers, directors and the holders of more than 5% of our outstanding common stock, in the aggregate, beneficially owned approximately 36.8% of our common stock. In particular, Gilead owns approximately 19.5% of our outstanding common stock, and we have appointed its two designees to our board of directors pursuant to the terms of our investor rights agreement. As a result, these stockholders, acting together, will have significant influence over all matters that require approval by our stockholders, including the election of directors and approval of significant corporate transactions. Corporate actions might be taken even if other stockholders oppose them. This concentration of ownership might also have the effect of delaying or preventing a change of control of our company that other stockholders may view as beneficial.

Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.

Our status as a Delaware corporation and the anti-takeover provisions of the Delaware General Corporation Law may discourage, delay or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder, even if a change of control would be beneficial to our existing stockholders. In addition, our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that may make the acquisition of our company more difficult, including the following:

 

a classified board of directors with three-year staggered terms, which could delay the ability of stockholders to change the membership of a majority of our board of directors;

 

the ability of our board of directors to issue shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;

 

the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of our board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;

 

a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;

52


 

 

the requirement that a special meeting of stockholders may be called only by a majority vote of our entire board of directors, the chairman of our board of directors or our chief executive officer, which could delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors;

 

the requirement for the affirmative vote of holders of at least 66 23% of the voting power of all of the then-outstanding shares of the voting stock, voting together as a single class, to amend the provisions of our amended and restated certificate of incorporation relating to the management of our business or our amended and restated bylaws, which may inhibit the ability of an acquirer to effect such amendments to facilitate an unsolicited takeover attempt; and

 

advance notice procedures with which stockholders must comply to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders’ meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of us.

In addition, as a Delaware corporation, we are subject to Section 203 of the Delaware General Corporation Law. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision.

These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer or proxy contest involving our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for our stockholders to realize value in a corporate transaction.

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our amended and restated certificate of incorporation and our bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws or any action asserting a claim against us that is governed by the internal affairs doctrine. In addition, to prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our bylaws provide that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. These choice of forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees and may discourage these types of lawsuits. While the Delaware courts have determined that these types of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of these provisions, which may require significant additional costs associated with resolving such action in other jurisdictions, and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.

General Risk Factors

Sales of substantial amounts of our outstanding shares may cause the price of our common stock to decline.

The price of our common stock could decline if there are substantial sales of our common stock, particularly sales by our directors, executive officers and significant stockholders, or if there is a large number of shares of our common stock available for sale and the market perceives that sales will occur. Certain of our stockholders have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or our stockholders, subject to market standoff and lockup agreements. We have also registered shares of common stock that we have issued and may issue under our employee equity incentive plans. These shares can be sold freely in the public market upon issuance, subject to vesting conditions and, in the case of our affiliates, volume limitations under Rule 144 under the Securities Act of 1933, as amended.

If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could result in sanctions or other penalties that would harm our business.

We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of the New York Stock Exchange. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal controls over financial reporting.

53


 

Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. Accordingly, we cannot assure you that we will not in the future identify one or more material weaknesses in our internal control over financial reporting, which may have a negative impact on our ability to timely and accurately produce financial statements, may result in a material misstatement of our consolidated financial statements or may negatively impact the confidence level of our stockholders and other market participants with respect to our reported financial information.

Ensuring that we have adequate internal controls over financial reporting is a costly and time-consuming effort that needs to be re-evaluated frequently. To the extent necessary, implementing any changes to our internal controls may distract our officers and employees, entail substantial costs to modify our existing processes and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

Not applicable.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

None.

Item 5. Other Information.

None.

54


 

Item 6. Exhibits.

 

Exhibit

Number

  

Exhibit Description

  

Incorporated by Reference

  

  

Form

  

File No.

  

Exhibit

  

Filing Date

 

 

 

 

 

 

  3.1

  

Amended and Restated Certificate of Incorporation

  

10-Q

  

001-38419

  

3.1

  

May 9, 2018

 

 

 

 

 

 

  3.2

  

Amended and Restated Bylaws

  

8-K

  

001-38419

  

3.1

  

May 26, 2020

  10.1**

  

Amended and Restated Common Stock Purchase Agreement dated January 31, 2021 between Arcus Biosciences, Inc. and Gilead Sciences, Inc.

  

SC 13D/A

 

005-90423

 

99.1

 

February 2, 2021

  10.2*

  

Fifth Amendment Dated April 1, 2021 to the Lease agreement dated September 30, 2015 between Arcus Biosciences, Inc. and Hayward Point Eden I Limited Partnership.

  

 

 

 

 

 

 

 

  31.1*

 

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  31.2*

 

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  32.1†

 

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  32.2†

 

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.INS

 

XBRL Instance Document – The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

104

 

Cover Page Interactive Data File (formatted as inline XBRL and contained in exhibit 101)

 

 

 

 

 

 

 

 

 

*

Filed herewith.

**

Certain information has been omitted because it is both not material and would be competitively sensitive if publicly disclosed.

This certification is deemed not filed for purposes of section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.

55


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

ARCUS BIOSCIENCES, INC.

 

 

 

 

 

 

 

Date:

 

May 5, 2021

 

By:

 

/s/ Terry Rosen

 

 

 

 

 

 

Terry Rosen, Ph.D.

 

 

 

 

 

 

Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

 

 

 

Date:

 

May 5, 2021

 

By:

 

/s/ Robert C. Goeltz II

 

 

 

 

 

 

Robert C. Goeltz II

 

 

 

 

 

 

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

56

EX-10.2 2 rcus-ex102_91.htm EX-10.2 rcus-ex102_91.htm

Exhibit 10.2

FIFTH AMENDMENT TO LEASE

This FIFTH AMENDMENT TO OFFICE LEASE ("Fifth Amendment") is made and entered into as of the 1st day of April, 2021 (the "Effective Date"), by and between HAYWARD POINT EDEN I LIMITED PARTNERSHIP, a Delaware limited partnership ("Landlord"), and ARCUS BIOSCIENCES, INC., a Delaware corporation ("Tenant").

r e c i t a l s :

A.

Landlord and Tenant entered into that certain Lease dated September 30, 2015 (the "Original Lease"), as supplemented by that certain Notice of Lease Term Dates dated April 8, 2016 and that certain Notice of First Amendment Lease Term Dates dated July 27, 2016 and that certain Notice of Second Amendment Lease Term Dates dated October 27, 2017 (collectively, the "Notices of Lease Term Dates"), whereby Landlord leased to Tenant and Tenant leased from Landlord those certain premises consisting of approximately 26,467 rentable square feet ("Original Premises") with a street address of 3928 Point Eden Way, Hayward, California (together with 3920 Point Eden Way, Hayward, California ("Building E")).  

B.

The Original Lease was amended by that certain First Amendment to Lease dated July 22, 2016 (the "First Amendment"), whereby Landlord and Tenant agreed to expand the Original Premises to include that certain space consisting of approximately 13,644 rentable square feet of space with a street address of 3920 Point Eden Way, Hayward, California (the "Expansion Premises").  

C.

The Original Lease and First Amendment were amended by that certain Second Amendment to Lease dated October 12, 2017 (the "Second Amendment"), whereby Landlord and Tenant agreed to expand the Original Premises and the Expansion Premises to include that certain space consisting of approximately 30,000 rentable square feet of space (the "Second Expansion Premises") with a street address of 26118 Research Road, Hayward, California ("Building J").  

D.

The Original Lease, First Amendment and Second Amendment were amended by that certain Third Amendment to Lease dated June 26, 2020 (the "Third Amendment"), whereby Landlord and Tenant agreed to expand the Original Premises, the Expansion Premises and the Second Expansion Premises to include that certain space consisting of approximately 36,303 rentable square feet of space (the "Third Expansion Premises") with a street address of 3967 Trust Way, Hayward, California ("Building F").  

E.

The Original Lease, First Amendment, Second Amendment and Third Amendment were amended by that certain Fourth Amendment to Lease (the "Fourth Amendment"), whereby Landlord and Tenant agreed to provide for the occupancy and use, on a temporary basis, of certain space containing 29,879 rentable square feet of space (currently referred to as the "Temporary Premises") in the building located at 4010 Point Eden Way, Hayward, California ("Building K").  The Original Lease, the Notices of Lease Term Dates, the First Amendment, the Second Amendment, the Third Amendment and the Fourth Amendment are, collectively, the "Lease." The Original Premises, Expansion Premises, Second Expansion Premises, and Third Expansion Premises shall constitute the "Existing Premises".

 


 

F.

As of the date of this Fifth Amendment, an affiliate of Landlord and Tenant have executed a new lease for Tenant's future occupancy of the entirety of a building being constructed and located at 1800 Sierra Point Parkway, Brisbane, California (the "Sierra Point Lease").

G.

Tenant desires to (i) expand the Existing Premises to include that certain space consisting of approximately 14,460 rentable square feet of space (the "26103 Expansion Premises") in Building K, with a street address of 26103 Research Road, Hayward, California, as delineated on Exhibit A attached hereto and made a part hereof, (ii) expand the Existing Premises to include the Temporary Premises on a long term basis (as opposed to temporary as set forth in the Fourth Amendment) (the Temporary Premises shall be referred to herein as the "4010 Expansion Premises"), and (iii) make other modifications to the Lease, and in connection therewith, Landlord and Tenant desire to amend the Lease as hereinafter provided.

a g r e e m e n t :

NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1.Capitalized Terms.  All capitalized terms when used herein shall have the same meaning as is given such terms in the Lease unless expressly superseded by the terms of this Fifth Amendment.

2.Modification of Premises.  

2.1.Amended Terms of Lease of 4010 Expansion Premises; Condition of 4010 Expansion Premises.  Landlord and Tenant acknowledge that Tenant has been occupying the 4010 Expansion Premises (i.e., on a temporary basis as the "Temporary Premises") pursuant to the terms of the Fourth Amendment.  As of the Effective Date, the 4010 Expansion Premises shall be deemed to be a part of the Existing Premises, and Landlord and Tenant hereby acknowledge that such addition of the 4010 Expansion Premises to the Existing Premises shall, as of the Effective Date, increase the size of the Premises to 136,293 rentable square feet.  Effective as of the Effective Date, all references in the Lease, as amended, to the Building shall mean (i) Building E when the context applies to Building E or any portion of the Premises located in Building E, (ii) Building J when the context applies to Building J or any portion of the Premises located in Building J, (iii) Building F when the context applies to Building F or any portion of the Premises located in Building F, (iv) Building K when the context applies to Building K or any portion of the Premises located in Building K, and (v) each of Building E, Building J, Building F, and Building K when the context applies to all of such buildings; provided; however, if any casualty causes damage that affects only one Building, the termination rights of the parties under Article 11 of the Original Lease shall apply only to the applicable portion of the Premises in such Building (in which event the rent, security deposit and other amounts herein related to rentable square footage and the definition of "Building" shall be correspondingly revised).  Accordingly, notwithstanding any provision to the contrary contained in the Lease (including, without limitation, the Fourth Amendment), Tenant's lease of the 4010 Expansion Premises shall be on the terms and conditions of the Lease, as amended hereby (i.e., the Lease Term with respect to the

 


 

4010 Expansion Premises shall be modified pursuant to the terms of Section 3.1 below and the Base Rent payment obligations for the 4010 Expansion Premises shall be modified pursuant to the terms of Section 4.2 below).  Tenant hereby acknowledges that Tenant is in possession of the 4010 Expansion Premises and accordingly Landlord shall have no obligation to deliver the 4010 Expansion Premises to Tenant.  Except as specifically set forth in the Tenant Work Letter attached to this Fifth Amendment as Exhibit B (the "Tenant Work Letter"), Landlord shall not be obligated to provide or pay for any improvement work or services related to the improvement of the 4010 Expansion Premises, and Tenant shall continue to accept the 4010 Expansion Premises in its presently existing, "as-is" condition. Tenant shall construct the initial improvements in the 4010 Expansion Premises only pursuant to the terms of the Tenant Work Letter.   Tenant also acknowledges that notwithstanding any provision to the contrary contained in the Lease, neither Landlord nor any agent of Landlord has made any representation or warranty regarding the condition of the 4010 Expansion Premises, or Building K or with respect to the suitability of any of the foregoing for the conduct of Tenant’s business.

2.2.Lease of 26103 Expansion Premises.  Effective as of the date (the "26103 Expansion Commencement Date") that is six (6) months following the Possession Date (as hereinafter defined), Tenant shall lease from Landlord and Landlord shall lease to Tenant the 26103 Expansion Premises.  The "Possession Date" shall be the date that Landlord tenders possession of the entirety of the 26103 Expansion Premises to Tenant in the Delivery Condition (as that term is defined in Section 1 of Exhibit B) (it is hereby acknowledged and agreed that Landlord shall be deemed to have tendered possession of the 26103 Expansion Premises on the date that Landlord provides Tenant with a key or access card to the 26103 Expansion [or makes such key or access card available for Tenant at the Project] and no action by Tenant shall be required therefor).  Landlord hereby agrees that the Possession Date shall not occur prior to April 1, 2022.  Tenant shall be permitted to use and occupy the 26103 Expansion Premises from the Possession Date until the 26103 Expansion Commencement Date (the "Beneficial Occupancy Period"), provided that (i) Landlord has received from Tenant certificates reasonably satisfactory to Landlord evidencing the insurance required to be carried by Tenant under the Lease; and (ii) all of the terms and conditions of the Lease shall apply to Tenant's occupancy of the 26103 Expansion Premises during the Beneficial Occupancy Period, except that Tenant shall not be obligated to pay Base Rent attributable to the 26103 Expansion Premises during the Beneficial Occupancy Period (provided that Tenant shall pay Tenant Share of Direct Expenses and all Additional rent for the 26103 Expansion Premises during the Beneficial Occupancy Period).  Accordingly, such addition of the 26103 Expansion Premises shall, effective as of the 26103 Expansion Commencement Date, increase the size of the Premises to approximately 150,753 rentable square feet and, effective on the 26103 Expansion Commencement Date, the Existing Premises shall be increased to include the 26103 Expansion Premises.  The Existing Premises, 4010 Expansion Premises and the 26103 Expansion Premises may hereinafter collectively be referred to as the "Premises".  Notwithstanding the foregoing, if the Possession Date has not occurred  on or before July 1, 2022 (the "Outside Date"), then, as Tenant's sole and exclusive remedy for such delay, other than the right to specific performance, the date Tenant is otherwise obligated to commence payment of rent as to the 26103 Expansion Premises shall be delayed by one (1) day for each two (2) days that the Possession Date is actually delayed beyond such Outside Date, which Outside Date shall be deemed to be automatically extended on a day-for-day basis to the extent of any delays in the Possession Date caused by (a) any Tenant delays, or (b) events of Force Majeure (which Force Majeure delays shall not exceed ninety (90) days in the aggregate).

 


 

3.Lease Term.  

3.1.Extended Lease Terms; 26103 Expansion Term.  Landlord and Tenant acknowledge that Tenant's lease of (i) the Original Premises, Expansion Premises, and Second Expansion Premises is scheduled to expire on October 31, 2025, (ii) the Third Expansion Premises is scheduled to expire on February 28, 2029, and (iii) the 4010 Expansion Premises is scheduled to expire on October 31, 2021.  The term of Tenant's lease of the 26103 Expansion Premises shall commence on the 26103 Expansion Commencement Date, and shall expire on the ”New Expiration Date” set forth hereinbelow.  In addition, Landlord and Tenant hereby acknowledge and agree that the Lease Term with respect to the Existing Premises and 4010 Expansion Premises shall be extended and shall expire on the lease expiration date of the Sierra Point Lease, but no earlier than December 31, 2031 (the "New Expiration Date"), unless sooner terminated as provided in the Lease, as hereby amended.  When the New Expiration is determined pursuant for the Sierra Point Lease, Landlord and Tenant hereby agree to enter into an amendment or letter agreement to document the New Expiration Date (the “New Expiration Date Agreement”).  The period of time commencing on the 26103 Expansion Commencement Date and terminating on the New Expiration Date, shall be referred to herein as the "26103 Expansion Term."  At any time during the 26103 Expansion Term, Landlord may deliver to Tenant a notice substantially in the form as set forth in Exhibit C attached to the Original Lease, as a confirmation only of the information set forth therein, which Tenant shall execute and return to Landlord within ten (10) days of receipt thereof.  

3.2.Option Term for Entire Premises.  Notwithstanding any provision to the contrary contained in the Lease, Landlord and Tenant hereby acknowledge and agree that as of the Effective Date all existing options to extend the applicable Lease Term currently set forth in the Lease are hereby deleted in their entirety and of no further force or effect, and Tenant shall have the option to extend the Lease Term for the entire Premises beyond the New Expiration Date pursuant to the terms of this Section 3.2 only.  

3.2.1Option Right.  Landlord hereby grants to the Original Tenant, and its Permitted Assignees, as defined in the Lease, two (2) options to extend the Lease Term with respect to the entire Premises (i.e., the Original Premises, Expansion Premises, Second Expansion Premises, Third Expansion Premises, 4010 Expansion Premises and 26103 Expansion Premises) for a period of eight (8) years (each, an "Option Term"), which options shall be irrevocably exercised only by written notice delivered by Tenant to Landlord not more than twelve (12) months nor less than nine (9) months prior to the New Expiration Date (or expiration date of the first Option Term, as applicable), provided that the following conditions (the "Option Conditions") are satisfied:  (i) as of the date of delivery of such notice, Tenant is not in default under the Lease, after the expiration of any applicable notice and cure period; (ii) Tenant has not previously been in default under the Lease, after the expiration of any applicable notice and cure period, more than twice in the twelve (12) month period prior to the date of Tenant's attempted exercise; and (iii) the Lease then remains in full force and effect.  Landlord may, at Landlord's option, exercised in Landlord's sole and absolute discretion, waive any of the Option Conditions in which case the option, if otherwise properly exercised by Tenant, shall remain in full force and effect.  Upon the proper exercise of such option to extend, and provided that Tenant satisfies all of the Option Conditions (except those, if any, which are waived by Landlord), the Lease Term, as it applies to the entire Premises, shall be extended for a period of eight (8) years.  The rights contained in this Section 3.2 shall be personal to Original Tenant and any Permitted Assignees, and may be

 


 

exercised by Original Tenant or such Permitted Assignees (and not by any assignee, sublessee or other Transferee, of Tenant's interest in the Lease).  In no event shall Tenant have the right to extend the Lease Term by the second (2nd) Option Term unless Tenant has timely and properly exercised the right to extend the Lease Term by the first (1st) Option Term.

3.2.2Option Rent.  The annual Rent payable by Tenant during the Option Term (the "Option Rent") shall be equal to the "Fair Rental Value," as that term is defined below, for the Premises as of the commencement date of the Option Term.  The "Fair Rental Value," as used in this Fifth Amendment, shall be equal to the annual rent per rentable square foot (including additional rent and considering any "base year" or "expense stop" applicable thereto), including all escalations, at which tenants (pursuant to leases consummated within the twelve (12) month period preceding the first day of the Option Term), are leasing non-sublease, non-encumbered, non-equity space which is not significantly greater or smaller in size than the subject space, with a comparable level of improvements (excluding any property that Tenant would be allowed to remove from the Premises at the termination of the Lease or the value of any improvements to the extent paid for by Tenant, including pursuant to an additional allowance), for a comparable lease term, in an arm's length transaction, which comparable space is located in the "Comparable Buildings," as that term is defined in this Section 3.2.2, below (transactions satisfying the foregoing criteria shall be known as the "Comparable Transactions"), taking into consideration the following concessions (the "Concessions"):  (a) rental abatement concessions, if any, being granted such tenants in connection with such comparable space; (b) tenant improvements or allowances provided or to be provided for such comparable space, and taking into account the value, if any, of the existing improvements in the subject space, such value to be based upon the age, condition, design, quality of finishes and layout of the improvements and the extent to which the same can be utilized by a general office/lab user other than Tenant; and (c) other reasonable monetary concessions being granted such tenants in connection with such comparable space; provided, however, that in calculating the Fair Rental Value, no consideration shall be given to the fact that Landlord is or is not required to pay a real estate brokerage commission in connection with Tenant's exercise of its right to extend the Lease Term, or the fact that landlords are or are not paying real estate brokerage commissions in connection with such comparable space.  The Concessions shall be reflected in the effective rental rate (which effective rental rate shall take into consideration the total dollar value of such Concessions as amortized on a straight-line basis over the applicable term of the Comparable Transaction (in which case such Concessions evidenced in the effective rental rate shall not be granted to Tenant)) payable by Tenant.  The term “Comparable Buildings” shall mean the Building and those other life sciences buildings which are comparable to the Building in terms of age (based upon the date of completion of construction or major renovation of to the building), quality of construction, level of services and amenities, size and appearance, and are located in Hayward, California and the surrounding commercial area.

3.2.3Determination of Option Rent.  In the event Tenant timely and appropriately exercises an option to extend the Lease Term, Landlord shall notify Tenant of Landlord's determination of the Option Rent within thirty (30) days thereafter.  If Tenant, on or before the date which is ten (10) days following the date upon which Tenant receives Landlord's determination of the Option Rent, in good faith objects to Landlord's determination of the Option Rent, then Landlord and Tenant shall attempt to agree upon the Option Rent using their best good-faith efforts.  If Landlord and Tenant fail to reach agreement within ten (10) days following Tenant's objection to the Option Rent (the "Outside Agreement Date"), then Tenant shall have the right to withdraw its exercise of the option by delivering written notice thereof to Landlord within five (5) days thereafter, in which event Tenant's right to extend the Lease pursuant to this Section 3.2 shall be of no further force or effect.  If Tenant does not withdraw its exercise of the extension option, each party shall make a separate determination of the Option Rent, as the case may be, within ten (10) days after the Outside Agreement Date, and such determinations shall be submitted to arbitration in accordance with Sections 3.2.3.1 through 3.2.3.7, below.  If Tenant fails to object to Landlord's determination of the Option Rent within the time period set forth herein, then Tenant shall be deemed to have accepted Landlord's determination of Option Rent.  

 


 

3.2.3.1Landlord and Tenant shall each appoint one arbitrator who shall be a real estate appraiser who shall have been active over the five (5) year period ending on the date of such appointment in the appraisal of other class A life sciences buildings located in the Hayward market area.  The determination of the arbitrators shall be limited solely to the issue of whether Landlord's or Tenant's submitted Option Rent is the closest to the actual Option Rent, taking into account the requirements of Section 3.2.2 of this Fifth Amendment, as determined by the arbitrators.  Each such arbitrator shall be appointed within fifteen (15) days after the Outside Agreement Date.  Landlord and Tenant may consult with their selected arbitrators prior to appointment and may select an arbitrator who is favorable to their respective positions.  The arbitrators so selected by Landlord and Tenant shall be deemed "Advocate Arbitrators."

3.2.3.2The two (2) Advocate Arbitrators so appointed shall be specifically required pursuant to an engagement letter within ten (10) days of the date of the appointment of the last appointed Advocate Arbitrator to agree upon and appoint a third arbitrator ("Neutral Arbitrator") who shall be qualified under the same criteria set forth hereinabove for qualification of the two Advocate Arbitrators, except that neither the Landlord or Tenant or either parties' Advocate Arbitrator may, directly or indirectly, consult with the Neutral Arbitrator prior or subsequent to his or her appearance.  The Neutral Arbitrator shall be retained via an engagement letter jointly prepared by Landlord's counsel and Tenant’s counsel.

3.2.3.3The three arbitrators shall, within thirty (30) days of the appointment of the Neutral Arbitrator, reach a decision as to whether the parties shall use Landlord's or Tenant's submitted Option Rent, and shall notify Landlord and Tenant thereof.

3.2.3.4The decision of the majority of the three arbitrators shall be binding upon Landlord and Tenant.  

3.2.3.5If either Landlord or Tenant fails to appoint an Advocate Arbitrator within fifteen (15) days after the Outside Agreement Date, then either party may petition the presiding judge of the Superior Court of Alameda County to appoint such Advocate Arbitrator subject to the criteria in Section 3.2.3.1 of this Fifth Amendment, or if he or she refuses to act, either party may petition any judge having jurisdiction over the parties to appoint such Advocate Arbitrator.

3.2.3.6If the two (2) Advocate Arbitrators fail to agree upon and appoint the Neutral Arbitrator, then either party may petition the presiding judge of the Superior Court of Alameda County to appoint the Neutral Arbitrator, subject to criteria in Section 3.2.3.1 of this Fifth

 


 

Amendment, or if he or she refuses to act, either party may petition any judge having jurisdiction over the parties to appoint such arbitrator.

3.2.3.7The cost of the arbitration shall be paid by Landlord and Tenant equally.

3.2.3.8In the event that the Option Rent shall not have been determined pursuant to the terms hereof prior to the commencement of the Option Term, Tenant shall be required to pay the Option Rent initially provided by Landlord to Tenant, and upon the final determination of the Option Rent, the payments made by Tenant shall be reconciled with the actual amounts of Option Rent due, and the appropriate party shall make any corresponding payment to the other party.

4.Base Rent.

4.1.Original Premises.  Notwithstanding anything to the contrary in the Lease as hereby amended, Tenant shall continue to pay Base Rent for the Original Premises in accordance with the terms of the Lease until the date which is six (6) months following the Effective Date (the "Rent Reset Date"), at which time Tenant shall pay Base Rent for the Original Premises as set forth below (and otherwise in accordance with the terms of the Lease).  Landlord and Tenant acknowledge that the Base Rent schedule below has been determined based on the assumption that the New Expiration Date shall occur on or before the next scheduled annual 3.5% increase in the Base Rent, and accordingly the parties agree that if, once determined, the New Expiration Date does not occur prior to the next scheduled Base Rent increase, then the Base Rent schedule shall be deemed to be modified to provide for such increase, and the same shall be set forth in the New Expiration Date Agreement.

Period During
Lease Term

Annualized
Base Rent

Monthly Installment
of Base Rent

Approximate Monthly Rental Rate per Rentable Square Foot

Rent Reset Date – March 31, 2022

$1,219,599.36

$101,633.28

$3.84

April 1, 2022 – March 31, 2023

$1,268,383.33

$105,698.61

$3.99

April 1, 2023 – March 31, 2024

$1,319,118.67

$109,926.56

$4.15

April 1, 2024 – March 31, 2025

$1,371,883.41

$114,323.62

$4.32

April 1, 2025 – March 31, 2026

$1,426,758.75

$118,896.56

$4.49

 


 

April 1, 2026 – March 31, 2027

$1,483,829.10

$123,652.43

$4.67

April 1, 2027 – March 31, 2028

$1,543,182.27

$128,598.52

$4.86

April 1, 2028 – March 31, 2029

$1,604,909.56

$133,742.46

$5.05

April 1, 2029 – March 31, 2030

$1,669,105.94

$139,092.16

$5.26

April 1, 2030 – March 31, 2031

$1,735,870.18

$144,655.85

$5.47

April 1, 2031 – New Expiration Date

$1,805,304.98

$150,442.08

$5.68

4.2.Expansion Premises.  Notwithstanding anything to the contrary in the Lease as hereby amended, Tenant shall continue to pay Base Rent for the Expansion Premises in accordance with the terms of the Lease until the Rent Reset Date, at which time Tenant shall pay Base Rent for the Expansion Premises as set forth below (and otherwise in accordance with the terms of the Lease).  Landlord and Tenant acknowledge that the Base Rent schedule below has been determined based on the assumption that the New Expiration Date shall occur on or before the next scheduled annual 3.5% increase in the Base Rent, and accordingly the parties agree that if, once determined, the New Expiration Date does not occur prior to the next scheduled Base Rent increase, then the Base Rent schedule shall be deemed to be modified to provide for such increase, and the same shall be set forth in the New Expiration Date Agreement.

Period During
Lease Term

Annualized
Base Rent

Monthly Installment
of Base Rent

Approximate Monthly Rental Rate per Rentable Square Foot

Rent Reset Date – December 31, 2021

$360,201.60

$30,016.80

$2.20

January 1, 2022 – December 31, 2022

$374,609.66

$31,217.47

$2.29

January 1, 2023 – December 31, 2023

$389,594.05

$32,466.17

$2.38

January 1, 2024 – December 31, 2024

$405,177.81

$33,764.82

$2.47

 


 

January 1, 2025 – December 31, 2025

$421,384.93

$35,115.41

$2.57

January 1, 2026 – December 31, 2026

$438,240.32

$36,520.03

$2.68

January 1, 2027 – December 31, 2027

$455,769.93

$37,980.83

$2.78

January 1, 2028 – December 31, 2028

$474,000.73

$39,500.06

$2.90

January 1, 2029 – December 31, 2029

$492,960.76

$41,080.06

$3.01

January 1, 2030 – December 31, 2030

$512,679.19

$42,723.27

$3.13

January 1, 2031 – New Expiration Date

$533,186.36

$44,432.20

$3.26

4.3.Second Expansion Premises.  Notwithstanding anything to the contrary in the Lease as hereby amended, Tenant shall continue to pay Base Rent for the Second Expansion Premises in accordance with the terms of the Lease until the Rent Reset Date, at which time Tenant shall pay Base Rent for the Second Expansion Premises as set forth below (and otherwise in accordance with the terms of the Lease).  Landlord and Tenant acknowledge that the Base Rent schedule below has been determined based on the assumption that the New Expiration Date shall occur on or before the next scheduled annual 3.5% increase in the Base Rent, and accordingly the parties agree that if, once determined, the New Expiration Date does not occur prior to the next scheduled Base Rent increase, then the Base Rent schedule shall be deemed to be modified to provide for such increase, and the same shall be set forth in the New Expiration Date Agreement.

Period During
Lease Term

Annualized
Base Rent

Monthly Installment
of Base Rent

Approximate Monthly Rental Rate per Rentable Square Foot

Rent Reset Date – October 31, 2021

$828,000.00

$69,000.00

$2.30

November 1, 2021 – October 31, 2022

$861,120.00

$71,760.00

$2.39

November 1, 2022 – October 31, 2023

$895,564.80

$74,630.40

$2.49

 


 

November 1, 2023 – October 31, 2024

$931,387.39

$77,615.62

$2.59

November 1, 2024 – October 31, 2025

$968,642.89

$80,720.24

$2.69

November 1, 2025 – October 31, 2026

$1,007,388.60

$83,949.05

$2.80

November 1, 2026 – October 31, 2027

$1,047,684.15

$87,307.01

$2.91

November 1, 2027 – October 31, 2028

$1,089,591.51

$90,799.29

$3.03

November 1, 2028 – October 31, 2029

$1,133,175.17

$94,431.26

$3.15

November 1, 2029 – October 31, 2030

$1,178,502.18

$98,208.52

$3.27

November 1, 2030 – October 31, 2031

$1,225,642.27

$102,136.86

$3.40

November 1, 2031 – New Expiration Date

$1,274,667.96

$106,222.33

$3.54

4.4.Third Expansion Premises.  Notwithstanding anything to the contrary in the Lease as hereby amended, Tenant shall continue to pay Base Rent for the Third Expansion Premises in accordance with the terms of the Lease until the Rent Reset Date, at which time Tenant shall pay Base Rent for the Third Expansion Premises as set forth below (and otherwise in accordance with the terms of the Lease).  Landlord and Tenant acknowledge that the Base Rent schedule below has been determined based on the assumption that the New Expiration Date shall occur on or before the next scheduled annual 3.5% increase in the Base Rent, and accordingly the parties agree that if, once determined, the New Expiration Date does not occur prior to the next scheduled Base Rent increase, then the Base Rent schedule shall be deemed to be modified to provide for such increase, and the same shall be set forth in the New Expiration Date Agreement.

Period During
Lease Term

Annualized
Base Rent

Monthly Installment
of Base Rent

Approximate Monthly Rental Rate per Rentable Square Foot

Rent Reset Date – February 28, 2022

$1,219,780.80

$101,648.40

$2.80

 


 

March 1, 2022 – February 28, 2023

$1,268,572.03

$105,714.34

$2.91

March 1, 2023 – February 29, 2024

$1,319,314.91

$109,942.91

$3.03

March 1, 2024 – February 28, 2025

$1,372,087.51

$114,340.63

$3.15

March 1, 2025 – February 28, 2026

$1,426,971.01

$118,914.25

$3.28

March 1, 2026 – February 28, 2027

$1,484,049.85

$123,670.82

$3.41

March 1, 2027 – February 29, 2028

$1,543,411.84

$128,617.65

$3.54

March 1, 2028 – February 28, 2029

$1,605,148.32

$133,762.36

$3.68

March 1, 2029 – February 28, 2030

$1,669,354.25

$139,112.85

$3.83

March 1, 2030 – February 28, 2031

$1,736,128.42

$144,677.37

$3.99

March 1, 2031 – New Expiration Date

$1,805,573.56

$150,464.46

$4.14

4.5.4010 Expansion Premises.  Notwithstanding anything to the contrary in the Lease as hereby amended, prior to January 18, 2021 Tenant shall continue to pay Base Rent for the 4010 Expansion Premises in accordance with the terms of the Fourth Amendment.  Effective as of January 18, 2021 and continuing throughout the remainder of the Lease Term, Tenant shall pay Base Rent for the 4010 Expansion Premises as set forth below (and otherwise in accordance with the terms of the Lease).  Landlord and Tenant acknowledge that the Base Rent schedule below has been determined based on the assumption that the New Expiration Date shall occur on or before the next scheduled annual 3.5% increase in the Base Rent, and accordingly the parties agree that if, once determined, the New Expiration Date does not occur prior to the next

 


 

scheduled Base Rent increase, then the Base Rent schedule shall be deemed to be modified to provide for such increase, and the same shall be set forth in the New Expiration Date Agreement.

Period During
Lease Term

Annualized
Base Rent

Monthly Installment
of Base Rent

Approximate Monthly Rental Rate per Rentable Square Foot

January 18, 2021 – January 31, 2022

$986,007.00

$82,167.25

$2.75

February 1, 2022 – January 31, 2023

$1,020,517.25

$85,043.10

$2.85

February 1, 2023 – January 31, 2024

$1,056,235.35

$88,019.61

$2.95

February 1, 2024 – January 31, 2025

$1,093,203.59

$91,100.30

$3.05

February 1, 2025 – January 31, 2026

$1,131,465.71

$94,288.81

$3.16

February 1, 2026 – January 31, 2027

$1,171,067.01

$97,588.92

$3.27

February 1, 2027 – January 31, 2028

$1,212,054.36

$101,004.53

$3.38

February 1, 2028 – January 31, 2029

$1,254,476.26

$104,539.69

$3.50

February 1, 2029 – January 31, 2030

$1,298,382.93

$108,198.58

$3.62

February 1, 2030 – January 31, 2031

$1,343,826.33

$111,985.53

$3.75

February 1, 2031 – New Expiration Date

$1,390,860.25

$115,905.02

$3.88

4.6.26103 Expansion Premises.  Commencing on the 26103 Expansion Commencement Date and continuing throughout the 26103 Expansion Term, Tenant shall pay to Landlord monthly installments of Base Rent for the 26103 Expansion Premises as set forth below (and otherwise in accordance with the terms of the Lease).  Landlord and Tenant acknowledge that the Base Rent schedule below has been determined based on the assumption that the New Expiration Date shall occur on or before the next scheduled annual 3.5% increase in the Base Rent,

 


 

and accordingly the parties agree that if, once determined, the New Expiration Date does not occur prior to the next scheduled Base Rent increase, then the Base Rent schedule shall be deemed to be modified to provide for such increase, and the same shall be set forth in the New Expiration Date Agreement.

Period During 26103
Expansion Term

Annualized
Base Rent

Monthly Installment
of Base Rent

Approximate Monthly Rental Rate per Rentable Square Foot

26103 Expansion Commencement Date – January 31, 2023

$493,881.30

$41,156.78

$2.85

February 1, 2023 – January 31, 2024

$511,167.15

$42,597.26

$2.95

February 1, 2024 – January 31, 2025

$529,058.00

$44,088.17

$3.05

February 1, 2025 – January 31, 2026

$547,575.03

$45,631.25

$3.16

February 1, 2026 – January 31, 2027

$566,740.15

$47,228.35

$3.27

February 1, 2027 – January 31, 2028

$586,576.06

$48,881.34

$3.38

February 1, 2028 – January 31, 2029

$607,106.22

$50,592.18

$3.50

February 1, 2029 – January 31, 2030

$628,354.94

$52,362.91

$3.62

February 1, 2030 – January 31, 2031

$650,347.36

$54,195.61

$3.75

February 1, 2031 – New Expiration Date

$673,109.52

$56,092.46

$3.88

5.Tenant's Share of Direct Expenses.  

5.1.Existing Premises.  Throughout the Lease Term (as extended pursuant to the terms of this Fifth Amendment) Tenant shall continue to pay Tenant's Share of Direct Expenses in connection with the Existing Premises in accordance with the terms of the Lease.  

 


 

5.2.4010 Expansion Premises.  Throughout the Lease Term (as extended pursuant to the terms of this Fifth Amendment) Tenant shall continue to pay Tenant's Share of Direct Expenses in connection with the 4010 Expansion Premises in accordance with the terms of the Lease based on Tenant’s Share of 67.39%.

5.3.26103 Expansion Premises.  Commencing on the Possession Date, Tenant shall also pay Tenant's Share of Direct Expenses in connection with the 26103 Expansion Premises in accordance with the terms of the Lease, provided that with respect to the calculation of Tenant's Share of Direct Expenses in connection with the 26103 Expansion Premises, Tenant's Share shall equal 32.61% of Building K, and accordingly Tenant’s Share of Building K will be 100% following the 26103 Expansion Commencement Date in the aggregate (when combined with the 4010 Expansion Premises).

6.Condition of the Premises.  Except as specifically set forth in the Tenant Work Letter, Landlord shall not be obligated to provide or pay for any improvement work or services related to the improvement of the 26103 Expansion Premises, and Tenant shall accept the 26103 Expansion Premises in its presently existing, "as-is" condition. Tenant shall accept all laboratory services, process utilities and emergency generator in their presently existing, as-is condition and Tenant shall be solely responsible for all costs related to their conditional use.  Tenant shall construct the initial improvements in the 26103 Expansion Premises only pursuant to the terms of the Tenant Work Letter. Except as specifically set forth in the Tenant Work, Landlord shall not be obligated to provide or pay for any improvement work or services related to the improvement of the Existing Premises, and Tenant shall continue to accept the Existing Premises in its presently existing, “as-is” condition.  Further, Tenant acknowledges that notwithstanding any provision to the contrary contained in the Lease, neither Landlord nor any agent of Landlord has made any representation or warranty regarding the condition of the 26103 Expansion Premises, or Building K or with respect to the suitability of any of the foregoing for the conduct of Tenant’s business.

7.Brokers.  Landlord and Tenant hereby warrant to each other that they have had no dealings with any real estate broker or agent in connection with the negotiation of this Fifth Amendment other than CBRE, Inc. and Newmark Cornish & Carey (the "Brokers"), and that they know of no other real estate broker or agent who is entitled to a commission in connection with this Fifth Amendment.  Each party agrees to indemnify and defend the other party against and hold the other party harmless from and against any and all claims, demands, losses, liabilities, lawsuits, judgments, and costs and expenses (including, without limitation, reasonable attorneys' fees) with respect to any leasing commission or equivalent compensation alleged to be owing on account of the indemnifying party's dealings with any real estate broker or agent, other than the Broker, occurring by, through, or under the indemnifying party.  The terms of this Section 7 shall survive the expiration or earlier termination of the term of the Lease, as hereby amended.

8.Letter of Credit; Security Deposit.  Landlord and Tenant acknowledge that, in accordance with Section 8 of the First Amendment and Section 8 of the Second Amendment, Tenant has previously delivered an L-C in the amount of $201,816.64 and a cash Security Deposit in the amount of $200,219.66 to Landlord.  Pursuant to the Third Amendment, Tenant is obligated to increase the L-C or cash Security Deposit by an amount equal to $235,556.52 prior to the Third Expansion Commencement Date.  Notwithstanding anything in the Lease to the contrary, concurrent with Tenant’s execution of this Fifth Amendment, Tenant shall provide an L-C (via

 


 

delivery of a new L-C in such amount or an amendment to the existing L-C, which shall in either event be in a form reasonably acceptable to Landlord and in conformance with the terms of the Lease) in the total amount of $1,218,810.74 (the "New L-C").  To the extent that the total amount held by Landlord at any time after the Effective Date as security for the Lease, as hereby amended, is less than the amount required, Tenant shall provide the difference to Landlord pursuant to the terms of the Lease.  Following receipt of the New L-C, Landlord shall return the cash Security Deposit currently held by Landlord.

9.Assignment and Subleasing.  Notwithstanding any provision to the contrary contained in the Lease, Landlord and Tenant hereby acknowledge and agree that in connection with the calculation of any Transfer Premium under the Lease, that the base rent, additional rent or other consideration payable by a Transferee for particular Subject Space shall be compared to the Base Rent and Additional Rent payable by Tenant for the Original Premises, on a per rentable square foot basis.

10.California Accessibility Disclosure.  For purposes of Section 1938 of the California Civil Code, Landlord hereby discloses to Tenant, and Tenant hereby acknowledges, that the Project, Building and Premises (including the 26103 Expansion Premises and 4010 Expansion Premises) have not undergone inspection by a Certified Access Specialist (CASp).  

11.Signage.  The provisions of Section 23 of the Original Lease shall apply to signage at the 26103 Expansion Premises and 4010 Expansion Premises and Tenant shall have such signage rights with respect to the 26103 Expansion Premises and 4010 Expansion Premises.

12.Lender Consent.  Landlord represents that there is no mortgage or deed of trust encumbering Buildings E, J, K, or F.

13.Right of First Refusal.  The right of first refusal set forth in Section 9 of the Second Amendment shall continue to apply during the Lease Term as extended by this Fifth Amendment.

14.Existing Lease of 26103 Expansion Premises.  Landlord represents that the existing lease of the 26103 Expansion Premises expires on March 31, 2022.

15.Surrender.  Tenant shall not be required to restore any of the existing alterations (including cabling) in the Existing Premises or Temporary Premises as of the date of this Fifth Amendment.  

16.Emergency Generator.  There is an existing generator exclusively serving Building K (the "Building K Generator").  Commencing on the Effective Date, Tenant shall have the right to connect to Tenant’s Share of Building K of such Building K Generator of all of the back-up power provided by such generator.  After the Effective Date, Landlord shall maintain the Building K Generator in good condition and repair, and Tenant shall be responsible for a share of the costs of such maintenance and repair based on the proportion of the Building K Generator capacity allocated to the Premises.  Notwithstanding the foregoing, Landlord shall not be liable for any damages whatsoever resulting from any failure in operation of the Building K Generator, or the failure of the Building K Generator to provide suitable or adequate back-up power to the Premises, including but not limited to, loss of profits, loss of rents or other revenues, loss of business opportunity, loss of goodwill or loss of use, in each case, however occurring, or loss to

 


 

inventory, scientific research, scientific experiments, laboratory animals, products, specimens, samples, and/or scientific, business, accounting and other records of every kind and description kept at the Premises and any and all income derived or derivable therefrom.  

17.Patio.  Commencing on the Effective Date, Tenant shall have the right to use the patio adjacent to Building K (the "Patio"), at no additional cost and in common with the other tenants and occupants of the Project.  Landlord shall maintain such Patio as an Operating Expense, subject to the terms of Section 4.2.4 of the Lease.  

18.EV Parking.  Tenant shall also have the right to use the electric vehicle chargers located adjacent to Building K (the "Existing EV Spaces") in common with the other tenants and occupants of the Project, which Existing EV Spaces shall be maintained by Landlord throughout the Lease Term as an Operating Expense, subject to the terms of Section 4.2.4 of the Lease.  Tenant shall have the right, at Tenant's sole cost and expense, to install additional electric car chargers, subject to Landlord’s review of the specifications therefor and compliance with the terms in Article 8 of the Original Lease and/or Exhibit B, as applicable, in spots adjacent to the Premises for the exclusive use of Tenant and its employees, contractors and visitors and to mark such spaces as being reserved (which spaces shall deducted from the number of spaces that Tenant is entitled to use under the Lease) (the "Tenant EV Spaces").  Any such Tenant EV Spaces and the Existing EV Spaces shall be used by Tenant in accordance with the applicable terms of this Lease, and the terms of the indemnification and insurance provisions hereof shall apply to Tenant's use thereof. Tenant shall maintain the Tenant EV Spaces and all associated equipment in good operating order and safe condition, in compliance with all applicable laws, at Tenant's sole cost and expense.

19.No Further Modification.  Except as set forth in this Fifth Amendment, all of the terms and provisions of the Lease shall apply and shall remain unmodified and in full force and effect.  

[signatures contained on following page]


 


 

 

IN WITNESS WHEREOF, this Fifth Amendment has been executed as of the day and year first above written.  

LANDLORD:

 

HAYWARD POINT EDEN I LIMITED PARTNERSHIP,
a Delaware limited partnership

 

By:HCP Point Eden Incorporated,
a Delaware corporation,
its General Partner

By: /s/ Scott Bohn
Name: Scott Bohn
Its: Senior Vice President

 

TENANT:

 

ARCUS BIOSCIENCES, INC.,
a Delaware corporation

By: /s/ Bob Goeltz

Name: Bob Goeltz

Its: CFO

 

 

 

EX-31.1 3 rcus-ex311_6.htm EX-31.1 rcus-ex311_6.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Terry Rosen, certify that:

1.

I have reviewed this Form 10-Q of Arcus Biosciences, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:     May 5, 2021

By:

 

/s/ Terry Rosen

 

 

 

Terry Rosen, Ph.D.

 

 

 

Chief Executive Officer

(Principal Executive Officer)

 

EX-31.2 4 rcus-ex312_9.htm EX-31.2 rcus-ex312_9.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Robert C. Goeltz II, certify that:

1.

I have reviewed this Form 10-Q of Arcus Biosciences, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:     May 5, 2021

By:

 

/s/ Robert C. Goeltz II

 

 

 

Robert C. Goeltz II

 

 

 

Chief Financial Officer

(Principal Financial & Accounting Officer)

 

EX-32.1 5 rcus-ex321_7.htm EX-32.1 rcus-ex321_7.htm

 

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Arcus Biosciences, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date:     May 5, 2021

By:

 

/s/ Terry Rosen

 

 

 

Terry Rosen, Ph.D.

 

 

 

Chief Executive Officer

(Principal Executive Officer)

 

 

EX-32.2 6 rcus-ex322_10.htm EX-32.2 rcus-ex322_10.htm

 

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Arcus Biosciences, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date:     May 5, 2021

By:

 

/s/ Robert C. Goeltz II

 

 

 

Robert C. Goeltz II

 

 

 

Chief Financial Officer

(Principal Financial & Accounting Officer)

 

 

EX-101.SCH 7 rcus-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100080 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Organization link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Accrued Liabilities link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Equity Investment in PACT Pharma link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - License and Collaboration Agreements link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Net Loss per Share link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Commitments link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Related Parties link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Subsequent Event link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Accrued Liabilities (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - License and Collaboration Agreements (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Net Loss per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Organization - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Fair Value Measurements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Fair Value Measurements - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Details) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Fair Value Measurements - Schedule of Investments Classified as Available for Sale Securities with Contractual Maturities (Details) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Fair Value Measurements - Schedule of Fair Value and Amortized Cost of Investments in Marketable Securities by Major Security Type (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Accrued Liabilities - Summary of Accrued Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Equity Investment in PACT Pharma - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - License and Collaboration Agreements - Summary of Revenues (Details) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - License and Collaboration Agreements - Summary of Revenues by Collaboration and by Category of Revenue (Details) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - License and Collaboration Agreements - Summary of Revenue Recognized as a Result of Changes in Deferred Revenue (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - License and Collaboration Agreements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Stockholders' Equity - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Net Loss per Share - Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Commitments - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Related Parties - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Subsequent Event - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 rcus-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 rcus-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 rcus-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Current Reporting Status Entity Current Reporting Status Entity Shell Company Entity Shell Company Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Interactive Data Current Entity Interactive Data Current Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation State Country Code Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Accrued research and development expenses current. Statement Of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Short-term investments Available For Sale Securities Current Receivable from collaboration partners ($4,924 and $943 from a related party) Contract With Customer Asset Net Current Accrued interest receivable Interest Receivable Current Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Long-term investments Available For Sale Securities Debt Securities Noncurrent Property and equipment, net Property Plant And Equipment Net Right-of-use assets Operating Lease Right Of Use Asset Restricted cash Restricted Cash Noncurrent Other long-term assets Other Assets Noncurrent Total assets Assets LIABILITIES Liabilities [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued research and development expenses Accrued Research And Development Expenses Current Other accrued liabilities Accrued Liabilities Current Deferred revenue, current ($67,571 and $67,571 to a related party) Contract With Customer Liability Current Other current liabilities Other Liabilities Current Total current liabilities Liabilities Current Deferred revenue, noncurrent ($110,097 and $117,808 to a related party) Contract With Customer Liability Noncurrent Operating lease liabilities, noncurrent Operating Lease Liability Noncurrent Other long-term liabilities ($9,703 and $9,703 to a related party) Other Liabilities Noncurrent Total liabilities Liabilities Commitments (Note 10) Commitments And Contingencies Stockholders’ equity: Stockholders Equity [Abstract] Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of March 31, 2021 and December 31, 2020; no shares issued and outstanding as of March 31, 2021 and December 31, 2020 Preferred Stock Value Common stock, $0.0001 par value, 400,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 70,965,513 and 65,114,685 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Accumulated deficit Retained Earnings Accumulated Deficit Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income Loss Net Of Tax Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Deferred revenue related parties classified current. Deferred revenue related parties noncurrent. Related parties contract liabilities noncurrent. Related party, receivable from collaboration partners Accounts Receivable Related Parties Current Related party, deferred revenue - current Deferred Revenue Related Parties Classified Current Related party, deferred revenue - noncurrent Deferred Revenue Related Parties Noncurrent Related party, other long-term liabilities Related Parties Contract Liabilities Noncurrent Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Interest and other income (expense) nonoperating net. Income Statement [Abstract] Revenues: Revenues [Abstract] Total collaboration and license revenues Revenue From Contract With Customer Excluding Assessed Tax Type of Revenue [Extensible List] Type Of Revenue Extensible List Operating expenses: Operating Expenses [Abstract] Research and development (($4,924) and $0 from a related party) Research And Development Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Non-operating income (expense): Nonoperating Income Expense [Abstract] Interest and other income, net Interest And Other Income Expense Nonoperating Net Gain on deemed sale from equity method investee Gain Loss On Sale Of Equity Investments Share of loss from equity method investee Income Loss From Equity Method Investments Total non-operating income, net Nonoperating Income Expense Net loss Net Income Loss Other comprehensive income (loss) Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Comprehensive loss Comprehensive Income Net Of Tax Net loss per share, basic and diluted Income Loss From Continuing Operations Per Basic And Diluted Share Weighted-average number of shares used to compute basic and diluted net loss per share Weighted Average Number Of Share Outstanding Basic And Diluted Related party transaction reimbursement from related party for shared costs. Statement [Table] Statement [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and Development Research And Development Expense [Member] Statement [Line Items] Statement [Line Items] Revenue from related parties Revenue From Related Parties Reimbursement from related party for shared costs Related Party Transaction Reimbursement From Related Party For Shared Costs Stock issued during period, shares, vesting of early exercised stock option. Stock issued during period, value, vesting of early exercised stock option. Stock issued during period shares stock options exercised and vesting of restricted stock. Stock issued during period value stock options exercised and vesting of restricted stock. Statement Of Stockholders Equity [Abstract] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-In Capital Additional Paid In Capital [Member] Accumulated Deficit Retained Earnings [Member] Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income [Member] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Common stock purchase agreement. Purchase Agreement Common Stock Purchase Agreement [Member] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Gilead Sciences, Inc. Gilead Gilead Sciences Inc [Member] Balance Balance, shares Issuance of common stock and rights to purchase additional shares in accordance with Amended and Restated Gilead Purchase Agreement, net of $55 offering costs Stock Issued During Period Value New Issues Issuance of common stock and rights to purchase additional shares in accordance with Amended and Restated Gilead Purchase Agreement, net of $55 offering costs, Shares Stock Issued During Period Shares New Issues Issuance of common stock upon exercise of stock options and vesting of restricted stock Stock Issued During Period Value Stock Options Exercised And Vesting Of Restricted Stock Issuance of common stock upon exercise of stock options and vesting of restricted stock, shares Stock Issued During Period Shares Stock Options Exercised And Vesting Of Restricted Stock Issuance of common stock upon exercise of stock options Stock Issued During Period Value Stock Options Exercised Issuance of common stock upon exercise of stock options, shares Stock Issued During Period Shares Stock Options Exercised Vesting of early exercised stock options Stock Issued During Period Value Vesting Of Early Exercised Stock Option Vesting of early exercised stock options, shares Stock Issued During Period Shares Vesting Of Early Exercised Stock Option Stock-based compensation Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Other comprehensive income (loss) Other Comprehensive Income Loss Net Of Tax Net loss Balance Balance, shares Offering costs Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Increase decrease in accrued research and development expenses. Increase decrease in operating lease liabilities. Proceeds from sale of short term and long term investments. Proceeds from issuance of common stock to related party. Repurchase of unvested shares of stock. Cash paid for amounts included in measurement of lease liabilities. Vesting of early exercised stock options. Statement Of Cash Flows [Abstract] Cash flow from operating activities Net Cash Provided By Used In Operating Activities [Abstract] Net loss Profit Loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Stock-based compensation expense Share Based Compensation Depreciation and amortization Depreciation And Amortization Amortization of right-of-use assets Operating Lease Right Of Use Asset Amortization Expense Amortization of premiums on investments Accretion Amortization Of Discounts And Premiums Investments Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Receivable from collaboration partners (($3,981) and $0 from a related party) Increase Decrease In Contract With Customer Asset Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Other long-term assets Increase Decrease In Other Noncurrent Assets Accounts payable Increase Decrease In Accounts Payable Accrued research and development expenses Increase Decrease In Accrued Research And Development Expenses Other accrued liabilities Increase Decrease In Other Accrued Liabilities Deferred revenue (($7,711) and $0 to a related party) Increase Decrease In Contract With Customer Liability Operating lease liabilities Increase Decrease In Operating Lease Liabilities Other long-term liabilities Increase Decrease In Other Noncurrent Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash flow from investing activities Net Cash Provided By Used In Investing Activities [Abstract] Purchases of short-term and long-term investments Payments To Acquire Investments Proceeds from maturities of short-term and long-term investments Proceeds From Sale Maturity And Collections Of Investments Sales of short-term and long-term investments Proceeds From Sale Of Short Term And Long Term Investments Purchases of property and equipment Payments To Acquire Property Plant And Equipment Net cash provided by investing activities Net Cash Provided By Used In Investing Activities Cash flow from financing activities Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from issuance of common stock to related party Proceeds From Issuance Of Common Stock To Related Party Proceeds from issuance of common stock pursuant to equity award plans Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options Repurchase of unvested shares of stock Repurchase Of Unvested Shares Of Stock Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net increase in cash and cash equivalents Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash, cash equivalents and restricted cash at beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Cash, cash equivalents and restricted cash at end of period Supplemental disclosures: Supplemental Cash Flow Information [Abstract] Cash paid for amounts included in measurement of lease liabilities Cash Paid For Amounts Included In Measurement Of Lease Liabilities Non-cash investing and financing activities: Noncash Investing And Financing Items [Abstract] Unpaid portion of property and equipment purchases included in accounts payable and accrued liabilities Capital Expenditures Incurred But Not Yet Paid Vesting of early exercised stock options Vesting Of Early Exercised Stock Options Receivable from related party. Deferred revenue from related party. Receivable from related party Receivable From Related Party Deferred revenue from related party Deferred Revenue From Related Party Organization Consolidation And Presentation Of Financial Statements [Abstract] Organization Nature Of Operations Accounting Policies [Abstract] Significant Accounting Policies Significant Accounting Policies [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Payables And Accruals [Abstract] Accrued Liabilities Accounts Payable And Accrued Liabilities Disclosure [Text Block] Equity method investment. Equity Method Investment [Abstract] Equity Investment in PACT Pharma Equity Method Investments Disclosure [Text Block] License and collaboration agreements. License And Collaboration Agreements [Abstract] License and Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Stockholders Equity Note [Abstract] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Earnings Per Share [Abstract] Net Loss per Share Earnings Per Share [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments Commitments Disclosure [Text Block] Related Party Transactions [Abstract] Related Parties Related Party Transactions Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Event Subsequent Events [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Principles of Consolidation Consolidation Policy [Text Block] Use of Estimates Use Of Estimates Cash Equivalents and Investments Cash And Cash Equivalents Policy [Text Block] Reconciliation of Cash, Cash Equivalents, and Restricted Cash as Reported in Condensed Consolidated Statements of Cash Flows Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy Concentration of Credit Risk Concentration Risk Credit Risk Leases and Rent Expense Lessee Leases Policy [Text Block] Reconciliation of Cash, Cash Equivalents and Restricted Cash Schedule Of Restricted Cash And Cash Equivalents [Text Block] Schedule of Financial Instruments Measured at Fair Value on Recurring Basis Fair Value Assets Measured On Recurring Basis [Text Block] Schedule of Investments Classified as Available for Sale Securities with Contractual Maturities Schedule Of Cash Cash Equivalents And Short Term Investments Table [Text Block] Schedule of Fair Value and Amortized Cost of Investments in Marketable Securities by Major Security Type Available For Sale Securities [Text Block] Summary of Accrued Liabilities Schedule Of Accrued Liabilities Table [Text Block] Summary of revenues. Gilead Sciences, Inc. and Taiho Pharmaceutical Co. Gilead and Taiho Gilead Sciences Inc And Taiho Pharmaceutical Co [Member] Summary of Revenues Summary Of Revenues Table [Text Block] Summary of Revenues by Collaboration and by Category of Revenue Disaggregation Of Revenue Table [Text Block] Summary of Revenue Recognized as a Result of Changes in Deferred Revenue Deferred Revenue By Arrangement Disclosure [Text Block] Summary of Stock-Based Compensation Expense Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Computation of Basic and Diluted Net Loss Per Share Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Number of investigational product. Organization. Organization. Organization [Table] Organization [Table] Balance Sheet Location Balance Sheet Location [Axis] Balance Sheet Location Balance Sheet Location [Domain] Cash, cash equivalents and investments in marketable securities. Cash, Cash Equivalents and Investments in Marketable Securities Cash Cash Equivalents And Investments In Marketable Securities [Member] Organization [Line Items] Organization [Line Items] Number of investigational product Number Of Investigational Product Cash and investments Investments And Cash Cash, cash equivalents and restricted cash Fair value assets transferred from level 1 to level 2 Fair Value Assets Level1 To Level2 Transfers Amount Fair value assets transferred from level 2 to level 1 Fair Value Assets Level2 To Level1 Transfers Amount Fair value liabilities transferred from level 1 to level 2 Fair Value Liabilities Level1 To Level2 Transfers Amount Fair value liabilities transferred from level 2 to level 1 Fair Value Liabilities Level2 To Level1 Transfers Amount Fair value assets transferred into level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 Fair value assets transferred out of level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 Fair value liabilities transferred into level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 Fair value liabilities transferred out of level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Measurement Frequency Fair Value By Measurement Frequency [Axis] Measurement Frequency Fair Value Measurement Frequency [Domain] Fair Value On Recurring Basis Fair Value Measurements Recurring [Member] Asset Class Fair Value By Asset Class [Axis] Asset Class Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Money Market Funds Money Market Funds [Member] U.S. Treasury Securities U S Treasury Securities [Member] U.S. Government Agency Securities U S Government Agencies Debt Securities [Member] Corporate securities and commercial paper. Corporate Securities and Commercial Paper Corporate Securities And Commercial Paper [Member] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Level 1 Fair Value Inputs Level1 [Member] Level 2 Fair Value Inputs Level2 [Member] Level 3 Fair Value Inputs Level3 [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Total assets measured at fair value Assets Fair Value Disclosure Cash, cash equivalents and available for sale investments. Cash and cash equivalents Cash And Cash Equivalents Fair Value Disclosure Short-term investments (due within one year) Long-term investments (due between one and two years) Available For Sale Securities Noncurrent Total cash, cash equivalents and investments in marketable securities Cash Cash Equivalents And Available For Sale Investments Reclassification out of accumulated other comprehensive income Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax Investment Type Investment Type [Axis] Investments Investment Type Categorization [Member] Amortized Cost Available For Sale Securities Amortized Cost Unrealized Gain Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax Unrealized Loss Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Fair Value Available For Sale Securities Other accrued liabilities. Accrued Liabilities Current [Abstract] Accrued personnel expenses Employee Related Liabilities Current Professional fees Accrued Professional Fees Current Other Other Accrued Liabilities Total Equity method investment number of shares purchased. Schedule Of Equity Method Investments [Table] Schedule Of Equity Method Investments [Table] Investment, Name Schedule Of Equity Method Investment Equity Method Investee Name [Axis] Investment, Name Equity Method Investee Name [Domain] PACT Pharma. PACT Pharma P A C T Pharma [Member] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Series A Preferred Stock Series A Preferred Stock [Member] Revision of Prior Period Restatement [Axis] Revision of Prior Period Restatement [Domain] Previously Reported Scenario Previously Reported [Member] Schedule of Equity Method Investments [Line Items] Schedule Of Equity Method Investments [Line Items] Purchase of common stock, shares Equity Method Investment Number Of Shares Purchased Investment balance Equity Method Investments Gain (loss) on equity investments net of prior period losses. Unrealized gain (loss) on equity method investments. Gains on dilution of equity investment Losses on accumulated in prior periods of equity investment Gain Loss On Equity Investments Net Of Prior Period Losses Unrealized loss on equity method investments Unrealized Gain Loss On Equity Method Investments Operating loss from equity method investments. Operating losses on equity method investments Operating Loss From Equity Method Investments License and collaboration agreements. License and collaboration agreements. License And Collaboration Agreements [Table] License And Collaboration Agreements [Table] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] Collaboration. Collaboration Collaboration [Member] Collaboration and License License And Service [Member] License And Collaboration Agreements [Line Items] License And Collaboration Agreements [Line Items] License revenue Revenues Gilead access rights. Gilead Access Rights Gilead Access Rights [Member] Taiho collaboration agreement. Taiho Collaboration Agreement Taiho Collaboration Agreement [Member] Collaboration and license revenue Amounts included in deferred revenue at the beginning of the period Deferred Revenue Revenue Recognized1 Performance obligations satisfied in previous period Contract With Customer Performance Obligation Satisfied In Previous Period Upfront cash payment. Option, license and collaboration agreement. Gilead Collaboration Agreement Option License And Collaboration Agreement [Member] Stock Purchase Agreement Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Maximum Maximum [Member] Minimum Minimum [Member] Prepaid Expenses and Other Current Assets Prepaid Expenses And Other Current Assets [Member] Other Noncurrent Assets Other Noncurrent Assets [Member] Taiho Pharmaceutical Co., Ltd. Taiho Pharmaceutical Co., Ltd Taiho Pharmaceutical Co Ltd [Member] Option and license agreement. Taiho Agreement Option And License Agreement [Member] Maximum WuXi Biologics license agreement. WuXi Biologics License Agreement Wu Xi Biologics License Agreement [Member] Abmuno license agreement. Abmuno License Agreement Abmuno License Agreement [Member] Genentech. Genentech Genentech [Member] Strata Agreement. Strata Agreement Strata Agreement [Member] Strata Oncology, Inc. Strata Oncology Inc Strata Oncology Inc [Member] Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Non-vested Restricted Stock Restricted Stock [Member] Upfront cash payment Upfront Cash Payment Issuance of common stock Issuance of common stock, shares Shares issued, price per share Shares Issued Price Per Share Collaboration term for current and future clinical programs. Additional collaboration term for programs entering clinical development prior to end of collaboration term. Option fee per program for current clinical programs to exercise option. Option fee per program for all other programs entering clinical development to exercise option. Contingent milestone payments receivable. Collaboration term for current and future clinical programs Collaboration Term For Current And Future Clinical Programs Contingent milestone payments receivable Contingent Milestone Payments Receivable Additional collaboration term for programs entering clinical development prior to end of collaboration term Additional Collaboration Term For Programs Entering Clinical Development Prior To End Of Collaboration Term Option fee per program for current clinical programs to exercise option Option Fee Per Program For Current Clinical Programs To Exercise Option Option fee per program for all other programs entering clinical development to exercise option Option Fee Per Program For All Other Programs Entering Clinical Development To Exercise Option Maximum ongoing research and development support. Ongoing research and development support Maximum Ongoing Research And Development Support Percentage of option to purchase maximum shares of common stock. Period over common stock to be purchased. Percentage of premium purchase price of common stock. Trailing days average closing price. Percentage of option to purchase maximum shares of common stock Percentage Of Option To Purchase Maximum Shares Of Common Stock Period over common stock to be purchased Period Over Common Stock To Be Purchased Percentage of premium purchase price of common stock Percentage Of Premium Purchase Price Of Common Stock Trailing days average closing price Trailing Days Average Closing Price Share Price Share Price Gross proceeds Proceeds From Issuance Of Common Stock Present value of research and development information access rights payment related to year two. Premium paid on stock purchase agreement. Contract with customer initial transaction price. Present value of research and development information access rights payment related to year 2022 Present Value Of Research And Development Information Access Rights Payment Related To Year Two Premium on stock purchased Premium Paid On Stock Purchase Agreement Initial transaction price Contract With Customer Initial Transaction Price Option payment upon achievement of certain development milestones. Deferred Revenue related to etrumadenant option. Etrumadenant option initial term of agreement. Option payment upon achievement of certain development milestones Option Payment Upon Achievement Of Certain Development Milestones Deferred revenue related to etrumadenant option Deferred Revenue Related To Etrumadenant Option Etrumadenant option initial term of agreement Etrumadenant Option Initial Term Of Agreement Domvanalimab option payment upon achievement of certain development milestones. Deferred revenue related to domvanalimab option. Domvanalimab option recognized term. Option payment upon achievement of certain development milestones Domvanalimab Option Payment Upon Achievement Of Certain Development Milestones Deferred revenue related to domvanalimab option Deferred Revenue Related To Domvanalimab Option Domvanalimab option recognized term Domvanalimab Option Recognized Term Current and future programs exclusive access period. Contingent milestone payment start period. Contractual obligation for first payment. Performance obligation period. Contractual obligation remaining amount not obligated to pay. Contractual obligation additional payment due. Deferred revenue related to research and development pipeline. Current and future programs exclusive access period Current And Future Programs Exclusive Access Period Additional payment due at each of the fourth, sixth, and eighth anniversaries of the agreement Contractual Obligation Additional Payment Due Contingent milestone payment start period Contingent Milestone Payment Start Period Contractual obligation for first payment Contractual Obligation For First Payment Performance obligation period Performance Obligation Period Contractual obligation remaining amount not obligated to pay Contractual Obligation Remaining Amount Not Obligated To Pay Deferred revenue related to research and development pipeline Deferred Revenue Related To Research And Development Pipeline Future development and promotion costs contract liability. Future development and promotion costs contract liability Future Development And Promotion Costs Contract Liability Revenue recognized from this performance obligation Contract With Customer Liability Revenue Recognized Consultant and legal fees. Direct offering cost. Consultant and legal fees Consultant And Legal Fees Direct offering cost Direct Offering Cost Amortization expense Adjustment For Amortization Cost sharing receivable Contract With Customer Asset Net Cost sharing receivable, current Cost sharing receivable, noncurrent Contract With Customer Asset Net Noncurrent Option period. Option period Option Period Non refundable and non creditable cash payments. Payment received for license agreement. Number of programs. Extended option agreement period. Payment for option exercise. Additional clinical and milestone payments received under license agreement. Non refundable and non creditable cash payments Non Refundable And Non Creditable Cash Payments Payment received for license agreement Payment Received For License Agreement Number of programs, IND enabling studies not initiated Number Of Programs Extended option agreement period Extended Option Agreement Period Payment for option exercise Payment For Option Exercise Additional clinical and regulatory milestone payments receivable Additional Clinical And Milestone Payments Received Under License Agreement Range of royalties receivable on net sales. Royalties payable description. Range of royalties receivable on net sales Range Of Royalties Receivable On Net Sales Royalties payable description Royalties Payable Description Non refundable and non creditable upfront cash payments. Estimated performance period of agreement. Non-refundable, non-creditable upfront cash payments Non Refundable And Non Creditable Upfront Cash Payments Estimated performance period Estimated Performance Period Of Agreement Clinical and regulatory milestones achieved under license agreement. Clinical and regulatory milestones achieved Clinical And Regulatory Milestones Achieved Under License Agreement Sales milestone and royalty revenue recognized under license agreement. Sales milestone or royalty revenue recognized Sales Milestone And Royalty Revenue Recognized Under License Agreement Clinical regulatory and commercialization milestone payments. Range of tiered royalty payments on net sales. Upfront and milestone payments. Sub license fees incurred. Sub-license fees incurred Sub License Fees Incurred Upfront and milestone payments Upfront And Milestone Payments Clinical, regulatory and commercialization milestone payments Clinical Regulatory And Commercialization Milestone Payments Range of tiered royalty payments on net sales Range Of Tiered Royalty Payments On Net Sales Milestone expense. Development milestone expense Milestone Expense Clinical regulatory and commercialization remaining milestone payments. Clinical, regulatory and commercialization remaining milestone payments Clinical Regulatory And Commercialization Remaining Milestone Payments Net expenses of inception. Net expenses of inception Net Expenses Of Inception Development expense Development milestone payable. Regulatory and commercial milestone payable. Reimbursement of research and development expense excluding acquired in process costs. Milestone payments. Development milestone payable Development Milestone Payable Regulatory and commercial milestone payable Regulatory And Commercial Milestone Payable Development cost recorded within research and development expenses Research And Development Expense Excluding Acquired In Process Cost Milestone payments Milestone Payments Development cost reimbursed Reimbursement Of Research And Development Expense Excluding Acquired In Process Costs Number of restricted shares of common stock issued Stock Issued During Period Shares Restricted Stock Award Gross Fair value of restricted shares of common stock issued Stock Issued During Period Value Restricted Stock Award Gross Shares probable of vesting Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number Compensation expense recognized Allocated Share Based Compensation Expense Stock issued during period value determined to premium on purchase of common stock and allocated to performance obligation. Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] May two thousand twenty public offering. May 2020 Public Offering May Two Thousand Twenty Public Offering [Member] Base shares. Base Shares Base Shares [Member] Underwriters option exercise. Underwriters Option Exercise Underwriters Option Exercise [Member] Class Of Stock [Line Items] Class Of Stock [Line Items] Common stock shares issued Shares issued, price per share Net proceeds from public offering after deducting underwriting discounts, commissions and other offering expenses Common stock share value Purchase price of common stock allocation to performance obligation Stock Issued During Period Value Determined To Premium On Purchase Of Common Stock And Allocated To Performance Obligation Deferred offering expenses Deferred Offering Costs Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Research and Development General and Administrative General And Administrative Expense [Member] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Total stock-based compensation Numerator: Net Income Loss [Abstract] Denominator: Weighted Average Number Of Shares Outstanding [Abstract] Weighted-average common shares outstanding Weighted Average Number Of Shares Issued Basic Less: weighted-average common shares subject to vesting Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation Weighted-average common shares used to compute basic and diluted net loss per share Net loss per share: basic and diluted Earnings Per Share Basic And Diluted Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Common Stock Options Issued and Outstanding Stock Compensation Plan [Member] Unvested restricted stock issued as part of collaboration agreement. Unvested Restricted Stock Issued as Part of Collaboration Agreement Unvested Restricted Stock Issued As Part Of Collaboration Agreement [Member] Unvested Early Exercised Common Stock Options Employee Stock Option [Member] Unvested Restricted Stock Units Restricted Stock Units R S U [Member] Employee Stock Purchase Plan Shares Employee Stock [Member] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of diluted net loss per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Commitments. Commitments. Commitments [Table] Commitments [Table] Credit Facility Credit Facility [Axis] Credit Facility Credit Facility [Domain] Standby Letters of Credit Standby Letters Of Credit [Member] Commitments [Line Items] Commitments [Line Items] Long-term line of credit Line Of Credit Percentage of outstanding common stock owned. Right to purchase additional outstanding voting common stock percentage. Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Percentage of outstanding common stock held Percentage Of Outstanding Common Stock Owned Right to purchase additional outstanding voting common stock percentage Right To Purchase Additional Outstanding Voting Common Stock Percentage Number of shares issued Sale Of Stock Number Of Shares Issued In Transaction Value of common stock issued Sale Of Stock Consideration Received On Transaction Future development and commercialization services contract liability. Cost sharing receivable Deferred revenue Contract With Customer Liability Long-term portion of revenue allocated Future development and commercialization services contract liability Future Development And Commercialization Services Contract Liability Reimbursement of milestone expense of cost sharing provisions. Revenue recognized Reimbursed under cost-sharing provisions of arrangement Reimbursement of milestone expense of cost sharing provisions Reimbursement Of Milestone Expense Of Cost Sharing Provisions Unconstrained consideration receivable. Funds received for stock purchase agreement. Fair value of stock purchased. Unconstrained consideration to be received Unconstrained Consideration Receivable Funds received for purchase of common stock Funds Received For Stock Purchase Agreement Fair value of stock purchased Fair Value Of Stock Purchased Operating lease commencement year. Operating lease, option to extend lease term. Lessee operating lease expiration month and year. Lessee operating lease allowance for tenant improvements. Lessee operating lease option to increase allowance for tenant improvements. Subsequent Event [Table] Subsequent Event [Table] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] Hayward, California CALIFORNIA Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Square feet of space leased Area Of Land Lease commencement year Operating Lease Commencement Year Operating lease, existence of option to extend Lessee Operating Lease Existence Of Option To Extend Operating lease, option to extend lease term Operating Lease Option To Extend Lease Term Operating lease, option to extend Lessee Operating Lease Option To Extend Lessee operating lease expiration month and year Lessee Operating Lease Expiration Month And Year Operating lease undiscounted amount Lessee Operating Lease Liability Undiscounted Excess Amount Operating lease, allowance for tenant improvements Lessee Operating Lease Allowance For Tenant Improvements Operating lease, option to increase allowance for tenant improvements Lessee Operating Lease Option To Increase Allowance For Tenant Improvements Lessee operating lease collateral amount. Collateral for operating leases Lessee Operating Lease Collateral Amount Issuance of letter of credit Proceeds From Lines Of Credit EX-101.PRE 11 rcus-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 rcus-10q_20210331_htm.xml IDEA: XBRL DOCUMENT 0001724521 2021-01-01 2021-03-31 0001724521 2021-04-30 0001724521 2021-03-31 0001724521 2020-12-31 0001724521 2020-01-01 2020-03-31 0001724521 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001724521 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001724521 us-gaap:CommonStockMember 2019-12-31 0001724521 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001724521 us-gaap:RetainedEarningsMember 2019-12-31 0001724521 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001724521 2019-12-31 0001724521 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001724521 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001724521 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001724521 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001724521 us-gaap:CommonStockMember 2020-03-31 0001724521 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001724521 us-gaap:RetainedEarningsMember 2020-03-31 0001724521 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001724521 2020-03-31 0001724521 us-gaap:CommonStockMember 2020-12-31 0001724521 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001724521 us-gaap:RetainedEarningsMember 2020-12-31 0001724521 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001724521 rcus:GileadSciencesIncMember us-gaap:CommonStockMember rcus:CommonStockPurchaseAgreementMember 2021-01-01 2021-03-31 0001724521 rcus:GileadSciencesIncMember us-gaap:AdditionalPaidInCapitalMember rcus:CommonStockPurchaseAgreementMember 2021-01-01 2021-03-31 0001724521 rcus:GileadSciencesIncMember rcus:CommonStockPurchaseAgreementMember 2021-01-01 2021-03-31 0001724521 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001724521 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001724521 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001724521 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001724521 us-gaap:CommonStockMember 2021-03-31 0001724521 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001724521 us-gaap:RetainedEarningsMember 2021-03-31 0001724521 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001724521 rcus:GileadSciencesIncAndTaihoPharmaceuticalCoMember 2021-01-01 2021-03-31 0001724521 rcus:CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember 2021-03-31 0001724521 2020-01-01 2020-12-31 0001724521 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001724521 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001724521 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001724521 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001724521 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001724521 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001724521 rcus:CorporateSecuritiesAndCommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001724521 rcus:CorporateSecuritiesAndCommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001724521 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001724521 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001724521 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001724521 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001724521 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001724521 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001724521 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001724521 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001724521 rcus:CorporateSecuritiesAndCommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001724521 rcus:CorporateSecuritiesAndCommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001724521 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001724521 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001724521 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001724521 us-gaap:MoneyMarketFundsMember 2021-03-31 0001724521 us-gaap:USTreasurySecuritiesMember 2021-03-31 0001724521 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-03-31 0001724521 rcus:CorporateSecuritiesAndCommercialPaperMember 2021-03-31 0001724521 us-gaap:MoneyMarketFundsMember 2020-12-31 0001724521 us-gaap:USTreasurySecuritiesMember 2020-12-31 0001724521 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001724521 rcus:CorporateSecuritiesAndCommercialPaperMember 2020-12-31 0001724521 rcus:PACTPharmaMember us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001724521 rcus:PACTPharmaMember us-gaap:SeriesAPreferredStockMember 2016-01-01 2016-12-31 0001724521 rcus:PACTPharmaMember 2021-03-31 0001724521 rcus:PACTPharmaMember 2020-12-31 0001724521 rcus:PACTPharmaMember 2020-01-01 2020-03-31 0001724521 srt:ScenarioPreviouslyReportedMember rcus:PACTPharmaMember 2020-01-01 2020-03-31 0001724521 rcus:PACTPharmaMember 2021-01-01 2021-03-31 0001724521 rcus:PACTPharmaMember 2020-01-01 2021-03-31 0001724521 rcus:GileadSciencesIncAndTaihoPharmaceuticalCoMember rcus:CollaborationMember 2021-01-01 2021-03-31 0001724521 rcus:GileadSciencesIncAndTaihoPharmaceuticalCoMember rcus:CollaborationMember 2020-01-01 2020-03-31 0001724521 rcus:GileadSciencesIncAndTaihoPharmaceuticalCoMember us-gaap:LicenseAndServiceMember 2021-01-01 2021-03-31 0001724521 rcus:GileadSciencesIncAndTaihoPharmaceuticalCoMember us-gaap:LicenseAndServiceMember 2020-01-01 2020-03-31 0001724521 rcus:GileadAccessRightsMember 2021-01-01 2021-03-31 0001724521 rcus:TaihoCollaborationAgreementMember 2021-01-01 2021-03-31 0001724521 rcus:TaihoCollaborationAgreementMember 2020-01-01 2020-03-31 0001724521 rcus:GileadSciencesIncMember rcus:OptionLicenseAndCollaborationAgreementMember 2020-07-12 2020-07-13 0001724521 rcus:GileadSciencesIncMember rcus:CommonStockPurchaseAgreementMember 2020-07-12 2020-07-13 0001724521 rcus:GileadSciencesIncMember rcus:CommonStockPurchaseAgreementMember 2020-07-13 0001724521 rcus:GileadSciencesIncMember srt:MaximumMember rcus:OptionLicenseAndCollaborationAgreementMember 2020-07-13 0001724521 rcus:GileadSciencesIncMember srt:MinimumMember rcus:OptionLicenseAndCollaborationAgreementMember 2020-07-12 2020-07-13 0001724521 rcus:GileadSciencesIncMember srt:MaximumMember rcus:OptionLicenseAndCollaborationAgreementMember 2020-07-12 2020-07-13 0001724521 rcus:GileadSciencesIncMember rcus:CommonStockPurchaseAgreementMember 2021-01-01 2021-01-31 0001724521 rcus:GileadSciencesIncMember rcus:CommonStockPurchaseAgreementMember 2021-01-31 0001724521 rcus:GileadSciencesIncMember rcus:OptionLicenseAndCollaborationAgreementMember 2020-07-13 0001724521 rcus:GileadSciencesIncMember rcus:OptionLicenseAndCollaborationAgreementMember 2021-03-31 0001724521 rcus:GileadSciencesIncMember rcus:OptionLicenseAndCollaborationAgreementMember 2021-01-01 2021-03-31 0001724521 rcus:CommonStockPurchaseAgreementMember 2020-07-12 2020-07-13 0001724521 rcus:GileadSciencesIncMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember rcus:OptionLicenseAndCollaborationAgreementMember 2021-03-31 0001724521 rcus:GileadSciencesIncMember us-gaap:OtherNoncurrentAssetsMember rcus:OptionLicenseAndCollaborationAgreementMember 2021-03-31 0001724521 rcus:TaihoPharmaceuticalCoLtdMember rcus:OptionAndLicenseAgreementMember 2017-09-01 2017-09-30 0001724521 rcus:TaihoPharmaceuticalCoLtdMember rcus:OptionAndLicenseAgreementMember 2017-01-01 2017-12-31 0001724521 rcus:TaihoPharmaceuticalCoLtdMember rcus:OptionAndLicenseAgreementMember 2018-01-01 2018-12-31 0001724521 rcus:TaihoPharmaceuticalCoLtdMember rcus:OptionAndLicenseAgreementMember 2019-01-01 2019-12-31 0001724521 rcus:TaihoPharmaceuticalCoLtdMember srt:MinimumMember rcus:OptionAndLicenseAgreementMember 2017-09-01 2017-09-30 0001724521 rcus:TaihoPharmaceuticalCoLtdMember srt:MaximumMember rcus:OptionAndLicenseAgreementMember 2017-09-01 2017-09-30 0001724521 rcus:TaihoPharmaceuticalCoLtdMember srt:MaximumMember rcus:OptionAndLicenseAgreementMember 2017-09-30 0001724521 rcus:TaihoPharmaceuticalCoLtdMember rcus:OptionAndLicenseAgreementMember 2021-01-01 2021-03-31 0001724521 rcus:WuXiBiologicsLicenseAgreementMember us-gaap:ResearchAndDevelopmentExpenseMember 2017-08-01 2021-03-31 0001724521 rcus:WuXiBiologicsLicenseAgreementMember srt:MaximumMember 2017-08-01 2017-08-31 0001724521 rcus:WuXiBiologicsLicenseAgreementMember 2021-01-01 2021-03-31 0001724521 rcus:WuXiBiologicsLicenseAgreementMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-12-01 2020-12-31 0001724521 rcus:WuXiBiologicsLicenseAgreementMember 2020-12-01 2020-12-31 0001724521 rcus:AbmunoLicenseAgreementMember 2021-01-01 2021-03-31 0001724521 rcus:GenentechMember 2021-01-01 2021-03-31 0001724521 rcus:GenentechMember 2020-01-01 2020-03-31 0001724521 rcus:StrataOncologyIncMember rcus:StrataAgreementMember 2019-04-30 0001724521 rcus:StrataOncologyIncMember srt:MaximumMember rcus:StrataAgreementMember 2019-04-30 0001724521 rcus:StrataOncologyIncMember rcus:StrataAgreementMember 2019-05-01 2021-03-31 0001724521 rcus:StrataOncologyIncMember us-gaap:ResearchAndDevelopmentExpenseMember rcus:StrataAgreementMember 2019-05-01 2021-03-31 0001724521 rcus:StrataOncologyIncMember rcus:StrataAgreementMember 2019-04-30 2019-04-30 0001724521 rcus:StrataOncologyIncMember us-gaap:RestrictedStockMember rcus:StrataAgreementMember 2021-03-31 0001724521 rcus:StrataOncologyIncMember us-gaap:RestrictedStockMember rcus:StrataAgreementMember 2021-01-01 2021-03-31 0001724521 rcus:StrataOncologyIncMember rcus:StrataAgreementMember 2021-01-01 2021-03-31 0001724521 rcus:StrataOncologyIncMember rcus:StrataAgreementMember 2020-01-01 2020-03-31 0001724521 rcus:MayTwoThousandTwentyPublicOfferingMember 2020-06-01 2020-06-30 0001724521 rcus:MayTwoThousandTwentyPublicOfferingMember 2020-06-30 0001724521 rcus:BaseSharesMember 2020-06-01 2020-06-30 0001724521 rcus:UnderwritersOptionExerciseMember 2020-06-01 2020-06-30 0001724521 rcus:GileadSciencesIncMember rcus:CommonStockPurchaseAgreementMember 2021-02-01 2021-02-28 0001724521 rcus:GileadSciencesIncMember rcus:CommonStockPurchaseAgreementMember 2021-02-28 0001724521 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001724521 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001724521 us-gaap:StockCompensationPlanMember 2021-01-01 2021-03-31 0001724521 us-gaap:StockCompensationPlanMember 2020-01-01 2020-03-31 0001724521 rcus:UnvestedRestrictedStockIssuedAsPartOfCollaborationAgreementMember 2021-01-01 2021-03-31 0001724521 rcus:UnvestedRestrictedStockIssuedAsPartOfCollaborationAgreementMember 2020-01-01 2020-03-31 0001724521 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001724521 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001724521 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001724521 us-gaap:EmployeeStockMember 2021-01-01 2021-03-31 0001724521 us-gaap:StandbyLettersOfCreditMember 2021-03-31 0001724521 rcus:GileadSciencesIncMember 2021-03-31 0001724521 srt:MaximumMember rcus:GileadSciencesIncMember 2021-03-31 0001724521 rcus:GileadSciencesIncMember 2020-05-01 2020-05-31 0001724521 rcus:GileadSciencesIncMember rcus:CommonStockPurchaseAgreementMember 2020-07-12 2020-07-13 0001724521 rcus:GileadSciencesIncMember rcus:CommonStockPurchaseAgreementMember 2021-02-01 2021-02-28 0001724521 rcus:GileadSciencesIncMember rcus:CommonStockPurchaseAgreementMember 2021-01-01 2021-03-31 0001724521 rcus:GileadSciencesIncMember rcus:OptionLicenseAndCollaborationAgreementMember 2021-01-01 2021-03-31 0001724521 us-gaap:ResearchAndDevelopmentExpenseMember rcus:GileadSciencesIncMember 2021-01-01 2021-03-31 0001724521 rcus:GileadSciencesIncMember rcus:CommonStockPurchaseAgreementMember 2021-02-28 0001724521 stpr:CA us-gaap:SubsequentEventMember 2021-04-30 0001724521 stpr:CA us-gaap:SubsequentEventMember 2021-04-01 2021-04-30 shares iso4217:USD iso4217:USD shares rcus:Product pure rcus:Program utr:sqft false Q1 0001724521 --12-31 rcus:CollaborationMember rcus:CollaborationMember P10Y true P5D P4Y P4Y P5Y rcus:CollaborationMember rcus:CollaborationMember 10-Q true 2021-03-31 2021 false 001-38419 Arcus Biosciences, Inc. DE 47-3898435 3928 Point Eden Way Hayward CA 94545 510 694-6200 Common Stock, Par Value $0.0001 Per Share RCUS NYSE Yes Yes Large Accelerated Filer false false false 70995860 390260000 173415000 436666000 555231000 4924000 943000 5235000 1049000 1029000 649000 8680000 5471000 841870000 735815000 57986000 6440000 14849000 10807000 12243000 12781000 1988000 203000 6183000 6246000 935119000 772292000 24544000 15682000 23023000 18307000 7536000 9543000 67571000 67571000 74571000 74571000 2381000 3566000 132055000 121669000 110097000 117808000 113369000 122830000 14706000 15243000 9703000 9703000 10199000 10246000 270329000 269988000 0.0001 0.0001 10000000 10000000 0 0 0 0 0 0 0.0001 0.0001 400000000 400000000 70965513 70965513 65114685 65114685 7000 6000 1065562000 830438000 -400777000 -328184000 -2000 44000 664790000 502304000 935119000 772292000 7711000 0 9461000 1750000 9461000 1750000 -4924000 0 66387000 23142000 15821000 7008000 82208000 30150000 -72747000 -28400000 154000 647000 482000 -482000 154000 647000 -72593000 -27753000 -46000 224000 -72639000 -27529000 -1.08 -0.63 67082161 44282607 44212195 4000 369100000 -205326000 64000 163842000 59939 643000 643000 77388 220000 220000 3462000 3462000 224000 224000 -27753000 -27753000 44349522 4000 373425000 -233079000 288000 140638000 63691901 6000 830438000 -328184000 44000 502304000 55000 5650000 1000 220295000 220296000 200828 1885000 1885000 54039 183000 183000 12761000 12761000 -46000 -46000 -72593000 -72593000 69596768 7000 1065562000 -400777000 -2000 664790000 -72593000 -27753000 12761000 3462000 800000 842000 538000 144000 -506000 248000 3981000 0 4186000 212000 4568000 3704000 -63000 91000 7722000 -2342000 4716000 2226000 -2007000 -1578000 7711000 0 -9461000 -1750000 -605000 -273000 -2000 -66316000 -31277000 192398000 8885000 251365000 49150000 7500000 3641000 209000 62826000 40056000 220235000 1885000 643000 33000 222120000 610000 218630000 9389000 173618000 58140000 392248000 67529000 927000 519000 2784000 76000 183000 220000 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Note </span><span style="color:#000000;">1. </span>Organization </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Description of Business </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arcus Biosciences, Inc. (the Company) is a clinical-stage biopharmaceutical company focused on creating best-in-class cancer therapies. The Company’s initial focus has been on well-characterized biological pathways with significant scientific data supporting their importance. Since its inception in 2015, the Company has built a robust and highly efficient drug discovery capability to create highly differentiated small molecules, which the Company is developing in combination with its in-licensed monoclonal antibodies through rationally designed, indication-specific clinical trial designs. The Company currently has five investigational products in clinical development: domvanalimab (formerly referred to as AB154), etrumadenant (formerly referred to as AB928), AB680, zimberelimab (formerly referred to as AB122), and AB308.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, the Company had cash and investments of $884.9 million, which are cash, cash equivalents, and investments in marketable securities, which the Company believes will be sufficient to fund its planned operations for a period of at least twelve months following the date of filing of this report.</p> 5 884900000 <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Note </span><span style="color:#000000;">2. </span>Significant Accounting Policies</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the Company’s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 or for any future period. The balance sheet as of December 31, 2020 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K <span style="color:#000000;">filed with the SEC on February 25, 2021. There have been no significant changes to the Company’s significant accounting policies described in Note 2, Summary of Significant Accounting Policies, in Notes to Consolidated Financial Statements in Item 8 of Part II of the Form 10-K. </span></p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of Arcus Biosciences, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as related disclosures of contingent assets and liabilities. Estimates were used to determine the standalone selling price of performance obligations and the timing of revenue recognition, the value of stock-based awards and other issuances, accruals for research and development costs, useful lives of long-lived assets, and uncertain tax positions. Actual results could differ materially from the Company’s estimates. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Equivalents and Investments </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents include marketable securities having an original maturity of three months or less at the time of purchase. Short-term investments have maturities of greater than three months and up to twelve months at the time of purchase. Long-term investments have maturities greater than 12 months at the time of purchase. Collectively, cash equivalents, short-term and long-term investments are considered available-for-sale and are recorded at fair value. Unrealized gains and losses are recorded in accumulated other comprehensive income (loss). Realized gains and losses are included in interest and other income, net in the condensed consolidated statements of operations and comprehensive income or loss. <span style="color:#000000;">The basis on which the cost of a security that is sold or an amount that is reclassified out of accumulated other comprehensive income or loss into earnings is determined using the specific identification method.</span></p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#212529;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reconciliation of Cash, Cash Equivalents, and Restricted Cash as Reported in Condensed Consolidated Statements of Cash Flows</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash at March 31, 2021 and 2020 represents cash balances held as security in connection with the Company’s facility lease agreements. <span style="color:#000000;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the condensed consolidated balance sheets to the total shown in the condensed consolidated statements of cash flows (in thousands):</span></p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.54%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">390,260</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,326</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.54%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,988</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.54%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">392,248</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,529</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents, short-term and long-term investments are financial instruments that potentially subject the Company to concentrations of credit risk. The Company invests in money market funds, treasury bills and notes, government bonds, commercial paper and corporate notes. The Company limits its credit risk associated with cash equivalents, short-term and long-term investments by placing them with banks and institutions it believes are credit worthy and in highly rated investments. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases and Rent Expense</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. The Company determines whether an arrangement is or contains a lease at contract inception. Operating leases are included in operating lease right-of-use assets, other current liabilities, and operating lease liabilities, noncurrent in our condensed consolidated balance sheets at March 31, 2021 and December 31, 2020. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date. The incremental borrowing rate represents the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company considers a lease term to be the noncancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company elected to not apply the recognition requirements of the new leasing standard to short-term leases with terms of 12 months or less which do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. For short-term leases, lease payments are recognized as operating expenses on a straight-line basis over the lease term.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the Company’s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 or for any future period. The balance sheet as of December 31, 2020 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K <span style="color:#000000;">filed with the SEC on February 25, 2021. There have been no significant changes to the Company’s significant accounting policies described in Note 2, Summary of Significant Accounting Policies, in Notes to Consolidated Financial Statements in Item 8 of Part II of the Form 10-K. </span></p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of Arcus Biosciences, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as related disclosures of contingent assets and liabilities. Estimates were used to determine the standalone selling price of performance obligations and the timing of revenue recognition, the value of stock-based awards and other issuances, accruals for research and development costs, useful lives of long-lived assets, and uncertain tax positions. Actual results could differ materially from the Company’s estimates. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Equivalents and Investments </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents include marketable securities having an original maturity of three months or less at the time of purchase. Short-term investments have maturities of greater than three months and up to twelve months at the time of purchase. Long-term investments have maturities greater than 12 months at the time of purchase. Collectively, cash equivalents, short-term and long-term investments are considered available-for-sale and are recorded at fair value. Unrealized gains and losses are recorded in accumulated other comprehensive income (loss). Realized gains and losses are included in interest and other income, net in the condensed consolidated statements of operations and comprehensive income or loss. <span style="color:#000000;">The basis on which the cost of a security that is sold or an amount that is reclassified out of accumulated other comprehensive income or loss into earnings is determined using the specific identification method.</span></p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#212529;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reconciliation of Cash, Cash Equivalents, and Restricted Cash as Reported in Condensed Consolidated Statements of Cash Flows</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash at March 31, 2021 and 2020 represents cash balances held as security in connection with the Company’s facility lease agreements. <span style="color:#000000;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the condensed consolidated balance sheets to the total shown in the condensed consolidated statements of cash flows (in thousands):</span></p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.54%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">390,260</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,326</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.54%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,988</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.54%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">392,248</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,529</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;"> </p> Restricted cash at March 31, 2021 and 2020 represents cash balances held as security in connection with the Company’s facility lease agreements. <span style="color:#000000;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the condensed consolidated balance sheets to the total shown in the condensed consolidated statements of cash flows (in thousands):</span> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.54%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">390,260</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,326</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.54%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,988</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.54%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">392,248</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,529</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;"> </p> 390260000 67326000 1988000 203000 392248000 67529000 <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents, short-term and long-term investments are financial instruments that potentially subject the Company to concentrations of credit risk. The Company invests in money market funds, treasury bills and notes, government bonds, commercial paper and corporate notes. The Company limits its credit risk associated with cash equivalents, short-term and long-term investments by placing them with banks and institutions it believes are credit worthy and in highly rated investments. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases and Rent Expense</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. The Company determines whether an arrangement is or contains a lease at contract inception. Operating leases are included in operating lease right-of-use assets, other current liabilities, and operating lease liabilities, noncurrent in our condensed consolidated balance sheets at March 31, 2021 and December 31, 2020. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date. The incremental borrowing rate represents the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company considers a lease term to be the noncancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company elected to not apply the recognition requirements of the new leasing standard to short-term leases with terms of 12 months or less which do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. For short-term leases, lease payments are recognized as operating expenses on a straight-line basis over the lease term.</p> <p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 3. Fair Value Measurements </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities are recorded at fair value. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the periods presented, the Company has not changed the manner in which it values assets and liabilities that are measured at fair value. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy as of March 31, 2021 and December 31, 2020. The following tables set forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Quoted Prices in</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active Markets For</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identical Assets)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Significant Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining Inputs)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Significant Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining Inputs)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362,762</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362,762</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206,460</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206,460</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,002</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,002</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities and commercial paper</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310,688</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310,688</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">884,912</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362,762</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">522,150</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Quoted Prices in</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active Markets For</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identical Assets)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Significant Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining Inputs)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Significant Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining Inputs)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,468</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,468</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301,112</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301,112</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency obligations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,001</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,001</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities and commercial paper</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,505</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,505</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.22%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">735,086</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,468</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">588,618</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as (with contractual maturities):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">390,260</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,415</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments (due within one year)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">436,666</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">555,231</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments (due between one and two years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,986</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,440</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and investments in marketable securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">884,912</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">735,086</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments in marketable securities are classified as available-for-sale. At March 31, 2021 and December 31, 2020, the balance in the Company’s accumulated other comprehensive income comprised activity related to the Company’s available-for-sale marketable securities. There were immaterial realized gains or losses recognized on the sale or maturity of available-for-sale marketable securities as of March 31, 2021 and December 31, 2020, and as a result, the Company did not reclassify any amounts out of accumulated other comprehensive income for the periods then ended. The Company has a limited number of available-for-sale marketable securities in loss positions as of March 31, 2021, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized cost for the investment at maturity. The fair value and amortized cost of investments in marketable securities by major security type as of March 31, 2021 and December 31, 2020 are presented in the tables that follow (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362,762</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362,762</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206,422</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206,460</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,002</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities and commercial paper</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310,730</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310,688</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">884,914</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">884,912</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,468</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,468</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301,075</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301,112</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,997</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,001</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities and commercial paper</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,502</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,505</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">735,042</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">735,086</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"> </p> 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 The following tables set forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Quoted Prices in</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active Markets For</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identical Assets)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Significant Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining Inputs)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Significant Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining Inputs)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362,762</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362,762</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206,460</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206,460</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,002</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,002</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities and commercial paper</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310,688</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310,688</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">884,912</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362,762</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">522,150</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Quoted Prices in</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active Markets For</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identical Assets)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Significant Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining Inputs)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Significant Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining Inputs)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,468</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,468</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301,112</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301,112</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency obligations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,001</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,001</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities and commercial paper</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,505</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,505</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.22%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">735,086</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,468</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">588,618</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 362762000 362762000 206460000 206460000 5002000 5002000 310688000 310688000 884912000 362762000 522150000 146468000 146468000 301112000 301112000 25001000 25001000 262505000 262505000 735086000 146468000 588618000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as (with contractual maturities):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">390,260</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,415</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments (due within one year)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">436,666</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">555,231</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments (due between one and two years)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,986</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,440</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and investments in marketable securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">884,912</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">735,086</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 390260000 173415000 436666000 555231000 57986000 6440000 884912000 735086000 0 0 The fair value and amortized cost of investments in marketable securities by major security type as of March 31, 2021 and December 31, 2020 are presented in the tables that follow (in thousands): <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362,762</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362,762</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206,422</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206,460</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,002</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities and commercial paper</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310,730</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310,688</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">884,914</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">884,912</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,468</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,468</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301,075</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301,112</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency obligations</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,997</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,001</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities and commercial paper</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,502</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,505</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">735,042</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">735,086</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 362762000 362762000 206422000 40000 2000 206460000 5000000 2000 5002000 310730000 14000 56000 310688000 884914000 56000 58000 884912000 146468000 146468000 301075000 38000 1000 301112000 24997000 4000 25001000 262502000 15000 12000 262505000 735042000 57000 13000 735086000 <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 4. Accrued Liabilities</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consisted of the following (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued personnel expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,128</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,632</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">295</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">341</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">616</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.02%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,536</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,543</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consisted of the following (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued personnel expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,128</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,632</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">295</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">341</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">616</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.02%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,536</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,543</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 7128000 8632000 67000 295000 341000 616000 7536000 9543000 <p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 5. Equity Investment in PACT Pharma</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company owns approximately 3.6 million shares of common stock, 1.0 million shares of Series A preferred stock, and warrants to purchase additional stock of PACT Pharma, Inc. (PACT Pharma), a clinical-stage biopharmaceutical company focused on pioneering individualized, non-viral precision genome engineered, tumor-specific T cell therapies for the treatment of patients with solid tumors. This interest in PACT Pharma is accounted for as an equity method investment, and as a result the Company records its share of PACT Pharma’s operating results in interest and other income, net, in its condensed consolidated statements of operations and comprehensive loss. The investment balance was zero at March 31, 2021 and December 31, 2020. Since the Company has no obligation to provide cash financing to PACT Pharma, the Company is not required to record losses beyond the carrying amount of the investment.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January and June 2020, PACT Pharma issued shares in its Series C and Series C-1 preferred stock financings. The Company did not participate in these financings. The decrease in the Company’s equity ownership percentage and increase in PACT Pharma’s estimated fair value per share resulted in gains on dilution totaling $1.3 million during the three months ended March 31, 2020. After applying $0.8 million in losses accumulated in prior periods when the equity investment balance was zero, the Company recorded a gain of $0.5 million for the three months ended March 31, 2020. There was no similar gain on dilution in the quarter ended March 31, 2021. For the three months ended March 31, 2021, the Company accounted for its $0.8 million share of PACT Pharma’s losses as unrecognized equity method losses.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s share of PACT Pharma’s losses for the three months ended March 31, 2021 and 2020 exceeded gains for the same periods. The Company recorded zero and $0.5 million for its share of PACT Pharma’s operating losses for the three months ended March 31, 2021 and 2020, respectively. The unrecognized equity method losses in excess of the Company’s investment was $2.1 million as of March 31, 2021.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March 31, 2021 and December 31, 2020, the Company determined the fair value of the warrants to be insignificant to the condensed consolidated financial statements.</p> 3600000 1000000.0 0 0 1300000 -800000 0 500000 0 -800000 0 500000 -2100000 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 6. License and Collaboration Agreements </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the revenues for the three months ended March 31, 2021 and 2020 received as a result of the Company’s collaboration agreements with Gilead Sciences, Inc. (Gilead) and Taiho Pharmaceutical Co., Ltd. (Taiho):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,461</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total collaboration and license revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,461</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"> </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes details of revenues for the three months ended March 31, 2021 and 2020 by collaboration and by category of revenue:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues recognized:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Over time</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Point in time</p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gilead access rights related to the Company's research</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   and development pipeline</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,711</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taiho collaboration agreement</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total collaboration and license revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,461</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized the following revenue as a result of changes in the deferred revenue balance during the period below (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized in the period from:</p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.6%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts included in deferred revenue at the beginning of the period</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,461</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.6%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance obligations satisfied in previous period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Gilead Sciences, Inc.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 27, 2020, the Company entered into an Option, License and Collaboration Agreement (Gilead Collaboration Agreement), Common Stock Purchase Agreement (the Stock Purchase Agreement), and Investor Rights Agreement, (collectively, the Gilead Agreements), each with Gilead Sciences, Inc. (Gilead). The transaction closed on July 13, 2020 following expiration of the antitrust waiting period. Upon closing, Gilead made an upfront payment of $175 million pursuant to the Gilead Collaboration Agreement, and made an equity investment of approximately $200 million in the Company by purchasing 5,963,029 shares of Arcus common stock at a per share price of $33.54 pursuant to the Stock Purchase Agreement. Pursuant to the Investor Rights Agreement, the Company appointed Gilead’s designees, Merdad Parsey, M.D., Ph.D. and Michael Quigley, Ph.D., to the Company’s Board of Directors.<span style="font-size:12pt;"> </span>See Note 11 for further discussion of the agreements with Gilead.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the Gilead Collaboration Agreement, Gilead has an exclusive license to develop and commercialize zimberelimab in certain markets and obtained exclusive options to acquire an exclusive license to develop and commercialize all of the Company’s current and future clinical programs during the 10-year collaboration term, contingent upon Gilead’s access rights payments of up to $400 million and, for those programs that enter clinical development prior to the end of the collaboration term, for up to an additional three years thereafter. Gilead may exercise its option, on a program-by-program basis, upon payment of an option fee that ranges from $200 million to $275 million per program for the Company’s clinical programs in existence at the date of the agreement, and $150 million per program for all other programs that enter clinical development thereafter should Gilead elect to exercise its options.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon Gilead’s exercise of its option to a program, the two companies will co-develop and equally share global development costs, subject to certain opt-out rights of the Company, and expense caps on the Company’s spending and related subsequent adjustments. For each optioned program, provided the Company has not exercised its opt-out rights, the Company has an option to co-promote in the United States with equal sharing of related profits and losses. Gilead has the right to exclusively commercialize any optioned programs outside of the U.S., subject to the rights of the Company’s existing partners to any territories, and Gilead will pay to the Company tiered royalties as a percentage of revenues ranging from the high teens to the low twenties. Gilead will further provide ongoing research and development support in the form of research and development pipeline access rights payments of up to $400 million over the collaboration term.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Stock Purchase Agreement and the Investor Rights Agreement, Gilead has the right, at its option, to purchase additional shares from the Company, up to a maximum of 35% of the Company’s then-outstanding voting common stock, from time to time over a five year period from closing of the initial transaction, at a purchase price equal to the greater of a 20% premium to market (based on a trailing <span style="-sec-ix-hidden:F_000428">five-day</span> average closing price) at the time Gilead exercises such option, and the $33.54 initial purchase price. Based on the value of the Company’s common stock at the contract closing, the right to purchase additional shares had no value. In January 2021, the Company and Gilead entered into an Amended and Restated Common Stock Purchase Agreement, which amended and restated in its entirety the Common Stock Purchase Agreement, pursuant to which Gilead purchased 5,650,000 shares of the Company’s common stock at a purchase price of $39.00 per share for total gross proceeds of $220.4 million. All other terms of the original Stock Purchase Agreement remain unchanged. The Investor Rights Agreement also includes a three-year standstill and a two-year lockup and provides Gilead with registration rights commencing at the end of the lockup period, pro rata participation rights in certain future financings and the right to designate two individuals to be appointed to the Company’s Board of Directors.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s assessment of the transaction price included an analysis of amounts it expected to receive, which at contract inception consisted of the upfront cash payment of $175.0 million due upon contract closing in July 2020, the $100.0 million payment related to the research and development access rights due in 2022, and the $90.6 million premium resulting from Gilead’s purchase of common stock. All payments to date have been made by Gilead as they became due and payable so given this successful collection history, the Company considers the entire $365.6 million outlined above to be the initial transaction price.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluated the Gilead Agreements under ASC 606 and determined that the performance obligations at the contract inception consisted of the following: </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Zimberelimab license</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective on closing, Gilead obtained an exclusive license to zimberelimab. The standalone selling price of this license was determined using a discounted cash flow method. The Company recognized the full revenues associated with this performance obligation on the date the transaction closed.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Etrumadenant option</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gilead has the right to exercise an option for exclusive rights to etrumadenant, the Company’s adenosine receptor program, in exchange for an option payment of $250.0 million, that expires after a proscribed period following the Company’s achievement of certain development milestones. The Company calculated the standalone selling price of this program using a discounted cash flow method and concluded that it exceeded the price of the option, creating a material right and a distinct performance obligation. <span style="color:#000000;">If the option is exercised, the performance obligations associated with the option will be identified and the Company will determine the accounting for the option’s transaction price. If the option is allowed to lapse after development milestones trigger the start of the opt-in period, the Company will recognize any deferred revenue allocated to the option at the time of the lapse.</span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March 31, 2021, the Company had $127.0 million of deferred revenue on its condensed consolidated balance sheets<span style="color:#000000;"> related to this performance obligation. The Company has evaluated the program’s status as of the balance sheet date and believes that some or all of the revenue associated with the opt-in will be recognized within the minimum <span style="-sec-ix-hidden:F_000439">four-year</span> term of the Gilead Collaboration Agreement.</span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Domvanalimab option</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gilead has the right to exercise an option for exclusive rights to domvanalimab, the Company’s anti-TIGIT monoclonal antibody, in exchange for an option payment of $275.0 million, that expires after a proscribed period following the Company’s achievement of certain development milestones. The Company calculated the standalone selling price of this program using a discounted cash flow method and concluded that it exceeded the price of the option, creating a material right and a distinct performance obligation. <span style="color:#000000;">If the option is exercised, the performance obligations associated with the option will be identified and will determine the accounting for the option’s transaction price. If the option is allowed to lapse after development milestones trigger the start of the opt-in period, the Company will recognize any deferred revenue allocated to the option at the time of the lapse.</span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March 31, 2021, the Company had $36.7 million of deferred revenue on its condensed consolidated balance sheets related to this performance obligation. The Company has evaluated the program’s status and believes that revenue associated with the opt-in will be recognized within one year.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Access rights related to the Company’s research and development pipeline</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gilead receives exclusive access to the Company’s current programs as well as the future programs for a period of ten years, contingent upon Gilead’s payment of $400 million, with the first payment of $100 million in 2022, and an additional $100 million payment due at Gilead’s option on each of the fourth, sixth, and eighth anniversaries of the agreement. The standalone selling price of this ongoing research and development pipeline access was determined using an expected cost-plus margin approach. The Company evaluated its rights and obligations in the Gilead Collaboration Agreement and determined that Gilead is contractually obligated to make the $100 million payment due in 2022 resulting in a minimum term of four years for this performance obligation. As a result, the amount was included in the transaction price. The Company uses a time-elapsed input method to measure progress toward satisfying this obligation, which is the method the Company believes most faithfully depicts the Company’s performance in transferring the promised services during the time period in which Gilead has access to the Company’s research and development pipeline. Accordingly, the revenue allocated to the performance obligation is being recognized using this input method over the minimum <span style="-sec-ix-hidden:F_000450">four-year</span> period. The Company further determined that Gilead is not obligated to pay the remaining $300 million due over the remainder of the term. Failure to pay the non-obligatory payments will result in Gilead’s loss of certain rights to access and obtain licenses to the programs arising from the Company’s research and development pipeline. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March 31, 2021, the Company had $114.0 million of deferred revenue on its consolidated balance sheets related to this performance obligation, classified between current and noncurrent based on the amortization of the revenue.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Development and commercialization services for zimberelimab monotherapy</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In conjunction with the license, the Company determined there existed a separate obligation to perform further development and commercialization services for Gilead. The standalone selling price of this obligation was determined using an expected cost-plus margin approach. This obligation includes a 50/50 share of the costs associated with all future development and commercialization of zimberelimab as a monotherapy. The portion of the transaction price allocated to this performance obligation has been allocated in accordance with the total costs forecast for the development and commercialization of zimberelimab as a monotherapy. The Company will recognize the amounts allocated to these services as the performance obligation is satisfied. Any additional payments received from or payments made to Gilead for the 50/50 cost share will be recognized as a reduction or an increase to R&amp;D expense, respectively. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March 31, 2021, the Company had $9.7 million of contract liabilities on its consolidated balance sheets related to this performance obligation. The Company has evaluated the program’s status and believes that revenue associated with these services will be recognized over the full term of the contract. As of March 31, 2021, no revenue had been recognized from this performance obligation.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gilead was also granted option rights to programs not yet in development. These programs were not determined to be performance obligations at contract inception, as there are no identified programs, revenues, or costs to compare against the option price.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurred $7.3 million in expenses to obtain the contract, which consisted of consultant and legal fees that were directly connected to the successful completion of the Gilead Agreements. The Company determined that $1.9 million of these expenses were related to the Stock Purchase Agreement and recorded them as offering costs. The Company allocated the remaining expenses between the various performance obligations, to be recognized when the underlying revenue is recognized. The portion allocated to the delivery of zimberelimab was recognized immediately, and the portion allocated to the remaining performance obligations will be recognized with timing consistent with the associated performance obligation. During the three months ended March 31, 2021, the Company recognized $0.1 million in expense from the amortization of these assets. At March 31, 2021, the Company had $4.1 million in prepaid expenses from costs to obtain the Gilead Agreements, of which $1.0 million was recorded in prepaid expenses and other current assets and $3.1 million was recorded in other long-term assets.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Taiho Pharmaceutical Co., Ltd </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2017, the Company and Taiho entered into an option and license agreement (the Taiho Agreement) to collaborate on the potential development and commercialization of certain investigational products from the Company’s portfolio in Japan and certain other territories in Asia (excluding China) (the Taiho Territory). The Taiho Agreement provides Taiho with exclusive options, over a <span style="-sec-ix-hidden:F_000461">five-year</span> period (the Option Period), to obtain an exclusive development and commercialization license to clinical stage investigational products from the Company’s programs (each, an Arcus Program). </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for the exclusive options and other rights contained in the Taiho Agreement, Taiho agreed to make non-refundable, non-creditable cash payments to the Company totaling $35.0 million, of which the Company received $25.0 million during 2017. An additional $5.0 million was received in 2018 and the remaining $5.0 million was received in 2019.<span style="font-size:12pt;"> </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that the Company has not initiated IND enabling studies for at least five Arcus Programs prior to the expiration of the Option Period, Taiho may elect to extend the Option Period, up to a maximum of seven years, subject to an extension fee. For each option that Taiho elects to exercise, it will be obligated to make an option exercise payment of between $3.0 million to $15.0 million, depending on the development stage of the applicable Arcus Program for which the option is exercised. In addition, the Taiho Agreement provides that the Company is eligible to receive additional clinical and regulatory milestones totaling up to $130.0 million </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">per Arcus Program, and it will be eligible to receive contingent payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145.0</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million per Arcus Program associated with the achievement of specified levels of Taiho net sales in the Taiho Territory. </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company will receive royalties ranging from high single-digits to mid-teens on net sales of licensed products in the Taiho Territory. Royalties will be payable on a licensed product-by-licensed product and country-by-country basis during the period of time commencing on the first commercial sale of a licensed product in a country and ending upon the later of: (a) ten (10) years from the date of first commercial sale of such licensed product in such country; and (b) expiration of the last-to-expire valid claim of the Company’s patents covering the manufacture, use or sale or exploitation of such licensed product in such country (the Royalty Term). </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the identified performance obligations, which include the combined performance obligation of the research and development services and the obligation to participate on the joint steering committee, are satisfied over time. The Company uses a time-elapsed input method to measure progress toward satisfying its performance obligation, which is the method the Company believes most faithfully depicts the Company’s performance in transferring the promised services during the time period in which Taiho has access to the Company’s research and development activities. Accordingly, the transaction price of $35.0 million is being recognized using this input method over the estimated performance period of five years.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the nature of the clinical and regulatory milestones, such as the regulatory approvals which are not within the Company’s control, the Company will not consider achievement of such milestones to be probable <span style="color:#000000;">until the uncertainty associated with the milestones has been resolved. When it is probable that a significant reversal of revenue will not occur, the milestone payment will be added to the transaction price, which will then be allocated to each performance obligation, on a relative standalone selling price basis, for which the Company recognizes revenue. </span>As of March 31, 2021, no clinical or regulatory milestones had been achieved under the Taiho Agreement.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also considers the contingent payments due from Taiho upon the achievement of specified sales volumes to be similar to royalty payments. The Company considers the <span style="color:#000000;">license to be the predominant item to which the royalties relate. The Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). As of March 31, 2021, no sales milestone or royalty revenue has been recognized.</span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Taiho Agreement shall remain in effect until expiry of all Royalty Terms for the licensed products, in each case subject to certain exceptions.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">WuXi Biologics License Agreements </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company entered into a license agreement (the WuXi PD-1 Agreement) with WuXi Biologics in August 2017, as subsequently amended, in which it obtained an exclusive license to develop, use, manufacture, and commercialize products including an anti-PD-1 antibody worldwide except for Greater China and Thailand. From the inception of the WuXi PD-1 Agreement through March 31, 2021, the Company has made upfront and milestone payments of $41.0 million and incurred sub-license fees of $11.3 million. These payments were recorded as research and development expense, as the products had not reached technological feasibility and did not have an alternative future use. The WuXi PD-1 Agreement also provides for clinical and regulatory milestone payments, commercialization milestone payments of up to $375.0 million, and tiered royalty payments to be made to WuXi Biologics that range from the high single-digits to low teens of net sales by the Company of licensed products.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurred $10.0 million in development milestone expense under the WuXi PD-1 Agreement during the three months ended March 31, 2021. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company entered into a separate license agreement (the WuXi CD-39 Agreement) with WuXi Biologics to develop anti-CD39 antibodies. Under the agreement, the Company was granted exclusive worldwide rights to anti-CD39 antibodies discovered under the collaboration and will be responsible for the further development and commercialization of those antibodies. From the inception of the WuXi CD-39 Agreement through March 31, 2021, the Company has paid $0.5 million in upfront payments which was recorded in research and development expense, as the products are still in research stage. The WuXi CD-39 Agreement provides for clinical and regulatory milestone payments totaling $16.5 million, and royalty payments in the low single digits of net sales by the Company of licensed products.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Abmuno License Agreement </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, the Company entered into a license agreement (the Abmuno Agreement) with Abmuno Therapeutics LLC (Abmuno) for a worldwide exclusive license to develop, use, manufacture, and commercialize products that include an anti-TIGIT antibody, including domvanalimab (formerly referred to as AB154). Under the Abmuno Agreement, the Company has made upfront and milestone payments totaling $14.6 million as of March 31, 2021.<span style="color:#FF0000;"> </span>The Abmuno Agreement also provides for additional clinical, regulatory and commercialization milestone remaining payments of up to $93.0 million as of March 31, 2021. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurred $5.0 million in development milestone expense under the Abmuno Agreement during the three months ended March 31, 2021.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Genentech Collaboration Agreement </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Company and Genentech, through F. Hoffmann-La Roche Ltd (collectively, Genentech) entered into a Master Clinical Collaboration Agreement (the Genentech Agreement) pursuant to which the parties may conduct combination clinical studies involving Genentech’s monoclonal antibody, atezolizumab and the Company’s investigational products. Pursuant to the Genentech Agreement, the parties entered into Trial Supplements for the evaluation of etrumadenant and atezolizumab utilizing the MORPHEUS platform in two separate study indications: second and third line metastatic colorectal cancer and first line metastatic pancreatic cancer. The Company and Genentech will each supply their respective investigational products for use in the collaboration studies and will share a portion of the development costs under specific terms as set forth in the agreement. From the inception of the Agreement through March 31, 2021, the Company has incurred net expenses of $0.8 million.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2021 and 2020, the Company incurred expenses pursuant to the Genentech Agreement of $0.3 million and zero, respectively. Net expenses related to this co-development agreement are recorded within research and development expenses.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Strata Collaboration Agreement</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 30, 2019, the Company and Strata Oncology, Inc. (Strata) entered into a Co-Development and Collaboration Agreement (the Strata Agreement) to pursue a clinical development collaboration utilizing Strata’s precision drug development platform and proprietary biomarkers to evaluate zimberelimab, the Company’s clinical-stage anti-PD-1 antibody, in patients in a tumor-agnostic fashion.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Strata Agreement, the parties will share a portion of development costs for the clinical collaboration under specified terms. Strata is eligible to receive $2.5 million upon the achievement of a development milestone, as well as regulatory and commercial milestones of up to $125.0 million and up to double-digit royalties on U.S. net sales of zimberelimab in the biomarker-identified indication. From the inception of the Agreement through March 31, 2021, the Company has made a milestone payment of $2.5 million and has incurred expenses of $3.3 million, of which $0.7 million had been reimbursed by Strata as development cost sharing. Net expenses related to this co-development agreement were recorded within research and development expenses.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As further consideration in connection with the Strata Agreement, the Company issued to Strata 1,257,651 restricted shares of its common stock with an initial measured fair value of $15.0 million, which are subject to vesting based upon the achievement of specified regulatory milestones within certain timelines. Expense relating to the restricted shares subject to these milestones is recognized if it is considered probable that the associated shares will vest. The probability of achievement is assessed at the end of each quarterly period. As of March 31, 2021, the Company determined that none of the restricted shares were probable of vesting and, as a result, no compensation expense related to the restricted shares has been recognized to date.<span style="font-size:12pt;"> </span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2021 and 2020, the Company incurred expenses pursuant to the Strata Agreement of $0.6 million and $0.4 million, respectively. Of these expenses, $0.1 million have been reimbursed by Strata as development cost sharing for each of the three months ended March 31, 2021 and 2020. Net expenses related to this co-development agreement are recorded within research and development expenses.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">AstraZeneca Agreement </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 29, 2020 the Company announced a collaboration with AstraZeneca to evaluate domvanalimab, the Company’s investigational anti-TIGIT antibody, in combination with AstraZeneca’s Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer (NSCLC). Under the terms of the agreement, each company will retain existing rights to their respective molecules and any future commercial economics. AstraZeneca will conduct the trial, and each company will supply its respective anti-cancer agent to support the trial. Under the terms of the agreement and subject to the parties’ approval of a final budget for the clinical trial, the Company may be obligated to reimburse AstraZeneca for a portion of the costs incurred.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consistent with the terms of the Gilead Collaboration Agreement, Gilead maintains an option to co-develop and co-commercialize domvanalimab. If Gilead exercises its option to domvanalimab, the trial from this AstraZeneca collaboration is expected to form part of the Arcus and Gilead joint development program and Arcus’s portion of the trial costs would be shared with Gilead.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2021, the Company incurred immaterial expenses pursuant to the AstraZeneca Agreement. Expense from this co-development agreement are recorded within research and development expenses.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the revenues for the three months ended March 31, 2021 and 2020 received as a result of the Company’s collaboration agreements with Gilead Sciences, Inc. (Gilead) and Taiho Pharmaceutical Co., Ltd. (Taiho):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,461</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total collaboration and license revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,461</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 9461000 1750000 9461000 1750000 <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes details of revenues for the three months ended March 31, 2021 and 2020 by collaboration and by category of revenue:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues recognized:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Over time</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Point in time</p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.86%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gilead access rights related to the Company's research</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   and development pipeline</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,711</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taiho collaboration agreement</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">*</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.86%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total collaboration and license revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,461</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 7711000 1750000 1750000 9461000 1750000 The Company recognized the following revenue as a result of changes in the deferred revenue balance during the period below (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized in the period from:</p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.6%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts included in deferred revenue at the beginning of the period</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,461</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.6%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance obligations satisfied in previous period</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 9461000 1750000 175000000 200000000 5963029 33.54 400000000 P3Y 200000000 275000000 150000000 400000000 0.35 P5Y 0.20 33.54 5650000 39.00 220400000 175000000.0 100000000.0 90600000 365600000 250000000.0 127000000.0 275000000.0 36700000 P1Y P10Y 400000000 100000000 2022 100000000 100000000 P4Y 300000000 114000000.0 9700000 0 7300000 1900000 100000 4100000 1000000.0 3100000 35000000.0 25000000.0 5000000.0 5000000.0 5 P7Y 3000000.0 15000000.0 130000000.0 145000000.0 high single-digits to mid-teens Royalties will be payable on a licensed product-by-licensed product and country-by-country basis during the period of time commencing on the first commercial sale of a licensed product in a country and ending upon the later of: (a) ten (10) years from the date of first commercial sale of such licensed product in such country; and (b) expiration of the last-to-expire valid claim of the Company’s patents covering the manufacture, use or sale or exploitation of such licensed product in such country (the Royalty Term). 35000000.0 P5Y 0 0 41000000.0 11300000 375000000.0 high single-digits to low teens 10000000.0 500000 16500000 14600000 93000000.0 5000000.0 800000 300000 0 2500000 125000000.0 2500000 3300000 700000 1257651 15000000.0 0 0 600000 400000 100000 100000 <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 7. Stockholders’ Equity</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, pursuant to a shelf registration statement on Form S-3 that was filed in May 2020, the Company issued 12,650,000 shares of its common stock at $27.50 per share in an underwritten public offering (the May 2020 Public Offering). The total number of shares sold consisted of 11,000,000 base shares and an additional 1,650,000 shares sold pursuant to the underwriters’ option exercise. Net proceeds from the May 2020 Public Offering were approximately $326.2 million after deducting underwriting discounts, commissions and other offering expenses.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company closed the Gilead Collaboration Agreement, Common Stock Purchase Agreement, and the Investor Rights Agreement, each signed with Gilead in May 2020. The transaction closed on July 13, 2020 following expiration of the antitrust waiting period. Upon closing, Gilead made an equity investment of approximately $200 million in the Company by purchasing 5,963,029 shares of Arcus common stock at a per share price of $33.54 pursuant to the Stock Purchase Agreement. Of the $200 million equity investment, approximately $90.6 million was determined to be a premium on the purchase of common stock and allocated to the performance obligations created by the Gilead Collaboration Agreement. See Note 6 in this Form 10-Q for further discussion of the agreements with Gilead. Net proceeds from Gilead’s equity investment were approximately $107.5 million after allocating the premium and deducting direct offering expenses of $1.9 million.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, the Company closed the Amended and Restated Common Stock Purchase Agreement with Gilead, pursuant to which Gilead made an equity investment of approximately $220.4 million in the Company by purchasing 5,650,000 shares of the Company’s common stock at a per share price of $39.00.</p> 12650000 27.50 11000000 1650000 326200000 200000000 5963029 33.54 200000000 90600000 107500000 1900000 220400000 5650000 39.00 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 8. Stock-Based Compensation<span style="font-weight:normal;"> </span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;"> </p> <p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company grants awards under its 2018 Equity Incentive Plan and the 2020 Inducement Plan. Total stock-based compensation expense was recognized in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,170</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,736</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.54%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,591</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,726</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.54%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,761</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,462</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> Total stock-based compensation expense was recognized in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.54%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,170</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,736</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.54%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,591</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,726</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.54%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,761</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,462</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 6170000 1736000 6591000 1726000 12761000 3462000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 9. Net Loss per Share </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated based on the weighted-average number of shares of the Company’s common stock during the period. Diluted net loss per share is calculated based on the weighted-average number of shares of the Company’s common stock and other dilutive securities outstanding during the period.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data): </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,593</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,753</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,476,799</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,953,213</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: weighted-average common shares subject to vesting</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,394,638</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,670,606</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares used to compute basic and diluted net loss per share</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,082,161</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,282,607</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share: basic and diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.08</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.63</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding potentially dilutive securities were excluded from the computation of diluted net loss per share because including them would have been antidilutive:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,708,625</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,725,835</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted common stock issued as part of</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  collaboration agreement</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,257,651</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,257,651</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested early exercised common stock options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,094</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">375,615</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock units</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,532,162</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan shares</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,591</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,706,123</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,359,101</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also excluded the effect of Gilead’s right to purchase additional shares of the Company’s common stock from its calculation as these rights had no intrinsic value at March 31, 2021.</p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data): </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,593</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,753</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,476,799</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,953,213</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: weighted-average common shares subject to vesting</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,394,638</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,670,606</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares used to compute basic and diluted net loss per share</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,082,161</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,282,607</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share: basic and diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.08</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.63</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> -72593000 -27753000 68476799 45953213 1394638 1670606 67082161 44282607 -1.08 -0.63 <p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding potentially dilutive securities were excluded from the computation of diluted net loss per share because including them would have been antidilutive:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,708,625</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,725,835</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted common stock issued as part of</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  collaboration agreement</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,257,651</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,257,651</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested early exercised common stock options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,094</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">375,615</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock units</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,532,162</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan shares</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,591</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.96%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,706,123</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,359,101</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 11708625 6725835 1257651 1257651 111094 375615 1532162 96591 14706123 8359101 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 10. Commitments</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Standby Letters of Credit</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has standby letters of credit up to an aggregate of $2.0 million provided as collateral for its leases. The letters of credit are secured by $2.0 million in deposits classified as restricted cash on the Company’s condensed consolidated balance sheets. At March 31, 2021 the facilities were not drawn down.</p> 2000000.0 2000000.0 <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.37%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 11. Related parties</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Relationship and transactions with Gilead Sciences, Inc. (Gilead)</p> <p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, Gilead held approximately 19.5% of the Company’s outstanding common stock. These holdings resulted from Gilead’s participation in the May 2020 Public Offering as well as purchases of stock under the stock purchase agreements. In the May 2020 public offering, Gilead purchased 2,200,000 shares of common stock for an amount of $56.7 million, net of offering costs. Under the stock purchase agreements, Gilead purchased 5,963,029 and 5,650,000 shares in July 2020 and February 2021, respectively, for a total investment of $327.8 million, net of offering costs. Gilead has the right, at its option, to purchase up to a maximum of 35% of the Company’s then-outstanding voting common stock, from time to time over a five-year period from the closing of the initial transaction in July 2020. Gilead also has the right under the Investor Rights Agreement to designate two individuals to be appointed to the Company’s board of directors. Pursuant to the Investor Rights Agreement, the Company appointed the Gilead designees, Merdad Parsey, M.D., Ph.D. and Michael Quigley, Ph.D., to its board of directors, in July 2020 and January 2021, respectively. See Note 6 for further discussion of the agreements with Gilead.</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.4%;margin-right:0.37%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.4%;margin-right:0.37%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March 31, 2021, the Company had a $4.9 million cost sharing receivable recorded on the condensed consolidated balance sheets under receivable from collaboration partners, to be invoiced the following quarter. The Company also had $177.7 million in deferred revenue at March 31, 2021, of which $110.1 million represented the long-term portion of revenue allocated to performance obligations not expected to be completed within one year of the balance sheet date, which was recorded in deferred revenue, noncurrent on the condensed consolidated balance sheets. The Company also had $9.7 million in contract liabilities for future development and commercialization services which Gilead prepaid, all of which was recorded in other long-term liabilities on the consolidated balance sheets.</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.4%;margin-right:0.37%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.4%;margin-right:0.37%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2021, the Company recognized $7.7 million in revenue under the Gilead Collaboration Agreement. The Company also recognized a $4.9 million reduction in research and development expense, including $4.0 million of cost sharing reimbursement related to milestone expense, related to its cost-sharing provisions of the agreement.</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.4%;margin-right:0.37%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.4%;margin-right:0.37%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company received a $175 million upfront payment from Gilead in connection with the Gilead Collaboration Agreement in July 2020 and identified $100 million in unconstrained consideration to be received in 2022. In addition, in July 2020 the Company received $200 million from Gilead in connection with the Stock Purchase Agreement, of which approximately $109.4 million represented the fair value of stock purchased at the transaction closing date with the remaining premium of $90.6 million allocated to the transaction price. In February 2021, the Company received $220.4 million from Gilead in connection with the purchase by Gilead of 5,650,000 shares of the Company’s common stock at a per share price of $39.00 pursuant to the amended and restated Stock Purchase Agreement.</p> 0.195 2200000 56700000 5963029 5650000 327800000 0.35 4900000 177700000 110100000 9700000 7700000 4900000 4000000.0 175000000 100000000 200000000 109400000 90600000 220400000 5650000 39.00 <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.4%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 12. Subsequent event</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.4%;margin-right:0.37%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2021, the Company entered into a lease amendment that modifies rent schedules for its existing operating leases in Hayward, California, extends the terms of those leases, and adds 14,460 square feet of additional space in Hayward in a new operating lease expected to commence in 2022. Any extension periods defined under previous amendments are cancelled under the lease amendment and replaced by two options to extend the lease term for the entire Hayward premises for a period of eight years each. The amended leases will end at the same time as the Company’s lease of its building in Brisbane, expected to be no earlier than December 2031. The lease amendment includes approximately $43 million in additional undiscounted future minimum lease payments throughout the expected term and provides additional tenant improvement allowances totaling $5.8 million with options to increase the allowance by $10.9 million.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lease amendment requires an additional $1.0 million in collateral for the operating leases in Hayward. In accordance with this requirement, the Company issued an additional $1.0 million letter of credit in April 2021.</p> 14460 2022 Any extension periods defined under previous amendments are cancelled under the lease amendment and replaced by two options to extend the lease term for the entire Hayward premises for a period of eight years each. P8Y 2031-12 43000000 5800000 10900000 1000000.0 1000000.0 The Condensed Consolidated Balance Sheet as of December 31, 2020 has been derived from the audited financial statements as of that date. The balances as of December 31, 2020 and 2019 have been derived from the audited financial statements as of that date. XML 13 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2021
Apr. 30, 2021
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Mar. 31, 2021  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q1  
Trading Symbol RCUS  
Entity Registrant Name Arcus Biosciences, Inc.  
Entity Central Index Key 0001724521  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Current Reporting Status Yes  
Entity Shell Company false  
Entity File Number 001-38419  
Entity Tax Identification Number 47-3898435  
Entity Address, Address Line One 3928 Point Eden Way  
Entity Address, City or Town Hayward  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 94545  
City Area Code 510  
Local Phone Number 694-6200  
Entity Common Stock, Shares Outstanding   70,995,860
Entity Interactive Data Current Yes  
Title of 12(b) Security Common Stock, Par Value $0.0001 Per Share  
Security Exchange Name NYSE  
Entity Incorporation, State or Country Code DE  
Document Quarterly Report true  
Document Transition Report false  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
[1]
Current assets:    
Cash and cash equivalents $ 390,260 $ 173,415
Short-term investments 436,666 555,231
Receivable from collaboration partners ($4,924 and $943 from a related party) 5,235 1,049
Accrued interest receivable 1,029 649
Prepaid expenses and other current assets 8,680 5,471
Total current assets 841,870 735,815
Long-term investments 57,986 6,440
Property and equipment, net 14,849 10,807
Right-of-use assets 12,243 12,781
Restricted cash 1,988 203
Other long-term assets 6,183 6,246
Total assets 935,119 772,292
Current liabilities:    
Accounts payable 24,544 15,682
Accrued research and development expenses 23,023 18,307
Other accrued liabilities 7,536 9,543
Deferred revenue, current ($67,571 and $67,571 to a related party) 74,571 74,571
Other current liabilities 2,381 3,566
Total current liabilities 132,055 121,669
Deferred revenue, noncurrent ($110,097 and $117,808 to a related party) 113,369 122,830
Operating lease liabilities, noncurrent 14,706 15,243
Other long-term liabilities ($9,703 and $9,703 to a related party) 10,199 10,246
Total liabilities 270,329 269,988
Commitments (Note 10)
Stockholders’ equity:    
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of March 31, 2021 and December 31, 2020; no shares issued and outstanding as of March 31, 2021 and December 31, 2020 0 0
Common stock, $0.0001 par value, 400,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 70,965,513 and 65,114,685 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively 7 6
Additional paid-in capital 1,065,562 830,438
Accumulated deficit (400,777) (328,184)
Accumulated other comprehensive (loss) income (2) 44
Total stockholders’ equity 664,790 502,304 [2]
Total liabilities and stockholders’ equity $ 935,119 $ 772,292
[1] The Condensed Consolidated Balance Sheet as of December 31, 2020 has been derived from the audited financial statements as of that date.
[2] The balances as of December 31, 2020 and 2019 have been derived from the audited financial statements as of that date.
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Statement Of Financial Position [Abstract]    
Related party, receivable from collaboration partners $ 4,924 $ 943
Related party, deferred revenue - current 67,571 67,571
Related party, deferred revenue - noncurrent 110,097 117,808
Related party, other long-term liabilities $ 9,703 $ 9,703
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 400,000,000 400,000,000
Common stock, shares issued 70,965,513 65,114,685
Common stock, shares outstanding 70,965,513 65,114,685
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenues:    
Total collaboration and license revenues $ 9,461 $ 1,750
Type of Revenue [Extensible List] Collaboration Collaboration
Total collaboration and license revenues $ 9,461 $ 1,750
Operating expenses:    
Research and development (($4,924) and $0 from a related party) 66,387 23,142
General and administrative 15,821 7,008
Total operating expenses 82,208 30,150
Loss from operations (72,747) (28,400)
Non-operating income (expense):    
Interest and other income, net 154 647
Gain on deemed sale from equity method investee   482
Share of loss from equity method investee   (482)
Total non-operating income, net 154 647
Net loss (72,593) (27,753)
Other comprehensive income (loss) (46) 224
Comprehensive loss $ (72,639) $ (27,529)
Net loss per share, basic and diluted $ (1.08) $ (0.63)
Weighted-average number of shares used to compute basic and diluted net loss per share 67,082,161 44,282,607
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenue from related parties $ 7,711 $ 0
Type of Revenue [Extensible List] Collaboration Collaboration
Research and Development    
Reimbursement from related party for shared costs $ (4,924) $ 0
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Purchase Agreement
Gilead
Common Stock
Common Stock
Purchase Agreement
Gilead
Additional Paid-In Capital
Additional Paid-In Capital
Purchase Agreement
Gilead
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Balance at Dec. 31, 2019 [1] $ 163,842   $ 4   $ 369,100   $ (205,326) $ 64
Balance, shares at Dec. 31, 2019 [1]     44,212,195          
Issuance of common stock upon exercise of stock options 643       643      
Issuance of common stock upon exercise of stock options, shares     59,939          
Vesting of early exercised stock options 220       220      
Vesting of early exercised stock options, shares     77,388          
Stock-based compensation 3,462       3,462      
Other comprehensive income (loss) 224             224
Net loss (27,753)           (27,753)  
Balance at Mar. 31, 2020 140,638   $ 4   373,425   (233,079) 288
Balance, shares at Mar. 31, 2020     44,349,522          
Balance at Dec. 31, 2020 [1] $ 502,304 [2]   $ 6   830,438   (328,184) 44
Balance, shares at Dec. 31, 2020 65,114,685   63,691,901 [1]          
Issuance of common stock and rights to purchase additional shares in accordance with Amended and Restated Gilead Purchase Agreement, net of $55 offering costs   $ 220,296   $ 1   $ 220,295    
Issuance of common stock and rights to purchase additional shares in accordance with Amended and Restated Gilead Purchase Agreement, net of $55 offering costs, Shares       5,650,000        
Issuance of common stock upon exercise of stock options and vesting of restricted stock $ 1,885       1,885      
Issuance of common stock upon exercise of stock options and vesting of restricted stock, shares     200,828          
Vesting of early exercised stock options 183       183      
Vesting of early exercised stock options, shares     54,039          
Stock-based compensation 12,761       12,761      
Other comprehensive income (loss) (46)             (46)
Net loss (72,593)           (72,593)  
Balance at Mar. 31, 2021 $ 664,790   $ 7   $ 1,065,562   $ (400,777) $ (2)
Balance, shares at Mar. 31, 2021 70,965,513   69,596,768          
[1] The balances as of December 31, 2020 and 2019 have been derived from the audited financial statements as of that date.
[2] The Condensed Consolidated Balance Sheet as of December 31, 2020 has been derived from the audited financial statements as of that date.
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)
$ in Thousands
3 Months Ended
Mar. 31, 2021
USD ($)
Purchase Agreement | Gilead  
Offering costs $ 55
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash flow from operating activities    
Net loss $ (72,593) $ (27,753)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 12,761 3,462
Depreciation and amortization 800 842
Amortization of right-of-use assets 538 144
Amortization of premiums on investments 506 (248)
Changes in operating assets and liabilities:    
Receivable from collaboration partners (($3,981) and $0 from a related party) (4,186) (212)
Prepaid expenses and other current assets (4,568) (3,704)
Other long-term assets 63 (91)
Accounts payable 7,722 (2,342)
Accrued research and development expenses 4,716 2,226
Other accrued liabilities (2,007) (1,578)
Deferred revenue (($7,711) and $0 to a related party) (9,461) (1,750)
Operating lease liabilities (605) (273)
Other long-term liabilities (2)  
Net cash used in operating activities (66,316) (31,277)
Cash flow from investing activities    
Purchases of short-term and long-term investments (192,398) (8,885)
Proceeds from maturities of short-term and long-term investments 251,365 49,150
Sales of short-term and long-term investments 7,500  
Purchases of property and equipment (3,641) (209)
Net cash provided by investing activities 62,826 40,056
Cash flow from financing activities    
Proceeds from issuance of common stock to related party 220,235  
Proceeds from issuance of common stock pursuant to equity award plans 1,885 643
Repurchase of unvested shares of stock   (33)
Net cash provided by financing activities 222,120 610
Net increase in cash and cash equivalents 218,630 9,389
Cash, cash equivalents and restricted cash at beginning of period 173,618 58,140
Cash, cash equivalents and restricted cash at end of period 392,248 67,529
Supplemental disclosures:    
Cash paid for amounts included in measurement of lease liabilities 927 519
Non-cash investing and financing activities:    
Unpaid portion of property and equipment purchases included in accounts payable and accrued liabilities 2,784 76
Vesting of early exercised stock options $ 183 $ 220
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Statement Of Cash Flows [Abstract]    
Receivable from related party $ (3,981) $ 0
Deferred revenue from related party $ (7,711) $ 0
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Organization
3 Months Ended
Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Organization

Note 1. Organization

Description of Business

Arcus Biosciences, Inc. (the Company) is a clinical-stage biopharmaceutical company focused on creating best-in-class cancer therapies. The Company’s initial focus has been on well-characterized biological pathways with significant scientific data supporting their importance. Since its inception in 2015, the Company has built a robust and highly efficient drug discovery capability to create highly differentiated small molecules, which the Company is developing in combination with its in-licensed monoclonal antibodies through rationally designed, indication-specific clinical trial designs. The Company currently has five investigational products in clinical development: domvanalimab (formerly referred to as AB154), etrumadenant (formerly referred to as AB928), AB680, zimberelimab (formerly referred to as AB122), and AB308.

Liquidity and Capital Resources

As of March 31, 2021, the Company had cash and investments of $884.9 million, which are cash, cash equivalents, and investments in marketable securities, which the Company believes will be sufficient to fund its planned operations for a period of at least twelve months following the date of filing of this report.

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Significant Accounting Policies
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Significant Accounting Policies

Note 2. Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the Company’s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.

Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 or for any future period. The balance sheet as of December 31, 2020 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.

The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K filed with the SEC on February 25, 2021. There have been no significant changes to the Company’s significant accounting policies described in Note 2, Summary of Significant Accounting Policies, in Notes to Consolidated Financial Statements in Item 8 of Part II of the Form 10-K.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Arcus Biosciences, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as related disclosures of contingent assets and liabilities. Estimates were used to determine the standalone selling price of performance obligations and the timing of revenue recognition, the value of stock-based awards and other issuances, accruals for research and development costs, useful lives of long-lived assets, and uncertain tax positions. Actual results could differ materially from the Company’s estimates.

Cash Equivalents and Investments

Cash equivalents include marketable securities having an original maturity of three months or less at the time of purchase. Short-term investments have maturities of greater than three months and up to twelve months at the time of purchase. Long-term investments have maturities greater than 12 months at the time of purchase. Collectively, cash equivalents, short-term and long-term investments are considered available-for-sale and are recorded at fair value. Unrealized gains and losses are recorded in accumulated other comprehensive income (loss). Realized gains and losses are included in interest and other income, net in the condensed consolidated statements of operations and comprehensive income or loss. The basis on which the cost of a security that is sold or an amount that is reclassified out of accumulated other comprehensive income or loss into earnings is determined using the specific identification method.

Reconciliation of Cash, Cash Equivalents, and Restricted Cash as Reported in Condensed Consolidated Statements of Cash Flows

Restricted cash at March 31, 2021 and 2020 represents cash balances held as security in connection with the Company’s facility lease agreements. The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the condensed consolidated balance sheets to the total shown in the condensed consolidated statements of cash flows (in thousands):

 

 

March 31,

 

 

 

2021

 

 

2020

 

Cash and cash equivalents

 

$

390,260

 

 

$

67,326

 

Restricted cash

 

 

1,988

 

 

 

203

 

Cash, cash equivalents and restricted cash

 

 

392,248

 

 

$

67,529

 

 

Concentration of Credit Risk

Cash equivalents, short-term and long-term investments are financial instruments that potentially subject the Company to concentrations of credit risk. The Company invests in money market funds, treasury bills and notes, government bonds, commercial paper and corporate notes. The Company limits its credit risk associated with cash equivalents, short-term and long-term investments by placing them with banks and institutions it believes are credit worthy and in highly rated investments.

Leases and Rent Expense

The Company recognizes a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. The Company determines whether an arrangement is or contains a lease at contract inception. Operating leases are included in operating lease right-of-use assets, other current liabilities, and operating lease liabilities, noncurrent in our condensed consolidated balance sheets at March 31, 2021 and December 31, 2020. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date. The incremental borrowing rate represents the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company considers a lease term to be the noncancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.

The Company elected to not apply the recognition requirements of the new leasing standard to short-term leases with terms of 12 months or less which do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. For short-term leases, lease payments are recognized as operating expenses on a straight-line basis over the lease term.

 

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements
3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements

Note 3. Fair Value Measurements

Financial assets and liabilities are recorded at fair value. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.

During the periods presented, the Company has not changed the manner in which it values assets and liabilities that are measured at fair value. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy as of March 31, 2021 and December 31, 2020. The following tables set forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):

 

 

 

March 31, 2021

 

 

 

Total

 

 

Level 1

(Quoted Prices in

Active Markets For

Identical Assets)

 

 

Level 2

(Significant Other

Observable

Remaining Inputs)

 

 

Level 3

(Significant Other

Unobservable

Remaining Inputs)

 

Money market funds

 

$

362,762

 

 

$

362,762

 

 

$

-

 

 

$

-

 

U.S. treasury securities

 

 

206,460

 

 

 

-

 

 

 

206,460

 

 

 

-

 

U.S. government agency securities

 

 

5,002

 

 

 

-

 

 

 

5,002

 

 

 

-

 

Corporate securities and commercial paper

 

 

310,688

 

 

 

-

 

 

 

310,688

 

 

 

-

 

Total assets measured at fair value

 

$

884,912

 

 

$

362,762

 

 

$

522,150

 

 

$

-

 

 

 

 

December 31, 2020

 

 

 

Total

 

 

Level 1

(Quoted Prices in

Active Markets For

Identical Assets)

 

 

Level 2

(Significant Other

Observable

Remaining Inputs)

 

 

Level 3

(Significant Other

Unobservable

Remaining Inputs)

 

Money market funds

 

$

146,468

 

 

$

146,468

 

 

$

-

 

 

$

-

 

U.S. treasury securities

 

 

301,112

 

 

 

-

 

 

 

301,112

 

 

 

-

 

U.S. government agency obligations

 

 

25,001

 

 

 

-

 

 

 

25,001

 

 

 

-

 

Corporate securities and commercial paper

 

 

262,505

 

 

 

-

 

 

 

262,505

 

 

 

-

 

Total assets measured at fair value

 

$

735,086

 

 

$

146,468

 

 

$

588,618

 

 

$

-

 

 

Classified as (with contractual maturities):

 

 

March 31, 2021

 

 

December 31, 2020

 

Cash and cash equivalents

 

$

390,260

 

 

$

173,415

 

Short-term investments (due within one year)

 

 

436,666

 

 

 

555,231

 

Long-term investments (due between one and two years)

 

 

57,986

 

 

 

6,440

 

Total cash, cash equivalents and investments in marketable securities

 

$

884,912

 

 

$

735,086

 

 

 

Investments in marketable securities are classified as available-for-sale. At March 31, 2021 and December 31, 2020, the balance in the Company’s accumulated other comprehensive income comprised activity related to the Company’s available-for-sale marketable securities. There were immaterial realized gains or losses recognized on the sale or maturity of available-for-sale marketable securities as of March 31, 2021 and December 31, 2020, and as a result, the Company did not reclassify any amounts out of accumulated other comprehensive income for the periods then ended. The Company has a limited number of available-for-sale marketable securities in loss positions as of March 31, 2021, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized cost for the investment at maturity. The fair value and amortized cost of investments in marketable securities by major security type as of March 31, 2021 and December 31, 2020 are presented in the tables that follow (in thousands):

 

 

 

Amortized

Cost

 

 

Unrealized

Gain

 

 

Unrealized

Loss

 

 

Fair

Value

 

As of March 31, 2021:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

362,762

 

 

$

-

 

 

$

-

 

 

$

362,762

 

U.S. treasury securities

 

 

206,422

 

 

 

40

 

 

 

(2

)

 

 

206,460

 

U.S. government agency securities

 

 

5,000

 

 

 

2

 

 

 

-

 

 

 

5,002

 

Corporate securities and commercial paper

 

 

310,730

 

 

 

14

 

 

 

(56

)

 

 

310,688

 

Total

 

$

884,914

 

 

$

56

 

 

$

(58

)

 

$

884,912

 

 

 

 

Amortized

Cost

 

 

Unrealized

Gain

 

 

Unrealized

Loss

 

 

Fair

Value

 

As of December 31, 2020:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

146,468

 

 

$

-

 

 

$

-

 

 

$

146,468

 

U.S. treasury securities

 

 

301,075

 

 

 

38

 

 

 

(1

)

 

 

301,112

 

U.S. government agency obligations

 

 

24,997

 

 

 

4

 

 

 

-

 

 

 

25,001

 

Corporate securities and commercial paper

 

 

262,502

 

 

 

15

 

 

 

(12

)

 

 

262,505

 

Total

 

$

735,042

 

 

$

57

 

 

$

(13

)

 

$

735,086

 

 

 

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued Liabilities
3 Months Ended
Mar. 31, 2021
Payables And Accruals [Abstract]  
Accrued Liabilities

Note 4. Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

 

 

 

As of March 31, 2021

 

 

As of December 31, 2020

 

Accrued personnel expenses

 

$

7,128

 

 

$

8,632

 

Professional fees

 

 

67

 

 

 

295

 

Other

 

 

341

 

 

 

616

 

Total

 

$

7,536

 

 

$

9,543

 

 

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Equity Investment in PACT Pharma
3 Months Ended
Mar. 31, 2021
Equity Method Investment [Abstract]  
Equity Investment in PACT Pharma

Note 5. Equity Investment in PACT Pharma

The Company owns approximately 3.6 million shares of common stock, 1.0 million shares of Series A preferred stock, and warrants to purchase additional stock of PACT Pharma, Inc. (PACT Pharma), a clinical-stage biopharmaceutical company focused on pioneering individualized, non-viral precision genome engineered, tumor-specific T cell therapies for the treatment of patients with solid tumors. This interest in PACT Pharma is accounted for as an equity method investment, and as a result the Company records its share of PACT Pharma’s operating results in interest and other income, net, in its condensed consolidated statements of operations and comprehensive loss. The investment balance was zero at March 31, 2021 and December 31, 2020. Since the Company has no obligation to provide cash financing to PACT Pharma, the Company is not required to record losses beyond the carrying amount of the investment.

In January and June 2020, PACT Pharma issued shares in its Series C and Series C-1 preferred stock financings. The Company did not participate in these financings. The decrease in the Company’s equity ownership percentage and increase in PACT Pharma’s estimated fair value per share resulted in gains on dilution totaling $1.3 million during the three months ended March 31, 2020. After applying $0.8 million in losses accumulated in prior periods when the equity investment balance was zero, the Company recorded a gain of $0.5 million for the three months ended March 31, 2020. There was no similar gain on dilution in the quarter ended March 31, 2021. For the three months ended March 31, 2021, the Company accounted for its $0.8 million share of PACT Pharma’s losses as unrecognized equity method losses.

The Company’s share of PACT Pharma’s losses for the three months ended March 31, 2021 and 2020 exceeded gains for the same periods. The Company recorded zero and $0.5 million for its share of PACT Pharma’s operating losses for the three months ended March 31, 2021 and 2020, respectively. The unrecognized equity method losses in excess of the Company’s investment was $2.1 million as of March 31, 2021.

At March 31, 2021 and December 31, 2020, the Company determined the fair value of the warrants to be insignificant to the condensed consolidated financial statements.

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.21.1
License and Collaboration Agreements
3 Months Ended
Mar. 31, 2021
License And Collaboration Agreements [Abstract]  
License and Collaboration Agreements

Note 6. License and Collaboration Agreements

The following table summarizes the revenues for the three months ended March 31, 2021 and 2020 received as a result of the Company’s collaboration agreements with Gilead Sciences, Inc. (Gilead) and Taiho Pharmaceutical Co., Ltd. (Taiho):

 

 

 

Three Months Ended March 31,

 

 

 

 

2021

 

 

2020

 

Collaboration revenue

 

 

$

9,461

 

 

$

1,750

 

Total collaboration and license revenue

 

 

$

9,461

 

 

$

1,750

 

 

The following table summarizes details of revenues for the three months ended March 31, 2021 and 2020 by collaboration and by category of revenue:

 

 

 

Three Months Ended March 31,

 

Revenues recognized:

Over time

Point in time

2021

 

 

2020

 

Gilead access rights related to the Company's research

   and development pipeline

*

 

$

7,711

 

 

$

-

 

Taiho collaboration agreement

*

 

 

1,750

 

 

 

1,750

 

Total collaboration and license revenue

 

 

$

9,461

 

 

$

1,750

 

The Company recognized the following revenue as a result of changes in the deferred revenue balance during the period below (in thousands):

 

Three Months Ended March 31,

 

Revenue recognized in the period from:

2021

 

2020

 

Amounts included in deferred revenue at the beginning of the period

$

9,461

 

$

1,750

 

Performance obligations satisfied in previous period

 

-

 

 

-

 

 

Gilead Sciences, Inc.

On May 27, 2020, the Company entered into an Option, License and Collaboration Agreement (Gilead Collaboration Agreement), Common Stock Purchase Agreement (the Stock Purchase Agreement), and Investor Rights Agreement, (collectively, the Gilead Agreements), each with Gilead Sciences, Inc. (Gilead). The transaction closed on July 13, 2020 following expiration of the antitrust waiting period. Upon closing, Gilead made an upfront payment of $175 million pursuant to the Gilead Collaboration Agreement, and made an equity investment of approximately $200 million in the Company by purchasing 5,963,029 shares of Arcus common stock at a per share price of $33.54 pursuant to the Stock Purchase Agreement. Pursuant to the Investor Rights Agreement, the Company appointed Gilead’s designees, Merdad Parsey, M.D., Ph.D. and Michael Quigley, Ph.D., to the Company’s Board of Directors. See Note 11 for further discussion of the agreements with Gilead.

Pursuant to the terms of the Gilead Collaboration Agreement, Gilead has an exclusive license to develop and commercialize zimberelimab in certain markets and obtained exclusive options to acquire an exclusive license to develop and commercialize all of the Company’s current and future clinical programs during the 10-year collaboration term, contingent upon Gilead’s access rights payments of up to $400 million and, for those programs that enter clinical development prior to the end of the collaboration term, for up to an additional three years thereafter. Gilead may exercise its option, on a program-by-program basis, upon payment of an option fee that ranges from $200 million to $275 million per program for the Company’s clinical programs in existence at the date of the agreement, and $150 million per program for all other programs that enter clinical development thereafter should Gilead elect to exercise its options.

Upon Gilead’s exercise of its option to a program, the two companies will co-develop and equally share global development costs, subject to certain opt-out rights of the Company, and expense caps on the Company’s spending and related subsequent adjustments. For each optioned program, provided the Company has not exercised its opt-out rights, the Company has an option to co-promote in the United States with equal sharing of related profits and losses. Gilead has the right to exclusively commercialize any optioned programs outside of the U.S., subject to the rights of the Company’s existing partners to any territories, and Gilead will pay to the Company tiered royalties as a percentage of revenues ranging from the high teens to the low twenties. Gilead will further provide ongoing research and development support in the form of research and development pipeline access rights payments of up to $400 million over the collaboration term.

Pursuant to the Stock Purchase Agreement and the Investor Rights Agreement, Gilead has the right, at its option, to purchase additional shares from the Company, up to a maximum of 35% of the Company’s then-outstanding voting common stock, from time to time over a five year period from closing of the initial transaction, at a purchase price equal to the greater of a 20% premium to market (based on a trailing five-day average closing price) at the time Gilead exercises such option, and the $33.54 initial purchase price. Based on the value of the Company’s common stock at the contract closing, the right to purchase additional shares had no value. In January 2021, the Company and Gilead entered into an Amended and Restated Common Stock Purchase Agreement, which amended and restated in its entirety the Common Stock Purchase Agreement, pursuant to which Gilead purchased 5,650,000 shares of the Company’s common stock at a purchase price of $39.00 per share for total gross proceeds of $220.4 million. All other terms of the original Stock Purchase Agreement remain unchanged. The Investor Rights Agreement also includes a three-year standstill and a two-year lockup and provides Gilead with registration rights commencing at the end of the lockup period, pro rata participation rights in certain future financings and the right to designate two individuals to be appointed to the Company’s Board of Directors.

The Company’s assessment of the transaction price included an analysis of amounts it expected to receive, which at contract inception consisted of the upfront cash payment of $175.0 million due upon contract closing in July 2020, the $100.0 million payment related to the research and development access rights due in 2022, and the $90.6 million premium resulting from Gilead’s purchase of common stock. All payments to date have been made by Gilead as they became due and payable so given this successful collection history, the Company considers the entire $365.6 million outlined above to be the initial transaction price.

The Company evaluated the Gilead Agreements under ASC 606 and determined that the performance obligations at the contract inception consisted of the following:

Zimberelimab license

Effective on closing, Gilead obtained an exclusive license to zimberelimab. The standalone selling price of this license was determined using a discounted cash flow method. The Company recognized the full revenues associated with this performance obligation on the date the transaction closed.

Etrumadenant option

Gilead has the right to exercise an option for exclusive rights to etrumadenant, the Company’s adenosine receptor program, in exchange for an option payment of $250.0 million, that expires after a proscribed period following the Company’s achievement of certain development milestones. The Company calculated the standalone selling price of this program using a discounted cash flow method and concluded that it exceeded the price of the option, creating a material right and a distinct performance obligation. If the option is exercised, the performance obligations associated with the option will be identified and the Company will determine the accounting for the option’s transaction price. If the option is allowed to lapse after development milestones trigger the start of the opt-in period, the Company will recognize any deferred revenue allocated to the option at the time of the lapse.

At March 31, 2021, the Company had $127.0 million of deferred revenue on its condensed consolidated balance sheets related to this performance obligation. The Company has evaluated the program’s status as of the balance sheet date and believes that some or all of the revenue associated with the opt-in will be recognized within the minimum four-year term of the Gilead Collaboration Agreement.

Domvanalimab option

Gilead has the right to exercise an option for exclusive rights to domvanalimab, the Company’s anti-TIGIT monoclonal antibody, in exchange for an option payment of $275.0 million, that expires after a proscribed period following the Company’s achievement of certain development milestones. The Company calculated the standalone selling price of this program using a discounted cash flow method and concluded that it exceeded the price of the option, creating a material right and a distinct performance obligation. If the option is exercised, the performance obligations associated with the option will be identified and will determine the accounting for the option’s transaction price. If the option is allowed to lapse after development milestones trigger the start of the opt-in period, the Company will recognize any deferred revenue allocated to the option at the time of the lapse.

At March 31, 2021, the Company had $36.7 million of deferred revenue on its condensed consolidated balance sheets related to this performance obligation. The Company has evaluated the program’s status and believes that revenue associated with the opt-in will be recognized within one year.

Access rights related to the Company’s research and development pipeline

Gilead receives exclusive access to the Company’s current programs as well as the future programs for a period of ten years, contingent upon Gilead’s payment of $400 million, with the first payment of $100 million in 2022, and an additional $100 million payment due at Gilead’s option on each of the fourth, sixth, and eighth anniversaries of the agreement. The standalone selling price of this ongoing research and development pipeline access was determined using an expected cost-plus margin approach. The Company evaluated its rights and obligations in the Gilead Collaboration Agreement and determined that Gilead is contractually obligated to make the $100 million payment due in 2022 resulting in a minimum term of four years for this performance obligation. As a result, the amount was included in the transaction price. The Company uses a time-elapsed input method to measure progress toward satisfying this obligation, which is the method the Company believes most faithfully depicts the Company’s performance in transferring the promised services during the time period in which Gilead has access to the Company’s research and development pipeline. Accordingly, the revenue allocated to the performance obligation is being recognized using this input method over the minimum four-year period. The Company further determined that Gilead is not obligated to pay the remaining $300 million due over the remainder of the term. Failure to pay the non-obligatory payments will result in Gilead’s loss of certain rights to access and obtain licenses to the programs arising from the Company’s research and development pipeline.

At March 31, 2021, the Company had $114.0 million of deferred revenue on its consolidated balance sheets related to this performance obligation, classified between current and noncurrent based on the amortization of the revenue.

Development and commercialization services for zimberelimab monotherapy

In conjunction with the license, the Company determined there existed a separate obligation to perform further development and commercialization services for Gilead. The standalone selling price of this obligation was determined using an expected cost-plus margin approach. This obligation includes a 50/50 share of the costs associated with all future development and commercialization of zimberelimab as a monotherapy. The portion of the transaction price allocated to this performance obligation has been allocated in accordance with the total costs forecast for the development and commercialization of zimberelimab as a monotherapy. The Company will recognize the amounts allocated to these services as the performance obligation is satisfied. Any additional payments received from or payments made to Gilead for the 50/50 cost share will be recognized as a reduction or an increase to R&D expense, respectively.

At March 31, 2021, the Company had $9.7 million of contract liabilities on its consolidated balance sheets related to this performance obligation. The Company has evaluated the program’s status and believes that revenue associated with these services will be recognized over the full term of the contract. As of March 31, 2021, no revenue had been recognized from this performance obligation.

Gilead was also granted option rights to programs not yet in development. These programs were not determined to be performance obligations at contract inception, as there are no identified programs, revenues, or costs to compare against the option price.

Prepaid expenses

The Company incurred $7.3 million in expenses to obtain the contract, which consisted of consultant and legal fees that were directly connected to the successful completion of the Gilead Agreements. The Company determined that $1.9 million of these expenses were related to the Stock Purchase Agreement and recorded them as offering costs. The Company allocated the remaining expenses between the various performance obligations, to be recognized when the underlying revenue is recognized. The portion allocated to the delivery of zimberelimab was recognized immediately, and the portion allocated to the remaining performance obligations will be recognized with timing consistent with the associated performance obligation. During the three months ended March 31, 2021, the Company recognized $0.1 million in expense from the amortization of these assets. At March 31, 2021, the Company had $4.1 million in prepaid expenses from costs to obtain the Gilead Agreements, of which $1.0 million was recorded in prepaid expenses and other current assets and $3.1 million was recorded in other long-term assets.

 

Taiho Pharmaceutical Co., Ltd

In September 2017, the Company and Taiho entered into an option and license agreement (the Taiho Agreement) to collaborate on the potential development and commercialization of certain investigational products from the Company’s portfolio in Japan and certain other territories in Asia (excluding China) (the Taiho Territory). The Taiho Agreement provides Taiho with exclusive options, over a five-year period (the Option Period), to obtain an exclusive development and commercialization license to clinical stage investigational products from the Company’s programs (each, an Arcus Program).

In consideration for the exclusive options and other rights contained in the Taiho Agreement, Taiho agreed to make non-refundable, non-creditable cash payments to the Company totaling $35.0 million, of which the Company received $25.0 million during 2017. An additional $5.0 million was received in 2018 and the remaining $5.0 million was received in 2019. 

In the event that the Company has not initiated IND enabling studies for at least five Arcus Programs prior to the expiration of the Option Period, Taiho may elect to extend the Option Period, up to a maximum of seven years, subject to an extension fee. For each option that Taiho elects to exercise, it will be obligated to make an option exercise payment of between $3.0 million to $15.0 million, depending on the development stage of the applicable Arcus Program for which the option is exercised. In addition, the Taiho Agreement provides that the Company is eligible to receive additional clinical and regulatory milestones totaling up to $130.0 million

per Arcus Program, and it will be eligible to receive contingent payments of up to $145.0 million per Arcus Program associated with the achievement of specified levels of Taiho net sales in the Taiho Territory.

In addition, the Company will receive royalties ranging from high single-digits to mid-teens on net sales of licensed products in the Taiho Territory. Royalties will be payable on a licensed product-by-licensed product and country-by-country basis during the period of time commencing on the first commercial sale of a licensed product in a country and ending upon the later of: (a) ten (10) years from the date of first commercial sale of such licensed product in such country; and (b) expiration of the last-to-expire valid claim of the Company’s patents covering the manufacture, use or sale or exploitation of such licensed product in such country (the Royalty Term).

The Company determined that the identified performance obligations, which include the combined performance obligation of the research and development services and the obligation to participate on the joint steering committee, are satisfied over time. The Company uses a time-elapsed input method to measure progress toward satisfying its performance obligation, which is the method the Company believes most faithfully depicts the Company’s performance in transferring the promised services during the time period in which Taiho has access to the Company’s research and development activities. Accordingly, the transaction price of $35.0 million is being recognized using this input method over the estimated performance period of five years.

Based on the nature of the clinical and regulatory milestones, such as the regulatory approvals which are not within the Company’s control, the Company will not consider achievement of such milestones to be probable until the uncertainty associated with the milestones has been resolved. When it is probable that a significant reversal of revenue will not occur, the milestone payment will be added to the transaction price, which will then be allocated to each performance obligation, on a relative standalone selling price basis, for which the Company recognizes revenue. As of March 31, 2021, no clinical or regulatory milestones had been achieved under the Taiho Agreement.

The Company also considers the contingent payments due from Taiho upon the achievement of specified sales volumes to be similar to royalty payments. The Company considers the license to be the predominant item to which the royalties relate. The Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). As of March 31, 2021, no sales milestone or royalty revenue has been recognized.

The Taiho Agreement shall remain in effect until expiry of all Royalty Terms for the licensed products, in each case subject to certain exceptions.

WuXi Biologics License Agreements

The Company entered into a license agreement (the WuXi PD-1 Agreement) with WuXi Biologics in August 2017, as subsequently amended, in which it obtained an exclusive license to develop, use, manufacture, and commercialize products including an anti-PD-1 antibody worldwide except for Greater China and Thailand. From the inception of the WuXi PD-1 Agreement through March 31, 2021, the Company has made upfront and milestone payments of $41.0 million and incurred sub-license fees of $11.3 million. These payments were recorded as research and development expense, as the products had not reached technological feasibility and did not have an alternative future use. The WuXi PD-1 Agreement also provides for clinical and regulatory milestone payments, commercialization milestone payments of up to $375.0 million, and tiered royalty payments to be made to WuXi Biologics that range from the high single-digits to low teens of net sales by the Company of licensed products.

The Company incurred $10.0 million in development milestone expense under the WuXi PD-1 Agreement during the three months ended March 31, 2021.

In December 2020, the Company entered into a separate license agreement (the WuXi CD-39 Agreement) with WuXi Biologics to develop anti-CD39 antibodies. Under the agreement, the Company was granted exclusive worldwide rights to anti-CD39 antibodies discovered under the collaboration and will be responsible for the further development and commercialization of those antibodies. From the inception of the WuXi CD-39 Agreement through March 31, 2021, the Company has paid $0.5 million in upfront payments which was recorded in research and development expense, as the products are still in research stage. The WuXi CD-39 Agreement provides for clinical and regulatory milestone payments totaling $16.5 million, and royalty payments in the low single digits of net sales by the Company of licensed products.

Abmuno License Agreement

In December 2016, the Company entered into a license agreement (the Abmuno Agreement) with Abmuno Therapeutics LLC (Abmuno) for a worldwide exclusive license to develop, use, manufacture, and commercialize products that include an anti-TIGIT antibody, including domvanalimab (formerly referred to as AB154). Under the Abmuno Agreement, the Company has made upfront and milestone payments totaling $14.6 million as of March 31, 2021. The Abmuno Agreement also provides for additional clinical, regulatory and commercialization milestone remaining payments of up to $93.0 million as of March 31, 2021.

The Company incurred $5.0 million in development milestone expense under the Abmuno Agreement during the three months ended March 31, 2021.

Genentech Collaboration Agreement

In December 2019, the Company and Genentech, through F. Hoffmann-La Roche Ltd (collectively, Genentech) entered into a Master Clinical Collaboration Agreement (the Genentech Agreement) pursuant to which the parties may conduct combination clinical studies involving Genentech’s monoclonal antibody, atezolizumab and the Company’s investigational products. Pursuant to the Genentech Agreement, the parties entered into Trial Supplements for the evaluation of etrumadenant and atezolizumab utilizing the MORPHEUS platform in two separate study indications: second and third line metastatic colorectal cancer and first line metastatic pancreatic cancer. The Company and Genentech will each supply their respective investigational products for use in the collaboration studies and will share a portion of the development costs under specific terms as set forth in the agreement. From the inception of the Agreement through March 31, 2021, the Company has incurred net expenses of $0.8 million.

For the three months ended March 31, 2021 and 2020, the Company incurred expenses pursuant to the Genentech Agreement of $0.3 million and zero, respectively. Net expenses related to this co-development agreement are recorded within research and development expenses.

Strata Collaboration Agreement

On April 30, 2019, the Company and Strata Oncology, Inc. (Strata) entered into a Co-Development and Collaboration Agreement (the Strata Agreement) to pursue a clinical development collaboration utilizing Strata’s precision drug development platform and proprietary biomarkers to evaluate zimberelimab, the Company’s clinical-stage anti-PD-1 antibody, in patients in a tumor-agnostic fashion.

 

Under the terms of the Strata Agreement, the parties will share a portion of development costs for the clinical collaboration under specified terms. Strata is eligible to receive $2.5 million upon the achievement of a development milestone, as well as regulatory and commercial milestones of up to $125.0 million and up to double-digit royalties on U.S. net sales of zimberelimab in the biomarker-identified indication. From the inception of the Agreement through March 31, 2021, the Company has made a milestone payment of $2.5 million and has incurred expenses of $3.3 million, of which $0.7 million had been reimbursed by Strata as development cost sharing. Net expenses related to this co-development agreement were recorded within research and development expenses.

As further consideration in connection with the Strata Agreement, the Company issued to Strata 1,257,651 restricted shares of its common stock with an initial measured fair value of $15.0 million, which are subject to vesting based upon the achievement of specified regulatory milestones within certain timelines. Expense relating to the restricted shares subject to these milestones is recognized if it is considered probable that the associated shares will vest. The probability of achievement is assessed at the end of each quarterly period. As of March 31, 2021, the Company determined that none of the restricted shares were probable of vesting and, as a result, no compensation expense related to the restricted shares has been recognized to date.

For the three months ended March 31, 2021 and 2020, the Company incurred expenses pursuant to the Strata Agreement of $0.6 million and $0.4 million, respectively. Of these expenses, $0.1 million have been reimbursed by Strata as development cost sharing for each of the three months ended March 31, 2021 and 2020. Net expenses related to this co-development agreement are recorded within research and development expenses.

AstraZeneca Agreement

On October 29, 2020 the Company announced a collaboration with AstraZeneca to evaluate domvanalimab, the Company’s investigational anti-TIGIT antibody, in combination with AstraZeneca’s Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer (NSCLC). Under the terms of the agreement, each company will retain existing rights to their respective molecules and any future commercial economics. AstraZeneca will conduct the trial, and each company will supply its respective anti-cancer agent to support the trial. Under the terms of the agreement and subject to the parties’ approval of a final budget for the clinical trial, the Company may be obligated to reimburse AstraZeneca for a portion of the costs incurred.

Consistent with the terms of the Gilead Collaboration Agreement, Gilead maintains an option to co-develop and co-commercialize domvanalimab. If Gilead exercises its option to domvanalimab, the trial from this AstraZeneca collaboration is expected to form part of the Arcus and Gilead joint development program and Arcus’s portion of the trial costs would be shared with Gilead.

For the three months ended March 31, 2021, the Company incurred immaterial expenses pursuant to the AstraZeneca Agreement. Expense from this co-development agreement are recorded within research and development expenses.

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity
3 Months Ended
Mar. 31, 2021
Stockholders Equity Note [Abstract]  
Stockholders' Equity

Note 7. Stockholders’ Equity

In June 2020, pursuant to a shelf registration statement on Form S-3 that was filed in May 2020, the Company issued 12,650,000 shares of its common stock at $27.50 per share in an underwritten public offering (the May 2020 Public Offering). The total number of shares sold consisted of 11,000,000 base shares and an additional 1,650,000 shares sold pursuant to the underwriters’ option exercise. Net proceeds from the May 2020 Public Offering were approximately $326.2 million after deducting underwriting discounts, commissions and other offering expenses.

In July 2020, the Company closed the Gilead Collaboration Agreement, Common Stock Purchase Agreement, and the Investor Rights Agreement, each signed with Gilead in May 2020. The transaction closed on July 13, 2020 following expiration of the antitrust waiting period. Upon closing, Gilead made an equity investment of approximately $200 million in the Company by purchasing 5,963,029 shares of Arcus common stock at a per share price of $33.54 pursuant to the Stock Purchase Agreement. Of the $200 million equity investment, approximately $90.6 million was determined to be a premium on the purchase of common stock and allocated to the performance obligations created by the Gilead Collaboration Agreement. See Note 6 in this Form 10-Q for further discussion of the agreements with Gilead. Net proceeds from Gilead’s equity investment were approximately $107.5 million after allocating the premium and deducting direct offering expenses of $1.9 million.

In February 2021, the Company closed the Amended and Restated Common Stock Purchase Agreement with Gilead, pursuant to which Gilead made an equity investment of approximately $220.4 million in the Company by purchasing 5,650,000 shares of the Company’s common stock at a per share price of $39.00.

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation
3 Months Ended
Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Stock-Based Compensation

Note 8. Stock-Based Compensation

 

The Company grants awards under its 2018 Equity Incentive Plan and the 2020 Inducement Plan. Total stock-based compensation expense was recognized in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Research and development

 

$

6,170

 

 

$

1,736

 

General and administrative

 

 

6,591

 

 

 

1,726

 

Total stock-based compensation

 

$

12,761

 

 

$

3,462

 

 

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss per Share
3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Net Loss per Share

Note 9. Net Loss per Share

 

Basic net loss per share is calculated based on the weighted-average number of shares of the Company’s common stock during the period. Diluted net loss per share is calculated based on the weighted-average number of shares of the Company’s common stock and other dilutive securities outstanding during the period.

The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Numerator:

 

 

 

 

 

 

 

 

Net loss

 

$

(72,593

)

 

$

(27,753

)

Denominator:

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding

 

 

68,476,799

 

 

 

45,953,213

 

Less: weighted-average common shares subject to vesting

 

 

(1,394,638

)

 

 

(1,670,606

)

Weighted-average common shares used to compute basic and diluted net loss per share

 

 

67,082,161

 

 

 

44,282,607

 

Net loss per share: basic and diluted

 

$

(1.08

)

 

$

(0.63

)

 

 

The following outstanding potentially dilutive securities were excluded from the computation of diluted net loss per share because including them would have been antidilutive:

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Common stock options issued and outstanding

 

 

11,708,625

 

 

 

6,725,835

 

Unvested restricted common stock issued as part of

  collaboration agreement

 

 

1,257,651

 

 

 

1,257,651

 

Unvested early exercised common stock options

 

 

111,094

 

 

 

375,615

 

Unvested restricted stock units

 

 

1,532,162

 

 

 

-

 

Employee Stock Purchase Plan shares

 

 

96,591

 

 

 

-

 

Total

 

 

14,706,123

 

 

 

8,359,101

 

The Company also excluded the effect of Gilead’s right to purchase additional shares of the Company’s common stock from its calculation as these rights had no intrinsic value at March 31, 2021.

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments
3 Months Ended
Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]  
Commitments

Note 10. Commitments

Standby Letters of Credit

The Company has standby letters of credit up to an aggregate of $2.0 million provided as collateral for its leases. The letters of credit are secured by $2.0 million in deposits classified as restricted cash on the Company’s condensed consolidated balance sheets. At March 31, 2021 the facilities were not drawn down.

XML 32 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Related Parties
3 Months Ended
Mar. 31, 2021
Related Party Transactions [Abstract]  
Related Parties

Note 11. Related parties

Relationship and transactions with Gilead Sciences, Inc. (Gilead)

 

As of March 31, 2021, Gilead held approximately 19.5% of the Company’s outstanding common stock. These holdings resulted from Gilead’s participation in the May 2020 Public Offering as well as purchases of stock under the stock purchase agreements. In the May 2020 public offering, Gilead purchased 2,200,000 shares of common stock for an amount of $56.7 million, net of offering costs. Under the stock purchase agreements, Gilead purchased 5,963,029 and 5,650,000 shares in July 2020 and February 2021, respectively, for a total investment of $327.8 million, net of offering costs. Gilead has the right, at its option, to purchase up to a maximum of 35% of the Company’s then-outstanding voting common stock, from time to time over a five-year period from the closing of the initial transaction in July 2020. Gilead also has the right under the Investor Rights Agreement to designate two individuals to be appointed to the Company’s board of directors. Pursuant to the Investor Rights Agreement, the Company appointed the Gilead designees, Merdad Parsey, M.D., Ph.D. and Michael Quigley, Ph.D., to its board of directors, in July 2020 and January 2021, respectively. See Note 6 for further discussion of the agreements with Gilead.

 

At March 31, 2021, the Company had a $4.9 million cost sharing receivable recorded on the condensed consolidated balance sheets under receivable from collaboration partners, to be invoiced the following quarter. The Company also had $177.7 million in deferred revenue at March 31, 2021, of which $110.1 million represented the long-term portion of revenue allocated to performance obligations not expected to be completed within one year of the balance sheet date, which was recorded in deferred revenue, noncurrent on the condensed consolidated balance sheets. The Company also had $9.7 million in contract liabilities for future development and commercialization services which Gilead prepaid, all of which was recorded in other long-term liabilities on the consolidated balance sheets.

 

For the three months ended March 31, 2021, the Company recognized $7.7 million in revenue under the Gilead Collaboration Agreement. The Company also recognized a $4.9 million reduction in research and development expense, including $4.0 million of cost sharing reimbursement related to milestone expense, related to its cost-sharing provisions of the agreement.

 

The Company received a $175 million upfront payment from Gilead in connection with the Gilead Collaboration Agreement in July 2020 and identified $100 million in unconstrained consideration to be received in 2022. In addition, in July 2020 the Company received $200 million from Gilead in connection with the Stock Purchase Agreement, of which approximately $109.4 million represented the fair value of stock purchased at the transaction closing date with the remaining premium of $90.6 million allocated to the transaction price. In February 2021, the Company received $220.4 million from Gilead in connection with the purchase by Gilead of 5,650,000 shares of the Company’s common stock at a per share price of $39.00 pursuant to the amended and restated Stock Purchase Agreement.

XML 33 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Event
3 Months Ended
Mar. 31, 2021
Subsequent Events [Abstract]  
Subsequent Event

Note 12. Subsequent event

 

In April 2021, the Company entered into a lease amendment that modifies rent schedules for its existing operating leases in Hayward, California, extends the terms of those leases, and adds 14,460 square feet of additional space in Hayward in a new operating lease expected to commence in 2022. Any extension periods defined under previous amendments are cancelled under the lease amendment and replaced by two options to extend the lease term for the entire Hayward premises for a period of eight years each. The amended leases will end at the same time as the Company’s lease of its building in Brisbane, expected to be no earlier than December 2031. The lease amendment includes approximately $43 million in additional undiscounted future minimum lease payments throughout the expected term and provides additional tenant improvement allowances totaling $5.8 million with options to increase the allowance by $10.9 million.

 

The lease amendment requires an additional $1.0 million in collateral for the operating leases in Hayward. In accordance with this requirement, the Company issued an additional $1.0 million letter of credit in April 2021.

XML 34 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the Company’s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.

Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 or for any future period. The balance sheet as of December 31, 2020 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.

The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K filed with the SEC on February 25, 2021. There have been no significant changes to the Company’s significant accounting policies described in Note 2, Summary of Significant Accounting Policies, in Notes to Consolidated Financial Statements in Item 8 of Part II of the Form 10-K.

Principles of Consolidation

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Arcus Biosciences, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

Use of Estimates

The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as related disclosures of contingent assets and liabilities. Estimates were used to determine the standalone selling price of performance obligations and the timing of revenue recognition, the value of stock-based awards and other issuances, accruals for research and development costs, useful lives of long-lived assets, and uncertain tax positions. Actual results could differ materially from the Company’s estimates.

Cash Equivalents and Investments

Cash Equivalents and Investments

Cash equivalents include marketable securities having an original maturity of three months or less at the time of purchase. Short-term investments have maturities of greater than three months and up to twelve months at the time of purchase. Long-term investments have maturities greater than 12 months at the time of purchase. Collectively, cash equivalents, short-term and long-term investments are considered available-for-sale and are recorded at fair value. Unrealized gains and losses are recorded in accumulated other comprehensive income (loss). Realized gains and losses are included in interest and other income, net in the condensed consolidated statements of operations and comprehensive income or loss. The basis on which the cost of a security that is sold or an amount that is reclassified out of accumulated other comprehensive income or loss into earnings is determined using the specific identification method.

Reconciliation of Cash, Cash Equivalents, and Restricted Cash as Reported in Condensed Consolidated Statements of Cash Flows

Reconciliation of Cash, Cash Equivalents, and Restricted Cash as Reported in Condensed Consolidated Statements of Cash Flows

Restricted cash at March 31, 2021 and 2020 represents cash balances held as security in connection with the Company’s facility lease agreements. The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the condensed consolidated balance sheets to the total shown in the condensed consolidated statements of cash flows (in thousands):

 

 

March 31,

 

 

 

2021

 

 

2020

 

Cash and cash equivalents

 

$

390,260

 

 

$

67,326

 

Restricted cash

 

 

1,988

 

 

 

203

 

Cash, cash equivalents and restricted cash

 

 

392,248

 

 

$

67,529

 

 

Concentration of Credit Risk

Concentration of Credit Risk

Cash equivalents, short-term and long-term investments are financial instruments that potentially subject the Company to concentrations of credit risk. The Company invests in money market funds, treasury bills and notes, government bonds, commercial paper and corporate notes. The Company limits its credit risk associated with cash equivalents, short-term and long-term investments by placing them with banks and institutions it believes are credit worthy and in highly rated investments.

Leases and Rent Expense

Leases and Rent Expense

The Company recognizes a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. The Company determines whether an arrangement is or contains a lease at contract inception. Operating leases are included in operating lease right-of-use assets, other current liabilities, and operating lease liabilities, noncurrent in our condensed consolidated balance sheets at March 31, 2021 and December 31, 2020. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date. The incremental borrowing rate represents the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company considers a lease term to be the noncancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.

The Company elected to not apply the recognition requirements of the new leasing standard to short-term leases with terms of 12 months or less which do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. For short-term leases, lease payments are recognized as operating expenses on a straight-line basis over the lease term.

XML 35 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Reconciliation of Cash, Cash Equivalents and Restricted Cash Restricted cash at March 31, 2021 and 2020 represents cash balances held as security in connection with the Company’s facility lease agreements. The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the condensed consolidated balance sheets to the total shown in the condensed consolidated statements of cash flows (in thousands):

 

 

March 31,

 

 

 

2021

 

 

2020

 

Cash and cash equivalents

 

$

390,260

 

 

$

67,326

 

Restricted cash

 

 

1,988

 

 

 

203

 

Cash, cash equivalents and restricted cash

 

 

392,248

 

 

$

67,529

 

 

XML 36 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Schedule of Financial Instruments Measured at Fair Value on Recurring Basis The following tables set forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):

 

 

 

March 31, 2021

 

 

 

Total

 

 

Level 1

(Quoted Prices in

Active Markets For

Identical Assets)

 

 

Level 2

(Significant Other

Observable

Remaining Inputs)

 

 

Level 3

(Significant Other

Unobservable

Remaining Inputs)

 

Money market funds

 

$

362,762

 

 

$

362,762

 

 

$

-

 

 

$

-

 

U.S. treasury securities

 

 

206,460

 

 

 

-

 

 

 

206,460

 

 

 

-

 

U.S. government agency securities

 

 

5,002

 

 

 

-

 

 

 

5,002

 

 

 

-

 

Corporate securities and commercial paper

 

 

310,688

 

 

 

-

 

 

 

310,688

 

 

 

-

 

Total assets measured at fair value

 

$

884,912

 

 

$

362,762

 

 

$

522,150

 

 

$

-

 

 

 

 

December 31, 2020

 

 

 

Total

 

 

Level 1

(Quoted Prices in

Active Markets For

Identical Assets)

 

 

Level 2

(Significant Other

Observable

Remaining Inputs)

 

 

Level 3

(Significant Other

Unobservable

Remaining Inputs)

 

Money market funds

 

$

146,468

 

 

$

146,468

 

 

$

-

 

 

$

-

 

U.S. treasury securities

 

 

301,112

 

 

 

-

 

 

 

301,112

 

 

 

-

 

U.S. government agency obligations

 

 

25,001

 

 

 

-

 

 

 

25,001

 

 

 

-

 

Corporate securities and commercial paper

 

 

262,505

 

 

 

-

 

 

 

262,505

 

 

 

-

 

Total assets measured at fair value

 

$

735,086

 

 

$

146,468

 

 

$

588,618

 

 

$

-

 

Schedule of Investments Classified as Available for Sale Securities with Contractual Maturities

Classified as (with contractual maturities):

 

 

March 31, 2021

 

 

December 31, 2020

 

Cash and cash equivalents

 

$

390,260

 

 

$

173,415

 

Short-term investments (due within one year)

 

 

436,666

 

 

 

555,231

 

Long-term investments (due between one and two years)

 

 

57,986

 

 

 

6,440

 

Total cash, cash equivalents and investments in marketable securities

 

$

884,912

 

 

$

735,086

 

Schedule of Fair Value and Amortized Cost of Investments in Marketable Securities by Major Security Type The fair value and amortized cost of investments in marketable securities by major security type as of March 31, 2021 and December 31, 2020 are presented in the tables that follow (in thousands):

 

 

 

Amortized

Cost

 

 

Unrealized

Gain

 

 

Unrealized

Loss

 

 

Fair

Value

 

As of March 31, 2021:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

362,762

 

 

$

-

 

 

$

-

 

 

$

362,762

 

U.S. treasury securities

 

 

206,422

 

 

 

40

 

 

 

(2

)

 

 

206,460

 

U.S. government agency securities

 

 

5,000

 

 

 

2

 

 

 

-

 

 

 

5,002

 

Corporate securities and commercial paper

 

 

310,730

 

 

 

14

 

 

 

(56

)

 

 

310,688

 

Total

 

$

884,914

 

 

$

56

 

 

$

(58

)

 

$

884,912

 

 

 

 

Amortized

Cost

 

 

Unrealized

Gain

 

 

Unrealized

Loss

 

 

Fair

Value

 

As of December 31, 2020:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

146,468

 

 

$

-

 

 

$

-

 

 

$

146,468

 

U.S. treasury securities

 

 

301,075

 

 

 

38

 

 

 

(1

)

 

 

301,112

 

U.S. government agency obligations

 

 

24,997

 

 

 

4

 

 

 

-

 

 

 

25,001

 

Corporate securities and commercial paper

 

 

262,502

 

 

 

15

 

 

 

(12

)

 

 

262,505

 

Total

 

$

735,042

 

 

$

57

 

 

$

(13

)

 

$

735,086

 

XML 37 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued Liabilities (Tables)
3 Months Ended
Mar. 31, 2021
Payables And Accruals [Abstract]  
Summary of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

 

 

 

As of March 31, 2021

 

 

As of December 31, 2020

 

Accrued personnel expenses

 

$

7,128

 

 

$

8,632

 

Professional fees

 

 

67

 

 

 

295

 

Other

 

 

341

 

 

 

616

 

Total

 

$

7,536

 

 

$

9,543

 

XML 38 R26.htm IDEA: XBRL DOCUMENT v3.21.1
License and Collaboration Agreements (Tables)
3 Months Ended
Mar. 31, 2021
Summary of Revenues by Collaboration and by Category of Revenue

The following table summarizes details of revenues for the three months ended March 31, 2021 and 2020 by collaboration and by category of revenue:

 

 

 

Three Months Ended March 31,

 

Revenues recognized:

Over time

Point in time

2021

 

 

2020

 

Gilead access rights related to the Company's research

   and development pipeline

*

 

$

7,711

 

 

$

-

 

Taiho collaboration agreement

*

 

 

1,750

 

 

 

1,750

 

Total collaboration and license revenue

 

 

$

9,461

 

 

$

1,750

 

Summary of Revenue Recognized as a Result of Changes in Deferred Revenue The Company recognized the following revenue as a result of changes in the deferred revenue balance during the period below (in thousands):

 

Three Months Ended March 31,

 

Revenue recognized in the period from:

2021

 

2020

 

Amounts included in deferred revenue at the beginning of the period

$

9,461

 

$

1,750

 

Performance obligations satisfied in previous period

 

-

 

 

-

 

Gilead and Taiho  
Summary of Revenues

The following table summarizes the revenues for the three months ended March 31, 2021 and 2020 received as a result of the Company’s collaboration agreements with Gilead Sciences, Inc. (Gilead) and Taiho Pharmaceutical Co., Ltd. (Taiho):

 

 

 

Three Months Ended March 31,

 

 

 

 

2021

 

 

2020

 

Collaboration revenue

 

 

$

9,461

 

 

$

1,750

 

Total collaboration and license revenue

 

 

$

9,461

 

 

$

1,750

 

XML 39 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Summary of Stock-Based Compensation Expense Total stock-based compensation expense was recognized in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Research and development

 

$

6,170

 

 

$

1,736

 

General and administrative

 

 

6,591

 

 

 

1,726

 

Total stock-based compensation

 

$

12,761

 

 

$

3,462

 

XML 40 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss per Share (Tables)
3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Numerator:

 

 

 

 

 

 

 

 

Net loss

 

$

(72,593

)

 

$

(27,753

)

Denominator:

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding

 

 

68,476,799

 

 

 

45,953,213

 

Less: weighted-average common shares subject to vesting

 

 

(1,394,638

)

 

 

(1,670,606

)

Weighted-average common shares used to compute basic and diluted net loss per share

 

 

67,082,161

 

 

 

44,282,607

 

Net loss per share: basic and diluted

 

$

(1.08

)

 

$

(0.63

)

Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share

The following outstanding potentially dilutive securities were excluded from the computation of diluted net loss per share because including them would have been antidilutive:

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Common stock options issued and outstanding

 

 

11,708,625

 

 

 

6,725,835

 

Unvested restricted common stock issued as part of

  collaboration agreement

 

 

1,257,651

 

 

 

1,257,651

 

Unvested early exercised common stock options

 

 

111,094

 

 

 

375,615

 

Unvested restricted stock units

 

 

1,532,162

 

 

 

-

 

Employee Stock Purchase Plan shares

 

 

96,591

 

 

 

-

 

Total

 

 

14,706,123

 

 

 

8,359,101

 

XML 41 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Organization - Additional Information (Details)
$ in Millions
3 Months Ended
Mar. 31, 2021
USD ($)
Product
Organization [Line Items]  
Number of investigational product | Product 5
Cash, Cash Equivalents and Investments in Marketable Securities  
Organization [Line Items]  
Cash and investments | $ $ 884.9
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Mar. 31, 2020
Dec. 31, 2019
Accounting Policies [Abstract]        
Cash and cash equivalents $ 390,260 $ 173,415 [1] $ 67,326  
Restricted cash 1,988 203 [1] 203  
Cash, cash equivalents and restricted cash $ 392,248 $ 173,618 $ 67,529 $ 58,140
[1] The Condensed Consolidated Balance Sheet as of December 31, 2020 has been derived from the audited financial statements as of that date.
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Additional Information (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Fair Value Disclosures [Abstract]    
Fair value assets transferred from level 1 to level 2 $ 0 $ 0
Fair value assets transferred from level 2 to level 1 0 0
Fair value liabilities transferred from level 1 to level 2 0 0
Fair value liabilities transferred from level 2 to level 1 0 0
Fair value assets transferred into level 3 0 0
Fair value assets transferred out of level 3 0 0
Fair value liabilities transferred into level 3 0 0
Fair value liabilities transferred out of level 3 0 0
Reclassification out of accumulated other comprehensive income $ 0 $ 0
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Details) - Fair Value On Recurring Basis - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total assets measured at fair value $ 884,912 $ 735,086
Level 1    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total assets measured at fair value 362,762 146,468
Level 2    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total assets measured at fair value 522,150 588,618
Money Market Funds    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total assets measured at fair value 362,762 146,468
Money Market Funds | Level 1    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total assets measured at fair value 362,762 146,468
U.S. Treasury Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total assets measured at fair value 206,460 301,112
U.S. Treasury Securities | Level 2    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total assets measured at fair value 206,460 301,112
U.S. Government Agency Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total assets measured at fair value 5,002 25,001
U.S. Government Agency Securities | Level 2    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total assets measured at fair value 5,002 25,001
Corporate Securities and Commercial Paper    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total assets measured at fair value 310,688 262,505
Corporate Securities and Commercial Paper | Level 2    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total assets measured at fair value $ 310,688 $ 262,505
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Schedule of Investments Classified as Available for Sale Securities with Contractual Maturities (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Fair Value Disclosures [Abstract]    
Cash and cash equivalents $ 390,260 $ 173,415
Short-term investments (due within one year) 436,666 555,231 [1]
Long-term investments (due between one and two years) 57,986 6,440
Total cash, cash equivalents and investments in marketable securities $ 884,912 $ 735,086
[1] The Condensed Consolidated Balance Sheet as of December 31, 2020 has been derived from the audited financial statements as of that date.
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Schedule of Fair Value and Amortized Cost of Investments in Marketable Securities by Major Security Type (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Amortized Cost $ 884,914 $ 735,042
Unrealized Gain 56 57
Unrealized Loss (58) (13)
Fair Value 884,912 735,086
Money Market Funds    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Amortized Cost 362,762 146,468
Fair Value 362,762 146,468
U.S. Treasury Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Amortized Cost 206,422 301,075
Unrealized Gain 40 38
Unrealized Loss (2) (1)
Fair Value 206,460 301,112
U.S. Government Agency Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Amortized Cost 5,000 24,997
Unrealized Gain 2 4
Fair Value 5,002 25,001
Corporate Securities and Commercial Paper    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Amortized Cost 310,730 262,502
Unrealized Gain 14 15
Unrealized Loss (56) (12)
Fair Value $ 310,688 $ 262,505
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Accrued Liabilities Current [Abstract]    
Accrued personnel expenses $ 7,128 $ 8,632
Professional fees 67 295
Other 341 616
Total $ 7,536 $ 9,543 [1]
[1] The Condensed Consolidated Balance Sheet as of December 31, 2020 has been derived from the audited financial statements as of that date.
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Equity Investment in PACT Pharma - Additional Information (Details) - USD ($)
shares in Millions
3 Months Ended 12 Months Ended 15 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2016
Mar. 31, 2021
Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]          
Gains on dilution of equity investment   $ 482,000      
Share of loss from equity method investee   (482,000)      
PACT Pharma          
Schedule of Equity Method Investments [Line Items]          
Investment balance $ 0     $ 0 $ 0
Gains on dilution of equity investment   1,300,000      
Share of loss from equity method investee 0 500,000      
Unrealized loss on equity method investments 800,000     $ 2,100,000  
Operating losses on equity method investments $ 0 500,000      
PACT Pharma | Previously Reported          
Schedule of Equity Method Investments [Line Items]          
Losses on accumulated in prior periods of equity investment   $ 800,000      
PACT Pharma | Series A Preferred Stock          
Schedule of Equity Method Investments [Line Items]          
Purchase of common stock, shares     1.0    
PACT Pharma | Common Stock          
Schedule of Equity Method Investments [Line Items]          
Purchase of common stock, shares     3.6    
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.21.1
License and Collaboration Agreements - Summary of Revenues (Details) - Gilead and Taiho - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Collaboration    
License And Collaboration Agreements [Line Items]    
License revenue $ 9,461 $ 1,750
Collaboration and License    
License And Collaboration Agreements [Line Items]    
License revenue $ 9,461 $ 1,750
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.21.1
License and Collaboration Agreements - Summary of Revenues by Collaboration and by Category of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
License And Collaboration Agreements [Line Items]    
Collaboration and license revenue $ 9,461 $ 1,750
Gilead Access Rights    
License And Collaboration Agreements [Line Items]    
Collaboration and license revenue 7,711  
Taiho Collaboration Agreement    
License And Collaboration Agreements [Line Items]    
Collaboration and license revenue $ 1,750 $ 1,750
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.21.1
License and Collaboration Agreements - Summary of Revenue Recognized as a Result of Changes in Deferred Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
License And Collaboration Agreements [Abstract]    
Amounts included in deferred revenue at the beginning of the period $ 9,461 $ 1,750
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.21.1
License and Collaboration Agreements - Additional Information (Details)
1 Months Ended 3 Months Ended 12 Months Ended 23 Months Ended 44 Months Ended
Jul. 13, 2020
USD ($)
$ / shares
shares
Apr. 30, 2019
USD ($)
shares
Feb. 28, 2021
USD ($)
$ / shares
shares
Jan. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
Sep. 30, 2017
USD ($)
Program
Aug. 31, 2017
USD ($)
Mar. 31, 2021
USD ($)
shares
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Mar. 31, 2021
USD ($)
shares
Mar. 31, 2021
USD ($)
shares
License And Collaboration Agreements [Line Items]                            
Cost sharing receivable, current         $ 1,049,000 [1]     $ 5,235,000         $ 5,235,000 $ 5,235,000
Development expense               66,387,000 $ 23,142,000          
Compensation expense recognized               12,761,000 3,462,000          
Research and Development                            
License And Collaboration Agreements [Line Items]                            
Compensation expense recognized               $ 6,170,000 1,736,000          
WuXi Biologics License Agreement                            
License And Collaboration Agreements [Line Items]                            
Clinical and regulatory milestones achieved         16,500,000                  
Range of tiered royalty payments on net sales               high single-digits to low teens            
Development milestone expense               $ 10,000,000.0            
WuXi Biologics License Agreement | Research and Development                            
License And Collaboration Agreements [Line Items]                            
Upfront cash payment         $ 500,000                  
Sub-license fees incurred                           11,300,000
Upfront and milestone payments                           41,000,000.0
WuXi Biologics License Agreement | Maximum                            
License And Collaboration Agreements [Line Items]                            
Clinical, regulatory and commercialization milestone payments             $ 375,000,000.0              
Abmuno License Agreement                            
License And Collaboration Agreements [Line Items]                            
Upfront and milestone payments               14,600,000            
Development milestone expense               5,000,000.0            
Clinical, regulatory and commercialization remaining milestone payments               93,000,000.0            
Genentech                            
License And Collaboration Agreements [Line Items]                            
Net expenses of inception               800,000            
Development expense               300,000 0          
Gilead Collaboration Agreement | Gilead                            
License And Collaboration Agreements [Line Items]                            
Upfront cash payment $ 175,000,000.0             175,000,000            
Collaboration term for current and future clinical programs 10 years                          
Contingent milestone payments receivable $ 400,000,000                          
Additional collaboration term for programs entering clinical development prior to end of collaboration term 3 years                          
Option fee per program for all other programs entering clinical development to exercise option $ 150,000,000                          
Ongoing research and development support 400,000,000                          
Present value of research and development information access rights payment related to year 2022 100,000,000.0                          
Premium on stock purchased 90,600,000                          
Initial transaction price 365,600,000                          
Option payment upon achievement of certain development milestones 250,000,000.0                          
Deferred revenue related to etrumadenant option               $ 127,000,000.0         127,000,000.0 127,000,000.0
Etrumadenant option initial term of agreement               4 years            
Option payment upon achievement of certain development milestones $ 275,000,000.0                          
Deferred revenue related to domvanalimab option               $ 36,700,000         36,700,000 36,700,000
Domvanalimab option recognized term               1 year            
Current and future programs exclusive access period 10 years                          
Additional payment due at each of the fourth, sixth, and eighth anniversaries of the agreement $ 100,000,000                          
Contingent milestone payment start period 2022                          
Contractual obligation for first payment $ 100,000,000                          
Performance obligation period 4 years                          
Contractual obligation remaining amount not obligated to pay $ 300,000,000                          
Deferred revenue related to research and development pipeline               $ 114,000,000.0         114,000,000.0 114,000,000.0
Future development and promotion costs contract liability               9,700,000         9,700,000 9,700,000
Revenue recognized from this performance obligation               0            
Consultant and legal fees 7,300,000                          
Amortization expense               100,000            
Cost sharing receivable               4,100,000         4,100,000 4,100,000
Gilead Collaboration Agreement | Gilead | Prepaid Expenses and Other Current Assets                            
License And Collaboration Agreements [Line Items]                            
Cost sharing receivable, current               1,000,000.0         1,000,000.0 1,000,000.0
Gilead Collaboration Agreement | Gilead | Other Noncurrent Assets                            
License And Collaboration Agreements [Line Items]                            
Cost sharing receivable, noncurrent               3,100,000         3,100,000 $ 3,100,000
Gilead Collaboration Agreement | Gilead | Minimum                            
License And Collaboration Agreements [Line Items]                            
Option fee per program for current clinical programs to exercise option 200,000,000                          
Gilead Collaboration Agreement | Gilead | Maximum                            
License And Collaboration Agreements [Line Items]                            
Contingent milestone payments receivable 400,000,000                          
Option fee per program for current clinical programs to exercise option 275,000,000                          
Purchase Agreement                            
License And Collaboration Agreements [Line Items]                            
Direct offering cost 1,900,000                          
Purchase Agreement | Gilead                            
License And Collaboration Agreements [Line Items]                            
Issuance of common stock $ 200,000,000   $ 220,400,000         220,296,000            
Issuance of common stock, shares | shares 5,963,029   5,650,000 5,650,000                    
Shares issued, price per share | $ / shares $ 33.54   $ 39.00 $ 39.00                    
Percentage of option to purchase maximum shares of common stock 35.00%                          
Period over common stock to be purchased 5 years                          
Percentage of premium purchase price of common stock 20.00%                          
Trailing days average closing price 5 days                          
Share Price | $ / shares $ 33.54                          
Issuance of common stock and rights to purchase additional shares in accordance with Amended and Restated Gilead Purchase Agreement, net of $55 offering costs, Shares | shares 5,963,029   5,650,000 5,650,000                    
Gross proceeds $ 107,500,000     $ 220,400,000                    
Premium on stock purchased               $ 90,600,000            
Taiho Agreement | Taiho Pharmaceutical Co., Ltd                            
License And Collaboration Agreements [Line Items]                            
Option period           5 years                
Non refundable and non creditable cash payments                       $ 35,000,000.0    
Payment received for license agreement                   $ 5,000,000.0 $ 5,000,000.0 $ 25,000,000.0    
Range of royalties receivable on net sales               high single-digits to mid-teens            
Royalties payable description               Royalties will be payable on a licensed product-by-licensed product and country-by-country basis during the period of time commencing on the first commercial sale of a licensed product in a country and ending upon the later of: (a) ten (10) years from the date of first commercial sale of such licensed product in such country; and (b) expiration of the last-to-expire valid claim of the Company’s patents covering the manufacture, use or sale or exploitation of such licensed product in such country (the Royalty Term).            
Non-refundable, non-creditable upfront cash payments               $ 35,000,000.0            
Estimated performance period               5 years            
Clinical and regulatory milestones achieved               $ 0            
Sales milestone or royalty revenue recognized               0            
Taiho Agreement | Taiho Pharmaceutical Co., Ltd | Minimum                            
License And Collaboration Agreements [Line Items]                            
Number of programs, IND enabling studies not initiated | Program           5                
Payment for option exercise           $ 3,000,000.0                
Taiho Agreement | Taiho Pharmaceutical Co., Ltd | Maximum                            
License And Collaboration Agreements [Line Items]                            
Contingent milestone payments receivable           $ 145,000,000.0                
Extended option agreement period           7 years                
Payment for option exercise           $ 15,000,000.0                
Additional clinical and regulatory milestone payments receivable           $ 130,000,000.0                
Strata Agreement | Strata Oncology Inc                            
License And Collaboration Agreements [Line Items]                            
Development milestone payable   $ 2,500,000                        
Development cost recorded within research and development expenses               600,000 400,000       3,300,000  
Development cost reimbursed               $ 100,000 $ 100,000       $ 700,000  
Number of restricted shares of common stock issued | shares   1,257,651                        
Fair value of restricted shares of common stock issued   $ 15,000,000.0                        
Strata Agreement | Strata Oncology Inc | Non-vested Restricted Stock                            
License And Collaboration Agreements [Line Items]                            
Shares probable of vesting | shares               0         0 0
Compensation expense recognized               $ 0            
Strata Agreement | Strata Oncology Inc | Research and Development                            
License And Collaboration Agreements [Line Items]                            
Milestone payments                         $ 2,500,000  
Strata Agreement | Strata Oncology Inc | Maximum                            
License And Collaboration Agreements [Line Items]                            
Regulatory and commercial milestone payable   $ 125,000,000.0                        
[1] The Condensed Consolidated Balance Sheet as of December 31, 2020 has been derived from the audited financial statements as of that date.
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Jul. 13, 2020
Feb. 28, 2021
Jan. 31, 2021
Jun. 30, 2020
Mar. 31, 2021
Stock Purchase Agreement | Gilead          
Class Of Stock [Line Items]          
Common stock shares issued 5,963,029 5,650,000 5,650,000    
Shares issued, price per share $ 33.54 $ 39.00 $ 39.00    
Net proceeds from public offering after deducting underwriting discounts, commissions and other offering expenses $ 107,500   $ 220,400    
Common stock share value 200,000 $ 220,400     $ 220,296
Purchase price of common stock allocation to performance obligation 90,600        
Deferred offering expenses $ 1,900        
May 2020 Public Offering          
Class Of Stock [Line Items]          
Common stock shares issued       12,650,000  
Shares issued, price per share       $ 27.50  
Net proceeds from public offering after deducting underwriting discounts, commissions and other offering expenses       $ 326,200  
Base Shares          
Class Of Stock [Line Items]          
Common stock shares issued       11,000,000  
Underwriters Option Exercise          
Class Of Stock [Line Items]          
Common stock shares issued       1,650,000  
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Total stock-based compensation $ 12,761 $ 3,462
Research and Development    
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Total stock-based compensation 6,170 1,736
General and Administrative    
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Total stock-based compensation $ 6,591 $ 1,726
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Numerator:    
Net loss $ (72,593) $ (27,753)
Denominator:    
Weighted-average common shares outstanding 68,476,799 45,953,213
Less: weighted-average common shares subject to vesting (1,394,638) (1,670,606)
Weighted-average common shares used to compute basic and diluted net loss per share 67,082,161 44,282,607
Net loss per share: basic and diluted $ (1.08) $ (0.63)
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss per Share - Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details) - shares
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of diluted net loss per share 14,706,123 8,359,101
Common Stock Options Issued and Outstanding    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of diluted net loss per share 11,708,625 6,725,835
Unvested Restricted Stock Issued as Part of Collaboration Agreement    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of diluted net loss per share 1,257,651 1,257,651
Unvested Early Exercised Common Stock Options    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of diluted net loss per share 111,094 375,615
Unvested Restricted Stock Units    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of diluted net loss per share 1,532,162  
Employee Stock Purchase Plan Shares    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of diluted net loss per share 96,591  
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments - Additional Information (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
[1]
Mar. 31, 2020
Commitments [Line Items]      
Restricted cash $ 1,988 $ 203 $ 203
Standby Letters of Credit      
Commitments [Line Items]      
Long-term line of credit 2,000    
Restricted cash $ 2,000    
[1] The Condensed Consolidated Balance Sheet as of December 31, 2020 has been derived from the audited financial statements as of that date.
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.21.1
Related Parties - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended
Jul. 13, 2020
Feb. 28, 2021
Jan. 31, 2021
May 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
[1]
Related Party Transaction [Line Items]              
Cost sharing receivable         $ 5,235,000   $ 1,049,000
Long-term portion of revenue allocated         113,369,000   $ 122,830,000
Research and Development              
Related Party Transaction [Line Items]              
Reimbursed under cost-sharing provisions of arrangement         (4,924,000) $ 0  
Gilead Collaboration Agreement | Gilead              
Related Party Transaction [Line Items]              
Revenue recognized         0    
Upfront cash payment $ 175,000,000.0       175,000,000    
Unconstrained consideration to be received         100,000,000    
Premium on stock purchased $ 90,600,000            
Stock Purchase Agreement | Gilead              
Related Party Transaction [Line Items]              
Issuance of common stock, shares 5,963,029 5,650,000 5,650,000        
Issuance of common stock $ 200,000,000 $ 220,400,000     220,296,000    
Funds received for purchase of common stock         200,000,000    
Fair value of stock purchased         109,400,000    
Premium on stock purchased         $ 90,600,000    
Shares issued, price per share $ 33.54 $ 39.00 $ 39.00        
Gilead              
Related Party Transaction [Line Items]              
Percentage of outstanding common stock held         19.50%    
Number of shares issued       2,200,000      
Value of common stock issued       $ 56,700,000      
Cost sharing receivable         $ 4,900,000    
Deferred revenue         177,700,000    
Long-term portion of revenue allocated         110,100,000    
Future development and commercialization services contract liability         9,700,000    
Gilead | Research and Development              
Related Party Transaction [Line Items]              
Reimbursed under cost-sharing provisions of arrangement         $ 4,900,000    
Gilead | Maximum              
Related Party Transaction [Line Items]              
Right to purchase additional outstanding voting common stock percentage         35.00%    
Gilead | Gilead Collaboration Agreement              
Related Party Transaction [Line Items]              
Revenue recognized         $ 7,700,000    
Reimbursement of milestone expense of cost sharing provisions         4,000,000.0    
Gilead | Stock Purchase Agreement              
Related Party Transaction [Line Items]              
Issuance of common stock, shares 5,963,029 5,650,000          
Issuance of common stock   $ 220,400,000     $ 327,800,000    
Shares issued, price per share   $ 39.00          
[1] The Condensed Consolidated Balance Sheet as of December 31, 2020 has been derived from the audited financial statements as of that date.
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Event - Additional Information (Details) - Hayward, California - Subsequent Event
$ in Millions
1 Months Ended
Apr. 30, 2021
USD ($)
ft²
Subsequent Event [Line Items]  
Square feet of space leased | ft² 14,460
Lease commencement year 2022
Operating lease, existence of option to extend true
Operating lease, option to extend lease term 8 years
Operating lease, option to extend Any extension periods defined under previous amendments are cancelled under the lease amendment and replaced by two options to extend the lease term for the entire Hayward premises for a period of eight years each.
Lessee operating lease expiration month and year 2031-12
Operating lease undiscounted amount $ 43.0
Operating lease, allowance for tenant improvements 5.8
Operating lease, option to increase allowance for tenant improvements 10.9
Collateral for operating leases 1.0
Issuance of letter of credit $ 1.0
EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 151 350 1 true 53 0 false 7 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) Sheet http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Parenthetical) Sheet http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossParenthetical Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Parenthetical) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 100060 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) Statements 7 false false R8.htm 100070 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 100080 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) Sheet http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical Condensed Consolidated Statements of Cash Flows (Parenthetical) Statements 9 false false R10.htm 100090 - Disclosure - Organization Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureOrganization Organization Notes 10 false false R11.htm 100100 - Disclosure - Significant Accounting Policies Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPolicies Significant Accounting Policies Notes 11 false false R12.htm 100110 - Disclosure - Fair Value Measurements Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 100120 - Disclosure - Accrued Liabilities Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureAccruedLiabilities Accrued Liabilities Notes 13 false false R14.htm 100130 - Disclosure - Equity Investment in PACT Pharma Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharma Equity Investment in PACT Pharma Notes 14 false false R15.htm 100140 - Disclosure - License and Collaboration Agreements Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreements License and Collaboration Agreements Notes 15 false false R16.htm 100150 - Disclosure - Stockholders' Equity Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 100160 - Disclosure - Stock-Based Compensation Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 17 false false R18.htm 100170 - Disclosure - Net Loss per Share Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShare Net Loss per Share Notes 18 false false R19.htm 100180 - Disclosure - Commitments Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureCommitments Commitments Notes 19 false false R20.htm 100190 - Disclosure - Related Parties Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedParties Related Parties Notes 20 false false R21.htm 100200 - Disclosure - Subsequent Event Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEvent Subsequent Event Notes 21 false false R22.htm 100210 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPolicies 22 false false R23.htm 100220 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPolicies 23 false false R24.htm 100230 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurements 24 false false R25.htm 100240 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureAccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.arcusbio.com/20210331/taxonomy/role/DisclosureAccruedLiabilities 25 false false R26.htm 100250 - Disclosure - License and Collaboration Agreements (Tables) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsTables License and Collaboration Agreements (Tables) Tables http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreements 26 false false R27.htm 100260 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockBasedCompensation 27 false false R28.htm 100270 - Disclosure - Net Loss per Share (Tables) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareTables Net Loss per Share (Tables) Tables http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShare 28 false false R29.htm 100280 - Disclosure - Organization - Additional Information (Details) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails Organization - Additional Information (Details) Details 29 false false R30.htm 100290 - Disclosure - Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Details 30 false false R31.htm 100300 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 31 false false R32.htm 100310 - Disclosure - Fair Value Measurements - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Details) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Details) Details 32 false false R33.htm 100320 - Disclosure - Fair Value Measurements - Schedule of Investments Classified as Available for Sale Securities with Contractual Maturities (Details) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableForSaleSecuritiesWithContractualMaturitiesDetails Fair Value Measurements - Schedule of Investments Classified as Available for Sale Securities with Contractual Maturities (Details) Details 33 false false R34.htm 100330 - Disclosure - Fair Value Measurements - Schedule of Fair Value and Amortized Cost of Investments in Marketable Securities by Major Security Type (Details) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAndAmortizedCostOfInvestmentsInMarketableSecuritiesByMajorSecurityTypeDetails Fair Value Measurements - Schedule of Fair Value and Amortized Cost of Investments in Marketable Securities by Major Security Type (Details) Details 34 false false R35.htm 100340 - Disclosure - Accrued Liabilities - Summary of Accrued Liabilities (Details) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails Accrued Liabilities - Summary of Accrued Liabilities (Details) Details 35 false false R36.htm 100350 - Disclosure - Equity Investment in PACT Pharma - Additional Information (Details) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails Equity Investment in PACT Pharma - Additional Information (Details) Details 36 false false R37.htm 100360 - Disclosure - License and Collaboration Agreements - Summary of Revenues (Details) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesDetails License and Collaboration Agreements - Summary of Revenues (Details) Details 37 false false R38.htm 100370 - Disclosure - License and Collaboration Agreements - Summary of Revenues by Collaboration and by Category of Revenue (Details) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesByCollaborationAndByCategoryOfRevenueDetails License and Collaboration Agreements - Summary of Revenues by Collaboration and by Category of Revenue (Details) Details 38 false false R39.htm 100380 - Disclosure - License and Collaboration Agreements - Summary of Revenue Recognized as a Result of Changes in Deferred Revenue (Details) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenueRecognizedAsResultOfChangesInDeferredRevenueDetails License and Collaboration Agreements - Summary of Revenue Recognized as a Result of Changes in Deferred Revenue (Details) Details 39 false false R40.htm 100390 - Disclosure - License and Collaboration Agreements - Additional Information (Details) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails License and Collaboration Agreements - Additional Information (Details) Details 40 false false R41.htm 100400 - Disclosure - Stockholders' Equity - Additional Information (Details) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails Stockholders' Equity - Additional Information (Details) Details 41 false false R42.htm 100410 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) Details 42 false false R43.htm 100420 - Disclosure - Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) Details 43 false false R44.htm 100430 - Disclosure - Net Loss per Share - Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails Net Loss per Share - Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details) Details 44 false false R45.htm 100440 - Disclosure - Commitments - Additional Information (Details) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails Commitments - Additional Information (Details) Details 45 false false R46.htm 100450 - Disclosure - Related Parties - Additional Information (Details) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails Related Parties - Additional Information (Details) Details 46 false false R47.htm 100460 - Disclosure - Subsequent Event - Additional Information (Details) Sheet http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails Subsequent Event - Additional Information (Details) Details 47 false false All Reports Book All Reports rcus-10q_20210331.htm rcus-20210331.xsd rcus-20210331_cal.xml rcus-20210331_def.xml rcus-20210331_lab.xml rcus-20210331_pre.xml rcus-ex102_91.htm rcus-ex311_6.htm rcus-ex312_9.htm rcus-ex321_7.htm rcus-ex322_10.htm http://xbrl.sec.gov/stpr/2018-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 true true JSON 66 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rcus-10q_20210331.htm": { "axisCustom": 0, "axisStandard": 21, "contextCount": 151, "dts": { "calculationLink": { "local": [ "rcus-20210331_cal.xml" ] }, "definitionLink": { "local": [ "rcus-20210331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "rcus-10q_20210331.htm" ] }, "labelLink": { "local": [ "rcus-20210331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "rcus-20210331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "rcus-20210331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 432, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 7, "http://www.arcusbio.com/20210331": 5, "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 16 }, "keyCustom": 95, "keyStandard": 255, "memberCustom": 21, "memberStandard": 27, "nsprefix": "rcus", "nsuri": "http://www.arcusbio.com/20210331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Organization", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureOrganization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Significant Accounting Policies", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Fair Value Measurements", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Accrued Liabilities", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureAccruedLiabilities", "shortName": "Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Equity Investment in PACT Pharma", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharma", "shortName": "Equity Investment in PACT Pharma", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - License and Collaboration Agreements", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreements", "shortName": "License and Collaboration Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Stockholders' Equity", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Stock-Based Compensation", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Net Loss per Share", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShare", "shortName": "Net Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Commitments", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureCommitments", "shortName": "Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210331", "decimals": "-3", "lang": null, "name": "us-gaap:InterestReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Related Parties", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedParties", "shortName": "Related Parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Subsequent Event", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEvent", "shortName": "Subsequent Event", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Accrued Liabilities (Tables)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureAccruedLiabilitiesTables", "shortName": "Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - License and Collaboration Agreements (Tables)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsTables", "shortName": "License and Collaboration Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Net Loss per Share (Tables)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": "INF", "first": true, "lang": null, "name": "rcus:NumberOfInvestigationalProduct", "reportCount": 1, "unique": true, "unitRef": "U_rcusProduct", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Organization - Additional Information (Details)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails", "shortName": "Organization - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": "INF", "first": true, "lang": null, "name": "rcus:NumberOfInvestigationalProduct", "reportCount": 1, "unique": true, "unitRef": "U_rcusProduct", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "shortName": "Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20200331", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Fair Value Measurements - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Details)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "Fair Value Measurements - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Fair Value Measurements - Schedule of Investments Classified as Available for Sale Securities with Contractual Maturities (Details)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableForSaleSecuritiesWithContractualMaturitiesDetails", "shortName": "Fair Value Measurements - Schedule of Investments Classified as Available for Sale Securities with Contractual Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Fair Value Measurements - Schedule of Fair Value and Amortized Cost of Investments in Marketable Securities by Major Security Type (Details)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAndAmortizedCostOfInvestmentsInMarketableSecuritiesByMajorSecurityTypeDetails", "shortName": "Fair Value Measurements - Schedule of Fair Value and Amortized Cost of Investments in Marketable Securities by Major Security Type (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Accrued Liabilities - Summary of Accrued Liabilities (Details)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails", "shortName": "Accrued Liabilities - Summary of Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GainLossOnSaleOfEquityInvestments", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Equity Investment in PACT Pharma - Additional Information (Details)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails", "shortName": "Equity Investment in PACT Pharma - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:EquityMethodInvestments", "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_rcusPACTPharmaMember_20201231", "decimals": "-6", "lang": null, "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "rcus:SummaryOfRevenuesTableTextBlock", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_srtCounterpartyNameAxis_rcusGileadSciencesIncAndTaihoPharmaceuticalCoMember_srtProductOrServiceAxis_rcusCollaborationMember_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - License and Collaboration Agreements - Summary of Revenues (Details)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesDetails", "shortName": "License and Collaboration Agreements - Summary of Revenues (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "rcus:SummaryOfRevenuesTableTextBlock", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_srtCounterpartyNameAxis_rcusGileadSciencesIncAndTaihoPharmaceuticalCoMember_srtProductOrServiceAxis_rcusCollaborationMember_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - License and Collaboration Agreements - Summary of Revenues by Collaboration and by Category of Revenue (Details)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesByCollaborationAndByCategoryOfRevenueDetails", "shortName": "License and Collaboration Agreements - Summary of Revenues by Collaboration and by Category of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_srtProductOrServiceAxis_rcusGileadAccessRightsMember_20210101_20210331", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredRevenueRevenueRecognized1", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - License and Collaboration Agreements - Summary of Revenue Recognized as a Result of Changes in Deferred Revenue (Details)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenueRecognizedAsResultOfChangesInDeferredRevenueDetails", "shortName": "License and Collaboration Agreements - Summary of Revenue Recognized as a Result of Changes in Deferred Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredRevenueRevenueRecognized1", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": "-3", "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - License and Collaboration Agreements - Additional Information (Details)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "shortName": "License and Collaboration Agreements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_srtCounterpartyNameAxis_rcusWuXiBiologicsLicenseAgreementMember_20201201_20201231", "decimals": "-5", "lang": null, "name": "rcus:ClinicalAndRegulatoryMilestonesAchievedUnderLicenseAgreement", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_srtCounterpartyNameAxis_rcusGileadSciencesIncMember_us-gaapTypeOfArrangementAxis_rcusCommonStockPurchaseAgreementMember_20200712_20200713", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Stockholders' Equity - Additional Information (Details)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "shortName": "Stockholders' Equity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_srtCounterpartyNameAxis_rcusGileadSciencesIncMember_us-gaapTypeOfArrangementAxis_rcusCommonStockPurchaseAgreementMember_20200712_20200713", "decimals": "-5", "lang": null, "name": "rcus:StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails", "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20210331", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails", "shortName": "Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": "0", "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Net Loss per Share - Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails", "shortName": "Net Loss per Share - Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Commitments - Additional Information (Details)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails", "shortName": "Commitments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_us-gaapCreditFacilityAxis_us-gaapStandbyLettersOfCreditMember_20210331", "decimals": "-5", "lang": null, "name": "us-gaap:LineOfCredit", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Related Parties - Additional Information (Details)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "shortName": "Related Parties - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_srtCounterpartyNameAxis_rcusGileadSciencesIncMember_us-gaapTypeOfArrangementAxis_rcusOptionLicenseAndCollaborationAgreementMember_20210331", "decimals": "-6", "lang": null, "name": "rcus:UnconstrainedConsiderationReceivable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_srtStatementGeographicalAxis_stprCA_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210430", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AreaOfLand", "reportCount": 1, "unique": true, "unitRef": "U_utrsqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Subsequent Event - Additional Information (Details)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "shortName": "Subsequent Event - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_srtStatementGeographicalAxis_stprCA_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210430", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AreaOfLand", "reportCount": 1, "unique": true, "unitRef": "U_utrsqft", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Parenthetical)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossParenthetical", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "role": "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_srtCounterpartyNameAxis_rcusGileadSciencesIncMember_us-gaapTypeOfArrangementAxis_rcusCommonStockPurchaseAgreementMember_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_srtCounterpartyNameAxis_rcusGileadSciencesIncMember_us-gaapTypeOfArrangementAxis_rcusCommonStockPurchaseAgreementMember_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "rcus:ReceivableFromRelatedParty", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100080 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)", "role": "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rcus-10q_20210331.htm", "contextRef": "C_0001724521_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "rcus:ReceivableFromRelatedParty", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } } }, "segmentCount": 53, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "rcus_AbmunoLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Abmuno license agreement.", "label": "Abmuno License Agreement [Member]", "terseLabel": "Abmuno License Agreement" } } }, "localname": "AbmunoLicenseAgreementMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rcus_AccruedResearchAndDevelopmentExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10140.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development expenses current.", "label": "Accrued Research And Development Expenses Current", "terseLabel": "Accrued research and development expenses" } } }, "localname": "AccruedResearchAndDevelopmentExpensesCurrent", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additional clinical and milestone payments received under license agreement.", "label": "Additional Clinical And Milestone Payments Received Under License Agreement", "terseLabel": "Additional clinical and regulatory milestone payments receivable" } } }, "localname": "AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_AdditionalCollaborationTermForProgramsEnteringClinicalDevelopmentPriorToEndOfCollaborationTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional collaboration term for programs entering clinical development prior to end of collaboration term.", "label": "Additional Collaboration Term For Programs Entering Clinical Development Prior To End Of Collaboration Term", "terseLabel": "Additional collaboration term for programs entering clinical development prior to end of collaboration term" } } }, "localname": "AdditionalCollaborationTermForProgramsEnteringClinicalDevelopmentPriorToEndOfCollaborationTerm", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rcus_BaseSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Base shares.", "label": "Base Shares [Member]", "terseLabel": "Base Shares" } } }, "localname": "BaseSharesMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rcus_CashCashEquivalentsAndAvailableForSaleInvestments": { "auth_ref": [], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableForSaleSecuritiesWithContractualMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash, cash equivalents and available for sale investments.", "label": "Cash Cash Equivalents And Available For Sale Investments", "totalLabel": "Total cash, cash equivalents and investments in marketable securities" } } }, "localname": "CashCashEquivalentsAndAvailableForSaleInvestments", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableForSaleSecuritiesWithContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash, cash equivalents and investments in marketable securities.", "label": "Cash Cash Equivalents And Investments In Marketable Securities [Member]", "terseLabel": "Cash, Cash Equivalents and Investments in Marketable Securities" } } }, "localname": "CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid for amounts included in measurement of lease liabilities.", "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities", "terseLabel": "Cash paid for amounts included in measurement of lease liabilities" } } }, "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rcus_ClinicalAndRegulatoryMilestonesAchievedUnderLicenseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Clinical and regulatory milestones achieved under license agreement.", "label": "Clinical And Regulatory Milestones Achieved Under License Agreement", "terseLabel": "Clinical and regulatory milestones achieved" } } }, "localname": "ClinicalAndRegulatoryMilestonesAchievedUnderLicenseAgreement", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_ClinicalRegulatoryAndCommercializationMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Clinical regulatory and commercialization milestone payments.", "label": "Clinical Regulatory And Commercialization Milestone Payments", "terseLabel": "Clinical, regulatory and commercialization milestone payments" } } }, "localname": "ClinicalRegulatoryAndCommercializationMilestonePayments", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_ClinicalRegulatoryAndCommercializationRemainingMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Clinical regulatory and commercialization remaining milestone payments.", "label": "Clinical Regulatory And Commercialization Remaining Milestone Payments", "terseLabel": "Clinical, regulatory and commercialization remaining milestone payments" } } }, "localname": "ClinicalRegulatoryAndCommercializationRemainingMilestonePayments", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_CollaborationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration.", "label": "Collaboration [Member]", "terseLabel": "Collaboration" } } }, "localname": "CollaborationMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "rcus_CollaborationTermForCurrentAndFutureClinicalPrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration term for current and future clinical programs.", "label": "Collaboration Term For Current And Future Clinical Programs", "terseLabel": "Collaboration term for current and future clinical programs" } } }, "localname": "CollaborationTermForCurrentAndFutureClinicalPrograms", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rcus_CommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments.", "label": "Commitments [Line Items]", "terseLabel": "Commitments [Line Items]" } } }, "localname": "CommitmentsLineItems", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rcus_CommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments.", "label": "Commitments [Table]", "terseLabel": "Commitments [Table]" } } }, "localname": "CommitmentsTable", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rcus_CommonStockPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock purchase agreement.", "label": "Common Stock Purchase Agreement [Member]", "terseLabel": "Purchase Agreement", "verboseLabel": "Stock Purchase Agreement" } } }, "localname": "CommonStockPurchaseAgreementMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "rcus_ConsultantAndLegalFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consultant and legal fees.", "label": "Consultant And Legal Fees", "terseLabel": "Consultant and legal fees" } } }, "localname": "ConsultantAndLegalFees", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_ContingentMilestonePaymentStartPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent milestone payment start period.", "label": "Contingent Milestone Payment Start Period", "terseLabel": "Contingent milestone payment start period" } } }, "localname": "ContingentMilestonePaymentStartPeriod", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "rcus_ContingentMilestonePaymentsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contingent milestone payments receivable.", "label": "Contingent Milestone Payments Receivable", "terseLabel": "Contingent milestone payments receivable" } } }, "localname": "ContingentMilestonePaymentsReceivable", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_ContractWithCustomerInitialTransactionPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract with customer initial transaction price.", "label": "Contract With Customer Initial Transaction Price", "terseLabel": "Initial transaction price" } } }, "localname": "ContractWithCustomerInitialTransactionPrice", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_ContractualObligationAdditionalPaymentDue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contractual obligation additional payment due.", "label": "Contractual Obligation Additional Payment Due", "terseLabel": "Additional payment due at each of the fourth, sixth, and eighth anniversaries of the agreement" } } }, "localname": "ContractualObligationAdditionalPaymentDue", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_ContractualObligationForFirstPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contractual obligation for first payment.", "label": "Contractual Obligation For First Payment", "terseLabel": "Contractual obligation for first payment" } } }, "localname": "ContractualObligationForFirstPayment", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_ContractualObligationRemainingAmountNotObligatedToPay": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contractual obligation remaining amount not obligated to pay.", "label": "Contractual Obligation Remaining Amount Not Obligated To Pay", "terseLabel": "Contractual obligation remaining amount not obligated to pay" } } }, "localname": "ContractualObligationRemainingAmountNotObligatedToPay", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_CorporateSecuritiesAndCommercialPaperMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate securities and commercial paper.", "label": "Corporate Securities And Commercial Paper [Member]", "terseLabel": "Corporate Securities and Commercial Paper" } } }, "localname": "CorporateSecuritiesAndCommercialPaperMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAndAmortizedCostOfInvestmentsInMarketableSecuritiesByMajorSecurityTypeDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "rcus_CurrentAndFutureProgramsExclusiveAccessPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Current and future programs exclusive access period.", "label": "Current And Future Programs Exclusive Access Period", "terseLabel": "Current and future programs exclusive access period" } } }, "localname": "CurrentAndFutureProgramsExclusiveAccessPeriod", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rcus_DeferredRevenueFromRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred revenue from related party.", "label": "Deferred Revenue From Related Party", "negatedLabel": "Deferred revenue from related party" } } }, "localname": "DeferredRevenueFromRelatedParty", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "rcus_DeferredRevenueRelatedPartiesClassifiedCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred revenue related parties classified current.", "label": "Deferred Revenue Related Parties Classified Current", "terseLabel": "Related party, deferred revenue - current" } } }, "localname": "DeferredRevenueRelatedPartiesClassifiedCurrent", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "rcus_DeferredRevenueRelatedPartiesNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred revenue related parties noncurrent.", "label": "Deferred Revenue Related Parties Noncurrent", "terseLabel": "Related party, deferred revenue - noncurrent" } } }, "localname": "DeferredRevenueRelatedPartiesNoncurrent", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "rcus_DeferredRevenueRelatedToDomvanalimabOption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred revenue related to domvanalimab option.", "label": "Deferred Revenue Related To Domvanalimab Option", "terseLabel": "Deferred revenue related to domvanalimab option" } } }, "localname": "DeferredRevenueRelatedToDomvanalimabOption", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_DeferredRevenueRelatedToEtrumadenantOption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Revenue related to etrumadenant option.", "label": "Deferred Revenue Related To Etrumadenant Option", "terseLabel": "Deferred revenue related to etrumadenant option" } } }, "localname": "DeferredRevenueRelatedToEtrumadenantOption", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_DeferredRevenueRelatedToResearchAndDevelopmentPipeline": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred revenue related to research and development pipeline.", "label": "Deferred Revenue Related To Research And Development Pipeline", "terseLabel": "Deferred revenue related to research and development pipeline" } } }, "localname": "DeferredRevenueRelatedToResearchAndDevelopmentPipeline", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_DevelopmentMilestonePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Development milestone payable.", "label": "Development Milestone Payable", "terseLabel": "Development milestone payable" } } }, "localname": "DevelopmentMilestonePayable", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_DirectOfferingCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Direct offering cost.", "label": "Direct Offering Cost", "terseLabel": "Direct offering cost" } } }, "localname": "DirectOfferingCost", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_DomvanalimabOptionPaymentUponAchievementOfCertainDevelopmentMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Domvanalimab option payment upon achievement of certain development milestones.", "label": "Domvanalimab Option Payment Upon Achievement Of Certain Development Milestones", "terseLabel": "Option payment upon achievement of certain development milestones" } } }, "localname": "DomvanalimabOptionPaymentUponAchievementOfCertainDevelopmentMilestones", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_DomvanalimabOptionRecognizedTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Domvanalimab option recognized term.", "label": "Domvanalimab Option Recognized Term", "terseLabel": "Domvanalimab option recognized term" } } }, "localname": "DomvanalimabOptionRecognizedTerm", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rcus_EquityMethodInvestmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity method investment.", "label": "Equity Method Investment [Abstract]" } } }, "localname": "EquityMethodInvestmentAbstract", "nsuri": "http://www.arcusbio.com/20210331", "xbrltype": "stringItemType" }, "rcus_EquityMethodInvestmentNumberOfSharesPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity method investment number of shares purchased.", "label": "Equity Method Investment Number Of Shares Purchased", "terseLabel": "Purchase of common stock, shares" } } }, "localname": "EquityMethodInvestmentNumberOfSharesPurchased", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "rcus_EstimatedPerformancePeriodOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimated performance period of agreement.", "label": "Estimated Performance Period Of Agreement", "terseLabel": "Estimated performance period" } } }, "localname": "EstimatedPerformancePeriodOfAgreement", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rcus_EtrumadenantOptionInitialTermOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Etrumadenant option initial term of agreement.", "label": "Etrumadenant Option Initial Term Of Agreement", "terseLabel": "Etrumadenant option initial term of agreement" } } }, "localname": "EtrumadenantOptionInitialTermOfAgreement", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rcus_ExtendedOptionAgreementPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extended option agreement period.", "label": "Extended Option Agreement Period", "terseLabel": "Extended option agreement period" } } }, "localname": "ExtendedOptionAgreementPeriod", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rcus_FairValueOfStockPurchased": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of stock purchased.", "label": "Fair Value Of Stock Purchased", "terseLabel": "Fair value of stock purchased" } } }, "localname": "FairValueOfStockPurchased", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_FundsReceivedForStockPurchaseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Funds received for stock purchase agreement.", "label": "Funds Received For Stock Purchase Agreement", "verboseLabel": "Funds received for purchase of common stock" } } }, "localname": "FundsReceivedForStockPurchaseAgreement", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_FutureDevelopmentAndCommercializationServicesContractLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future development and commercialization services contract liability.", "label": "Future Development And Commercialization Services Contract Liability", "terseLabel": "Future development and commercialization services contract liability" } } }, "localname": "FutureDevelopmentAndCommercializationServicesContractLiability", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_FutureDevelopmentAndPromotionCostsContractLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future development and promotion costs contract liability.", "label": "Future Development And Promotion Costs Contract Liability", "terseLabel": "Future development and promotion costs contract liability" } } }, "localname": "FutureDevelopmentAndPromotionCostsContractLiability", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_GainLossOnEquityInvestmentsNetOfPriorPeriodLosses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (loss) on equity investments net of prior period losses.", "label": "Gain Loss On Equity Investments Net Of Prior Period Losses", "negatedTerseLabel": "Losses on accumulated in prior periods of equity investment" } } }, "localname": "GainLossOnEquityInvestmentsNetOfPriorPeriodLosses", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_GenentechMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genentech.", "label": "Genentech [Member]", "terseLabel": "Genentech" } } }, "localname": "GenentechMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rcus_GileadAccessRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gilead access rights.", "label": "Gilead Access Rights [Member]", "terseLabel": "Gilead Access Rights" } } }, "localname": "GileadAccessRightsMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesByCollaborationAndByCategoryOfRevenueDetails" ], "xbrltype": "domainItemType" }, "rcus_GileadSciencesIncAndTaihoPharmaceuticalCoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gilead Sciences, Inc. and Taiho Pharmaceutical Co.", "label": "Gilead Sciences Inc And Taiho Pharmaceutical Co [Member]", "terseLabel": "Gilead and Taiho" } } }, "localname": "GileadSciencesIncAndTaihoPharmaceuticalCoMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsTables" ], "xbrltype": "domainItemType" }, "rcus_GileadSciencesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gilead Sciences, Inc.", "label": "Gilead Sciences Inc [Member]", "terseLabel": "Gilead" } } }, "localname": "GileadSciencesIncMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "rcus_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in accrued research and development expenses.", "label": "Increase Decrease In Accrued Research And Development Expenses", "terseLabel": "Accrued research and development expenses" } } }, "localname": "IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rcus_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in operating lease liabilities.", "label": "Increase Decrease In Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rcus_InterestAndOtherIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10050.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest and other income (expense) nonoperating net.", "label": "Interest And Other Income Expense Nonoperating Net", "terseLabel": "Interest and other income, net" } } }, "localname": "InterestAndOtherIncomeExpenseNonoperatingNet", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "rcus_LesseeOperatingLeaseAllowanceForTenantImprovements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease allowance for tenant improvements.", "label": "Lessee Operating Lease Allowance For Tenant Improvements", "terseLabel": "Operating lease, allowance for tenant improvements" } } }, "localname": "LesseeOperatingLeaseAllowanceForTenantImprovements", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_LesseeOperatingLeaseCollateralAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease collateral amount.", "label": "Lessee Operating Lease Collateral Amount", "terseLabel": "Collateral for operating leases" } } }, "localname": "LesseeOperatingLeaseCollateralAmount", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_LesseeOperatingLeaseExpirationMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease expiration month and year.", "label": "Lessee Operating Lease Expiration Month And Year", "terseLabel": "Lessee operating lease expiration month and year" } } }, "localname": "LesseeOperatingLeaseExpirationMonthAndYear", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "rcus_LesseeOperatingLeaseOptionToIncreaseAllowanceForTenantImprovements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease option to increase allowance for tenant improvements.", "label": "Lessee Operating Lease Option To Increase Allowance For Tenant Improvements", "terseLabel": "Operating lease, option to increase allowance for tenant improvements" } } }, "localname": "LesseeOperatingLeaseOptionToIncreaseAllowanceForTenantImprovements", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_LicenseAndCollaborationAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License and collaboration agreements.", "label": "License And Collaboration Agreements [Abstract]" } } }, "localname": "LicenseAndCollaborationAgreementsAbstract", "nsuri": "http://www.arcusbio.com/20210331", "xbrltype": "stringItemType" }, "rcus_LicenseAndCollaborationAgreementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License and collaboration agreements.", "label": "License And Collaboration Agreements [Line Items]", "terseLabel": "License And Collaboration Agreements [Line Items]" } } }, "localname": "LicenseAndCollaborationAgreementsLineItems", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesByCollaborationAndByCategoryOfRevenueDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesDetails" ], "xbrltype": "stringItemType" }, "rcus_LicenseAndCollaborationAgreementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License and collaboration agreements.", "label": "License And Collaboration Agreements [Table]", "terseLabel": "License And Collaboration Agreements [Table]" } } }, "localname": "LicenseAndCollaborationAgreementsTable", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesByCollaborationAndByCategoryOfRevenueDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesDetails" ], "xbrltype": "stringItemType" }, "rcus_MaximumOngoingResearchAndDevelopmentSupport": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum ongoing research and development support.", "label": "Maximum Ongoing Research And Development Support", "terseLabel": "Ongoing research and development support" } } }, "localname": "MaximumOngoingResearchAndDevelopmentSupport", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_MayTwoThousandTwentyPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "May two thousand twenty public offering.", "label": "May Two Thousand Twenty Public Offering [Member]", "terseLabel": "May 2020 Public Offering" } } }, "localname": "MayTwoThousandTwentyPublicOfferingMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rcus_MilestoneExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone expense.", "label": "Milestone Expense", "terseLabel": "Development milestone expense" } } }, "localname": "MilestoneExpense", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_MilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone payments.", "label": "Milestone Payments", "terseLabel": "Milestone payments" } } }, "localname": "MilestonePayments", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_NetExpensesOfInception": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net expenses of inception.", "label": "Net Expenses Of Inception", "terseLabel": "Net expenses of inception" } } }, "localname": "NetExpensesOfInception", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_NonRefundableAndNonCreditableCashPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non refundable and non creditable cash payments.", "label": "Non Refundable And Non Creditable Cash Payments", "terseLabel": "Non refundable and non creditable cash payments" } } }, "localname": "NonRefundableAndNonCreditableCashPayments", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_NonRefundableAndNonCreditableUpfrontCashPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non refundable and non creditable upfront cash payments.", "label": "Non Refundable And Non Creditable Upfront Cash Payments", "terseLabel": "Non-refundable, non-creditable upfront cash payments" } } }, "localname": "NonRefundableAndNonCreditableUpfrontCashPayments", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_NumberOfInvestigationalProduct": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of investigational product.", "label": "Number Of Investigational Product", "terseLabel": "Number of investigational product" } } }, "localname": "NumberOfInvestigationalProduct", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "rcus_NumberOfPrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of programs.", "label": "Number Of Programs", "terseLabel": "Number of programs, IND enabling studies not initiated" } } }, "localname": "NumberOfPrograms", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "rcus_OperatingLeaseCommencementYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease commencement year.", "label": "Operating Lease Commencement Year", "verboseLabel": "Lease commencement year" } } }, "localname": "OperatingLeaseCommencementYear", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "rcus_OperatingLeaseOptionToExtendLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease, option to extend lease term.", "label": "Operating Lease Option To Extend Lease Term", "terseLabel": "Operating lease, option to extend lease term" } } }, "localname": "OperatingLeaseOptionToExtendLeaseTerm", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rcus_OperatingLossFromEquityMethodInvestments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating loss from equity method investments.", "label": "Operating Loss From Equity Method Investments", "terseLabel": "Operating losses on equity method investments" } } }, "localname": "OperatingLossFromEquityMethodInvestments", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_OptionAndLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option and license agreement.", "label": "Option And License Agreement [Member]", "terseLabel": "Taiho Agreement" } } }, "localname": "OptionAndLicenseAgreementMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Option fee per program for all other programs entering clinical development to exercise option.", "label": "Option Fee Per Program For All Other Programs Entering Clinical Development To Exercise Option", "terseLabel": "Option fee per program for all other programs entering clinical development to exercise option" } } }, "localname": "OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_OptionFeePerProgramForCurrentClinicalProgramsToExerciseOption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Option fee per program for current clinical programs to exercise option.", "label": "Option Fee Per Program For Current Clinical Programs To Exercise Option", "terseLabel": "Option fee per program for current clinical programs to exercise option" } } }, "localname": "OptionFeePerProgramForCurrentClinicalProgramsToExerciseOption", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_OptionLicenseAndCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option, license and collaboration agreement.", "label": "Option License And Collaboration Agreement [Member]", "terseLabel": "Gilead Collaboration Agreement" } } }, "localname": "OptionLicenseAndCollaborationAgreementMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Option payment upon achievement of certain development milestones.", "label": "Option Payment Upon Achievement Of Certain Development Milestones", "terseLabel": "Option payment upon achievement of certain development milestones" } } }, "localname": "OptionPaymentUponAchievementOfCertainDevelopmentMilestones", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_OptionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option period.", "label": "Option Period", "terseLabel": "Option period" } } }, "localname": "OptionPeriod", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rcus_OrganizationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization.", "label": "Organization [Line Items]", "terseLabel": "Organization [Line Items]" } } }, "localname": "OrganizationLineItems", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rcus_OrganizationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization.", "label": "Organization [Table]", "terseLabel": "Organization [Table]" } } }, "localname": "OrganizationTable", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rcus_OtherAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": { "order": 10030.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other accrued liabilities.", "label": "Other Accrued Liabilities", "verboseLabel": "Other" } } }, "localname": "OtherAccruedLiabilities", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "rcus_PACTPharmaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PACT Pharma.", "label": "P A C T Pharma [Member]", "terseLabel": "PACT Pharma" } } }, "localname": "PACTPharmaMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rcus_PaymentForOptionExercise": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment for option exercise.", "label": "Payment For Option Exercise", "terseLabel": "Payment for option exercise" } } }, "localname": "PaymentForOptionExercise", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_PaymentReceivedForLicenseAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment received for license agreement.", "label": "Payment Received For License Agreement", "terseLabel": "Payment received for license agreement" } } }, "localname": "PaymentReceivedForLicenseAgreement", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_PercentageOfOptionToPurchaseMaximumSharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of option to purchase maximum shares of common stock.", "label": "Percentage Of Option To Purchase Maximum Shares Of Common Stock", "terseLabel": "Percentage of option to purchase maximum shares of common stock" } } }, "localname": "PercentageOfOptionToPurchaseMaximumSharesOfCommonStock", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "rcus_PercentageOfOutstandingCommonStockOwned": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of outstanding common stock owned.", "label": "Percentage Of Outstanding Common Stock Owned", "terseLabel": "Percentage of outstanding common stock held" } } }, "localname": "PercentageOfOutstandingCommonStockOwned", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "rcus_PercentageOfPremiumPurchasePriceOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of premium purchase price of common stock.", "label": "Percentage Of Premium Purchase Price Of Common Stock", "terseLabel": "Percentage of premium purchase price of common stock" } } }, "localname": "PercentageOfPremiumPurchasePriceOfCommonStock", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "rcus_PerformanceObligationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance obligation period.", "label": "Performance Obligation Period", "terseLabel": "Performance obligation period" } } }, "localname": "PerformanceObligationPeriod", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rcus_PeriodOverCommonStockToBePurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period over common stock to be purchased.", "label": "Period Over Common Stock To Be Purchased", "terseLabel": "Period over common stock to be purchased" } } }, "localname": "PeriodOverCommonStockToBePurchased", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rcus_PremiumPaidOnStockPurchaseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Premium paid on stock purchase agreement.", "label": "Premium Paid On Stock Purchase Agreement", "terseLabel": "Premium on stock purchased" } } }, "localname": "PremiumPaidOnStockPurchaseAgreement", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_PresentValueOfResearchAndDevelopmentInformationAccessRightsPaymentRelatedToYearTwo": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of research and development information access rights payment related to year two.", "label": "Present Value Of Research And Development Information Access Rights Payment Related To Year Two", "terseLabel": "Present value of research and development information access rights payment related to year 2022" } } }, "localname": "PresentValueOfResearchAndDevelopmentInformationAccessRightsPaymentRelatedToYearTwo", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_ProceedsFromIssuanceOfCommonStockToRelatedParty": { "auth_ref": [], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10040.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock to related party.", "label": "Proceeds From Issuance Of Common Stock To Related Party", "terseLabel": "Proceeds from issuance of common stock to related party" } } }, "localname": "ProceedsFromIssuanceOfCommonStockToRelatedParty", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rcus_ProceedsFromSaleOfShortTermAndLongTermInvestments": { "auth_ref": [], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from sale of short term and long term investments.", "label": "Proceeds From Sale Of Short Term And Long Term Investments", "terseLabel": "Sales of short-term and long-term investments" } } }, "localname": "ProceedsFromSaleOfShortTermAndLongTermInvestments", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rcus_RangeOfRoyaltiesReceivableOnNetSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range of royalties receivable on net sales.", "label": "Range Of Royalties Receivable On Net Sales", "terseLabel": "Range of royalties receivable on net sales" } } }, "localname": "RangeOfRoyaltiesReceivableOnNetSales", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rcus_RangeOfTieredRoyaltyPaymentsOnNetSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range of tiered royalty payments on net sales.", "label": "Range Of Tiered Royalty Payments On Net Sales", "terseLabel": "Range of tiered royalty payments on net sales" } } }, "localname": "RangeOfTieredRoyaltyPaymentsOnNetSales", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rcus_ReceivableFromRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivable from related party.", "label": "Receivable From Related Party", "negatedLabel": "Receivable from related party" } } }, "localname": "ReceivableFromRelatedParty", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "rcus_RegulatoryAndCommercialMilestonePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Regulatory and commercial milestone payable.", "label": "Regulatory And Commercial Milestone Payable", "terseLabel": "Regulatory and commercial milestone payable" } } }, "localname": "RegulatoryAndCommercialMilestonePayable", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_ReimbursementOfMilestoneExpenseOfCostSharingProvisions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reimbursement of milestone expense of cost sharing provisions.", "label": "Reimbursement Of Milestone Expense Of Cost Sharing Provisions", "verboseLabel": "Reimbursement of milestone expense of cost sharing provisions" } } }, "localname": "ReimbursementOfMilestoneExpenseOfCostSharingProvisions", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_ReimbursementOfResearchAndDevelopmentExpenseExcludingAcquiredInProcessCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reimbursement of research and development expense excluding acquired in process costs.", "label": "Reimbursement Of Research And Development Expense Excluding Acquired In Process Costs", "terseLabel": "Development cost reimbursed" } } }, "localname": "ReimbursementOfResearchAndDevelopmentExpenseExcludingAcquiredInProcessCosts", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_RelatedPartiesContractLiabilitiesNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Related parties contract liabilities noncurrent.", "label": "Related Parties Contract Liabilities Noncurrent", "terseLabel": "Related party, other long-term liabilities" } } }, "localname": "RelatedPartiesContractLiabilitiesNoncurrent", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Related party transaction reimbursement from related party for shared costs.", "label": "Related Party Transaction Reimbursement From Related Party For Shared Costs", "terseLabel": "Reimbursement from related party for shared costs", "verboseLabel": "Reimbursed under cost-sharing provisions of arrangement" } } }, "localname": "RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossParenthetical" ], "xbrltype": "monetaryItemType" }, "rcus_RepurchaseOfUnvestedSharesOfStock": { "auth_ref": [], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repurchase of unvested shares of stock.", "label": "Repurchase Of Unvested Shares Of Stock", "negatedLabel": "Repurchase of unvested shares of stock" } } }, "localname": "RepurchaseOfUnvestedSharesOfStock", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right to purchase additional outstanding voting common stock percentage.", "label": "Right To Purchase Additional Outstanding Voting Common Stock Percentage", "terseLabel": "Right to purchase additional outstanding voting common stock percentage" } } }, "localname": "RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "rcus_RoyaltiesPayableDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalties payable description.", "label": "Royalties Payable Description", "terseLabel": "Royalties payable description" } } }, "localname": "RoyaltiesPayableDescription", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rcus_SalesMilestoneAndRoyaltyRevenueRecognizedUnderLicenseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sales milestone and royalty revenue recognized under license agreement.", "label": "Sales Milestone And Royalty Revenue Recognized Under License Agreement", "terseLabel": "Sales milestone or royalty revenue recognized" } } }, "localname": "SalesMilestoneAndRoyaltyRevenueRecognizedUnderLicenseAgreement", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfRestrictedStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares stock options exercised and vesting of restricted stock.", "label": "Stock Issued During Period Shares Stock Options Exercised And Vesting Of Restricted Stock", "terseLabel": "Issuance of common stock upon exercise of stock options and vesting of restricted stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedAndVestingOfRestrictedStock", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "rcus_StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period, shares, vesting of early exercised stock option.", "label": "Stock Issued During Period Shares Vesting Of Early Exercised Stock Option", "terseLabel": "Vesting of early exercised stock options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOption", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value determined to premium on purchase of common stock and allocated to performance obligation.", "label": "Stock Issued During Period Value Determined To Premium On Purchase Of Common Stock And Allocated To Performance Obligation", "terseLabel": "Purchase price of common stock allocation to performance obligation" } } }, "localname": "StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfRestrictedStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value stock options exercised and vesting of restricted stock.", "label": "Stock Issued During Period Value Stock Options Exercised And Vesting Of Restricted Stock", "terseLabel": "Issuance of common stock upon exercise of stock options and vesting of restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfRestrictedStock", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "rcus_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period, value, vesting of early exercised stock option.", "label": "Stock Issued During Period Value Vesting Of Early Exercised Stock Option", "terseLabel": "Vesting of early exercised stock options" } } }, "localname": "StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOption", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "rcus_StrataAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Strata Agreement.", "label": "Strata Agreement [Member]", "terseLabel": "Strata Agreement" } } }, "localname": "StrataAgreementMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rcus_StrataOncologyIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Strata Oncology, Inc.", "label": "Strata Oncology Inc [Member]", "terseLabel": "Strata Oncology Inc" } } }, "localname": "StrataOncologyIncMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rcus_SubLicenseFeesIncurred": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sub license fees incurred.", "label": "Sub License Fees Incurred", "terseLabel": "Sub-license fees incurred" } } }, "localname": "SubLicenseFeesIncurred", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_SummaryOfRevenuesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of revenues.", "label": "Summary Of Revenues Table [Text Block]", "terseLabel": "Summary of Revenues" } } }, "localname": "SummaryOfRevenuesTableTextBlock", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsTables" ], "xbrltype": "textBlockItemType" }, "rcus_TaihoCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Taiho collaboration agreement.", "label": "Taiho Collaboration Agreement [Member]", "terseLabel": "Taiho Collaboration Agreement" } } }, "localname": "TaihoCollaborationAgreementMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesByCollaborationAndByCategoryOfRevenueDetails" ], "xbrltype": "domainItemType" }, "rcus_TaihoPharmaceuticalCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Taiho Pharmaceutical Co., Ltd.", "label": "Taiho Pharmaceutical Co Ltd [Member]", "terseLabel": "Taiho Pharmaceutical Co., Ltd" } } }, "localname": "TaihoPharmaceuticalCoLtdMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rcus_TrailingDaysAverageClosingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trailing days average closing price.", "label": "Trailing Days Average Closing Price", "terseLabel": "Trailing days average closing price" } } }, "localname": "TrailingDaysAverageClosingPrice", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "rcus_UnconstrainedConsiderationReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unconstrained consideration receivable.", "label": "Unconstrained Consideration Receivable", "terseLabel": "Unconstrained consideration to be received" } } }, "localname": "UnconstrainedConsiderationReceivable", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_UnderwritersOptionExerciseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriters option exercise.", "label": "Underwriters Option Exercise [Member]", "terseLabel": "Underwriters Option Exercise" } } }, "localname": "UnderwritersOptionExerciseMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rcus_UnrealizedGainLossOnEquityMethodInvestments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrealized gain (loss) on equity method investments.", "label": "Unrealized Gain Loss On Equity Method Investments", "negatedLabel": "Unrealized loss on equity method investments" } } }, "localname": "UnrealizedGainLossOnEquityMethodInvestments", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_UnvestedRestrictedStockIssuedAsPartOfCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested restricted stock issued as part of collaboration agreement.", "label": "Unvested Restricted Stock Issued As Part Of Collaboration Agreement [Member]", "terseLabel": "Unvested Restricted Stock Issued as Part of Collaboration Agreement" } } }, "localname": "UnvestedRestrictedStockIssuedAsPartOfCollaborationAgreementMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "rcus_UpfrontAndMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront and milestone payments.", "label": "Upfront And Milestone Payments", "terseLabel": "Upfront and milestone payments" } } }, "localname": "UpfrontAndMilestonePayments", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_UpfrontCashPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront cash payment.", "label": "Upfront Cash Payment", "terseLabel": "Upfront cash payment" } } }, "localname": "UpfrontCashPayment", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rcus_VestingOfEarlyExercisedStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Vesting of early exercised stock options.", "label": "Vesting Of Early Exercised Stock Options", "terseLabel": "Vesting of early exercised stock options" } } }, "localname": "VestingOfEarlyExercisedStockOptions", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rcus_WuXiBiologicsLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "WuXi Biologics license agreement.", "label": "Wu Xi Biologics License Agreement [Member]", "terseLabel": "WuXi Biologics License Agreement" } } }, "localname": "WuXiBiologicsLicenseAgreementMember", "nsuri": "http://www.arcusbio.com/20210331", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r40", "r84" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsTables", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investee Name [Domain]", "terseLabel": "Investment, Name" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r203", "r204", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r333", "r336" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum", "verboseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r203", "r204", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r333", "r336" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r146", "r188", "r191", "r294", "r332", "r334" ], "lang": { "en-us": { "role": { "label": "Product Or Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesByCollaborationAndByCategoryOfRevenueDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r146", "r188", "r191", "r294", "r332", "r334" ], "lang": { "en-us": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesByCollaborationAndByCategoryOfRevenueDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r193", "r203", "r204", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r333", "r336" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r193", "r203", "r204", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r333", "r336" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsTables", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r88", "r89", "r90", "r91", "r92", "r93", "r94", "r95", "r96", "r98", "r99", "r100", "r101", "r102", "r115", "r159", "r160", "r220", "r227", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346" ], "lang": { "en-us": { "role": { "label": "Restatement [Axis]", "terseLabel": "Revision of Prior Period" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r88", "r89", "r90", "r91", "r92", "r93", "r94", "r95", "r96", "r98", "r99", "r100", "r101", "r102", "r115", "r159", "r160", "r220", "r227", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346" ], "lang": { "en-us": { "role": { "label": "Restatement [Domain]", "terseLabel": "Revision of Prior Period" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r88", "r90", "r91", "r92", "r93", "r94", "r95", "r96", "r98", "r99", "r101", "r102", "r115", "r159", "r160", "r220", "r227", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346" ], "lang": { "en-us": { "role": { "label": "Scenario Previously Reported [Member]", "terseLabel": "Previously Reported" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "label": "Schedule Of Equity Method Investment Equity Method Investee Name [Axis]", "terseLabel": "Investment, Name" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r147", "r148", "r188", "r192", "r335", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373" ], "lang": { "en-us": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r147", "r148", "r188", "r192", "r335", "r364", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374" ], "lang": { "en-us": { "role": { "label": "Statement Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CALIFORNIA", "terseLabel": "Hayward, California" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10130.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedPartiesCurrent": { "auth_ref": [ "r37", "r86", "r276", "r278" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.", "label": "Accounts Receivable Related Parties Current", "terseLabel": "Related party, receivable from collaboration partners" } } }, "localname": "AccountsReceivableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r72" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion Amortization Of Discounts And Premiums Investments", "negatedLabel": "Amortization of premiums on investments" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10150.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities Current", "terseLabel": "Other accrued liabilities", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities Current [Abstract]" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r6", "r8", "r31" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": { "order": 10020.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees Current", "terseLabel": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r19", "r42", "r43", "r44", "r322", "r342", "r346" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10080.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r41", "r44", "r45", "r88", "r89", "r91", "r241", "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r17", "r220" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid In Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r88", "r89", "r91", "r217", "r218", "r219" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r71", "r163" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Adjustment For Amortization", "terseLabel": "Amortization expense" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r205", "r207", "r222", "r223" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r174", "r181" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs", "terseLabel": "Offering costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r207", "r214", "r221" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Compensation expense recognized", "verboseLabel": "Total stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Antidilutive securities excluded from computation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area Of Land", "terseLabel": "Square feet of space leased" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r82", "r134", "r138", "r144", "r156", "r235", "r242", "r258", "r308", "r320" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r2", "r3", "r39", "r82", "r156", "r235", "r242", "r258" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10180.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r248" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "terseLabel": "Total assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAndAmortizedCostOfInvestmentsInMarketableSecuritiesByMajorSecurityTypeDetails": { "order": 10030.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available For Sale Securities", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAndAmortizedCostOfInvestmentsInMarketableSecuritiesByMajorSecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r152" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAndAmortizedCostOfInvestmentsInMarketableSecuritiesByMajorSecurityTypeDetails": { "order": 10010.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax", "terseLabel": "Unrealized Gain" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAndAmortizedCostOfInvestmentsInMarketableSecuritiesByMajorSecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAndAmortizedCostOfInvestmentsInMarketableSecuritiesByMajorSecurityTypeDetails": { "order": 10020.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax", "negatedLabel": "Unrealized Loss" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAndAmortizedCostOfInvestmentsInMarketableSecuritiesByMajorSecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAndAmortizedCostOfInvestmentsInMarketableSecuritiesByMajorSecurityTypeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available For Sale Securities Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAndAmortizedCostOfInvestmentsInMarketableSecuritiesByMajorSecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableForSaleSecuritiesWithContractualMaturitiesDetails": { "order": 10020.0, "parentTag": "rcus_CashCashEquivalentsAndAvailableForSaleInvestments", "weight": 1.0 }, "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10250.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.", "label": "Available For Sale Securities Current", "terseLabel": "Short-term investments", "verboseLabel": "Short-term investments (due within one year)" } } }, "localname": "AvailableForSaleSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableForSaleSecuritiesWithContractualMaturitiesDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r151", "r161" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10190.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Available For Sale Securities Debt Securities Noncurrent", "terseLabel": "Long-term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableForSaleSecuritiesWithContractualMaturitiesDetails": { "order": 10030.0, "parentTag": "rcus_CashCashEquivalentsAndAvailableForSaleInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.", "label": "Available For Sale Securities Noncurrent", "verboseLabel": "Long-term investments (due between one and two years)" } } }, "localname": "AvailableForSaleSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableForSaleSecuritiesWithContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available For Sale Securities [Text Block]", "terseLabel": "Schedule of Fair Value and Amortized Cost of Investments in Marketable Securities by Major Security Type" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r208", "r215" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r246", "r247" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r75", "r76", "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred But Not Yet Paid", "terseLabel": "Unpaid portion of property and equipment purchases included in accounts payable and accrued liabilities" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r25", "r73" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 }, "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10240.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableForSaleSecuritiesWithContractualMaturitiesDetails": { "order": 10010.0, "parentTag": "rcus_CashCashEquivalentsAndAvailableForSaleInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash And Cash Equivalents Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfInvestmentsClassifiedAsAvailableForSaleSecuritiesWithContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r9", "r74", "r79" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash And Cash Equivalents Policy [Text Block]", "terseLabel": "Cash Equivalents and Investments" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r9", "r74", "r79", "r307" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy", "terseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash as Reported in Condensed Consolidated Statements of Cash Flows" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r68", "r73", "r78" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r68", "r259" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r80", "r82", "r105", "r106", "r107", "r109", "r111", "r118", "r119", "r120", "r156", "r258" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r228", "r229", "r231" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "License and Collaboration Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r34", "r168", "r311", "r326" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments (Note 10)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments Disclosure [Text Block]", "terseLabel": "Commitments" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureCommitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r88", "r89" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r16", "r174" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r16" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock, $0.0001 par value, 400,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 70,965,513 and 65,114,685 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r48", "r50", "r51", "r57", "r315", "r331" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r124", "r318" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk Credit Risk", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r79", "r237" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation Policy [Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r183", "r185", "r189" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract With Customer Asset Net", "terseLabel": "Cost sharing receivable" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r183", "r185", "r189" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10260.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract With Customer Asset Net Current", "positiveLabel": "Cost sharing receivable, current", "terseLabel": "Receivable from collaboration partners ($4,924 and $943 from a related party)", "verboseLabel": "Cost sharing receivable" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetNetNoncurrent": { "auth_ref": [ "r183", "r185", "r189" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.", "label": "Contract With Customer Asset Net Noncurrent", "terseLabel": "Cost sharing receivable, noncurrent" } } }, "localname": "ContractWithCustomerAssetNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r183", "r184", "r189" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract With Customer Liability", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r183", "r184", "r189" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10160.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract With Customer Liability Current", "terseLabel": "Deferred revenue, current ($67,571 and $67,571 to a related party)" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r183", "r184", "r189" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10100.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract With Customer Liability Noncurrent", "positiveLabel": "Long-term portion of revenue allocated", "terseLabel": "Deferred revenue, noncurrent ($110,097 and $117,808 to a related party)" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r190" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract With Customer Liability Revenue Recognized", "terseLabel": "Revenue recognized from this performance obligation", "verboseLabel": "Revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": { "auth_ref": [ "r186" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.", "label": "Contract With Customer Performance Obligation Satisfied In Previous Period", "terseLabel": "Performance obligations satisfied in previous period" } } }, "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenueRecognizedAsResultOfChangesInDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r38", "r162" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "terseLabel": "Deferred offering expenses" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.", "label": "Deferred Revenue By Arrangement Disclosure [Text Block]", "terseLabel": "Summary of Revenue Recognized as a Result of Changes in Deferred Revenue" } } }, "localname": "DeferredRevenueByArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredRevenueRevenueRecognized1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue Revenue Recognized1", "verboseLabel": "Amounts included in deferred revenue at the beginning of the period" } } }, "localname": "DeferredRevenueRevenueRecognized1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenueRecognizedAsResultOfChangesInDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r71", "r164" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation And Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue Table [Text Block]", "terseLabel": "Summary of Revenues by Collaboration and by Category of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Basic And Diluted", "terseLabel": "Net loss per share: basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r112", "r113", "r114", "r116" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": { "order": 10010.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee Related Liabilities Current", "terseLabel": "Accrued personnel expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock Purchase Plan Shares" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Unvested Early Exercised Common Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r88", "r89", "r91", "r93", "r99", "r102", "r117", "r158", "r174", "r181", "r217", "r218", "r219", "r226", "r227", "r260", "r261", "r262", "r263", "r264", "r266", "r337", "r338", "r339" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r26", "r135", "r153" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Investment balance" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments Disclosure [Text Block]", "terseLabel": "Equity Investment in PACT Pharma" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharma" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAndAmortizedCostOfInvestmentsInMarketableSecuritiesByMajorSecurityTypeDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r248", "r249", "r250", "r256" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAndAmortizedCostOfInvestmentsInMarketableSecuritiesByMajorSecurityTypeDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r250" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value Assets Level1 To Level2 Transfers Amount", "terseLabel": "Fair value assets transferred from level 1 to level 2" } } }, "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r250" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value Assets Level2 To Level1 Transfers Amount", "terseLabel": "Fair value assets transferred from level 2 to level 1" } } }, "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value Assets Measured On Recurring Basis [Text Block]", "terseLabel": "Schedule of Financial Instruments Measured at Fair Value on Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r248", "r256" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Fair Value By Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r202", "r249", "r284", "r285", "r286" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r248", "r249", "r251", "r252", "r257" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r194", "r195", "r200", "r202", "r249", "r284" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r194", "r195", "r200", "r202", "r249", "r285" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r202", "r249", "r286" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value Liabilities Level1 To Level2 Transfers Amount", "terseLabel": "Fair value liabilities transferred from level 1 to level 2" } } }, "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value Liabilities Level2 To Level1 Transfers Amount", "terseLabel": "Fair value liabilities transferred from level 2 to level 1" } } }, "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": { "auth_ref": [ "r254" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3", "terseLabel": "Fair value liabilities transferred into level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": { "auth_ref": [ "r254" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3", "terseLabel": "Fair value liabilities transferred out of level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "auth_ref": [ "r254" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3", "terseLabel": "Fair value assets transferred into level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "auth_ref": [ "r254" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3", "terseLabel": "Fair value assets transferred out of level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r202", "r284", "r285", "r286" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r255", "r257" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Fair Value On Recurring Basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfEquityInvestments": { "auth_ref": [], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10060.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence.", "label": "Gain Loss On Sale Of Equity Investments", "terseLabel": "Gain on deemed sale from equity method investee", "verboseLabel": "Gains on dilution of equity investment" } } }, "localname": "GainLossOnSaleOfEquityInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r60" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10110.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.", "label": "Income Loss From Continuing Operations Per Basic And Diluted Share", "terseLabel": "Net loss per share, basic and diluted" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r54", "r71", "r133", "r153", "r312", "r328" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10070.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income Loss From Equity Method Investments", "terseLabel": "Share of loss from equity method investee" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r70" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase Decrease In Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "auth_ref": [ "r70" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Increase Decrease In Contract With Customer Asset", "negatedLabel": "Receivable from collaboration partners (($3,981) and $0 from a related party)" } } }, "localname": "IncreaseDecreaseInContractWithCustomerAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r70" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase Decrease In Contract With Customer Liability", "terseLabel": "Deferred revenue (($7,711) and $0 to a related party)" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r70" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase Decrease In Other Accrued Liabilities", "terseLabel": "Other accrued liabilities" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r70" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase Decrease In Other Noncurrent Assets", "negatedLabel": "Other long-term assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase Decrease In Other Noncurrent Liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r70" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivableCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10270.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Interest Receivable Current", "terseLabel": "Accrued interest receivable" } } }, "localname": "InterestReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAndAmortizedCostOfInvestmentsInMarketableSecuritiesByMajorSecurityTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAndAmortizedCostOfInvestmentsInMarketableSecuritiesByMajorSecurityTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsAndCash": { "auth_ref": [ "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.", "label": "Investments And Cash", "terseLabel": "Cash and investments" } } }, "localname": "InvestmentsAndCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee Leases Policy [Text Block]", "terseLabel": "Leases and Rent Expense" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee Operating Lease Existence Of Option To Extend", "terseLabel": "Operating lease, existence of option to extend" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r272" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Undiscounted Excess Amount", "terseLabel": "Operating lease undiscounted amount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee Operating Lease Option To Extend", "terseLabel": "Operating lease, option to extend" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r30", "r82", "r139", "r156", "r236", "r242", "r243", "r258" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "LIABILITIES" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r82", "r156", "r258", "r310", "r324" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r32", "r82", "r156", "r236", "r242", "r243", "r258" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10090.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAndServiceMember": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License And Service [Member]", "verboseLabel": "Collaboration and License" } } }, "localname": "LicenseAndServiceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r13", "r309", "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Line Of Credit", "terseLabel": "Long-term line of credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAndAmortizedCostOfInvestmentsInMarketableSecuritiesByMajorSecurityTypeDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r121", "r130" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature Of Operations", "terseLabel": "Organization" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureOrganization" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r68" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flow from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r68" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flow from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r68", "r69", "r72" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flow from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r46", "r49", "r55", "r72", "r82", "r92", "r94", "r95", "r96", "r97", "r101", "r102", "r108", "r134", "r137", "r140", "r143", "r145", "r156", "r258", "r313", "r329" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income Loss [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing And Financing Items [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r61" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10040.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income Expense", "totalLabel": "Total non-operating income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income Expense [Abstract]", "terseLabel": "Non-operating income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10090.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r134", "r137", "r140", "r143", "r145" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10030.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r269" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10110.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Operating lease liabilities, noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r268" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10210.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r71" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease Right Of Use Asset Amortization Expense", "terseLabel": "Amortization of right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10230.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r47", "r50", "r52", "r56", "r174", "r260", "r265", "r266", "r314", "r330" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r47", "r50", "r233", "r234", "r240" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r5", "r6", "r31" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10170.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10120.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities Noncurrent", "terseLabel": "Other long-term liabilities ($9,703 and $9,703 to a related party)" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Noncurrent Assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables And Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r64" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments To Acquire Investments", "negatedLabel": "Purchases of short-term and long-term investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r63" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r15" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "terseLabel": "Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of March 31, 2021 and December 31, 2020; no shares issued and outstanding as of March 31, 2021 and December 31, 2020" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r2", "r23", "r24" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10280.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses And Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "positiveTerseLabel": "Gross proceeds", "verboseLabel": "Net proceeds from public offering after deducting underwriting discounts, commissions and other offering expenses" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r65", "r216" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options", "terseLabel": "Proceeds from issuance of common stock pursuant to equity award plans" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r66", "r85" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds From Lines Of Credit", "terseLabel": "Issuance of letter of credit" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r62" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds From Sale Maturity And Collections Of Investments", "terseLabel": "Proceeds from maturities of short-term and long-term investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r0", "r46", "r49", "r67", "r82", "r92", "r101", "r102", "r134", "r137", "r140", "r143", "r145", "r156", "r233", "r238", "r239", "r244", "r245", "r258", "r316" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r11", "r165", "r325" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10200.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r44", "r45", "r52", "r260", "r264", "r266" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax", "verboseLabel": "Reclassification out of accumulated other comprehensive income" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r201", "r275", "r276" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r201", "r275", "r278", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r273", "r274", "r276", "r279", "r280" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Parties" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r225", "r375" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10100.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development (($4,924) and $0 from a related party)", "verboseLabel": "Development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r225" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research And Development Expense Excluding Acquired In Process Cost", "terseLabel": "Development cost recorded within research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development", "verboseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r4", "r12", "r78", "r365" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 }, "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10220.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "verboseLabel": "Non-vested Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Unvested Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r18", "r181", "r220", "r323", "r341", "r346" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r88", "r89", "r91", "r93", "r99", "r102", "r158", "r217", "r218", "r219", "r226", "r227", "r337", "r339" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r131", "r132", "r136", "r141", "r142", "r146", "r147", "r149", "r187", "r188", "r294" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": { "order": 10080.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Total collaboration and license revenues", "verboseLabel": "Collaboration and license revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesByCollaborationAndByCategoryOfRevenueDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r59", "r348" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue From Related Parties", "terseLabel": "Revenue from related parties" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r53", "r82", "r131", "r132", "r136", "r141", "r142", "r146", "r147", "r149", "r156", "r258", "r316" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "License revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfRevenuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale Of Stock Consideration Received On Transaction", "terseLabel": "Value of common stock issued" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale Of Stock Number Of Shares Issued In Transaction", "terseLabel": "Number of shares issued" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule Of Accrued Liabilities Table [Text Block]", "terseLabel": "Summary of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Schedule Of Cash Cash Equivalents And Short Term Investments Table [Text Block]", "terseLabel": "Schedule of Investments Classified as Available for Sale Securities with Contractual Maturities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Computation of Basic and Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r207", "r213", "r221" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r207", "r213", "r221" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Equity Method Investments [Line Items]", "terseLabel": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r0", "r82", "r155", "r156", "r258" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule Of Equity Method Investments [Table]", "terseLabel": "Schedule Of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r83", "r277", "r278" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule Of Related Party Transactions By Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r9", "r78", "r307", "r321" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Schedule Of Restricted Cash And Cash Equivalents [Text Block]", "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r35", "r80", "r118", "r119", "r171", "r172", "r173", "r175", "r176", "r177", "r178", "r179", "r180", "r181" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule Of Stock By Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r70" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number", "terseLabel": "Shares probable of vesting" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r206", "r209" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued Price Per Share", "terseLabel": "Shares issued, price per share", "verboseLabel": "Shares issued, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandbyLettersOfCreditMember": { "auth_ref": [ "r169", "r170", "r232", "r347" ], "lang": { "en-us": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.", "label": "Standby Letters Of Credit [Member]", "terseLabel": "Standby Letters of Credit" } } }, "localname": "StandbyLettersOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r14", "r15", "r16", "r80", "r82", "r105", "r106", "r107", "r109", "r111", "r118", "r119", "r120", "r156", "r174", "r258" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r36", "r88", "r89", "r91", "r93", "r99", "r102", "r117", "r158", "r174", "r181", "r217", "r218", "r219", "r226", "r227", "r260", "r261", "r262", "r263", "r264", "r266", "r337", "r338", "r339" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInPACTPharmaAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsTables", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossParenthetical", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r88", "r89", "r91", "r117", "r294" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsTables", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossParenthetical", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Stock Compensation Plan [Member]", "terseLabel": "Common Stock Options Issued and Outstanding" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r15", "r16", "r174", "r181" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "positiveTerseLabel": "Common stock shares issued", "terseLabel": "Issuance of common stock and rights to purchase additional shares in accordance with Amended and Restated Gilead Purchase Agreement, net of $55 offering costs, Shares", "verboseLabel": "Issuance of common stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r174", "r181" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period Shares Restricted Stock Award Gross", "terseLabel": "Number of restricted shares of common stock issued" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r15", "r16", "r174", "r181", "r210" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r15", "r16", "r174", "r181" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "positiveTerseLabel": "Common stock share value", "terseLabel": "Issuance of common stock and rights to purchase additional shares in accordance with Amended and Restated Gilead Purchase Agreement, net of $55 offering costs", "verboseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r15", "r16", "r174", "r181" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period Value Restricted Stock Award Gross", "terseLabel": "Fair value of restricted shares of common stock issued" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r36", "r174", "r181" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r16", "r20", "r21", "r82", "r150", "r156", "r258" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r81", "r181", "r182" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r267", "r282" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r267", "r282" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r267", "r282" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r267", "r282" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r281", "r283" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRevenueExtensibleList": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.", "label": "Type Of Revenue Extensible List", "terseLabel": "Type of Revenue [Extensible List]" } } }, "localname": "TypeOfRevenueExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossParenthetical" ], "xbrltype": "extensibleListItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r194", "r317" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "U S Government Agencies Debt Securities [Member]", "terseLabel": "U.S. Government Agency Securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAndAmortizedCostOfInvestmentsInMarketableSecuritiesByMajorSecurityTypeDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r194", "r202", "r317" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "U S Treasury Securities [Member]", "terseLabel": "U.S. Treasury Securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueAndAmortizedCostOfInvestmentsInMarketableSecuritiesByMajorSecurityTypeDetails", "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r122", "r123", "r125", "r126", "r127", "r128", "r129" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted-average number of shares used to compute basic and diluted net loss per share", "totalLabel": "Weighted-average common shares used to compute basic and diluted net loss per share" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails", "http://www.arcusbio.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": { "auth_ref": [ "r104" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails": { "order": 10020.0, "parentTag": "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).", "label": "Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation", "negatedLabel": "Less: weighted-average common shares subject to vesting" } } }, "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "auth_ref": [ "r103", "r104" ], "calculation": { "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails": { "order": 10010.0, "parentTag": "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).", "label": "Weighted Average Number Of Shares Issued Basic", "terseLabel": "Weighted-average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesIssuedBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number Of Shares Outstanding [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.arcusbio.com/20210331/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2646-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r157": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=27011391&loc=d3e105025-122735" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r167": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121596127&loc=d3e12803-110250" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r182": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL108322424-203045" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r231": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r283": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1,2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r376": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r377": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r378": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r379": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r381": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" } }, "version": "2.1" } ZIP 67 0001564590-21-024084-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-024084-xbrl.zip M4$L#!!0 ( %F"I5)5C9,+(1(" ,>.'@ 5 B2F4]$/)&1D9&__N_7F4'( M"[4=W3)_.Y.JM3-"3=72=//YMS//G9QWSO[WM__G__[U_ST_)Y=7PQO24UW] MA5[JCFI8CF?33^,?G\G0-'23DO_^?G=-+BW5FU'3)>=DZKKSBR]??O[\6=4F MNNE8AN>R]SA5U9I](>?GX8/[-E7X#^12<2D1_UP0N29+Y[7F>:UQ+]5MC0J%72,PQRQV]SR!UUJ/U"M6KPU*G+$& HF,[% MZY-MZ+^=+8T:_Z9JV<]?Y%JM_H6-H,M>0,^6KM?>;UB^N/7%_S&\U%8]9^7) M"O_F2;<$%+P?M7I="J_VG'/W;4[?[Y@HSI-X=/@+OZ5V7I/.5VYZ5I3YQGOX M#QMN<=RYO=I\AZK59^OE"_^%W2!UUFZPW6TM6_RTZ3VVN_&&39?JZI86Z>J& MRTU%5YW--XB?>!_:J[?05W6Z^0[^RZ9W>+/-0J&Y]A?>Y2_L"FKKZN(&)I$? MWV.9YVOW:50_=UQM<^."'S>TC__"]'WWK<$%FV_?>MN&RU7/MIF%>MM\3_CK MIALMSW3M;??Y/VZX[959MC]6QO)G78RDU.UVOXA?%QK@VENUM_N%_1I>&'GD MJI[SGY\49Z'GNF,U9*F]RS+X5RS:[.B;6LPNE;[\]X_KL3JE,^5\W9SHK]O> M('';PRT\-_#OE[N;KW^_](MK*Z8SL>R9,._\2R^=R:^DAYPR#E0>%F'ST MG,X[2MOQX>;U3-A9JFC\WS/J*H*8SNF?GO[RVUG?,ETNG?=,*\Z(ZO_UVYE+ M7]TOXF[RA=_GZJY!V0=N-\^EVI^/H=&LLHO8[U_""W[]$KZ*$\;-[XPS3$:P M+K7)"ZO)TMZ^_:KI+\1QWPSZVYFF.W-#>>,:3'FK_Z]?]=<+_CAJ M\[_\/W5-HZ;X4_S-KKWQ]9CH3 &O'FO\'S8RIC+CCZ3Z18_QL<8Y^@V+< MLFLM[8I]YQS6CK]+!S:BO=R(@>NS9MB*,30U^OI?].VP!KS_>F!#.LL- MZ0O[% S&OZAB#TR-.SV'M>7\7)*9\!_4$*G1#!L2$/(%E_C1Y(Z^4-.C@U??4GEU9=H!OS]2N/)=YQWUFPG0N][;U;"NS74+/_)$^9R%JSQ7;?;MA+^J] MZLXC?]?ONL&,P%C5&;=1A[F4?O,?@X'RQZEG,ROY3+FR+6X$OAJNP=H[#)=X2W^G?+QG$_YV(K.QWPL'9.P].NI?YQZ]GJE"&QCQ T+P\;A'IW91 & M;!AGC,/8[,CUT1Z:NLOF25QI6$/#%D!7CG6S=]LX3#<:S=K*N# R%#X-5X,G M0W\6[_49$OI01$3DT*%H22M#X;__J+[?*_K4NITJ;$!5RF;?S#+TK6M7.VP( M6-_#48CT6FK7ND( ^ =N'FZ;.WM]92NJ"&MX3-Q%9QX> T_]87QYMN0DM.OK M1I-KJN[RUSL"#I.;3H:J3C]TG/R)O*-?F+K!_%AFPLZ^A'MM.J&VL!-!'_BT\\(1$]P#YMC[3IV9)*WVYWT< MUCKNCX5C,3Y<#(6(Q%T$: @X/Q(7<5]X(Q73C>"[\$M=XU]/=#8/%(VB&R>] M_>%_K'WP6#N#*PW,Z(47UX%%\XS&HS>[':BQGS$YD'_2UHHK@D M?&CXV\J;^%,/P$\X>.!A\X,T;@!!X[Q>6SP[^.5H")9,_68$@@LNV!5) I / MO5D%8%D'C@-@U]CXW)BKL:F%(8G4A'.'J=#T%]:9M<;QAP@.5%PK[.'!HKTJ MW)''+;WJDIK63#=WO>Q#2[;ZMN@3PU^7^QM+^=9]"?"2ML)>M8/9JY8D>VT= MV,#%8],N:T87H8IK2_5G44L!"+X(R-RD*7.9+YDG:%AS?N7@=& M:3'Z])FW;U6N-=:$U[FAJWHP0R*:/N/>+%](#KW='6-Q]BV\:(_1^/7+QE>N MJ\UJ0W/M(YU.RK(V!J66,N"V;#&F@S\]OH)BS>:6*2;[2W*V%%5\CY5TL_%A MCA>FG5U^%Z=(IT\C/.\NE]1-TN5*1!!ZFJ9SQ5.,6T77AF9?F>NN8I1'*'8. M H(8R17T4VJ#13;U,UGISR2L;GG*!+SGJIZ,\]@5VHC=TIM?I5-IWR87ZA/ M[.61DKT'HZ""DQW$\,?F6(^L 'X^;->L<'[]1^Y<>20*@%]7/.DZ@/A+)&FP M/(#"2=W6&4AY1"S+J4CAY&F+IU5L" M8DL&C-@70)$XT 4NMI0 \WQ/+C@YRL8 K52;/;*"!XXA>&30@J ?>V0%%PIH M'ADT =GAD15<,L!X9-!$XC"/K.!2 MDC.X7@'+'3+J:GDM &SOSGC:;D]AS0 M@HT8+'9=?83"\>U@PG>Q2?J")FR1OPRBN%#S9-/6WMWN)6KRZ7Q5U&K4ZA.4 M11IBZ=5; G*?L7Q-.4X$G:6BBT4 'PDT *RBWF*+1E 5ASA MB<2!+G"QI028YWMRP3DHNMDSM8TU+XO@SAX:*=P]%N7S:Y%$,ZI<0'9HO MU/$+B@[-'XK]!R..)X..J>K9S+>@1>#,;<,2AN*/&9B"6L:5#5HYV2)^]&:G ME227=">Z5XIN_T,Q//K]K>G2A1(U+0>.0)U,U ZAD)U:RXH@.+H_E719Q M;0JB@J!'5%8%*9OS 20Y*;>EG_*A#L"3DTY:MZP$R4FH3?G1II(X@+!4/)/D M)-3*?*51H!+D82*%6I4OK2K)? Z:JF>>G(1ZFN=4"5009$;4.$Q.*JH9@).< MA%J;YU0)5!#D2=0X3$XJC!E )><-#-M._@[5BN+*@" 5J[!",&>8?KBB@30Y9RL M!>30^%31! 1\'#-K ?G0A\BMTYL#'P*( [G;ARBD #R(< (P?X^1$%% J@/ MD;6 Q/ A"B4@X'V(DQU3/F80:9Y!1Q/_?(4?U)U:2Q7#H]]2NG*XP&VO?^_7 MSE\-UL4^_TAJ!=6ZI5;>1(Z?/7#,@ :"N3ZDR87F8)_0M%SU7&H=6O6%1RV.;+'U'[1U>5POF$H M3SR>S8 MBCD\V4&N>[9GT^@O5A,BXX^6%XH6Y-L'1BTHCL^;NA8$8?)K]K?I M4/:0X$>DA%,J0[A8L04&9 9@.H$$44:= ,P36ST<']">RM!T[O3GJ>L4Q;+O M<"NV=1KMZ%XR(Q1^Q37K/=M4Q"Y+(#P?]AZE*#DIRC>1YDR* //7_C[=:@H4 MS]$<37JVK9C/[^MG_,;1G _ZN_/PL22V)3G\4,^3)(:.TL:Q",3QD-%(QJD[ MQ,G,4B/:YY)\F$:P.^IYU(BE-,U;SU:G"I.$LNG!QV. TE]VZ4>A+YC0KZ21 MK0AP>FED!PLP3P/BV(4)0#^45WWFS=)T=PHGZ 7PZUI?JJNY0]?FO3N:)K@]*F[D3JG= M]VR; \;/_G'0%2F7L3Z@1=O$ZSTO?G\!0P?I4.45(WECF2IJ*VIK(MJZ0Z)* MJ)X;MQ1=N]IA*L;@#8&.:)74KG7]XH;L0[U6(/7:/7:GU+*MXW]Z#U-JG]>Z MA]4O%'?4:QEZF"?1@J#$9SN/A>M0"P[7@@.K>+9/5<4S2RWHA%K002TH@19T M#M:"3AFTH!MJ01>UH 1:T#U8"[I):L%2CI*H@V9;S[8RVY*EY%<%\R\Y09[2 M!\J62-8P3D[RJ8JY3!$NXO0GD4QAU,)2:6&V:<&HA3&U$)4/E2^.\KW'M-<5 MJ9 Q[>)FX^1?9\J4A[-+"_[I_;?^7;<,ZUE7G2V2O#AH4+5F='&$TZ9UV#OJ M4,56IPR52_I"#6O.KPR6O)S'&2[-\!7I*+[+T<+ZOH/63G/? SW8(:A 5;%T'O83]-$6?+ M'5@7,>OUPCUM+LHV2M('DM1[FGFF54+:WM5QY.O]TJPI/PZ4,;SN_@78#?VGAQ=TQ7[;:P8#$1! M>@N9_:&\W?^T[J>6YRBF=O^3#<';K??$AFXTF; 6F,_+8MP*Q;B5SYGVUK$( MA&K?T5W"/A@Z<&VXK1,[6>-M-- MW>%1 _V%1C:CY3\,N5U7JCC4FTM86'H.![5 M>LXM&XW1I+@G"9Y$\(/(V9$#C18_E[J!I%!,W2@Q;P2O&,SFAO5&J<#*7PQ M2CC0%]HZAFCMH4DT&O+<233:Z#5&?3!UU[D;/Z"=/E"J=XXCVNJL;37*\S%6 M&J5XLQ3W;:KI[I6BZ@;KW&H@4#&UI[=KZHI$F(E_90%VQD6[O!RWV][I+!:! M3[!E;,&B!I,RC<]#W^YMQ704E2N?\_UM^9?D*-24)C((>U3J4Q M_N)/6(/?U(J?1?3Q$83[C4999\-YTJ)D*X$F&1K*NQ;!8Z#\UN^$KD70O+>< M3G-2=9'@J6XJP=?D]A1ZINY+_,.CY]K.GQ-W3:9F5'$\FWYCOU[PG\.'A=^O MO($_;>]%B(6-^IU:S[8RG_+CEOU%"7=N]WO+M0[HGQXW4"_L_]9+&Z[]O*PA M.:M_RU<:M@[*V3<^*A?]7G(:L&5@EU91-PUM%O)^FL,$3B"0H;N#DIE;R5QW M61H'NRQ)E&/67R]L3E.=9:P*"+^Q:MG/7W@>Z!>;_?R%7W=& MF.]G[[XXN.++A+'B^<2R7--RZ1EQK3LZ<7X[N[JYY\K#_CDC$]N:!=^*[^HU M$GR0PP^-\$,K_- )/C3"BQOAQ8WPXD9X<2.\N!E>W PO;H87-\.+F^'%K?#B M5GAQ*[RX%5[<"B]NAQ>WPXO;X<7M\.)V>'$GO+@37MP)+^Z$%W>8;_;KES64 M@&$G1;"3&EV__5(XU%)3"C_(X8=Z^"'HM=0.OVDOOFF&'UKAAW;X8>O(!-\Z M%G/]J,._$M],F=NA?RW/WZ9-GL MXO,GRW6MV<6EY3T9E,A5N__&M>;B3ZYR MY[K)3>E%[:]?)TP)SW_ZKWNR#.VK_XVC_YM>--CE9]_^XR]2J_;UUR^\2^_- MC/6>#Y\J;E(,_=F\4"DOR7%\?]Y?+'78Y>+/B3+3C;>+>V:G'7)#?Y([:Z:8 MP:6\)1>F9<\4PW^XRWWI"?N"?6M2_ZH7Q=899U^0X,*S;P\WP_O!)1G?]^X' MXP+U:SSH/]P-[X>#,>G=7)+!?_?_UKOY?4#ZHQ\_AN/Q<'1SVL[*:7;VG[WQ MWX8WO]^/;BKDLD]D9HZ['W=O547'EJ%KI%9MQ]70X$^#3MR+!AN-X&];# ?_ M(EG5XJ]M;6P7%!&\&MW]()QDV$4WWHRY$JIP=Z\6C&TJW)/4J,X,I.K- @_K MC 0N!B.$->=X0ZQ.JIW_79CG][=\*PCV2R]I'(ETJD!_^J'8?Y"123\'/6#T M&/;!'W4^,%_Y1.-75^%$Z __;V=,!E1J&,Y<4=F0+_X.(!!_!\\) %/Y"L#< MH1?AAZ_DIZZYTPNIQ@; ?X.@:%O/J>[2<_YN MWNF?;"IQMFWX-RO:YO$.1GA,GRU*'H9D_#9C/RYKW>+>N /^*VNT&38SNU9L M4VVYO4FU_^ZQ.0FUC;<[.K=L]R M)[PQBOO;FY&]R. M[N[)[B.2,U/VFWT+U-GX3VZ_YQ)&39Q)U2\FJ::\O5'%IN;9MQ]\'834IE*=U3% M^!=[S!7[QCF,/?FGJ-8A@+0HJE%+"-/"[_XUIDJ\8N'D@"67U<_8<4 M:,SXNJ_N\#4 XVUVR5A3_._HLJFJ:+B]*?)@,]/@*/_FN6TZPO%\A0U.MQG;) MCAS:$ZC;X>7'2.PR!/SOU<'A7V0FQ-L=S0WV@6?& MV?,@BU6L9HM"YO9;W]+B3RJ%S^GPI\UMZX6_D\\J+ZFA_&03S$T&9(._B>"M MD'LS"MZ]\CH,\AG\A,8X3-]H,Z+O=AKUYBYIIF4\<)_G6MFU0ZS%K6NW*'W%HZ*C$E'=HJ+2WHM)G'T?VO?73/ R3OREO_!#G=1QV!*^ESM9&"-L^LF^9W\)L MW8$S)I[NM]J('6WH;FW#K<5\)^/_U^<'.V'?NHUF8R>10S++^X;SWF<6Z(YL M8)I :OB,=6XSH=7GBD'H*U5%!3'V->,;ZH EY\4([0"ZB*N![]&%__A+1Y;: M7QWB4H/.I^P>8@I/OD(8G(;'9\>$39P49@HT>D$^;9_BK22R<(/:8[<=;D:: M4FW=B'S>;LID:?FM?'>5<CY*Y%F%7<-?6[[TD?WKZS.T2 MC_WW5/?BX)C3>\^Z:PM*R^M"\;JS/+"M5K75_NO*P/VOM9'[7QMB7*#7;>N- MJM3ZZU>R*O?.DMR3T"TL,#W>ZZY!!3D.%'5*^H;B.#M6.%>'4*JV/AA!T8@Y M3YMP,QG%/3ATMY#4J_4&"HFM")+UU_T_;766-DI(I]@2(G?1C)Q]"]>$A!$9 MO*I3OE.76";Y.=79-W<+-MQGFO*AK>;CD>D('^),)$;(N]8N5M:V S?D39*? MA'D_<)8N-E03L:.Z0FX5F_Q#,3Q*?JE5^8WDEMI$E&+>67 **\!GB,(&[ZS^,CY&E3CYD:8TH,I%:ZWW;,+%N_@OR_[#MW0+TMICF2]>N*4>*]RR4^Z.SD_8\J9=4_2# M)N1+T\;56>J)A&UH:GPQB7\MG\GY[.Y_)L"O]$@PO8,X/I/,^5M.P@5S*8SR_% A;^ M$)OC\Y]YKB31V*_,I>:7SFVJ4N%@2S(1R>8.^<2>Q[I''(^Y3\[4XJDT85*@ M.U7<];;_5%9;R9OHWQSTX7.%**9&/LE^'Y^8'K#?G_Z']8!?+RYE-_%6!,_A M>;:.:(1HI.*XI%LCFO+F5(DO&]'_WQ[/EZ/Q_+YG<[??S^#EY.$J[J%9\?^B MSKK&KK0GDBJY)9=Y:6.*R)SN[)1:P8):9Z_ M/YR,S^_))XY1^RN1ZW(UN,*=Z@YKLC+GB6EIJZ#?X(5F4>=S]6"UD>N;DI(6 MH\4'*]"B0JK-AK6NDFH1DUN%&*Q#E"BJRK3(YO6FA%S9W+)O_):]S#S?^(/# MVL ^!N3 Y5ZU9FQ(WRJ^;FNA^%GZ&E[VX07;VQ=>R,DLN'A+6\,K==.W$FPZ?"Z']+S,R=4B MYGJ&]P>%+J1:M3,/P^\[)U3=:GU]0I7HE./4>K9] KLAQ8 3C]UG&:AL3GA:XWU MZW[^!@#6E[>'3)D7P[WYW\[DLUWFO55MI&O>CVZB+%6;Z:K:\4VLMM-5AFTM MW'^MKW .Z,VF21A:[U)[=8U#O1KT[8KIVXW]0(<_#HMHA_]G$,= 4U%21V_[ M8DHM&KD0@O3=MH<0NAP*2W7>X2-EI3JQ&I4]]L9J5.A/%:E7ZS% < MP4K=4.(D(&++!YO7*, (4A>FA8)#N5*40]GU$3TV]V<\: -KJ6,T" MJ6(G<6KC;"U,=(TTIROXDQTKY7QSXL8%?GVR*4-&Y,50C3US5[+3%9=RV^/V! =TA-5%\AF35UDK?7FMFZ0>JU"N&&J1(EY47;\RO;/ M>B3\O$)AX!X>Q2%;#M\*Y9PMYVQN2G5^/Z52[)UR1IXK6)BI\4=VDQ_\QAA" MU5G+G=_.AC=7JR7*36^F66YPP=FW=JW2[38KG=:B2$#8]F_$;RSON>KO\G+\ M75[AWJZY8G-I]2AW,ORK*\1Z;VHD4^X49R>E6)KQL%H$RP='Q>[-X55=6*.F M"YL]5Y[I^9--E3_.E0EKU(5B_%3>F/Q].7Y(8C6M"(5-[P7I,JWH*]5[30W4M^V$E][';1SJN6L$Z'1D:L=^21P;'9#$(OEK[Z_CZ0/3[M: M^Z!<0I8[CH\"+RY2MPK?D_GQ&D)VH/D6+IW)119L>-N[NR?#*CCE"&Q7BK.X M_8H^)KG#6]Z-_UA[_J1>?FCNQ\]?A+'VA$MXO',VP^J MS%ZPH:U2\-'/NS2(39HL>*P./[=@6^"TK'#YR#Z-1]?#R]X]^^-[[YKY2(/'\=\&@_OQ 8:M;_$> M\D55]DFX*2*=_[MB,'M'R7A*J>N03YZI>)K.?OF,5@^M'EH]M'H0K-[XGOWK MQ^#F?OPXNAW<]>Z/-WSO[AT/G8_FU+_5$:49>$Z 3:?L-E[4Y=IRT#)"M8PR M6L987@[OQX^#O#\.D;9E8IY]:!KO-"4X?((,_/=U] M0R,&U(C5T8BA>U=FD[AP[_J]\=\>KY(VB7W%F9(KP_J)?AQ4$]A $X@FL 0F M\&9T/Q@_WH\>'VYZ#Y?#>]\61JWB 2;PQG)9XUV+;+&%F]8TT X"M8/-@MM! MF NS,B[,GG9AEOE[C_+CC]Y-[_? \[L^\ZA>SU2,-T<7'N&[3>1&T]^:QJ^YHXYGK,<$T4 " M,I!2&RUD!A:RCA;R]!:R_OCWA][-_9#-CX?_&/ _KL//W%Q>C\8/!UC(O_,M MLCIS ?FB!C=V[ LC_)O;2L-R/+[#IO=D>2[YH=A_4)?OQX>S?J#RX?[@8'IKRXMF7X2[JWMJ52 MC9LW-&9HS$ 8L^RV1^#^B"SV1PQ'=S%W1HSN_S:XR]>N"-ST ,K6X*:'TA@; MX3M)C]>#WWO7ON,TN!S>_'Z(YW1-GQ7#=YG$N6+H,X'RF8J^5@K4CO70D&5@ MR'J/=\/Q?SU>]?KWH[M#C!@/7)$K174M&^T7VJ_2VR]I3.;><#K MP1%%@0(G#BT@) O81 N(:Y@EL8#UQ\O!5>_A^G[\^' [NF%6[X8'P@+C-SPH MHG]))XI(SWB8\V.RJ:E;]I+=0QN'-J[L-F[K,B7:N#17*G\,;P;,N[L:,+\N M3,TX;+7R!_L7\^DFE+ER2\D8:-/0II7=IC71IIW>IC4?XR]7BL,#AJ9?YYG] MBD8,C5C9C5@+C=A)C=C@O_\V_#X\J$;2X'6J/^E8\ V6N=JY(VK3P>'9*517 MKG8+JU#CX>\WO?L#9S7O-Z%205*J%BK5D?ECI1+<9'+MDCV.[[@#/\KQRB59 MB!YR)$[WB#8J?BN2ME(Z'B!S@IQPH _5MI4A(4?LX-(D[M3Q',36G0NBK2N>N?WJK5]&NG?Q_RF?T#6#\56ISXN=:D"3Q_^^O7GE/'?.;>\O'\_;65^ M@NV@F6"!-@EM$MHDGF6HTMD3M=$L@8!C_ZV[J0.RXJ'&.X:TP'J3+7\LD04> M$)L;4L'38IQH+U">X7VZA![5?M/-%@ />'=->GZ5U>UJ_ZI M8K>G'/YNM9DF +WQ>' _CBOQJ0W[R2(D>8R5IS?J>QS]?0K;A#A]@).\PMSQ ML2IT1B!4\$[#[P@#,@S 44>&R0=.R# Y!J_T#!-O$GG:!* 4@UU[SAD3A*#O MV3R>1Q3'H:YS 6]Y$=F^N(NZ",->9(Y<#1$;5!$0," _H/"7%@;D![C8E%Y% M"K<@R-?=H4_G^.GR?*N0RC_0/SV=C3K?,@@OUH'$C1&FU&'X!1X"R-EGWW[5 M7_GO5[:BBN../5-W[WAEEX='W;$:LM1^&%_ZFV.O'GECY>X9,949&Q?/.7]6 ME/D%MW0]4^/_&KR;N9[;5VS[C8W\/Q3#HV=$90U@[1(/[_-'26VYT92E1Y[@ M6*O7I3.B455GS7)^.SNOGQ&_4-QO9_HKZZHWTRPW^)T)BZIP9.IGW^K=6D5N MU7[]LMJ/V-5D4-\+;G:1[%#XD>R0[/8BNWHM!;*K27),LI/:]4I#:B+901.L M$BR?YF#*/9Y:-KN6VC.BFR_4<6?'S+2UH2[46]56JU68CX(*GS!%1[9#H6_M# @V\5A.SEAMHL_ MXVXVFQ5V+[(=-*'"16X(,^X[JE+]112EG-C6C(A:DD]!R7\R5VS7I+9#/OUR ML WH1):9>JHJ*FV^O_..&KSNZBU[S0G\WDJ7'U&]9@?$"O_AO>M&XHJ)]&ZC MG7OO0K=1CW9 X*80VW^;P.SM,[R (GJ1&,8M+0SH1<;Q(NN1M1OV9'[[/W5W MVO<<-B;4[O'=-C?439D]N!>)ZS;@A JJPB/;H?"7%@9DNSALUTB<[8[(4ZC4 M&EUD.VA"A5D*$&(F;*9O>VRFK?.R?]1QV=0[G/+#BRJB(X*QW-+"@(Y('$>D MN>Z(# -#]Q[:3'FRS=P/.3GW ]6\X&J.'(?"7UH8D./B<%PK(8[[8,&NE> L M&C49V"SZV+!& L?.%&UJ?6O3N<(Z3E_G_'A61ZS.6^Z4VD1=J:Z652@*Z/$. M4!0)2E1PG_,<2F[S8$ E[WW\!GHXAWDX[74/)["M ]^T]DQMQ.VJ6%!(._6J M4VEUX.SPW\M*+%MPM!3(K^6# OFU % AOZ;%KYW$^?6(30Z51CNY+0[(KWF( M/@!>P]\;@8RB#/>6JQ@)!11P5:-8X70\FR4?..'9+*EX-=%-6R>)#S2D2J>= M7(0 ETH*KOW(C">0GCB!%75D>=0^$L+ _)<')Z+U*&+SW-'%*"K53JU-O(<-''" M1>_,Y]EB:,ZMR;GGT(QWPZ/? 6O42V^,8," ?D<'BK2[U";8<,H&/"%#70IJ8HSA1=T0J<#0WVEA0&=CCA.1Z0!3W04EWN99<=!@5 M&=BD.6\EW:'/I$4)1&(LMFEC\7; *@,EW(?%97,"%1:73'I4]W@5=*A^@7>##N M6<4V$2C165IQEJ+5YX3532O>T*TW*Y($9U?[-O]HJXTOE:G(UNPC X.! AD8 M&1@9.!T&CE; VX.!CR@RWY8K*5/:H0! S(,,@SBA Q3 M0/!*SS"XUWQ^VE7MX/1 8NC*DVZ(0PPNX$4"D?)Q$T]I8<#=>'"Q014! 0/R M PI_:6% ?H"+3>E5I' K@U*]V@8^I^NI*AM,UR%SY8T?6@.*+$[ LE7/N0ALWUU@^GJF=OEN^ :! MW4M[ZEVOU&2L=PI.MJ#J/9(>"G]I84#2BT-ZK91([X@I>:=2Q[.GXI I2<:#$ M@_$DU9Q A2>IIN7Z1 X'$[;T= D22<[9P;-4BVL=D%/!0(&<6@"HD%/3 MXM3(<5^Q.#5^!*%>:;;@)!TBIY8\2V-O!#(]BCS!Z &N;10KJ+['J9DEMUDP M<-KSA%-T9PYS9R(% T\7'9#J0[=X19D]J53JV3ZHX+W,5;K/6,TA,,#!@P S6."]D\* /U%.Q2K]03 M]"M1[0NN]LAY*/REA0$Y+P[GM5+AO&-B*7*E4Z\AYT$3+J+1KR65R MHKX77-^1[%#X2PL#DETZAZ GY*+H@>& MQ4;)I?9L>4H>*[MA];RRM4J+061N*;$I?>^WRYS?J#V(F]_02J=[QY3-W=@] M0!D.N.,V!VL/N.,V-U#ACMNTO-A(P'6T1W@8>^$2 L]]SRFPB>Z#RM.$^1TII+?E-J MY33;M4I=AK,?>)N[M-7:H]% +BX?%,C%9< 2N3@S+HZ4Y-R;B^-'+N16M]+M M1#>Q(Q=#E"DH:2X0-IED@T#?FLUT=\8:YI!/-Y9+B53#Z@Z9JP&,45_E3?1Q MH.(4]7'0?XGZ+ZSC9MC3JY_KK^5376%,O H>E_@XQOQ@WH6:-&52%0SI" M.D*AXI*+5X@9A#WBKVR!Z[?,/W/Q3#H[?4 M'O.'')@C.+RYVC,S8FM#(\5 DFAH)(%"-+16Y5=MR(U8WP\_5VPN\_SXAAV= MV]:CR,;0U1Z)YCL]SYU:-A,G+<:0[\@%V87&Y@9+MT__M+L?CT< M4*D62:K=-#Y#Q_&.!I,'0OGX_+1LS:%F+#0C:4=Q6_LADDFT-G+0WZ;6CCS7 M<1FFC!T #'#DZ*6CFGSX*)O6QXJRORKI0A*$QECO;3Y K>"%Y7%BB8LAI84! M)Y9QAZY?^;?U+8TQ9F>?3L'L[,8M1FX-B.5H?"7%@:DLCA4 M%CGBY& J^W#["5(98(DI098._' NWU=BF8G$"#<218_=VH/CMXT:^ !N)"(?&9U$HK?'XRA%0LV1EB87 M"UUO;KM6Z;::E::TJ2#ZIHK(,?H766J(A<3!,AJCI9$P>GPD#FXN0T&2&I56 MIWG".&Z%L,?,*7OJ"S7>X*W*XU08-,A7?Y<'%#NN^U%MI@JBR@ M^@)77^0N%/[2PH#<%8>[=LWHX\9PW[D+#W@$)R*8A@L A![K.U<'Q2!S1==8 M(XFJS'57,>"M:Z!3@:M)I84!G8HX3D4D$/YN[VZ9N1N:?=_8I79@4:7&(\PM M&9>-H0D35$5'ED/A+RT,R'(Q6*X3662,Q7+QB_!VZK5*HYY<$5Y4S///&M;H1%=U%U[L";T.C/B5%@;T.LZ^?3K<[8CD;MU15]%-J@T4 MVV0C[2Q9ODO?\,59?Q;2<;ZG*\*3\]IM7*D&)U^QB\PCYQ7+V)9,[J'"@)P7 MB_,B6;+'N#.*\N=RI2IX&_N+WKD-ZMQRF79CIN\9.VF7K. MYC:=4M/17RCY9%B.\YGH)ON:9GP"]H9C ], #;@:00U6[\8&CR@ !-7J$05' MP84>T:I'%"EHM61@1]R^]I?-ZU"8U6MF8F^H.YK<*Z_'A 26S@$$L_BPEW$H M[0F F9TUAXR: S.-C)H;J)!1TUK-CY1;3)10/\B3;R071D B+K2P>$*7VJ7^#!&,^=B@F M4)9VB=TIXAY?7(6-#OM6TU^VJ9W*ND/MC_5NI?=_7>IM:^ZNM"&%]V04MYA2 MHJA\@X=BOC%Y9+^X/'AALZ]-HK/N/-NB]*'M\F,#W"EU*%='UG2':OR3L)MB ML\A$-Q53U45Z!_MBQGKG5(/18N"$X^4/%1K6Q:>_51G7B*+;F MF\RX05V&_WG0^(OS6E7>1TU2M,ZL*6;8?'"M^\]?O_#V;3.X'*7$QC^Q9A\P M7CX[3BS+Y5KE<^#-_:-O2\_(Z\RX,!0NU-0\?QC[RMA?Z%9_6;>^*^Q*E9+Q ME%(W.,,C)P[55S"WU85C!@V M^QT=87&WV]L/T5DF&Z%ORV;P7'QST. >:(YYPR1Y8\O@V&,IZ,[4#OLS5Y[I M^9--E3_.E0GKSH5B_%3>G#/RY3"JC]_'E(DO&+TGYO(=Z=;&WO%XUW\8D^_# MT;@_'-ST!^,*&=[TJT7MKS!$_='-Y>!F/+A\9)_&H^OA9>^>_3&^9__Z,;BY M'S^.;@=WO7M^(SFU%:X]^PO?*QD8!.>?%W4P?SVR3,#X_JY MN'T+,]AV#H50E]5RJ8BXIPI 3<#/_QKQF9$KA,9BOBNMS#9:R8HH)ZX MGJ/_Z@O%0KN6CQ M +K:Z6ZH.BC87Z0,PCOZ0DV/.A?PLD1+&.H',.I[$$:9S1,,D.2]B/V0W.BB M\3A4Y,I-[C P0&)!8D'50&(I%'+E)I9,JXL>L3IS$"2'G%XB0.CR34LG)9\^ M3^!C(R&R48GM3R[)IU\.W:@F-2*%^X.9ZI5MS>ZH*#=\J]A\V]I'N\?9?X[; M1MZNM"4ILE%-Y%[&Z%BD@'+,CM7"CM4V'D*P:'VTW)^_,4%A\/CGS/#]16^9 MG8"'ZVA@5@#V<=Z.JCM6I,A9['W5:9:0ZR8$%.Z:7K;9TBXRZK.7\"?]4W>G M?<]APT/MP:MJ>!RDGN-0]E]MCY-DCJ:I;J71BM)4YHL96$@.G)V'2KEEQ (Y M%SD7.7<#Y^Z:)R7#N;MG4'MQKE1I-[&>>CY$$',-,@; +].JKH2(>!#%T%6^ MQ3D,%SGP@JLG6S&"HADPAAW(DA'B=/)5(W2 )"E21K7X08>\+X^!D3:HE@*) M%(D4<4(B/2F11FJ>%C^2@$0*+&APTFI$10(@J&UF/A/Z.N=A@OA;%0I0E0B* M$L 8]M+;(A@P"*^EW$X)5&A00T# @/R TE]>&) ?P$)3>@TIVA)P#O8(W%&' M\M)F8NU7HR_4L.:\E#7Y%&>?P&*5Q%8]YV(I@?[MGK?&?\X=U6=/GNV(DMEK MB?9O5Y8]YN63M;[EN+N2[H/PT=!4K1E=5."^ME2QE-U[U9WPDK"+/5.[?._@ MP)_ _A#G!GR\_N((03S?,W[4J'3EZ#'"G^/N4NCD>%BA[(S 992"A>=+SY8P M8$!_,L8B2#>Z"++#F*:>-]!J5>J=-JYW0!,LJ#J/C(?27UX8D/$.9SRYEB#C M);# +]:>H\\!6^ $7D\@&F-^I2?GQISR"H6@SW=0=EZ<"O%#<-PD! M'[@Q;=PWF1.HA,V,GZ= BNR\2"K M4!TZ1'F(T2=TTD[);2 ,+/?;AXDN5?(N5:32XF+_5^!#I5_NMR-7Y 2]J(2L M/WI1 "T(,C,<+)"9RX E,G-6S!RIQW@@,R<0WJC7*A*@(@G(S'G(JTAOKPUP M *XMQ_$W- 2A#,N,'<+ K;$%6Q/ BE#YP DK0GV,W:?#G9GF5F?&WX;&;>0+C?19=$*:P ?^QO+/'_/6-"%5I)/0>;"Y]@E$W%#9\'BYR4S M25!AP V=8*%!#0$! _(#2G]Y84!^ M-Z36D:,NX\'?"#TV7VM1QQ59XRYU2 M.YCA58A)77AQ#^1N##>5%P;D[AC99:ME7$.#US.U$3=W?I0YR#.[LH0* ^@( !&2\&XW528KQ] MJU^W,.,(GAA!V11>YMGV[XIN$J;"&J4SJA&'*8R?1DW_]'3WCCP] Y!@81!G1&4H#F'!XJJ!P@8,"9*Q @4!] P(!D$6/F&CE*A'O, M/ 5X9(Z9LSR:#(2C/!0.,B^Q?EQN\/L15QTLGPY.?*"L#V/Y]#5@Q.%KQ)H0 M8[$/.-D)+-9YA<.06.<5H<(ZKRG/CK$>:G&U"LD(#A9(1@6 "LDHI-GE6+6TN+8".1@.%LC!9< 2.3@K M#HXK010*CN26;ERI.8\F'.D MYN)@B=2<&35'SD$[@)H3K8+>KK2;2,WYD#, 21A;C4D)MO2+DAI,,V=SFTZI MZ>@O=%$CG<FO9_/$]U[7U)\]5& [WUJU@^40B%4M9IRTP2SBX ?38J -R9\%L M,G)G/G!"[DPCGR%Z1EJ:U+EOUH,LP\D\1,K$! ? J*RH*J8Z@,$%:@Q^-S:E M]'A^@8?2IGVHZ.\D$2MHKSL\&WR=T,\Y:<9"J][%99%<2!UF+(" 1DV-U A MP^85N1@,VTF,81-./&C*R+#YD#H B0<89=BTC8+,J4T<7J.Q0IX41U?%X7Z: M;G@NU0#N/RTA5%#C]WL$[]%O2LIORGH9!AVK9!RKQ]O5 MR-*-#XI>)L;2VP,ERRQ=J[:2VWF!+ T\ ()I%DD" M\D_Q**J=*R],4Y\I,;W9$[7Y216^WA//H1IQ+0Y<40?!=UK\_Q?[4IAYBH:! M>#G0M6 1+IC!@0_>4@SZG,7!$AW/U#-YMSF;D?*@(6?U?,JZ$8PUF@A_R4,9VB>,I=NE\$?NTV+>: M_K)-'?<]2GNE]W\]1-V6&YA9(Y(>\_LI)8K* R**^<:$E?WBLO?SDTP5D^BL M.\^V8A FC2X/&+E3ZE"NK!JO$ZSQ3Z(0DL*#)Q/=5$Q59YI. 6INO=H M\;&1Y/DFDPIGN.2@.U,[[,^<6;GS)YLJ?YPK$]:="\7XJ;PQ*_F%79>"F 2= M>;(,[4CFB#L&O;O^PYA\'X[&_>'@IC\85\CPIK\_T#GKKZ"[_NCF7@;OPX^/O#D&]J"W6COZP;XX5&<#4:NY;Z MQY1UB=K.?_RE(TOMK\0_1JRHH_CMDV!BR&\))4:!GA0.6XETJ&_-9I;)NLJF:YF'#$&Q#!HO-%["$SZA\?)A\0U5B8Q0CPT$7[10 MC 0")_GI]JVB:^=#,W.S"^G$."C8P#'/Y1KBS,TNSK.BYEE5O9EG*$?L(D=; M50I;A:XDVK1\ +5FTTK3;U%!N%0]7BEPA/P%$"'D+]A0('_! ^K>"%!D0GQ;EU 7>5B/L3[G!!;]@56L2\DZV,?<&DU6[,6 M2UG0[J'=RR^P/9$-CG8O:UW"-TO+OZ=FJE_=,JSG#D>"=8->"[8BBF2HGBDDNJ4E%FNRY5B%R3NN0_ MX9VU<+(B#AGAD8^C2C9R19:%WQ"H\ B!_1:WH)2-S B\&'4C(V> ^3NM11:; MGQ.P5"QR1W7(X/9%=2W?[>!)S:R]INOT7G4GO&CI%3^$:7[D9EF25TM*#F^N M/BPJ*8( "LDSG[@=3IZ1\XA2(\^>%A;WX?5N MAF:0BO4!D6Z?GRYQ;+W5K4BU&C(M.(&$:O&1:9%I00"%3)M/W/8[3U>#LZ?W(5JXU*W6YA60+3B9CITXASR+/%EPW MD&?SB=OA-%L_W8SVO7:8**>U4F'*SVG=.TS @L(U:BOEA,GM43?(_U ]+ MP&YV*]UZ=U^_!PU(V0T($BC*?YEQ0 )E/3T'!PNJ!Q ,=-:7VNMXZ0*G&0"M1K(FBC_9<8!61,G51 @ *H> M2 \H_V7& >D!Z0$"!$#5 ^D!Y;_,." ]Q(JYM=.,N6&D+.?R5(+RMSE(N_P' M=5S6>YY7217;>%MD6FK)Y%GB]I'B;1\INYT"@0/Z)/'R+#NA4V*KGK,[R3*P MC:/)@%O&A5.RY*G S+ALMROU3@=WFH 35Z"F!*D4Y;_,.""5[HC^HGJ473V0 M'E#^RXP#TD.LZ&]WGXF6"/V>;)Z56.ZE+&.95G@R"M1^E)L_/UQ10?DO. [( MG\-Q1_LN. ](#T@,$") > (X[RG_9<4!ZB!-]:]5.$WU+)V:& M6I^[+$PL?GD,"D+9SI\4GG:I6K,Y-1V%*PA6M\Q>'V",.]HE$#B@-W),J@BJ M1\'5 ^D!Y;_,." ](#U @ "H>B ]H/R7&0>DAUBQS,CI[CWM?SS'Y=E^SKVU M):E/;.$2$97^4D#ECO[IZ0X;_S&U7W25^G'0.ZI:SZ9XB@B)PD@WW._0^$JC ME=RA0FB!"FZ!RLW 6-VA[#@@ V.A+P@0(#T ''>4_[+C@/2 ] ! J0'@... M\E]V') >8L7O9$#QNPRB;F@W($ 5#W*30^XB;_L." ]8&4G"! @/>"XH_R#PP'I(58V17T]FT(LM_:7 M5UN'8K'UVG*<&^J.)O?*:U([FE35FWD&NU+;]M8XQ=0;6$P=G& "-1KE)DUT M&LN. Y)F+-)L)$R:Z= ;JG?N,@6/S=U<20LD3Y:M43L<8L/H@4S]B,#7,:OO#LJ-Q D3RIRDP]J+L!B<J>L?D9^!H$#4)N/_)P?K)"?<<*8:UQPPI@7,#*M7X>$ ME!.LD)#2FS"VXDX8,YWMI2Z+R+#[S_:RJ8.Y*[M5L[PG@Q*Y6B*>_:X8BJE2 MHKCDAV*K4U*7*H3K9E;[;';X067$!^JFIW=P^*AN9-5=Z*&C! C,54GVQ#=W@)<6?%DVJO>U)]:S:SS+%KJ7^(BN/.R',=5S$Y=@E%XI=> ML1R$7_/&AC=7N[RP;XU&I=[H5IIR^S,'VA]D]E*"@*)B_@,,1 M23V[O;V==4X75#NU##;2CD_,)V7RU>V_<&I;(%T#9@BD:T!@(%TC72-=IT37 MW9/1=4_;>++8!]2]WP%@[7JE(3>1V_,AI-V0\G=NETL_;#:DSOKKW9Z2"' MYT,D<8J.8""1(Y$CD:=+Y/)11'Y4T%QJU"JM.C)R3F0+2HGLK68DV%=0*@A M;#XN]R$<(#;H\U%%WP8J4%$'!YV7W("'9V$ P0%9!ED&@4*6*21XR#) <$"6 M099!H)!E"@D>L@P0')!ED&40*&290H*'+ ,$!V099!D$"EFFD. ARP#! 5D& M60:!0I8I)'C(,ICF=VH(ELH"7U)5;&Y95 8F_PE/1= !0--48AQ\?B\Y?1]> M?+==!U-\5Y(/*[[;JE=:7:G2K4E@CKI#*P'<2B!+HOS#WM^'! EK:UXCXT*V MZZRXNI>^A=0'3L:@FF"D/I1_I#ZDOKVI+W(D>H9%83?1X%[[VSOU6J61X/YV MM!-%M]?(DRC_R).EY39.243R#%2G<'6!M(A_"$#ZIM1DY$^4=.1$[,N4D MBJD18;PMK_>([+'^O<6UO6 M6X3UX1VG6MC]ON6XS@X;Y-ANGPF=2^VY8KMO-^R=PA6W5<_Q.S96=Y##' M._"Z@R;=O\WI:-*S&1S/HK^+&Y*GE.Q[S*2WU-GAH[SR9J75K%78&.SK&Z.]*KN]0KY&^2\S#LC7 M<<(_GGH.#A94#R X(#V@ M_)<8!Z0'I <($ !5#Z0'E/\RXX#T$"O\)P,*_X$)VNU=90K-3NZRQ %7B,YS MEK@W9Q_I*[55W1&_^E];U:/@ZH'T@/)? M9AR0'F)%Z1O[S+M$B#ZC:=?NI-QD8O-2I=-)+IT634W!30U2+H 5#U0'I ^2\S#D@/L0)US2P"=1A>*Y>!P/+( MIT?A'^_9G52QC;=%KJL6S73%TKI@"#3#<4<[!0('=&3BI7JV]D_U7+@L VX9 M%\[,DH<#,[FSV:C4ZMW$3H1 4U)P4X)4BO)?9AR02G>$C%$]RJX>2 \H_V7& M >DA5LBXO7?(^&3SK".S.9=BRITZ3J_ R2A0^U%N_L12(F7' ?D3"]Q!@ #I M >"XH_R7'0>D!Z0'"! @/0 <=Y3_LN. ]! K^M8Y3?0MG9@9:GWNLC"Q_.@Q M* AE.W]2>-JE:LWFU'04KB!88#-[?8 Q[FB70." WL@QJ2*H'@57#Z0'E/\R MXX#T@/0 0*@ZH'T@/)?9AR0'F+%,KOK9SGUM/_Q')=G^SGWUI:D/K&%2T14 M^DL!E3OZIZ<[;/S'U'[15>K'0>^H:CV;XBDB) HCW7"_W>URI=V2$DM&1!-4 MD!P@0(#T ''>4_[+C@/00 M)X#7K0$*X&41=D/#D;M\1JPJ>0P*(W=*;9'):-,I4UW]A1+#D#Y+S,.2 ](#Q @ *H>2 \H_V7& >D!Z0$"!$#5 MH]ST@)OXRXX#T@-6=H( =(#CCO*/S@9T-QV=0_7$D.)$^6K5$['%W',G2-^!<2 MT:.Y8K-A+'@2(=/ HY(&DX'$=S9.@ AT)8&Z)64W..'(ENN1]?7UR!OJOB] )I2QI-E!LDR'L')R>LU<]E+9< M:7;W/M\-21K0>B?R,]I\Y.>\8H7\C!/&7.."$\:\@)%I%3LDI)Q@A824WH2Q M$7?"F.EL+W591(9-.[OUV%3C7=FMFN4]&93(U1+Q['?%4$R5$L4E/Q1;G9*Z M5"%<-[/::[/##RHC/D!W3"Z9.#ZJ&UEU%WKH* $"<]512A?/8GM2.QRIUR?; MT!U>2=Q9\:2:ZYY4WYK-+'/L6NH?HO"X,_)\L>'- MU2XO[%NKRWRO5J7=ZH#9*[O-_]K*'&A_D-E+"08R>Z)@_@(.1R3U$Y#ZENA( M:YW3!=5.+8.-M.,3\TF97,15WF,F2-?Y$#RD:P0#Z1KI&NDZ7;INGXRN>]K& M \8^H.[]S@&KU%K-2K,E([OG0TZ1W1$,9'=D=V3WE',5.B>C]UT9[D>G.C1J MM4J[C9/WG AJ9L4JD=F1V8L*)C([,OL2LW=/-W$_K-KT?A4X<:J>$]%$+H>! M W)Y@< M H5=HRX0DFHA0&"8.+WM>2<[CP.'?;L#!,FY09QV.C@(%5"HLCOY F% 0LE\ MV-%*Y0(G))3<0(6$ @,&)!0D%,0)"27W4"&AP( !"04)!7%"0LD]5$@H,&! M0D%"09R04'(/%1(*#!B04)!0$"O_7+(7N?DJ)HJK6;*Z8;PQ_]HO+WJ_8[&N3Z*P[S[9BD+EB MN\2:$'=*'&>Y9?_B>K6Q2?OW[A[=N6=,Q12FS\$VOV >/EYX1/+,OE6N5G?M_)J^32.#![M3Q25<;ZLB!SQLY#L6PN[%L'H<'4G>" \G#/RY3"FB]_'9>Y)@5^"T7NR#.U( MGR?NH/?N^@]C\GTX&O>'@YO^8%PAPYM^M:C]%?K>']U<#F[&@\M']FD\NAY> M]N[9'^-[]J\?@YO[\6._-_[;X]79M_Z"5/O+I#I^5URFM7W%F9(KP_KI%'74 MOGWRS,!\?2YN'X:[6HK$HJ)(4D?3V%P\K@A#-9JG28,)H:VD_EDT>5S(JY7;-A;9P 0D+O5 M5N7*ID?>(L<@QP#'BCD&) <(T/@ M&*E>;1Y>FJ;<''3,*9;(/ 4P:+'4!"T>6KR\JB!?%$6+!]#7=E,]T_JP>/^) MAO\$2T=B!7!B6#_]U7YK3FW%Y8D[O(#;B^[JU %78_!TJP!Y7'S)M$0G9E@" MP$G>B_6AE-=$[$Z_EH,P(,- ''9DF'S@A R37^Q*SS#Q)IBG32@K$@(WU"6& MY<2>1Q8@FPR*Z,,8]I)9H-B'-*2'@.#OD-[R# /2&T148M!;/2Z]U4)ZJQU/ M;W*[TFXBO8&3I\\E7*(%,_@][7\\Q_5W;;H6L2G31E4W*#&#J37_EG]6^6JN MQS=]ZN;&M=P+>/$H]%(P#%A>&-!5 0L-:@@(&) ?4/K+"P/R UAH2J\AA5M( ME>K5-FP0Q(G.YT^*7RQO-J>FHXCP#GWEGRF\. G2-X:GR@L#TG>,<^P;D7/L MIXI-OW.CUU^R><>LN>X5BY;D2KLE82P:FD1!57:D.I3^\L* 5!>#ZII)4-WN M]=>]J*Y>:;1D9#IH E6"W;'PY]R7=&XSC?'GV;Q.:*@X5:(PF#P[M<9NW;!4'?O). M,E/K9KV#@7QHT@15T9'F4/K+"P/27 R:ZZ9+<_O.MZ5& VD.FC3A>C4 $-;G MVW.;SG1OYA"+G\#^0H.=Q/""4^B,8$RPO#"@,W*X,R+5UIV1GJK:5 3YEZS@ M:'*I.RJ#T75ZIG8;V,/ANRT\7?FN9JV%RP30Y ZJ24!"1.DO+PQ(B#&J>$G2 M*1AQWTFZW$@N%HWZ#J>4%ZZ''S'^_:EB/K,7KI;H$NO@(KWN M&!0L5%TR&P45!O1)P$*#&@("!N0'E/[RPH#\ !::TFM(X99BY5JU"1N$.ZI2 M_45Y,JA_O"YKF*$\6;:_-CM7;->DMD,^??KEX$!/<_'^IBOVHCMJ M*"[5;MD+WE(ODU.O=#O1*CF?Q5PV1K^ZB?1KWPA5=!NBCY1";/]= J6WV*=[ MX.) P:+2I:<1&#"@HQ5G<2!R@M705&V>M7=)_7\/S3Y[&7_@/W5WVO<<-DS4 M%IE\J?-(HR)U<'$#)=PAS@X22KV M8CC\",FM3>>*KH7UR_T5<,N=4INHGFVS!N,6\3S2'\9Q"PX#>B%QO)!(:?.H M%Q)8Q$LZH\[%FRW<1@Y.XO"0:32_I11\J# @ M"\9AP4C5\S18,)&JZ.T:[C(')W'%/HL:_IQ=J" Q+-9_E]JS(R?HN$Q0L/AT MR:P15!C0-8FQGSQ2"3WJF0CK=V.907CR^ GY81O(6W5<1( F9U!- !(@2G]Y M84 "C#,WCU1.3X0!]UTC[R9WW";J-YSI-BZ1'S'^/=4OU$#FRAM/A(<7?T(_ M \-^Y84!_8P8$^U(L?2HFQ':O5O?[*6^YMVNM&4\ Q6<;$%5>R0]E/[RPH"D M%V=R':F=?B3K?3"M/BBP+%?J"1YAA@8 SNP;%[N/FWW;'M6(31VJV.I4)*AK M](4:UIQ72EQDKL.+4Z&'@N'!\L* 'LKATW*YME)\8Z-WPJWA76 ,>Z9V^6X* M@R2]4V2GMR7<*0Y.W*!: N1!E/[RPH \&(,'I?1Y,('\=+DBR\B#X,2M!*>. MPY^W^TGJ2C![7ZJI#B^BA?X)!A++"P/Z)S%6$N0]*KGY.^5\ WC];O].EZHN M5VJU-JXH0),VW$2.IK>4@@\5!F3 . RX1T&W6 R8Y)JZ5&FVL8P*.&G#-?5L MQS^LZD!L^D)-C\8J@-]:7:L*GWGG/_+D5?#;E;:47!7\EI1]:6 @_ M:V6!NJY0,LZ "@,ZCW&8.K*R8ZY)8: M,;I;0Y+=?=J35S(@29/F,J QK64@@\5!N2X M.!S73H?C]IQ^+R7LM9,K+HNJ#F>&?6RT8V4Z39XL6Z-V.+B.9>@:\2\DHD=S MA5>%+/BT>ZT$?@+3[F1 \OV/$V $7&N@AJEW8Q,.7*D,'%2HA"^3"%KH[ZSZ M.WL4_UNK,9S>O![.F;Q[68AEZUTJ*Y'9@COR:AZ,-?)J;J!"7MT+OG/D(8BP M0-G;U1E6$CJU*/<$J@@D1!'I=L!;ZD;?S8.N1MXN#)?)V5KQ=KZ7%VTEN!*A+%;D- MIZP0\C;PY(44MP=L'OSE,7RR#.U(-.(./5=<,C&LGV1B6S.BFR_422@8@GL8 M"Q:2WX-P2V6VH.*TGV]4;K\'*G8E2UN$"@,R##(,XH0,4T#L2L\PA=M_+M6K M;=@@W'JV.E4<]DIK0IRI9;M^0CPO>_>>'N]//OG9&+@K/7LU@3'LI;=6,&# M'7MQ(N72>J3\5GD3YNW>ZJE_>KI-A^\F+_7:HU)7KM2[6&@8G&3A_G0TLZ44 M?*@P(-O%8;O(83/QV2Z!4^\ZE4X':[& DZMB+_7F8"9N6RJEFN,O]S(U\FRQ MR)OVQ!Q#]1A&1!C054D!FL,]EJMY%P8- 4%-P5(A"C]Y84!B3 &$48..$F<"!.8R3>Z%0F+NL,3 M-UQ9!P "5U)<58>*#M0 =^DM%0P8T&>)X;,T5\K@KCLLH\F8&\)[9OF8SW+- MK"#_>,IY>[O2K"7GK: -*+@-0 9$Z2\O#,B \2NXH7( F\CFK8 Z_-GM2M[X MW.:EVMPW,;^E?WKZG#MT6/ 5 E!0H\)8\#4W4&'!U[02\UH?)N;=!J;UUF O M8_/F06A=4Y\MURNM!IR#R[%,"Q97!P\#5 ..7)L;J)!KT^+:=EI<^T%QM/>T ML5H7Z307T@7@4'0L#[^U//P\J&9(GMX2K8J&I6;A$"R6FD4LL=0LW*7^R EP M6RK-#D/[G$R%^/T*P\N5CHR%X?,A>MF:%J1L.%@@99_&)7^IQ,&# @PR##($[(, 7$KO0,@]O7,RY'ISN.QV:9E&?[J]9L9IFL MVY;Z!W$M8E-#<:E&YHKMOL&+.*)?@#N5R@L#;N,[/%3>J&W=R#X,[.!HTA=6 M<,R-X+UUYYO 6VX!TR\_)]-$AI'<,RI47!J3W&!/X MXZEB4^>!]=D>LB],5W^A/5,37W]7'*JQ2?" @_?G[.SN3MW[Y.9>=>3 MFW@CC0(O]):WTO(Y+?0&:9V<>2$C*^1 N*.D( M*>Y+ (X CW;HIFI3GGB@FW[D@Y^C)S[P_0<, 3PB'H1NP!AVK+B3#YRPXDX: MSDWDR#SNV?#_#=Y-Y1UU7%M77:KQ'WJFMOK%TI6WU-8MY@KY]O>2^O]>)&4. M7M6I8C[3.\6E@\F$JND?NR=+G4JKCL?4@Q-5J&8&61A9&'%"%CXI"T<.TX/$ MP@D4I.]6ZIWD3NM##@86KLA;T@9P6+@Z5R(!"Q'%L!I* B:RY@8J3&1-R>&*'+AWE,.U<*TN=6=N.8KQ.Y./.;N# M_MV]"N5UI2!]>*/P/,L5\$KIEOT"#\98&;/QD$27;=EE:]; NFQ'9)+4NW)%;B07 M74EK*_)6(BF5/0);T0-Y'@Q!(,\CSR//'\'SD;K7<'@^?JY*JUUIRG"259#F M\Q":27'##?Q2GU#Y'5-Y ;A5Z#)!Q2GB-Z%/E!OL2I^H"@,&9!AD&,0)&:: MV)6>80IWHN1F!)8'\LDRM",AB3O^8V\^-^B,-4LQB*8[JF$YGDV="WB97DCZ M>+)->6' \Z[ 0H,: @(&Y >4_O+"@/P %IK2:T@YTK;A+QCVQ7$$BJ[Q%7FB MS-AHNPXOVV=X_'P"W20SJO#I'Y\/\JQM0Y3S,W3E23>..JL $[O@&+H3'M6$ M(6+H>5N8EI5<6I:\3:VYDK]]M[#&U M^99*_\AMS*7*A:!ARC1B@5L%Y=O M+/-<[ /7Q2&E.C_VT-0V'H*(Z\W9*P>,8<D9!M>\82#S8(H%[[EEBU@3+T5F6W-JNV]B+LHKF,W%Q+VV/_8X+X\# QO!];J#"\'U>D3L\?-^(UBN9 MZZYB#%[GU-1TEV\X&9JJ9]M4^^ZY-Y;[+^KR"'_ZQ]15VIT&1O-S(7>X3HY8 M(-$BT2+1;B7:9CI$N^_*>+N%5)H+R=H_7)%Z" DC%NO@_"-8*KA11YS@SR:[U4 ?;^\?:E3!W\\#3I1V5M^9&$X6" +(PLC"Z?" MPNUD67C?2(8LPS\D#AH+^V(32LTN 3M%)..+RY?KV;>:_K)-P536'6I_K&$K MO?_K(0JTW,#,&I'TF-]/J]GPD<4D^BL.\^V8A FC:*( M@#NE#N5:R9K.@QCLDS@I0N''Q 5[ =CECLN^X)D83G5]M" !Q%\IR?--=AD. M0HV@.U,[[,]<>:;G3S95_CA7)JP[%XKQ4WECUO)+UB,-"=S#&I']!IO>7?]A M3+X/1^/^<'#3'XPK9'C3C^A/4?HK'(.;T?U@_'@_>GRXZ3U<#N\'EX_]T7O?L!WW[$S9)KD?["]O27;<_5PO:,%[9',(E/_#?>C-JZNN2- MM.3U]94;A:^IC";['X.V&@6@S.6880??N5^1UFV(GOV]9U M?'#(KU_XU:OWK#;[[)M4#2\;V<^*J?];C#/98D;X>+5B#==2K_F2F:X>,F0' M#- EP]S6YV$VXG?/T4WJ.,ET*!NZZ7'GG'S7+4?5J:E2AYDA4ZV23XSZF1 MJ>*PIU"3/_8G-8QSE;V=^?=,T?_-7L::8UC/HAUSQ9URAB0_=7=*'&8[]0G[ MP72)Z*3+_R+,CBC$\>8BNY0UD+5%MXD^XW_SUE7)6&?_(KI?9HGZJ.LFD6M2 MLT*6AL=OF:<;+ALDVWKR'%>DFDX92'P):,)>QU]+--M[%H5ZK1=JO[%!F/LY MJ&_ ML'8R-)Z8E13-%@/A]^26::F&9;(18V.C/UF:SFWNE"G]\Y3X-I&] MEC6&\C&D6H7=KK&!Y#^P.0J;?_&!#,6"S6,X6/[%JX@2L6QMNH8_5CNFDEP: M;VU+\U1W>2[97:W/PLS[$[5'DZ&_-_4Y:.KBQGC!W.'-U4KJV;E#59Y^]I-- MW1QJGGV;Z"\T,K4,-\B&C> YRKP5CL @')L &LY3%T2S9B\*NY2]]XE\XF^D M?*W0I@QRFP'#I(&-4N^[U&Q\KA#*"&:F,%/!!7C'U5VYPZ[N?6]U:A7R;YV/ M$/WX%;+,;N+2VOM>KW6VN>^"RCJ@;?.U_J>G:WJ0&QXD3Y [ZEB>K?I)WGDU MT0XGFQ^*S32^+E4(E]UU Q0>VFUJ@3P*CXC?]\O!@9MN?=U5&KX_LF>*,^AV MZ%APTW?%X&9T/*74O;9\H]%[U1VAXAL.O6,/7GK-T&3]_8.*0,"8&3U;9.K_ MH%RJ-Z_$-!B ,/8-]",TGG_6J&T]$KT1&DA?86[2(.(LF M;3+%3TSOF+YS_F%6^XE=[BTX@"G>Q.//YOL2V B9G"<7'JA?W"\X<9VCI[BB MD!^[CU'>"^4VVYWRRPS#^AG0%J,#+QDP_<*:,#FW(NJ_H!EA6_>(>; M',%^_$Z?/7]#!7O'+7/$67^<>R8!WPU+_>,(UYDL#BKLN>_->-14TWU4FVJM MI?T?]MZ\NVTDR1?]*CCNZ7[V.R2+!'?[ML]1R7:-^I8MC27/W'?_J0,"21%= M(,#&(IG]Z5]$9F('P9U($'F7+HLDEHS(C%_L,>VUY]V)VAX8PV%[2@:C=E^= M3V83?6#TM=D>_C$JP@[0O3-GNU0,B*)[JY'NG>"@$K-0"7E8:C:-<_G?OVJ> MZ=W/,WMAS?[W%/MA=W:.#H>?W3BZ!_\H6?#H/;C$PY$,99;.?LO98_>=TU,8 MV%H ^,J\@+OZ P&:0&I1M7T%\DASX](LUT!\8*KIC\YC1WDF-LA!5#CA:]"W MB1&6<.'C5RYHX>8*M%_E+?WY;SU?!XG>ZR+SOI/GP&*7/;;_#_> *C$ T4L^_P3+PWZF M\GYI>A[^^NWCY]MW'7J\7 P"6&N*T* [.^AB#>O2%%3C^5VS[SAW')]Y8UU$ M(J34;*U$2Z4K1798!"1 H>\5++'@UM@'@'5!GIXU>X@O>48:;!L&7LPFH59[FKCEHS36PGU;)W<\7"A\%%E-& M$DB'2Z:P.P+>)J!K2!:^RMD!+Q^9*"]D"SU_07H$DL-M1.%_ 3CC1Y93O4U MT5Q\'+P7N_-A2\,;R.ZRR5A)39(EM@07155/^9!? /!WBWPW$[]( =N^^.4RW$$^YX MAL'(S/P@26EOX026@7O.)9K!W!+V/P-;C]T2T=[?@_'P7+:WV;.9V$1O$D'] M.K.IX0<;-F"R6KA(<-[8=D"-2%2DT>\48L?_5DIU+U#$X:;AZA3 !GHQF;D! MRDMUR(X3/3!P?&()9SLI=Q7#&>H'+WJ]Y$^32,D5.W3%Z*XY8^NCBJ/:4AZ# MY1)? H[%%L6P%5X6.N++W>_XZSOXMS*A:A!&$._NPM,7$2[22O6_8[LWZD_%([1D3;71J M8^12ZNM#K%T!QU+$O2HE=KML":'#YY<&W(^RR5&N<6/^=0$V^;KMO*)%[P4S M4)-,>!_T;=]8%M-10P4*F\[&J];KSM@XV.0@?;0XKGXW:X]E@HHUG M_8$QF;PI>Y.]I=@OF7N52.=15CK_\,C]_#,8%J &[-L5_4!G@%#B%-:/,B.B M0-UE*+/=4U9=5AG91V]D @V?C/[ZV - U7"NG'M@K-APS)?<:[K4_@3#)2(H M[>7B><&2I0XR0T";S\&NX:HAZFSH0EA&(AQ^3]"WF^C]TH(?OA X9(H58!\Q@GI\^3+0;G>>,6Z* M]C[^Y$6S GHO6H#6GFGX$MJKYAKL-@ZJS8KIH7^$HAKMD*-9S#!%*YR:GOC3 M1! +5N\A*6%)\\""5;\PHL RGML6->9":N.5 89[?0W5;.TG**@>?4&$1MT/ MJ+>!&:DZM198\%-!RF%($^K6N]Z"XDNP&S1!KV<^E.;%2Z42LO E:"PN M=BYJ+YII(0/:P,6VIX7=NUPFX5PTVN&%J,^12KB.\L.&][9H+L@S2!HNCAW/ MX_FMT77,_QPL R;6F0!$U=PE"Y#^Z#N#C># ,M_BY>\ZRO?2&R>]"%3-)SP! MA(M6>J^68A,_]#-LP,H$0A;X2HM>$+<9O$BGW!W!W'(T/F$GPI4HPBDLAIM\ MS5 4?@?O9"C4Q\?Q,_H&J(@9/.;<1-(%[ :[49._+-+(P?)H&TZ3Q_)6.![" M=O;"H&:47V(:/&6'J1]+XB\<= $?X$68[";TOP,#X4I83ADHB(P%? >H/76H M3L^$#-_A/(%F!PI/J!;>TEAZ%C&8!A#3E/T ]*KOH8H&IV)#FN=CZD30"[]@ MN* <=$:[@4ZE=33YW3GIY4+O^H(8@06FU+8=>2[7UZ3W!]J,/>1VQ#^6:>)G M,E(HEZE7%51O%KSQV$\C;\>"6*@6QN*&V0$V27N#7--9FAR;::@!0(41 MKZUR+Y$I0?%\Y3HO(%$PG]'-;>"R9! W0P!\VW)QGHJ$1$Y[ 0>O)SW[GTD#[-.H5+W1,Q?.$V\VH;1B=4K_?U-%_8%6"58 MD01$C/[FM4[T[]09?*\%OO.!5SL!0RQMY9'WX3\^**PB:MKES;/W;UIRFNXR M0[4S'.3*LBCM%?;#\U;?)H2,6GG9U>7)G^\7#L\R)C%)D"[ MK\&@,]C"JUC<'EFVLN.AV255:W+.3"T*>U$@L?(F69>H&!6#\"?L?"4 B%SQ M":DUPC2-+Q'@J"( C@H_2+=K* 0;"4@)MJ+U)6&HJ=+MH#-R:05[=ZY<3+^6 MXJZFYP]]3%+<":AU+TW#L$@539ZX(GZ]KH+;L+@OZYL4KM_6.4;B"L.&>K2J M*X0'V8:N6A9-=P)ZV6)NOTKE@NDT1>&Q&_]6[H9:A(T:^(I.,V8G6)/00,GJMT6EC$553%5.Q?I,E.#!6=6 MC>,DTTP#P^)/IK1Q/LWZ##;2" M*S[A4 E>O;O[/)O#\QS4ECHXG7.C*5/V!!1*%U+-)-(+C X2Z1N4-2%!_O0@ M/Q47Y(]*T!BJ^1DJ$N.O8I+ND5W:TH_,-0K=N2%3_N0X-M8KL;W]W?3^O'6) M >D)^NIPPCJ D'3\^K8@]G4)UC*FG<$I*.;X(5]EVA>X*Z5 MF6E9S+%&6]"WE&<<[6?3#IDSA_Y6=Y9+G'5.YQ*"U.;-W-R5X^+8 GI=^N'8 M^!F?C?V3XA?$?IJ.SL8!TDY)!S;:FZUQ[A0V\T'Z+-F]9IK]I\=G7GF^Z0>, M1/#H:)85;=#'7N<5'K-8\Y^'$PM=WJHZ>M*>'3DGW:PL^)UX'B&_8\^G$_;A M+&QSU66]D;N3VMT@34X_ M'X_2D?=BLWTFOS^S?K?'#L..%PXY1$/!KLE[3E)+\V;.R[CN9+P"%V":AH=&P*_U7B=A;T75QP ,5%R9M&HJ;D_68#%_9IY^A^A6/(>TH\1@9B_,UTXC2 M2?^ +;;MS-M!2 <0&+Q9(PO;I=LBT_Z5F7ND?F!'\3[ZN,#=L0U:<>.X<$!' M^&DWM\2B%60[+D=]/BG?C;!E*;N>"F)X$4IM-C)&XU-J?=;B&GO6Q?V2V54K M;LE>W&DB1Z<*';S1/M0 MP"F<$.LDWC&FK(W#A;%#G(_SO]@T7]:N-*0Y13':JI1>FQDNR]O&QH>&_AQ? M@[TZ;E7<@HQ0?+@B:VCJTR%$M&'X-FG0XN>+?@"/#2=5O=(9+B;OCJIYC@V/ M6=/FY'32:I)V. ^2_$1U@#_$86.%L2'J3U!@C+ ?(#WP'>6!/X-.#&;SBK#] MFWR?_IJWL*-0TI2QN+UC"D9U7],R=%31O;6I$OW0Y+[NT^?/H R MN\\Z&>5*CK]HIDM+I3[%\R'.9:B,!IQ/6M<8]/11>]:=]]J#45]M3X@.A!Z/ M!T3O:MT)*394BO?8[DVFSS\(E\XIZX/4PM;NE*[*5VIMD]K/&XBGIFU17XO: MVX>CK/B0MN? 9/-3T1J)?Y?L;SQW89^"K?XG_;@!ZM8:2;]@A$ ;*',$F >G3(VH(SGN1\^CU@Y7$>,;LLD]&M]4 1RP\-EE MSZ'#(WPO7DS9&*1_!L9S/ DSM'^P3[KO@!D4C4[@3XQ.3W14ZKUM/K%34#@N M.&U;HW&'FC8;I,FL*W@CFX[EX(?2Y':ZMTDJL]%2+MFP+]/&:,+K%,HH+Q(W M=#-&5D5B(T22@@_,I:89>F#F&5F4F+0++T2G2NT;K^QW MDT/_JSZ%R[BAIOR>245WW[ZD HYMC^@8= 1<,H!C^X=;^]W'$Z_A$GS(U6=N7(.X1R%7 M$7/B-5R"#[D$U6@-":OK?TQ_\<-V9AYQ7]"'>D?UUO0 H.\XU 5Q^5=T"%%9 M$"WVSO;9^OO[V<-G77DN]Z#*E7?#E5^ Y[W-^'_"E=\'_OU<-*;W-NL.52S] MHES?K'?LN?10N*V%/M^]S4A_]'K%W-N;-;.+,?BB&WJS&G0Y!A^Q8-LI2*YL M] <)BSDQ72UK&^^6/; YSVB;_<4WCW&?D?%G2SY2PQEL!?/J<%@>S5C9-!IO M.\2G;ALZIB:%SQP7!JIZ@ MUK2I>=U.5ZR!1_6MYSE1Z;[X0=*7^ MB1E/7QRW08N_PQ/B;3N>RQN M;M#B[Z,8=X,6_9TL-59[S0+[U6.Y2+VBQ>"1Q/R:\$1B?NWYRC"_WR $:#3F M)S/;&K1LB?KB\VCW\#*LK(J&J3S)U[26JF77RX(:MWR6[9PK M9=%T-^57MFK>KV8@5W;(0@ %/5Q*LKSYM=%%OZ[I76ZQ-\'-3],+?T %,(NQ M?$'Q^Y4FJ1=%%V.K_M<2,=1FIK/%*%:?=<)KH: M)9E$11 )W!*X!>"3!.Y:LFU_X,[5V@L!W-$__S,LCJ(.N$+L9JX*U@9 :@)2 M$[@62)*:@-0$!."3U 1JR;:V<&R3N"(&&R2N2%P1@$\25VK)-HDK57/@5 '@ MLR4877T ^$?GL1//*O/02T!;$E:5+2&Q7C"R-UXB"<$&AN?-ANO]'<*YQJ7G M= C_>'SB8O0QDJ("^W#5[J@U&'5/YL.5$NBZ)9#$7[G[F\L&B;]'F,OR<%SW MX9#0('=_<]D@H>$0TRPW64$8T^S ?!U5VGI2I%V)2). +G=_<]D@ 5W:>M5S M0-;&5LT!&AI]QJGU-IVLJCVCYG:"&*G,A[JZ?*B&BR8AV"!Q^P!#7,T-^CNO M(?Y;)$]O4)R"%/U$9GXM(J;#5KG'U'!#T M<$AHD+N_N6R0T'"(F98;2BZHF7:%T5-I]PEYA@05;Q+YO+ALDN$N[KWH. MB%)6>H*9M=?$EEO'73FNYI-$#%71;!PJL%P25SR 86@K$IWH3B*6U>M,>SO#E OX@YP]<"+A'9L_-_8QFTDL1]08 ML MO?=[W=9H,A$F]UG(<1#"G 3QYD!)_!<,5"3^UX95$O\%S[:68"3NJ9)@) XO M)!C5GU42C,YEC/9K8HQ>86Q:6K=U.EI2H9"\D K%M;!**A32NJTQ6W8/DB]- MP[#(&1,7RN+DAA/,+**HG>9 TY/C:Y:B425:63+5T5 T7YF#/HE<"4A5*28E M.D0#&25H$M8N\QG*F-=():.V,QQ.PLFK5D#V]V@,SN/1J-Y?,)D,6M.>.-GL MFU2TC6#2*)E4+;Y(K!>'%Q+K)=9+K#\+U@_/@_5R[*]4'AH,6%)Y$(<74GF0 MRH-4'LZB/(R$4AY$SE08JFJK-SQ=#W*I/%PO8$GE01Q>2.5!*@]2>1"Y[+\N M2,9('U*^C$F7R'+XQ=> .O"I8;[LM_C46O^:7)NZ97')UX%'\B?3%^&\^_N; M+BB*Q+*0.\#GZ&_.=_IWZD7?:X'O?."_RGC2YY(X+ M9>$,NQU5/33O,"$W=/B6N*<0'/6%]%,E@O8KS --4G3F6,9&@3'916"(%3(P;?/A&=FJ1*O]=2P"SM5IYB> E,%8/V MN^<--A9:1&64!!EA^!"!C"H"QO321VA7*[#9($33="7P-$N>'7E(I+B3XJZF M?*41)J7'?1=-6/';_PH"0AOQXLD9!?>[XR MR.\W" :#?D_;$>"O@1]$7ETJADM9TN,Y&'EZ\U%_0K?K94E]? I_]RKO$EIZQ2^*O;4P\L MWNH-1JW!Z'1M9N6DNZM'$$ESB=H2M25J7P"U)T*BMK -8*0:<'6B3E1(DN:[ M5 2JYY-4!&K)-CE'O6H.B"K@)*Q(6*F>3Q)6:LDV"2M5<^!4H=^SI19=?>CW M1^>QH_@N]1.L%2\:IB?1.>3C$/AS2+).;O[%L MD,AP@%G6[PIKE@D[;$':>5*D23R_8JK+S2\"&R2>2TNO>@[(>MBJ.4"#HL_. M"W%MU,@4[1D5-\69 =DU5)]D?6SE9T(,JC=>- G!!HG;A]CAO@X(>CBDC28W M?V/9()'A$!M-K8F-=H614VGTB7F(!)5O$MSEYF\L&R2X2[.O>@Z(4DUZ@F&T MU\266\==.:[FDT1YJ:+9.$5@N22N;FJ6LM)6K!V[(',?FLLM05-SMG1.;V3; M"4%9-=TJ]V3[B<.\ ?V+> -V<1L)[ >4UR(;[R.U->P.A4E[ M%G+\@S G08BQ3Q+\JV:$!/_ZLTJ"O^!IUA*)Q#U5TA 5AA42B^K/*HE%YS)$ M!S4Q1*\Q+"TMVQH=+:E/2%9(?>)*6"7U"6G;UI@MHM05EX7'#2>86411.\W! MI2?'URQ%HPJTLF1JHZ%HOC('71)9$I"J,DLVZP\-Y).@J5>[#&,H8UXC%8S: M#FPX"2>O6OG8WYDQ/(\SHWI7P;@_;'4G(V%2V#>I9QO!I%$RJ5I\V9LWDA$2 MZ,7GI01Z"?01T(_. _1RO*]XZ-0H(2>$YB"=!-6S0NH.4G>0NL-9=(>Q4+J# MR D*P\FD->I)W:$>)T'J#I(54G>0NH/4'82O\Z\+D#'2AY0O8](EDAM^\36@ M#GQJF"\?J5*"ZIEI![21]W[D2*W^K\G5JEN6FWI!IAA]"Y;$-?58R50GN?K. M1WU!C, B]_-;S5O@___\K\"$'8=:VXUM/"X3Y6Y)USO$[SI MKY:C_UFBC8*6U^O"_V7_H/V ":AQ*SS ;D#VW"H9VFS<%]T+;PR:3FS.3%I@G,9 M_P MX.5@Z\4-\(D/G9FVQC54C'C8J0#H0G[BDTH23]9XYE;)2U MDUU$[:%<^XK>"L:Z?J^E((94GO9Y"85'#.K77'Q=\;F0TJR.7/M$=.KZ3 FT MKA1H%1X;T89>,5WY>M4PM"Y96S;\!XGM3.%<611XKI<1-?8#2Q]OM2P:)X'] M<"Y=M?]V_]CO).N60U&)5>AI?]Q^L>#8Z7;(5.=IMZ6.NL+$6,N$1J-D@JBR M6R*F1,SJ^201LY9LVQ\QIV="S",RFL?]UJ!WNK8I$C$%JTH_F[?LZ@U_&D1N M^\1=*F8<1E;>&@%1,%QJV@I'U&PJ:EK3<"$E!ANH]B*5D[V4 MDT$WE\K]HID6)GM\<=Q'4!CB5G.W@8O1JW.9\8/^J#4:G:Y 6Y[W*S_O$NSD MYF\L&R38'0!VO1.#W1%U0<-A"ZZ58"?:IA(E]"Y&3JHP;/G= ?(46^4SXK\2 MPLQRC-C[KPXUS[V#[?-3%7+)A-9:A"/*^.;9^7OM_.&Y-:]"?3;;/K5Y42( 5AA428*^ 51)@SP2P^1FE1P/LX3Z' M46LP$"=+3N)K'1(!RMP0#>Q*PMK38TU *U<90)T/2>^$:2NPM#\)*YV.Q[V+ M5ZC60$Z*ZM>7_64NF$EYYO",["]3@/#@7GOBSN%9+6P1,.0$Z@%F=.3%. 6O1&=W&3N4K: MW)6\PL9.(O@*]"GYERQZJVH._ICWB5NXX7I6VC-ISURB_=G6YK"<]YKUJJWA MP/YR/.5W6V.VP6"RR6&BQ>!H\(>AV_X?4ZUK#'KZJ#WKSGOMP:BOMB=$G[<' MX_& Z%VM.R&#XQH 'OCN)]JHW0N?RKL=G& *""M%3[4CU$)AWX8GM#T0R!WE MQE>^8F\M)6RK1;UL88.:\--N2_$71)EIEF;K!)^)?]XZRY5FK__VEPF@SP>X MOZX'R\#2?'B< S]P 4&6*Y\4>-:<>8[/QYI##\OH6>ZX4^+?H>,@1?Q LMO)5>O&* F[8_Z MN;$SWTFX"W1Z/K^XSO(FYM0],NHVR:<[RB:>G_D %'2,;\2_GS]I/_?K[QDK M!W??OJ2T@S80#36$5T!Y%OF76V^WUV/4@#/$[*RO%,7$#Q.6@IH#?!WZD=[L#EMN/#+7QBT^/O$DM#S_$)<>FKQ04 YUZ?'6W<\ M/R))'$3 R;?A4>\HFWOE#G:/,YZB&:[" 948-W[\#G\@EO;>?$3NQ>-ZF1!) M+Q26OTN@1)FMX8M_ E7X9VO%7Z_(=CD6X0)%&=A['NI51@@,]#FXXW"NL&-9 MSJOREG[E!![.T5J):B].B]D"4T['9Z Z%:+3;7.Q8Z*M51 MU7V3!6S9)UZG2S@Y6XH)&M?J\B8$IJRY=<5KO@4(KMR;U>1FGE)$B\,(*:)% M9]L/._2/-$A&_Z:9MI31#931C3G64AK7DFV-E,:_.U[56;MBYXLV2%[3-JI28 O'E]VKFJHKAN3QA2OEP$U!Z.R]> 6I!:!Z-2P0 MM0A8D/[LDDDE3)JF5)N3=&B_-NP7E'/2G28 #R2L2%B13)*P:30&QI6D8%JED MY-_1 ;%>OS,N9((PW2N^PG=K7H2FS(&JE:7[7-IY*0P+Q.WS(UOT5,H!!N6R MN\Y^]>>3W2N"HQHH+ PJJ0KF=XJ[.SRM5^3FI^F%WU I^I4*T2\H0[_28MSC M^N;U1VIK/!*G;YX4%(++:PF3*K.ACT:%4:=R;#& ME)<'0 *#! :1N-*T8%[OH$X[KJ5L8@#".:G9@@V2"UEM.' Z<5A -_/#YQ:1K?_!1J MC-H=M0;JZ=08*3&N6V)(O)2[O[ELD'AY %X.]QC%[<(0V;./Y* M._^7SVPX!Y+&<"G0S&\I*T[B#9=(>5TB6NY^(=@@D?+-Q[?[0V5NTM$A4(D= M-JN'2FE3"KVPDCR+]% M8O4&I2K<_!.9^:?5;H8M>">9%"?:%A54>DCLE+N_N6R0V'D(=NXQGOTBT>0C M4?4<#G,I.(0(+4O8O"YY+7>_$&R0L"EK<*OG@(0&\<@N=W_#V2"AX9" JGJI M@.JE')#2DA)N5YZP.>^Q >]4,'77N:)7'72]==R5XVH^2<19%T*P:KKS5&^I2^WGG=XC.>WX MR*ZK!UXDNQ,WMN&6H>!^0+E]DH8GO6YKW!#"[-QJ!8_$:W%X(?&Z M_JR2>'TNO!Z*$4T^%9+'<-T;2*2NQ9ZMMGQ9(G4-Q+]$ZMJP2B+UV6JC]YG" M<\;:Z--#]7 DH;H6F[:R^FF)TC40_1*E:\,JB=+GRB78H]=7/5S>H\E$HG,M M-JM \W_+4@P,)X#3H*B=Y@#VD^-K5E4I."6Z4P-9(6CB7F^'^?)ES&ND05[='T[KT=;G-X"=<%DMHW"752VX2Z1 M#/"+CYL&/C7,E_T6GUKK7Y-K4[]+T6^,X'SGF@NJ6M//(^_,<'A4NL+F\&E,N!N-#V''8[W8/;+"1D MH [?$O<40K"YZDFD+6[)?;LP0Y)$GCF6L5&&3':1(2=E#;P)$ )XH[X10/WH M=7=.6VP,VZ)8-I>M35@SANTK5SHNH4R(06XIM.O%&BFT16=;["QMD-3&P*V4 MV@V4VHTYUE(:UY)MC93&&*6K7!J+5,8C!ENDU!:#Y%)JB\ZV+YKI-DA>_[=F M!40*;.'XLGO19775WCP&<:4%;ZO9:B=M7N>^&*[B6N"L&% M'1(8FBR^ACHDF^R21R.-UJ>,E3T_5/)! (P(7)-"(SR0)-'7EG 0: 7@@ M@48$+DB@$9])$FCJRCD)- +P0 *-"%R00",^DR30U)5S#0>:37$S6%D5,??C M@V;BSSW]"M^M%7CG/XFOS(&JE:4$[87\UU0)*F[!MJRU%J#66I9)[U?U;D\]L-:Z-QBU!B-Q^I](02&XO)8P*7>_A,EF MPF1;.*XT[5R(*IXD*LC=+U%!HH(87&G:N:BV;[%$!;G[)2I(5#C2I38>GWFB MH?2B-4\VG"KZ)W#)G/C1OQ^=QX[BNT3S G>M>-$I%B\P+A66*\Y'D&R06LOI M X'[S!HZ52#PQ^,3EZ;QS4^AQO2[O59W/!1F#+.4&&)+#(F7$YD&6GUYT(,LC=>/ G!!JG#'!)"WB/Q[80A MY-\BN7J#8A5N_HG,_-.J-^J@-9V.95J<:'M44/$AP5/N_N:R08+G(0Z GF#Q MY"-A-<;.@81-T7:GH()#PJ;<_[O^%LD-!PB$4U MO51(]2(>R&$+WDF:4J)M2U$*.J_DD4:FK:#:.*EXN MB:N;FJ6LM!5QJ\I12&HV%^!8[0Z2*/DBNTR1;KC,$X)5TYUG?DM-:K_ [A[) M:<<'=ET]\"+9G;BQ#;<,!?<#RNV3J%4CM37LBI.W)N3@<&%V;K6"1^*U.+R0 M>%U_5DF\/I?G0Q4CEGPJ)$^47XG3TT,BM;@B1R*U.+R02%U_5DFD/EMM]#[S M=\Y8&WT&J)9&=3TV;67UTQ*E:R#Z)4K7AE42I<]D3T_VZ/55%Y>W-*3KL5EW MSR\X>W)>68J!X01P&A2UTQS ?G)\S:HJ_Z9$=VH@*P1-V^OM,%:^C'F-5*Y$ MG8)R&4Y*Q2N5>+!'"N>NB0='Z4[C_K#5'9S.LW$B&-@= QHE2JJ%!0G1XO!" M0K2$: G19\DUZ%\RUV![V&$H3I<6"<[B H($9W%X(<%9@K,$Y_.D%^PSU>OH M]((=D@+Z$IUKL=4.3@J0P"R!60*S!.9& ?/^&05[='L[JR][,I* O.<68]LH MW$5E&^X2:0"_^+AIX%/#?/E(>8F[Q;0#VE=\/W*D5O_7[*%)OL31M^6DF3F6 M\:'L0?D5\;/V+5@2U]3C,Z6.\JFTN@X;U/<>M#42Z<8VX!,W (76U&:F14_7 M)]/3+<<+0+>%U_S5/P(E:H8"#&^^Q_48[$*9(:I4* MN ,WUS?')\J@HW#J* GR4!YLHO@D1_%'?4&,P"+W\SREGY '8A!Y#YJ>\ R' MY+5BFB 1/-,#DTMQYHJ_(""Z+_O^D"!XEEH?B%MXW^YH*=_IUZT?=:X#L?N&@'L6II*X^\ M#__Q0>$J29=W^M,!^YN=9&:/D-JB1_3@9O4@ FYQ3(A8R M-X%E R?4-P+8#FI_:Z>AD&@;#0$=R$[<4U@"8K#MQD,I_E5S]07C8+_74A#$ M*E>I+Z$JB\$#*<-$9H248:*S[<9CC'/F[+^?B$YK#B*!QOZ!G@ML9)] .KIH5@E;@[1(7D3&/ M2EFDJBG,/YQ-,J"1"FCD6@Y]7JXL9TW(=T)3"A*.P-O 1<5WFP>P?VA/LWB&\FF:&%:=/"H,9^[]1?5S]2I-PA*&%>(' ,KRKAHNSX1@5280 M2LU\X?@F:XO!"@F;]625! M\VR@.3X>-+=8^Z/>Z.[HA6PC5($J--D0 KEDMOVP+WL(U6-_"5L;+3%9%&$N,5EBLL3DHS Y/[/F M,$P^/*]_VAH.9*/=:^OK%[=@.U=7OTL]9F,'OURWZL__"DQ__97X"\>(YV:> MN&F?POL+$N/&CU_E#T.W_3]&<[6GZ=JH/1A/]?: 3-2VUAN,V]WI9#CK][M] M?:3ML3DG&PA56=>_84=A-%9B\BJFK3S(7LE_A&-F'?O1AX,4C9B%X\H.36^40Z)A!#>C-Q_[G;P!J !_+:0I MHR'VQ=+I,V 7P4-:A]"^5U_:WUJ:Y\%;X=J3='\$"4B\FP>7S FH!,:!'.AU MNKMP@#U-N5%6X?-";FBVH;QJ+APJWU-\1UEQPBD(YSXK@J(_Q=LD9$,+Q(;> M4=XF/GH'=U-TR[1->#TXN=HS46:FLZ)?ZB3P\7/<#/14SAT@'W:_M)45/(; M&]K/(( ]4PC8.,'6G"@[?:+Z<)U\.:ZB:F=RC.QG251B VB!R[#G_G!TG%! M<8"?S %8GFA#2NRJ"2H$+ASD!>VQZ;M$8Y(.5K/20"/#9;^:_D)A6C*]D==1 MGA:F!R_CP^V]K%A4X"N--9B%]\=;:_"!K1 F3I=TM\ UX29B1,;?*'"WP/+I MJX32"98%RA$\#%Z$,BQ#Z+_]90*JY@=@XPI6XR.1V%WP_>)7Q$8^&GW8[R:.). M2YX<$%,@'Q1G!N8,W;=4?KD.R ^BZ)JW4.:F#?L3CPQ\DQ)>R?N8>!L?3A50 M""4C_)8=2KKI07K,R!K.#[U&!U&YQAMJ2SS_8>_>^$QT-BA-H8J4UZ'$49KN M;.4?FAUH[IHRX1^!32CQ6QGIYV$O+ XN7,!P@+FE%X9_M'M9O(DYPH5)R ,# M9"\R 0Q!@ D31#,2%6D+4)2]"+8CR'$O_$5XDTA2A]QO86YPKY=V*T/ M 0G?#W92='V1I 564D41A+MFNF@O!P3OP>4S$[\$[Z,\:R:(2]AZAFD%? _Z M %ZP0_YC?TF0J]'#Z7@X@^?>QLD X=&N6":$%E4W)R0SJDG>$Q&I)D9 X9YB M\L(E1 $%T5\ Z>$<&&F) &?_9@XHARJ\M3Z0LL.4!AF3-4?0;\2_GS^XIN,^ MP"YVZ 2DTIP2(/-W$@$II1RE/+'A?#F@W[V83N!9Z^]DY;BP:S@A*^(.=?RT MDVSJ=O(MDR(VP0[G,E"+9T3AIRND$)X)(!$H4* E4%[RDWO?M2^E>_6CG]R?(#B"TYO+]F$ \CL+_ L4!Q70! MQ7L=Y'@W8)MI+;N)@HTX?K\P@W7LP(ULCV#/?1G M6T.]Y+UFO6IKV"N_'.\VWVV-69=Z[IE;+4X$%L,OFWA4NF$6* MN*&0GSHA^ .F]H=W\.!0A[I0VJR)8'Q?H37HIOW-]Z'SYZI@IE 1HN3>6\H/ MNKVZ$.QDRLX>+L.#]WP+S=T5@:>_$&O-=O=63$"5 ,^*YX4.DNP!35@(J(4= MP&ZU1J#>/2&HJYU\65^T*[1X#DFL>]4XC'>SFWP2/AR^ M&9/QCAEZ@9 #&#B #_$SZN@K]IAS5Q0-BH2^\U@#VG%<7Z:WOD"T>\QT!%4=] T MFZIU0H6[1QWE=U-'CM(ME* X')N;9Q"'+ Y2/O8N7;7[&"QAS>O[^7?R0H"N MNP^Z T%S2^T:%QV>ZY0 ^4H&T6V!V/'E*7T_T070X@C,!I2P?F-J"5GMHM6KQ;:.20 M,4P).19&1MG'[^@3*?^4- /A*9V6\KMOP&_I]^_>-W/JWF14]/ L/K3>25O!"<%]'\L)$0\\,FG>F6=@F-FQ_V1+'W*\/>SS'V1O/#*D]# MEE/#&@OS8@LW"322%Y(7H@\-[?4[ZFC_TJIF:P5R"'+%P%]%H6]_B M!ZEDCHC,.67+$-FU5+QQGSWU=$J>;!FR7Q93KO8O3"6X4/( W.O!=8Q ]^_= M1^*^F'I\KQ1\[Y2AO'N;DL%(-B>OQYX60C%(>12D8B (@@1U&:0/V;-*J;2@63X ^ MTA-WQL#WCLRZ:JP0(H0GF2,BD.A"K [G.8[51!X1SPS5% M'6C2&(%DUE_V\.[4\7^2:X+PR?2TYV>7L%ZN45']SC7U#:V#-XBOF1;M^W%, M.?QL7> PQ \UGSP[[CIQ_V:5J6]$9^YN/I=D^?*E:M 45;FEOLGKU4,EV<4A MNY!5YXTII!"VHKS,\):%%[+(O&I9%MJJ2MRG[[UX9V5KMG_C*L?N7P@H[G!' MR2SQF?7@F&QB6@'#9!5G[=DK"]WO:(]LE/<7D.7",/+_E4P2GTDU+MB3R4"U M*,:3B3[[)?KD\A"X\Q1GQMS"0_!._V/ZB]O _(0]_-/W0J013F7"E;A#E+HJ9'[I8= MT7! $H-5:7U.=BTZG3-E4ITSA6)LJC-1--7QI%Z5>M1&R19%U0N@XY-*)"\D M;DM62=P^.VY/!5W<6L<'?N1IKB];1IXE0(1O\B<,+"=L2MB5L MGP>V>V>';>&<5DV![:MHQ"=T3[K-;?UR$>!/9$Y/VZOG'A$<_4P?O) M]'3+\0+W) W^Z)4F/,.X\>/W^4.W_3]ZK(T>K^Q+M$6A!7]Q=SWNOE(T3]&P M^B^P?&Q\IR_PC3W:[ %^;_ E13^?:99FZ_!%X.)=\#T@N= MP--LPWOW/KL)PD:)_/V95RU)TW -C6FZQUY@U.]4F3XHFMH9E=P/12BY[P^W M!K:KK*B/&=3,%F75%MA?B/K"93PW5V)Q>$]"*T=+CH1ST*NS3<@$:R(R[O0F M-6XB3 N2TKH&TKI6\KE_8OE\=7')JN6S4!+Y8 /H;,Z"ZS. 'HA+ MCPG&_)P9T)>&[#S%@_]Z*YB5HDHAT,,PC-D;!KP'=P@ M2)Z JSL!DO!2]$C1Z?EL(G8].JU%19N1+5E2MO.1TW?/^NA4]9PD>/OJ/_J3P$KK[0 MX)Z).^"K;/H6KL>GW]DOQ/,=5V&]?>/O6\I;S+4C8#6_$&O-UL5?*?J1!W\"' %?J9N(S(T?]CO]\9#O($SDJ= M3;#6P<]2ORQ!N.0A 2F$LQ(!C]BR__:7"=#_ \ZN]T /)XAG7XEK@*A[T%R/ M ")^[7SJM)2'!?R'2KFO)KP,L93_"LQG"W] OVIE1O9$-_[5T5P#]\$GTP68 M=5RO\[\P?2I4D1*:C4KU0N5__8+??WPD1/GF^$3I]7"[*O/ A?N[BF%Z0'PO MB9814"<1^BJ5L2S;84(:B5R>NK\%_@51_$M^C5S@S_ @V5WQO9\7\L:@9 MZH"++CG@V9IEA6O,;B\]<#&!EUXT#_P [J];IFT"A( (@3%X,P-;;7 M;:^)YK(_TAU4D* M7K[RC#<.4.'*');TS"JN;5$V!"M+ MNBGA"86C[1']/1S)5\C3R@T\D5ZV'@NYXQ)M#HOIQ-8.F)P_43H MZTT\=]S>Q(W!SC3?$.W9NLW_R3Z?@7(("$?/=,)( @:S>RAS>!&ZB5Q69H:I M\@<<9[67V@J,>%\(JBJ<\; %;IGH"CD?[@C@.%\?N9C7J*'EJOZ MC&GAH3](L*IJ?3AQ?H&[&R<*[.(T)U#+Y^>*2^$"8,ZAL(FX;WH^DB',237 M',ZI<E;: M,VG/@%)_MBFQWFO6J[8&$_B7X]WBNZTQ%2#87/H\&O]A8.VSJ@[Z YUH[?E4 M[;8'#YH05XP^R<_BMR88]?#2[2=P&=_ MO"0UVXQ_!LQ'ZG44 MD,[,S\[( +^,: #_>#$-WB0@=&:@(6L[?D1% VFX<0VMW+6QVN<[$3GA24O' MYX8B=S'^ .2!NS_Z\/K$ @&D\ 6#*)BXSS.%A M('I\HODE#/JZSUBP?]R3MTP"X@5(99!HC"90$O"8\DS#& GV!O!O\5KC43!*,/#_T^? O 3GMV6(,(-A$Z M-RG9"U8KQ_5#_S >3/8V&WX?3E8^@UFOIF,I7,.[9ROXSE\(D#VA=#RRMZ^O MKK&#'9]6-IP7XFZPPG,^O!K)^ZRK;F, $_?C%A=ND0!IH0Z=-'_A.:OP[@E_ M!7?:1VI_?T0'?_[.=M03TZX8+[WF?<> M'1J1\UQC[=U6WWSLYXVEOVZ2OO"9C;#D^1I#Q1>'"N-D'*7%.06[ MD^X<_"\](5J)YVF498/I&/=P46*I3\ZO)%RN40^2E_F,YN@\1I=1SF.4:'(0 M!LI#?H"9X@/ )L/S+1ZW"@\."ULQ=.<'%UY40S,&'47[GY#QQA/RX)*E&2Q# M@M!8UA4=##4O]_^*F=BX9B0M"QPH;V<:3X_0D"^F1:.WR0@1\KYM_FPO3 /$ M^GM.UPG; VU#6_. D:+!CD?5(^0ZY>6[T-5 3U)H@W*-$134(-(W6Y$D/BYD MJ>9&.%"A1_DK+DMWCE&&ARA]9#K*KR$?D8(OF(2P,6:3"1LS[&=]_N+F\U9N@&*H'V!/P'%S*>Z_);4 MHY;RNC!1H4QY?=+QG_9O?GKANLW#DALZ.?:(M6C]7//W [X=]1)&26"14 X#=O,/;PY2? M7NUV"N0S-ZLZRDWDM$UE"8"-#P83$'VC00(8C9']P&;-%@V6T[C1/%'@W9RP M P5Z 6@\CT;8%:KI>C[:\2@=-71DL6^PPV3 @OW'R&S+UCWJ,%+A:HYX.4S=7J3LE$AAXUL <:$)O[45J0(0^ M+#D&0Q7HAP/KTH3W!0V1>B]F))%5LT<2S!5FISP5+%VC/7K#2*N?28YE\C/J M7H*1=MB::\^DVU4+NYOXU-FH_,0_OD_']PZ=.K4PY 5-.S^1M MU7[,HQ<-AEH?4XM5,XWX##-:!*;L# M65_CR#6>B0Y%6B;V/4[HH S:(_\T A1BTP+L7T C8K-$]-DZQ%/F-5S#=SK0 MC/*6PJZVIJV+ ;R?09RBX692@Q@WPCQ@L\4(XS1\ ZBU3IM35,0:-(A H1@M MG4,VR2B7^Y;M^'[';,ZG&#DJL:;/M5GZHV'9;G$"WZ)IE?"L%\)UC@W^+&Z- MU]AOGNP.3M"J9^*KJ"X']A9L/^7F\589=4=UGBG?)[/6>&64E 3%>4B;THW3B8T M,PN'&BN:!4]4/&)9D0N1;0*0C>'5KYJ7W&@!U7DTFIE.98[!E,PY!C67Q%\X MW(3:U/0^ '$>!4M!879TDVYZ:@C1)Q=OX=#;1L5_5K5F=6+^QO/ MA>;JL$PQ;_',.:SYQ--.,^1HMH^GN^8,TSUX "NJ#RUD=$Q5JAYR9T92HU]& ME$U+'WA1/; B5-TJ]<)$P!W$'*_=",UYNE)JO*,?CC\O<7,215YTC+&QVV.% MI(M:#3LAS&UDT+05P.AB0=A)1XS27?K>?+Q+/DPQX[PKHU6N(.1$<703FIH" M:IB)DL6DC89",RFD,_U)!!,LQ56GE*,*/\^;9?>+0\0Y54[)O;V&&X.9='1* M"-]$Q;R'.YK/SSS# GCM^@G:MTT[6XTR()AO5(1\[W'$W[ M+]1QF?\"MDYNRSDLI@;+-O =J*BAG0SI-@Q'_W@+0GRO5""DO2(;]:NTW$3D M3ALD46U)F.WH:WY 4^'XQD^]$E/34$K,0.N$)?$D:L_!D^(FJ]SBX4>% @B/ M;2B $KHD_H0GO2U95<<.@?3^],W'N1.X;99,P2+I*+-VJRH\[:FN1,W\Y"Q? MT.M,K2*I9CJ*D2#(!C43,*S]=/?;W9.R=&P'3 T,*.&G,\=8GTW5'*0K[)*, MDVJG6NJLEVKG-:N=4M64JN8N\K.WDZJ9EZNBR\@MJF9_U!F?3],\LS*9TQ>/ M4@XWYA /U"W8&C>UKD/]>7;R05DN,6)042IQG7VG-ZEP;B8(G$7UK:4Q457F MQ@:!]:[+['7K7YBY4UUE66$F&:BJUB7#]GBL#=J#R6C8GLY&H_9X:!#2GY+) MU.CMT193+#SE9A%/'?(2=@]/?-AP-,+^,E$-'LCM5X+I;!Z/W=#LL>AK:NV$ MNG1<45,@;]-)1+P% 4BV+_2.47EZ^)[L0+-$7=&%[U[-/XA=W/IC:Q>>XTS) M0>4-=RZ0,#3:M:-.*U8AYJ;K'=E"^..X7?%+]4^9&F:RL MTHZ%F^5!/@NF>$,^HF%52SF 0QC5_#&GIG:JQ=(!.VZX? 40J3/5@?59A16ES*S:UT*SC6C%K61?[ M7;COO-SA79AEQ"\QO2B9B+5@X'=GFO=2^Y,I&LSE?T5RRK8J)\U,:P0,)FN'MXJ\=S(L[($.:+,-5"",!L+?9 K4_>]0IL@20]<'C5 L'\& M=YIC"Q':CL0C[@LL-=F DCDKN7V GIIDE1]M2E)JCFP5G, 570?FPN/"=N8; MO:@;DLJ 6C/"I'3D/6*"EY(WQ9:H=\/N <=AMR#@&+8W3^Z)J.'K1F&+S5]2 M(I8V*J%+Q@HF?.7]9>VPMUW6?@_OS^;O?G/\^_ UGAP0P'63$)N$;[],^*+0 MC?C/*&ZP,GFZS[%]A_)%,RT\LPG>P+W:G&F.NX[3V'D@ *4)'HR,NH*M=)(1 MISA:R0],W'\V3-.,#E%LN[NFE^I#<\#QDC&%S'%1=XHI%!?L/'"RBGY>MJ6R M] :'I[(<&59H*;JE>1Z+!G9$U3II,T6VN$RJC@I-I:8RX#0HZV6M?XF-_1^H5_!K;.0\;(V!,8HE-L)ETMR@.TRUY"5%IFL473'UOIU(= M+I&1D#S7!2-C<&(Q@&3F!;">_"T.>XLFFT)+@&K>?-F^L&@NZL <)RGKL:P(G@.8< MC?=@ M4BR;S'H["%YS03%TKF@45W\GSYKUA5Q/^O.XTR\-O(;; H\!]Q,E829T%:![YDU3F,#$PPIBF?,$Q2CN3H\:&/!;_&H^L$FV#0:W$!GTS#7/!+:>L" M:\W\[ QJ32_QR[2)F//=&Z" @>ZTSEED"%R)YYE@P1DF'3H9-W+9>-=XN9LP M:4-F*88U&$'9\<$H4&AR)K3"37KHIT1\A X#@MWE+[![(K*MS/!(O,/HT(2'C+1Q>1F[2]]UKJ=WBYB,G:1%[@)/T D_84HEW:I510;*X@*AJ'9YG#S':AK3 MHD[6R*%/%W/@?*11KA%L&4N_17&#:KA*>1B_1*5L[)<=TBP;&<DMM+8VXU=7S^>HL-=B\D5A^6#O6@DD3K6;VD[L1$.J:(R:1P?H'$#[T-7T M%E,Z6[2M.9W3S8L)WM4Z G%G1PT'&>G"R$U^V'",FU'C8)MW ^.Z4F8#M?@' M]'#%R9J8JN*2.9AJF/[?HG_K<#Y!"F+CQ&0GV6S&%@NT'9:!-$JG5'S#?*/P M)0#+X._;Z"427670I:>E[JT#$G<_K$6?$H?;'+SVQMPZZ8U[:BG.%I6P MIZ8%)73:C!G(PGT'4#L=A(J:Q;(;@AF875;]R:QN)7.8L8CWPB#K<=GYH\'5 MD'@2DGA23N+M%.9J(]NV-'FY-XE;CQ^1P#@:7@VUIR&UI_M3.ZN?)PD][:1T M@ 2JJ2E%NNY=!.X8VJ%_T5>B?JC9^8FLC2SZY^Z^?0(=%' %=Y[G@SK&LW;@ M2C#F/+\L[(H\Y9I&:CNF'='? F0N3C]BRLIY-M])IEQOD;53+FN[4YRPLD>X M%37+_'9-J6I>9E0]MFU)9>JE%-!0?:&3T>/QNC[ATB3SX\V#W_)5$:-T*=]G M>E-B< *%9#FJ+F)?5AXR)GLO5I;52WAXEC85K"9&<5(S &CE44V5D-QT4W8< MN=F'//.279I:V+\F]+7GJXABTS!JZY0HV PC% = QZ0(.N#-&17#<=A7>F:3 M_IZS#*,?344B[]G/T4;R]G90\PT2C@X.FQPG1[R&(V9IA&*U BN:6F0I&4J! M*S85"MHPT7%AH6;;*C(,8\]"#CWQ1G N37QN/)0DJ2A'!CT+0CYC]RLL>4AV M3 JM1"J3&0GVWU?C=%^TN- U'&H/;-M0UTZ,'QB(O(Q**-(6[!M*K?]>3G9J6E'4]&0^T_EP=Z^V9/NBW!\.^WM8,W6CW>@-MWIWH6G<^V[/K M284*_R:SYM+O@4/>4L*8)1\DE)HBV9EH^)&;OAW*1FZ3";+._45UOKKP7'U' M1!#&:1FA'8]LMMZ\(F;)DFF5@!P-(S+51AZ)9F:H9-0)4! M*SY$^\D MV%P\IF3$(:.-VVLC?=-.\8BP#VQFU">"76./:0U9 5FC1408%$[ PA!KCFKM MV;J=_8P'\6!-[AJ_Y__$PDHS5>4?-P"C]?Z)P97&S&>>RCM M8Q$^BK9D8881;8K%FIZR^>3OE;?:.R:IL*W6VU[W'7-5Q#%#VH,<'K/Q^70@ M=M$KT"_X6_SM+\/I!_HJ;V?\@7D7E:5Y("2<-NLYC .:30.+5,*T_6"VS*6^5],UB=)$^47L[H?3:-(@HKB#=4T,?5?=PIF:DJ MC::T1CD+_\29JD!_$N;J+I>F#W^U:.%#5 /(:XB J&=I*8+2=U/E=4VZBS"Q M?T1S$53-7FCQ64%[D7S9ZD$]X\:#W8/>^8FK]4'W_6+?<2;H(4U9,']DF4N\ MWJ$YY3@=0OPUEEN M=5*V&'J& R7BG] "^Q<<@\T',?,"M\0^!;O.*"9Z$!ZA>9;8D'1/7T(!(=ZP4]Q?^#A1NFK[#) M!.S!%%(U!8># Y[JFLU*85U03_"UP[J.:'V.K@=N*_VP*' 3*J5@+<4%&3GA M&H(._;6/[S3+] F@,:9-B$4U75H[@_M\8_\%JL^V,@[T7,F%%_4+">W4$Y7J MCC.],&,O]O=H]\4#//BDCTLZLL^+"P?5ZT;G&'A6'&N(*GGYZ3+X^-2"L$>= M95VZF,MS,F.*BWR,V,F*6DB,#)%=M=&1PTSM%\<*EI$X\DQ8GD9#]BZW+<(' M9 :AI-ZG5'@ELD/YR-\5*$&@_]&1F*9/EOA5?$03;A1:'U?:CB.JVO=31J3R MUGP7EZF%=7;T@X>+&?OSM9=X!Q.L^!>HPB$8."A[UNKBM 8X1.J*GVB\4/VQ\QJJ$4XAR..PEX MV4X"5S"HI2@=W5MH]*0M60Z]0NB@8H6I(M0=0NLV\4=)-X07I33G/'ALI!8B MNX[UK8E$DS"S'H<=L?3G_80WC5**4@'R/\'_,95?39""SZ;N*7P?)R=^UWRG M1/V(4X4>FXH[*#D>/K5[R0(/JJ]F"(5%%,%SX/F\N@1.&FP1C_PK@$M 8(*4 MP:RM5NP3,/WM$[*Y"X!ZW5II/URVF($D?M_?#--EU!.!Q. 8%B&:\ M@'S+LJY@.(@+X(>6?K""F(4&<&J#YOTE]%W&\]DYAA30!^N'G>!YL:4LE;>! M"I@C@3XPIY%[!SHRTDD^W%=1E(%Q($S@JB/6;Q#U'"ON;& 2>?2!MOAE49E= M<6-&7DN9C.5-=O)B#(HJ'M-I%300'':U@&T:>ME99X7#:)[.6WL,9IPNV.'B MCC_K&LG=ZY6TO8A:T$0M5EGG!%ZJJ)5X_*(&9F$OMO!THQ&!IJR+8(0&)]$7 M-B,.[8T!AB/KG\1N:;)?+[07FK0(4$=R!:FI18=9JJ_1RE8*"BV MNBNBU;8*JJV*SSC+A]U_UTVZA69J;*/2PM/,.UQ2"I2'^!/;#/]1H XFG).% MPR4S*7O4LV]27,M:0-R""7OO9>"+-1%CTT)#8;_1-SGI%85^G^ASN385DO;H MX.\N1-XY@(OS*C<$<.>) .YLG<*JHGCNM9CG1_0VFJ03 *)3Q27I1?F]63H7 MY1@FFSL4SM&,>G#$[IDBV6CLT3.E[H6?GX@>%D^KW;0NE]&DHZ:U92KU[:=V M?[I-IXX58*;%WGZ":[@62R-A/R+V1,_(^+4!/,/V<;&"'>N_B1[F!0]@ V]? MZ.+BG:"GII)$LU]I1QYOA9XE=$R'=N3N/7JI1NW0\=#Q"K=HWADR[JQZTR87 M!QSY?I%BG0@"UDC! \A5F0CIEE>V=3O#4@D26C"QCL?" YF>%/LK>C3&[N/> M2EY.$^\3^EIV"QRHJQU3+3T95!TLV!$U=F5Y;U3"J-2[-L >9PN6;CC'S_1QMW4W>PIO_]^J[QE M7[SCHRQ3[II3^8C8A':>712ZB9[N?KM[BOQ$K80CR4@,(U;>(M&P=1Z(%#Y4 M 5?O*3>_]H:#=TE&9?$%OA"33506>T&6>T@AA+IRAP]>4+ M#UR% >&G BX46/4%15.M5*9!HG#>[N8\B)Z;T<#"?1L:K0&G\C-HHN6,NF@9_7HSY. M\WWGHN6W(O/]2T?Y3V<^A_>QV[]K\&8Z7(,=^-ZB\R&<9M**+WV7542_:AX- MYH7VWR;*4O4T9D!"0UT%KA=@CDLJO85F@&":@4:S:&AR/\M+9W=.=%!CK4M, M^\6Q7G 71T^)4A%Q:HUN49TCUCG!L/^W Y >T.$V=BJ=.[IR4V>V#C:@CEY[ MP]I:J96D"/?D8B'&8[!:63S:';4X8W,YN .&^&Z BJL=-B9/O35H\O#/\.1^ MO?_^\)^??SPJ*U!=Z-PF-!5?G=A1AK1"\6B8S)GAO8?OD+I\_::+S0=MFN"N MX0@04U>HN@<[ ?4U3/IQZ6]934GVMT Z')!#+Z._S?3;3FY"YLRB>0X>DH': MJZ:;&*-3TA8/:(7E(5%C]^2>"S=$Y#!C,WZT[ RFI+!D/7:9@.2I7SH=44(G M%'F$1J[]1?C Q"SDS7ZS_9UE$6ZA&1]UACTH2CI)1TF_D= MY=W/[\(W/;39 M:\C"0UI23S:',&LL?+_PP[L5/.FNS'NV(\Y'7%]M%R\'[HQZ1D MN@.2;^\E3W/-D"^TY&ZXY&YNR:.=,O" '/\F;CX'+SMM[%M28&0G0NE..Q44 MB(WS9(H S^3?YCVNL]?P$7[F:YM4E!J+GWM8QLHU+:7?;6U0_OC:[VW$\V=0 M?P %.LI;]G%.J[MUVMGAFJ6*';][NCE!OJ.;@ZX%N !0 501+=$V@LOLG3;MVHD%GJ=D9K4)M+WS1-FLZ ME,]HHUEU*WCET!.O*7ZP=-RV]FR#"@%*PUSS%GN#V9XMP(?;.X#C745WRL3. M6Z9I<;TINY?26O0FC2ZOS84*=;3[,CLNJ>S1["9XAT[X] T=G_:'VVDZA25Q MJI+.PR-:?[ 7#L_U'L,MV(6%G3@'9;T\U+(PY:9Z"JW8-T%CD:\$6$J#F!N< MP,G*EB-\O=-,(XEB'^^9V7)D*Y;=F99M@E78"#BE5S&Z&DXP"W.9$D4F\)L? MG<=.NOM$:AH1MXTBX=M.%)_')N=I+28:T]$**NP.4HVG@V+GWY'>_2TG]$2) M!L=LG>%.BGGIP<<-E+)AC[-?I_V]5/;/X4"!&_U?@0F/O[,?7 <+X+>,/[NT M9-V-TOT2$^BH23_3848$P@$&+8V^YOW\"!*?Z6R(<:HJET[6/M<5""T5D[>_&BU+6TK,>3#N$?OS*;6L48(C_12."R^:^(0 M2/JS&VPF\IOK>"*=!% )-NL&"?<#NAX,Q^<_ &6AI0['K=&P8!*2&RV;:>%4 MOK,9U3@G$C8B3F>D7*,#TTTZB88W7S&P,8J+[8&" UN'3'-C_#8PZ;_Q&77F M429IHTQ[:R6:,B3*!:GS'"SJ&>T(L;W2N;B4G,NBL/80N\Z@VQ],)0X,O,< M!B'"R9+9+9)X*9^6J23N;Z9G6,YYXX50)K!\M40/!KJ$N*4#?P(U"W'!?)8F MO805IZ#UD5BRZ=$I71[2A-\.>Z=CK 5C$?\*@.LTY8CU3ME4=9P4/MG.2P?( MGMP81"ID:"\/? K0F2F%\=[Z=1W_A"NH='^SRF#OOPE.M@4D1RXA+YX<_.@^ M\&DG"& 7Z\Y_GI- WP2/0T:+39[&8\_.:9HIV%%WE/RVI: <[3[X67BB@(#4 MT1 "O+SSQD'"A81-=(T)+P M6H:@@Q+=*1U)N\_.(&\=0NZLI_'JS.R=-_/^M.M?/>UVW[=Y ZS,9_%"#G-: MT% )FU^8T%>,(U-O( _Y6&!G7GZ<6C1I^E\R=@P?4A@XY[6V0C11QI3OKN[ MH[-%O26V!-(Q]&4%V/*6Y=:]_?9X^_OMNPX+[FZ(D"9J4%F?H'33+]XCR&2V M2EQYFLNO6SH6T0.+Y\KA'7BCAD3H#=,#G:6I8SO8!)?HH\*\3-:]T,1"#MJR M.O=./,$/W42)QU->A3F%M$L;O"3^U'$3]TP6^113@3XT[6((P\6!\AP+@*LG)M)BBHZ28(P5O1=-.<(]%H4LZ*8(F MN+*78!VM4^DJX1@)^!']>6J0=F*[L+=BF^;5"2R#MAQ$\Y5W,&6/N)Y]M+-9 MNL$:-9?8L9A2;:-A6@C L0\SW@-G4%FNNK*J7__*JIT+HW)\W-2Y1AWE';KH M0UN SDE<[S.8)V!E.#[Y9'JZY6!LY E6^ZL%ORDQ4PKL+@+FP@IWD1N0/8JW M>I.=E>/=1<*A>P@)H8PQ]RHF48C(+I7'=I^%%;#1PQQ$/^WR\!54D@(''0N#[AV &'8'>P4_@7KT MJS*;FM_H,9AYIF%J[AJ[,]W/620NM)%A&4^OSM/""3P0H4^OL/#U0P!ZEGX_ MG]-A$$FS>12:S:,]XYEJ:S3LMN#E"KJ9;HYB LUW\_ULI.JP,*SC,;(^8/]M MH"K][,*$3--/??-1'7>&!=3!*5@LVQ+M()XU^>KB< XP=NC]@73L 2P5.-R8 M"GNZ$C[^'8O,T0I[Q::Q)QI^Y!%"./4LYH=AJ\3 @GWV\'X!_)/M80S5L%N> M9*_V<)\6[]49;0C+*,9,MF0Y_0$4VS6:?F**_0AW$0CZ]#SM1- B?:VR/6D#C[(7<+ P_CGAK^HY^M1TMD^A;)SD2?@>0FG*U1DN(3 MD5'[8U O%^L]&H.$I/ VU!JVIJ-^JZM.RU14YF;**JE:0DW;VXE.X959IN\DK#QG%Z M(VWMK&%5)M(L'#.V"L\*R)VT<$(C)3FQ:O,$&1!K=#" $;8N+%=I.LHC(0KU M'(T8))D>\Y?TNNW_HG&8J",J*(\!U1ASH2,OY5 OT.[9-Y&G/J]BG$3#[^6\ M+\=H^#78=+WNN+28B-H"?./$PS#9GF.N]M!,,$QL3I+7_P]+/.OE'#:?>./! MT.XY)I/DTI"7H7FG0+78TGNCEM;2%S)S ZP#SX>,$A;3S9)%F' [8:8K%3U; MS*2DM&@5-"ZZA$'2V]7+50=5HM=5PVB&JDY*2@_5LAR^DYLDIW>+"4GC[2;) M#E[SPCX*%S!0BBLFZF.@Y+B!!LJT4T#L.(:<&"2Q.?*8.3NR7H7BD=.>#RRS0;J)@F7KQ-( ]C66H']8MYTQ>/M/3^* M[[J)L-6WZ:3S$CQ%P]J3L/D:QN! 7$UXW!>[U& 3@1>B/%B:'7DIJ0OQ#K// M&"[CEYV-D Y&CBC(K7-*OH*"V#":0!A/5W8(0^9SRZR/<FC;;C#X/$GCOWN=D5'GZ M1;RVTQP1*D/*-G/F_!CF"_Z'96?.,*_'_?N;[AN:E FG5P>8C_Y>89R-_YUZ MT?=:X#L?V-5MFC.V\LC[\!\?0&,T_,7[*;PH7:;OTO\UL ;6?+;__H:M,[KI M3-/_?'8!DHQVU&<;_\\'_@)MB\Q]2H;P ^JG?]_MC(>)#Y^05NPC]@*#26AIL$0[Z)A( MD2=%7FW/(/K"I,@34-N&E960_O;+E^Z7V_.8JZA]7T*.5>.]^;ZAZ.[00W V M3C!DNEY&'(?^YR/[#@AR"7DE#)_^0S@6J;W=@'XKFQ*X3AL=G +6A>';_KDA MIV\J=_)IV"6-@_IEV0AA-DC_S<=1JS?.A\F%V^074HN$V:ZBPH%$88G" O!) MHG ]^;8W"JNYBB;Q4+BD!=VN*-QKC?OYR@'A-KE$XQ2RI4*84J5XQ\ M086*"VZL TV)[?,X-H;3HI:_%0=W=D4'*84D>#>0%Q*\Z\\J"=YG ^]S<^VJF387-Q#)L%5MH)T5TH[/5?$4$)]ZP :G,J\7;ZO+'D^, MMO9"7!P>F1N;LDO_/8,V+ P[[](V^I],*\"G5?$Z\TMY1 ]PT /> M(? ]'WZ";YQ_\;"A5.'AG^8;R<=-OC)B@'(#4R09(9Y0XIVYX=THO3L+YO%5 MN#NQ+5L\D8%UQ/*(C^V^7#[8$3VQ@1_-:9C1_4PK\#9OIK>T_1CO#]92R$^= MK'S^'5X:_]+0?.W=^U"0-*DSUW#242<5!O'K:Z">AOYJIZ=62/X<] E2U"Q< M%Z[^I#.47;AVZ\*ER 9BAMP58TIHK)%HHLXC!"K\TQOW)D>VT6HO79HJ!+%GRD476_$O\;9&XW*S!"53Z/=+)IFIUZ(RKS&-ZT0@@T28B3$2#Z5 M0"=+>*^%,*Y!J4N4)7?O.%B2@PV,&NRV4A>XO/^.7,MDTFQ ME--[G'5ZAQ+PA@G ;[2YS_V<]LOQ[CPO( 9MFW-HD+E;Y@7_.)JT!N-1:SR= M"N/_EB=?[),O<4_N_@:S@9FX$O?VQ+W)>7!O^WQ#RK3-[@6S?Q(=2.(H+\3SCS#=3\,]F0EG0^%^KIG]A5#X4#]& MKS4:=UNC[NDFX$H4%C]]_9R5\ T@GD/C@Y9-!2 ;E'W;%$[EILP)ID MC#00Q[_E/"/O\_X3 2-3#625J.&.-$07PJ]4N4[52.F2W0?.Q\JKUK9VZ[2T M4?/J;YO5?B+GB!JW8?K8ZW3%3Q.1JI2H:2(2C(61XA*,KP2,LZX/"<95@/'@ MI&"\V=^1!.-N9W2ZHA<)QI?.%OG%UX R\*EAOGP,^4CGQ9EZ[N\-YS ](!() MTU-710M9N.&"5MHS:<]:]:JMX8#]LM^& M.'R1*9P&RN/A-.V YGO%QUP==_\P=-O_HV<8NMJ?SMK:2-7;@_EPUIY.U&%; MTR?#[G"HZR.UO^=F/LV['_U(=ELUY/N&-\B2*]ZH"6)-06*)/NJ*"O'A],+R'9+6WGD??B/#PK#H&F7%[57E8XWZFZMKCFK[5-?<^=$P97.L$KR)TDJ MTNS?Y CMD0@CM/M@O QVRW]OS(3LIX5+B/(5OEQXRF<;!?57S=472K_7JCQD M*2=G-Q931&6+1!=Q&!&ABRH"NF"<2MT_*ZC9\(.V4N4P(U*]D1AL$4_N'72< MI&"4@K&F?$5?O!2,PK%E=ST=5E9%@([K[=<;V;CE%998.JTX*_0B>HI)N[[1 MS, 3-'X^7_240MKU\D;YL'2[*\$*SC**N#'@O#EGK]&S]L['U-# 4DC>^:.OY33_H\0E^'IZPTUU><^=YY>#6B M!MN/[']IWM7,<5GFF/;L$K*$-Q:O/8!4).6P@^:R02J2!RF2N?%>5Z!(NGK@ MA7CV/8(SJE>R.2TWW@-@V/W\-BG:;T+)?A)'4$L=CENCH3BMM*0 $UR 2?B6 MN[^Y;)#P?1!\YZ:42?@^A:M(PK>PAT2FPE3-@YO+ALD.K_YV!:/+8T_'=5D"XC1W4X8MH2^ M+87J:85-WBOMON=,(P2U5V^6SO5AHLZ,5@U3+7A.HI= M5ZTL'&#*YX:27H\IGXI^G,* GXY:P^GI\CG/-4>DTF9GPIR%:F695 '$X854 M :Z 55(%.+._0*)1'9P(YVR1?XZ1D[U^9RPV9YX<7[-$ZA=]1F[4[I"(XO#< MMP.T' J*B^'!W7TEE- 3^%KR(WA/K>OX;AP_: U[HY:/?5TDT//U=Y<3@ZM M7N1(*!>'%Q+*F\!+">7507ENB/<%H/SP@H5)JS^1[;DBVZ<(]=Z&Y MO1N=):5SP N(@4L7?LHW3BG&LZ'9:P5VLQ//'<:1PV0^)SKVRE1^,RVB&7_[ MRT3MC3]X"A5#BN\HJS#S 7<9;FK-XOD/>)4?WSVZ--5D@0XW-GWX5+/TP.(M M*CV\$.Y)G^(I"\V %U9,VW=-VS-U/"@!/-&/1VXJJ&-W&-,R8\$W#[X>YS*) M<4B*Z6,3%N^3Z>F6XP7G&V*]Y_Y(SO#9=\,MV.DB#,AK:IQZZ& MO:+I@PS4]UG?'JMYQ/DVL[7R._%]XM(->NL2V+8E2QK5Z/S".50\OD8K7J-. MUZ@$*SRO&G: ?7;)LP:J#M 33+M3N/,_UO M-6_QS;'A[@BUHM+/M.&ZE>-166UIGF?.34;-9+]E6(H"/RX6^WA<6)<=FZK* M&EXRTRS-UH&\"T)\8,!-5JC3F\W9:D&G4UX),,-V?,5PM5=X*>?5CN5^.2#O MJ)UT^N._'G'"4QK$1NC)9;Y\)[@G#6P,MG["H\\X< $<.I8LU0%3KZ-PLM&> MWB:I,3C1A2##%^:*#F3S$YM >37]!=?!E$?=)'!DO)9R9^L=Y2W[^%UVZ19( MY?:"K:17N/0,MT^SY6N*HS=4WJ=%3RND^()8(.I6@"$_07+ZQ%HKVZQ6T(M) M"@&B/L78'? ]6)XX>5-[!N"\CR?OL2%]K&#^U2;&=C38)#9^72>_B=H2L@6% M.PCV3PDZ]"-P:*MO/O:FG7S-_5\W*?F):8(IA9\B+&CV"SA::($C>@06'F!J M"62L#'JH=7/%S *3 81G"?#FYE@]ZHAATK4T6!KFBHS+L"1O0R,6_7<_J=\+)QRO^LX-Q M^J+&)8&<2XN$N1ED.?U)?[&3EJ>]7RZ #-"4MF^_Z,A;T\+1"\-Z>G!H M_G%TDWMP'#X_.0KW#Y^O$A%5_"V.?,5N?)A'?@"'+4;LX>&SFQWYR?%FT0-Z MY+_J3"0\DN&5&I=U5"Y%Z<-G%BK&4'*V#%DP@><,MA]\$_$U<*6WE% K.>@U MU/LG!KAVF'CKLMYMZ79T>#IZ=G/Q9HPR#A-RD##$:"#ZIHS:&K9"DQ+Y".81 MF&_U')]Y8_/M6@8U].K;HO'3D<./_S" M:VX3Z#,:?72]'+.O9]C86J,/?I?ON9;?)1U!2]&';.A58-TC4>B_Q:7".S:! M&[>W5%$9+.@2R"?A1>@ XX/DO2D0*X7KZ'A(K4MM680"VBT^<88(ZNN,/*9HM^(F>LYB7$1E@@M. MTA*$25$"XP*[Z#KB%VQ<0>@^TGT7_%:VQ@M4Z 7^HLH$?@,TUPH$UB^C%Z,P M>#.#_Y!T^R4%'E59\(\ZG6;X ?H3W1"\,*L+#5*160.WY" MLG)2E[#,$AZG@?4TTD;(UE@?KCL[^K0Q7*.G?S&_*"7K=7?AFP$MZ\[]W6Z< MK3G-;#[7)5G6JOJ5U6=;QOS_(P"KZV2GHYZ M3#43 T7]0T8$RJ*2? C,".(_,8V:F-#G5J%.D43.8TCUH0.<*[R2+'; M "G26"3!!#Y:7.%:_H3+6:F2P]>M;![2\1947 GQ]U'QYS0:4PQZ0/0[.#W= MX#%Q%!NLB9(PTBY5WI=&#%%@7C2-1E*#7R7+'6U",LW3*$4\*YZN/ MJ%/XH-V(8PFB+/TWG=([55["U=>&G89X^YY? M<_=B67N0R>(QH<-& YX /-<> 9D= S C:AF.E YDG23_8)TG^:PJEM= MSY6A1!ME^%L6*V_M*X?CKS/J[L]P8T"VD52Y[;S ]D6_3LD:Z=]X6W)36PMH M')X>R>I0\%:&Z/.VP]Y_X&]5.A^#5T:+P#)!]W/ >A1%@U/3U19!&* +\,6[ M"AZ C_L9]1X>?;BK7H/1*RUMQ#A%^RHQ)-C?'V=#.^2M5>\!S]LQS%O: 5[QZKR#O MO0"LE+S6K23FR4'KVOVV '\TK[ ZZ4VTG&_V4'19G6/B3I7HL2Y_A<<,ZN*< MM'W$U9BFO3@U;QL\;]JSFY86"S97?* 4P[I>M:T&TU+D&BZ?N@65#MM4RM%D M!4Y)<]13*SE.#"P,GVZ;R=67RG%LC=H] K+@[1F(+VFO!7P:WG=(>7Y3K]R) M=E9]U^D69#KJ>'AYHDW6&>V*W@S*ER;4)V=S6G0ZW$2G+:Y1!TG/"89;CZY= M@G,+JCQM4R5*2\JT28V >?0;00U3SG-=@L2';?KI/A9;\"[?[WF@':;6,_W M1R?K:=6*GG7IL"A!Q)(LZR2P[TJ&K80R'VBV>EVI0:<\^G!_T[7:0L+9A/1X M:3ZY12IZM0CDY-07@7QJ$<@VS4D@^R*,6?-W^+YM+]764F\ENN06^[W!EYB^ MQ!TD6)M.6$#P?-1'AD4G%PX'0D$]-)"QHX"$WCJ3X',4_'\1W]-IY,52$%6Z MZQI\KR .W:+]S$JSH44T57OC4D4?]J()[.>[*+N*EL#OW]Z,'O?@YG_N#H_5 M6J]ZK-6?-0;\+K$*XK[[.9X.K9T#'+/FC (,(:_KS-NYF%+?*SMG]X7:F\%< M/ --EO78BB21R$VF3G^%YF[T&&\3_2173,EJ ]QEE7))7 M+]%DS6/H!/ISB4DFW"1N;]9U# MQW]&00Y\U:%,*_-.&=>+TO7A(G#VO#9WBO<5U4B<>%E1I+(BA: MQODY<-@OTZ+6S5W7U/(:8_H[R^SGJ-BC(Q387EMD4)Y+4Q3@HO,=P* 4.M B3R%2!-BY2#WT.-W!BFRSTJ_?P]D'1Q[WS>UK% MWR5U>564B5;YHQ](Z%/1B^[R;*"B>#9:^>U[QY(6L7L%_BDFS$TD1T=8>8ME MMU(7VW6!F$YPZE0=6J?4J(7RX,,H5V&W5B<'.D?@ZQ"+1)L$1SO^UG>7 M7GYDX6^45BCB!#Y N\\'J8(.;#K'/W*N M!^-U5R@U-7>,W"X!?GIR[34Y,R]Z593O:1T7S3(V!7KNA8#MGK8-/1\<*W/T M!UR-DO7&3#6G>SL0AM/3:X_5J(P+>>T.'_/!_H9RCIOGZC<[, _ +^H3S"4< M?(K1PJ@E6&[!>L^N9;US"THR3"'<9JYKH$(Z""MX>3?X@YR/C;%2DVZW!,Q3 M;0BPVA.34K#TT^FRXB&^*8M8J41C,1CBVN@M@&WNP02Y%6$8V,;!M4G=6, ] M!E7IQC_[?'+D@89C3WPX]LY?>0_13Y)'%^]?_O+'X1^_G/UZ]M/+7U[^^O[= M'R\NWIW_]N[=Q>M?_X#?_OP_[R[>_?'JT0\7(&B"PU'P2Y1'G*6QKMN+IN<. MC=8S$(I+G5) [54*U@M6TH,(S5EBTF?>$OX&?43T$5A>-S,/3M;=OQ70G%MK M]AO MK5;X?IU'-7R-ZY#Z&DJ:%VBC,32](2\J1?YXJOKNR_X;V9]/+0'8)RCP=6>VA[9"4O!]5W! N%K:'1L9<5Q0=D"><<*,*- M/7;9)?8+ZP_TS!ILDA*_BBL- UUC)9)VOR?%\AUKXY\^^N$5-]*&*PO$ZWZX__T5N$$J2]6EHE\ M(5?7"[+T.!1"IW\9P8NQCQ'8!V.)-L>>"-3@]?S+)W0U UX)FNWQB;OOPG_! M&_"":[#\\*6PJI0#A_3I9LWAZM?GT1+#5AD<%5X)S%SDIM^,EX!'Y6Q;Y FV MJ5$Y8<3%T2 A8FH11ZK >F?1)7>2U10\ -*JC[.HUL@+\&DT99>47 GQG1AT MQ6C\A-N6%@7Q!?QSZ9REI8FS?N";;Y%Q?GB-ESRN\,H9 1730I,4(1,"C".5 M_$1II<>DBMP8OK6,L]J]$LU-:@YA%+R*J#V)3F_/$\^I>&H(NFH="]RGA0%6(M0O)5&NZV9]_H2>][4U=WHY'OQK7]71/0HB#,0.>"LP)/ =@G& M:;&81?"A6-45_I[:/M&_FQ3 "-Q1C9$8\AO'2N-^]@A^DI,3I*3 W4H1NQ.O M@X&&H.\3],-8*6P>)6BP/5 PZ!7!K<"^(GA]5DSIO8NHFJ&ES!H*H172"?R! M4IPIEVO'*,@BX.T%M;G"@N#=:8GQ/_@95S,*?AQ!EYT+#A=%PDJ;(AT8"-'1(B@CF1 MA$;TP1_V$ J"3L?0-JA0YLB'A2S<,P)>>[.WT"ZLV^FY;MO.ZGNHO]O70]J1 MLR63<,(: ^%!I$D:>;0L4+-0Y,0>MM-]16$4-LRN5">9GP>O!1A'ZO+IU->U M+#S>W-+P9!LX2N1*6(!3ZCBNN$1?4+UA6?].T: $+3^/QFR/4V9JSV@&PB+7 M>!8<$B88'V[Q1<8U/=SX38GOPQE-RPB,@X3*(.DN@&5!9FP;6@%#^R,T/2B5 M9KZ(;VBU%JN/R)::36.X[19?".LY&7.44VQQL6<8>IH58];CQ-E[;>86U886 M<&A,+;H6;&3BIM7",1AE(?02>[\M_GK[V;0JV0D"\:2),E;8;WG*)75PEW3K MQ?9YUI"U11P&?\)='QP<&.U%2;>...[@= /'T1X,TSDL]CY*9\4*3_%OW[25 MPGD!)_5SE8SD6T]:U8-,+OXB"OP.#S6<8[D)*)/)@L@^O;;KO.%8XA5C[AM> M0ZOSOR(TY>GK$VG4;!8\;8QP,^GX%$>P*6=B$0!LT^#.%QTXZIJK*>X[Y&S+XKY)7K\)&X>X\?)$2D-/@2RK0[.?CPX?@KBRY[+^XN? M+M[W:,EEB IMK.A8L8&"M%1;S3)7M^0&VPY*>9DR+RA\MA#T;SHXZ8EV$J( !S,516A%0\:&@C\\T'+YW2( M<2B1M&?/]H^_%P?C>/\OB)6QQP8'UH($68V 7J1]^UH/K@PZ%QX%+O9@/Y3( M"JP(CGJ:8JN6R:#2>N7L*#SC4NC:DT3N77M8>)+Q3,W=TR,?@@H@M*KPA;O, MS2]=OMG S<\/GPDWM^W& /',@K._@B9898=GQW_Y/@"[E 2PA,AE+,T/AQ&P M1SW^X=O;?'?,W^WA0C=:^.@'X^-N%'"]%Q LCIIDK0:YCADHYZ+ MUMW!;1% M7!;@3S\-*3_G(3F)E*<%?[Y'#93)Q0@>NBM6K>C#^UJZ U]^$#=!B4CDJ4U UCPF.N"@7,P6;XF\\V6EC]^S'DV?[ M#C_N67X\?W%Z!"H,-<)U\@RV[3X7U=X;E*(AX>N0B1#89T^9!B=$JU& M@A4PMKHCR4D#J.F2_&4J-+3>CZ,+7,D>!BHEKZ]A8Q;BU^-(<+J.0 CON6 (&AX#G MYI[ +FNJLQ^/]I_Q.;V*]Q0%;)-;VE81V A8LXPI;\--* /<\\2@.R5O:HT4 MX7;[)<5C*=3"6$)72GV0))#\?H(KI%_3.U"LT-*OM42XK*]_8>2W&5!,LQ6I MQ)RH"C8J(3 ,O2J0-!R<-[],ECD0*2;7;,O%W"SP>;CU#(S/'^KL"SOL,-^_ MSGF2P&FX)BQS/7H$2)J >^_6-L.QC;#NKT]"P^,;T&8?8VBD@;QVEF4_I.%! MY/RZT*W$]MW6<([:$J+"P1'OW$G *EO?:P%D,)A?8ICT*DHYZD"%WZ/@MT73 M;6X!Z]'DQ>UT@3JP+_/@]+@9^-1I,+SVG)M0BWD%%A]5RP[J=Z=&]W!_OP5& MH=%^DT9?W(M%@'<:3T4?;M%H>G0T.GZZLI6U;9'=#3BU4:M[X=6N[@AG#ER# MP1UV-FG'/3B;?&"U-J-#[AN^,Q( MW-6A;"\8V'IN 'U^-;"E*\(C'-BB'%#XSLPD PP_L 7K@:TG'-H-813_@2UJ M:(?$,PX&MJC6R(6!K6WC!(B!K154P\!6!!I_8"L*?C3C.E[8N2)FB;OK*'>M M P<&X'K'S1D'1!5WIF3 IGB+#94FK?011E8D>0M']4%)9:PM7.B6(U 6-HJI M1>46[]Y=7&RB M-U$%M_W&_9CY>L(3%CJ+D%PV_)])J'.9-H;)PD"G'_$_^ ;B,<09SN%82QU1 M'GT%>39@E'",O]G3HBI%AR9, MOF\.CO?7OH'XG^NUMR6:>W87D]4:G>;LF)UE4I&IEN!HL[R-PG%4EHAPXR " MIJE4+PMFGE#RF^,V]]M"72YB+]6TSB(0Q,LF=F]!E?7*,MP,]TJD]LWMD^:=5JMZA9/^M1P)93A>, :>VJZ$-J8&K0@I"3945 MQSN<4BM@,OZ=^K.FDBOVWKD"J\4Z$KCJ*;AB&FGYAD!G:]O'Q[^/DG_5'';33LT9;UPES:[ME'I3R\F344PA M$+ZT=X7FXXT J I[5O#0.? L_VRJS]QJ,&;2CB5"K9NQ=R6A6OX<*<,:[6J#B2H-"U4*07GRV(9 M9=R7HCDJ)(/[G,DVFD0KOLN.J<.R57B38L. 1^-< 1B!:G]PARA(87D$DR!?'O1G,E9/Q&15&0#4\+V#)N@=)9P MZ;!T@BMXKPK^"T+;U8LV?(:]=J05FP2YN<>"/T5"M>J:9O) <_CP4*Q.CSIC MPN5)CC$O%K6TON'4<7,H5C3=:-XCLE*O'_9I%WLP2KNE"=;:))3?-(,AFRD\ M5\J5K]V:X#,'YO.M@?F\)L%I^AMZ(4*!O 0[1TA2V/# ( &;G[=:/KPR#5MD M2V"19*_/W[7% *7O$/NT22KP,.$IU:4L!&> 4PP(+6RQ.5A1GUGKN.4-@PH# M%J*BZ&LVV12Y]+LOGUNVMH4JPX-C+R7U>":WTH:#*E8X?_W/BQ=[!\^#-[!A M$.KQ#BMV*E]1R#O-E;#[2\$"Q[83ZA^ML193:Z<-.EP_#LA: _O( M2^J6+*?S0AJ7J06#&XNI MIF=1"JPW_G29EGB%1%-3%8.T=G)W%CD6DPE77O"Q\@(OHSC&!;$98HMMM3#C!*7UFU](9=FA$JGB=KA[;YEWF3>\<_'UJH6'(]"D,LZ'#ROS)U;_VX@%%8!U+*HRG MRPF^U>^F.9K\/8W-C>2*,=VDWU#E99%ES*MZ7(=*-;E+,R=.Y8:*-^ M+&DP_,4-S.8807#@G$:JHH0O5&E5LS7;0%FB$YW/(D$:I=$5,Y7!H6.+*.%1 M!G,5P:*4S.T\(T0;N GG7-_YKHA3M!@H<,P3Y[ *D_IMQ/95B*CQI>"4K1/6:1)OR8*/Q%,;.E:JL%NS*=; MW7[";!5<$D67''$7EP%WT_)KM-A'@C+0>E1!M;"9*6;@IXU @='?I2!15#7S M#)C6$<%1(?/#TUD.72DK-U@ FI"I:KI*K2MN,2F0 [H]C3JM6/2DV'Y/>S=4 MX^ED>8IU\]@G6]9-T-WNB"1HKBE@+BM*$$H*92FZ8(8.-.6G"S$E@LV(./* LRFD^43>DNM,%Y+]W MHIOPCGJ"D 2EV3?6-F--H0/G<+72[JKK=EC1#LX-8*F3G$ZO9"2B5]F'#3J:8US60 M,FF'9BF:%!2XP\I&V/[==0;39)4 M+4LE@K]R=2*=B@@3;II,F&P*SKA8*E,U;:6$@\=2D'$)*ZC8S7?1XUA2@-LR MJ<@<$?08E.LZ*ZYD%!)!9HL_T^P$+!W0"[I!!OG[Q:N]P__\C^=/C[^W"8T4 MIUA?M9!Q-^0Q&G@+5)^S*,,*RP:%;4<9 +7LI&Z4FIFQ8NZ),I&QZW M4G>YPNM&-H7F ZN_N9K]*YX-;$T='#J&?]'&[R(TG;K,",P%2.V:UT)+.'.-X\HR M/G0,AB_ +K>:NN$,JZI#!X\"ITI,(P:Y$L'?C0FL"P"1H2W6DG$]9Q:/RCR. M7C56%L_*V 1.5I58U$'FJ0OB):#3$';:.=N85#+NK)6\X8[[*C][KN%IM1PE\V*"EQ'KZKF;3F=R78 MN-.<>M]MHMST;I%C3-D\:LU>FJB2C*RDSS,@2I-2XB3*VI"S56OP7&IH-H M3BE>04!A:\"5FE$G-N]2K&[>ML6Q.4DK;8H8FA(7LZD;>OF#8NSFDK[D(I@; MWM)UG'P?>WGK\LT+AV_N=FOW=TG77@QE-BB75 PW_AT88759JK632]<^U4 A MI0M%@ E-5(M-/?<-6#R <;0]ZQ)33:SYP7PTQ$N#D5 C'L0V:?[>9(0HN2CF M*E:*P0 M)X@H\6XR>%P%=STOV&BMK9>>FD,F4 )J5 M43>A44:['>UM(IO"T*(:D7SCY3J=&G(5G0NJ*3D%,A.NXU$C.2Q3V4I.CONY MTD+*B7MDAHO,9CF25VZ3<+@S9K9F\/F:/7&PF!"PN/H(8T#A2K7ORIH%C<3$ M&!5^63"&!01DCL)GD6U@5"-C;22K2Q2NA+^.++O.BN(O%ELI/7>4$!;G5I'! M6G:Z*G)X?S"!-7.AOGB9^ (I#UJU@ DU"'.E'P2,D4"DF^17-W/'DRQ9D+4P M!*E BF:F"#9NYYM2M*1ZZ\V-MEMGU(;M][9K[BT2!;]Q%/R\?A4(H(,_4D*; MKV4$JRZG\,"\)G1X3,1R!!=?6W(,(J!L;MDJVK!/F!=8L;V2'!\%9ZS4G./J MX >WZDM(8G,0BNC1")PYSTC !H#U-Z/ MHJ[@]IO"N=ZLI;G(5S..UK5)B*\"[]%42BZ[**-<1M0H3NP#D(R);3=I;*,K M9;M8[():[VH*@S&DGU0S$RO\%]:Y]ND;MBZY",F!_T56=_IWU-+N@LECD DB9,N+!@Z19#MCP51Z#TG+BUVKN0LG0X4MNU24@3 M(Y<*SE/9UJ3^^@.N)0M$QDQ28V"T5%!__Q9\QY%NLJ)U67M'H/$5RA A'4^M MB&,4'*P@-CY<;<9%* /!.[P9Q3)\OE-C,#9!X STPY&P5W,!A@2)$8 MQ(4LA1O/$BR.X?IYN.4/(7[A;B]J;V\E>K$ 7L7:"C1%L,3)F/Q[QO]RF8@[ M@AHW86/8H/$>R%50<8TK""4<#_^8U7.NIX2[$[,Z:&:+(&IGCA)L&3;%LBRF MR@672#G"(72\ELZ.39A ?];8 H:,IEL#>UVU BWN@9EU-SE#NUP4%?2A M*PS"TL (CEE$^GIG8=4QVO%<_O.'E,L?CK@:2O[W=^56FI'.+;:\UER">E/' M6)Q>"5C0NTI&]]LBN-8.WT83BD)'5-,;ND8 FAB(UKLT(J&Y^"9>2!5?E1DK MUA02@#PN(]AL3?5_Y.;=KOMR4,K_->W]UR+?:Q(R%SBW2A%*WYJ-F6LS9 '% M.T,HWD:4I\W.FK0BEW*EK/(IMJ:PVCTJSQTZ3CDDQJ[ M:Y"?A4V7-HHK?KZ@)\[!<2N2#HCBF[/S]S*Q@D:@!(^=W[BC':9<\R9#PG!' MBCI%^/>P_"3-:M)@Y#ICC=5$*#<#YE&[ZH\%ICQUO,#6RRG>8,1L'/ M!=OYG4O5!#%,MXC)'5$#_$P"//UOK4Q'^ Z7*^#YH =UUI@Q;XH,BY5!)+US M0MK_52?3IM+T-X8W>*FY4GRGS7+._6\_SI(G8&%GBH3DDK[B>^J4$1V%HW)B M1/=7+7M1;'QPM8/'/YV=O7G"L1Y^JHLAJ]6-%FC'>G-9P#SZ@+C-AE(N^MPJL MMW-G&6-J#@N8:1G9^PO9XDUO?J093T>"G703;O N MEF*M2-MG'$)MPG4W&3*\Q=1BCI@C V.K @T.@#,8\_-_Q3: 0PMF%-;F>,W\,H\A]Z*;'#$=/W="E^X4OQLN=2$#L@7VS>X\G I8N#L"_^ M33U'5^G?2IL,><\ 4OOS; MH_U'-%1%8\5X/K4_+]#)EY];9_U=5%?%]_SM/S ;DVKVW7,X MZT?TLI+^-Z&$QC3_VR.9,64>.EX'7"(+V,O4I"+F-;\@V)OO]D>GQ\XOWV.H MBW_%"SC>'^T__GTD<7V,37ZTJVTS'O[B/GWW M)HKWUV^KY'XH;2==@T'TE9%NGLIB<()'O^;+]Y7OPN"JUAW(=]W=51HL.=1X, M+;QTVRW2>.DV=+*=DZM[[R)LV^OT-8NZ;\7"WD4[^P[(\DE4\!;VUR#,-NN@ MPR'HH(/]T8%#.CSA7@7DE91#5PQYW+N*^II5SWU+N%M=$R\"O0A\,'0U(7$O M K\R$?C5<+B77 ^3KM_YPR# M#%[G#(007N?L!)V\SME=VGF=,PPR>)TS$$)XG;,3=/(Z9W=IYW7.5].Q<' T M.ATV<=K3D 2&9$@%( .HX!T,L>ZW/&<;HV%39<=7+O0&0:JVW?!)U'K0IL/S M\.G)_;>6#*E 9S"D&5Z-HE=10Z&.5U&[3RJOHK:$"P]/C^^_]<>KJ,'=+*^B MADP=KZ)VGU1>16U'OM/P],![48,DC5=1.T>=>^GYZFWPNC6I'IZ(^[]>O V1 M++Z1:P!$>%]4-"6P.XS7S)7\Q&R3KT89B#7@JU&^(O,IYV#?(JYRA$,*KG)V@DU(TQ6-+X&S(,,GB-,1!"^/LP!#)XC3%8TO@;\A"[?H8/*O=6:165 M\8RZ?1)UJ;)B,8=E#B_OZG7Y0 CQU4NJ09#!Z_)'/YR!0>/#T<'&G\#1D&&;S&& @A_'T8 AF\QGCTP].C M\/#I\>!(XV_(,,C@-<9 ".'OPQ#(X#7&HQ\.?$CJWFGPET$T+/D91EVZ_*1R M548999NB9)[FJ:ZPL^G2#S(:*,6&FR_W$-R[02H/P;VEW7 =!*Z&#PQ-_D89(F+M)#'YJGO9+)P8'3A2>/E6L M@!S>5QK=6PH[67RR#3J[]W9W@Y9;(KA[=_A:=_@P/+Q]R/:.)*DW1@9X][R6 M&S)UO);["FCIM=P=T?=H/SRXO_E97LL-]^YY+3=DZG@M]Q70TFNY.Z+O\6&X M?^Q]N4'2QFLY3QU_8/AJ=/;XVTX*NL/B=QGG@- M-TS"#%0J>@WW<&CI-=Q=:;C#9^'3_5LG-;V&\QK.:[BA2$6OX1X.+;V&NRL- M]_1I>.1]N&$2QVNX@1)F"+V _M(,ES8^EWD3S#7?ISE(PFR5RX1]/: FS>&C MM_Y:Y'M-EV::Q\5WC_5Z%?=P+YY7<4.FCE=Q7P$MO8J[LY3F<]\= M,TC*W#J?Z=7;0Q:)_M(,G38^G[D]O?9.;YW/]!?IWO.9]]J;F13U.%/!X>CK MZQ&+6^+G%^EX_O-X,AX.Y_W=I1\T$8'MF(>W][M M_5R%5&M%Z%=U[X98QNN5FU=N#^J2>>7V<)7;X6EX>NR5VR")XY7;0 GCE=O# MH:57;@]7N3U]&CY[.CB( :_1ZT!CHX.?07 M:8B$&4;"=U MSC#(X'7.0 CA=7 "),Z^^NW^/$?\"RVWN_!X;H-NUFTOIOT61)GYT6616"7TJ3% M(,J3X.<4E*M6P5MUJ?):W6AS)YN(>9N=?!(U5_>6R=Y*WAMBLI8JTBH)OCD= MG0:PJ@P^&O( RF\.1L_,KP)X65#-%/S_4JE@#B^ROW(JVSV_R^!KK4Q[>U>O0!_/WX^./-R7_(1L'),5W>_NC+VUXM':>.#M79N=6G#.[ M??/T:'34"/6BY%\?/#O]"XMX^=CAT>C ?(Q_M5YF\]_;@H=_5Q7RN).3T=-M M'[>B M[/&JV$,K;<9M-9G9"\.Q[MNVK _3C\6ND*3K?UQ;HL51*"OLAUJ@FE MO)@$$3QIWWE2\]5%M*2'): Z04?\7O^_-/@Q!;MTFL8Z0+T0I6@:X1__G<[' M"C1..H_&M'AX[/$V3ST;S^N\Z#PM*>:741[1TT+6-O 9G<)3HM)L"?>,QZRC MN0K^K*,2&-;\;E&F0(0EG"6=<0DJ"U10E&E0=7ESXK!]W/RQ>XQJOLB*)1 N M+N;X'M9I<:$K#?IL 1KQ(RP+=.0R^.9I0WI\%O@%0#HY7HV_ 0;?BR,]@UM9 MQ!_VQF1\N _&Y:7:X0$=)&4*&CP8+TD=@U=SA:C5S#:Z\1O[ W\,!3LMHWEE1!=<_ MTW0T46 HV" MOI20!?XF+T2BN!;$\1IN+/V??[+T;]F9_4;7 MHQ\^@XH0J_$L25)<2-1(/WQ3,$ESD@+D1:LI_+DY1M2FH(:G> ;-0EAV&6F" M1ZOKQ:(H*[O$BH6IT39X#EG:R)I%/8;+SQH@7X+0^K-.2Y(QL-S?%2MO^_RH M67B/X!?BXIOA5_#6SO'@,EAS4!!OG1"[H0NX*L1N[13>!*8)F.RU'3MS(6-G M?N6Q,SLJN=:.T@'-:&V3?=?X*H-3(ZCP+R>WC.3LCPYO$\E!<616UB]GLN)* M<6P%+(M*MB36$NZ1%FX^= D?(\OCE( U[4*#BCW_=$;&?P ME&^>/>M8"6@/A/2_=%R7\%;:!VZSN?FDA)TKWMSJL'57OSD].G:H$-%:7JA8 MD;=E1!OX2;AL?&?W-? @4(P9'4P4(/\HHJ 557MCQ3Y%FH-)5:^<.IR$6LI2 M@TF=)_#7WT;O1L$4W:J#6JVI_=EJ6N@$O@ M,6"8H>V3$F4*HAFK%WA3KM#> ^>3>+V1#O!*N!6@N(QP +8ZNID>&-:I@T$Y MCZR5Z9J3L2@%.!HR456E2#ZX00!R,_(E20)5QBE8?/]F:24B@H]=>)WS*$D= MHR6+-W%25S6\U+S)-7692(D".Y:88HZOP5A.4;K7[CO#\4EZ:4Z?DQB8ON1L M-$L.+D+[VZ/]1T$,+H&H(ONSI+GI9Y-+Y[(UDL(+K;XS__@^D 3X_KZ4ZFP< M./*]D]]8 M0X"=824R,V(0JV% &LQ$0U'.4S34Q/^Z85$3J5TG5ER'/RGK:9"D\![0K,L0 M/J/LXUHR# .WCIX5DZL -5TI4BS_^1_'SQO&I[J/E:H/+W^\_/'R9T=8">6/ M)&+(JT)1U!(W-C=S1?&,-"&/"/PN72N2!H$7!UX<>''P<,0!RX"6\3%O98^[ M;D_C\G0^V-@37E(,@KQ>4GA)<8>2HDKG=,TQ]#&G-!K("I-PV95X>34()O/RRLNKSRVO5LH0M521*RP565LU M3D^YMM8=([8+^NU$P?J:IVW^IA<_@^ 9+WZ\^+E#\0,/E@0;UX6!F(EB3C85 M&,C=,\U)!7QZ4V07C1X5SW*JN_;.U4!([*6%EQ9W*"W0I0E=DZ6H*RKG INE M5-,ZX\1,J2Y3>- U268O(@9!5R\BO(BX8Q'!U@!+"8R^:+RJJ9Y1]TX$K@U] M@(NQN#)H$8VE.#H,T@D5K5PC/:PWU#R&RO;@X+82+ ^EL_9@^)VU7H9[&>YE M^(ZPTE!.UASI0);3!/2I&DHMJ-HX#":@ML06!N6#M;Z2#2"W6IHFI9)X'J6Y MZ1[&+Z@<7AN3DEP+:"'9!F[OG"AN$>K]Z)Y);L19E#;9@C9C>B/;"V@OH'=: M0*.L8&MYB6$[:UR+31G@9 ML2.L1)4)$W@BPV:I?$8-S+93!LP&O=25$GB+CDB)*EA07(7!C'I.X .E(J'R M)]@;Z20%&P,>I(L\5YG;8V5_Z;95=WM2?%!P%QC(RR(OB^XX*+A:"C56Y EU M(!58 J#4\5+ 2P$O!1Z6%%@1 FYO:A,*Z3<.R&>!)RTW!/]'6P?^=Z@-^&)" M]5^(#=""E,$^=D2U2;6N\1 $V<#M3:=Z4X0 F!49R#9-_<18#UNF"FW"),UJ MQO@YPQ9>KH)-U+@2" :)-SGU(90DH<>D\T4!*ZH7"&6J6]W)Q:6";Z/YB7W@ MV*%?IG'507-PC<K2O 8D(K8 M60"?X8/LG&![S4(F.AI+5SQ01'[#=Y*'SG_'2N&\J%SWO<##EE9+E[2C@/D$ MOU+GYK-KN.9JIO(@5RI!3+4K?OU8F29O*I%.5!8M\3#A\BF"V<)UP9X0U8"R M_B6&#XQ)WZI@WH">1S!)^#J"2NJ\4V-[:%%:3&2LU,;*(^V@ &],"SJ4@]7" M+2A*!)FA8J;$Q&+MT5\5=8:16S7!&LC"[*'30@)W'E\*:[O<<12'=TH%I%SV MOW^;Z@_!*V[9IU\=?$\UYPZGE/"1-17L]5A7\.C402)H06%]+NP=VO?- ?AN M!H9L0_D9I M5"L)PH<45\%C G,J:@T/T4^^N]GAKL4]H\,]O.9P5W/7G^)0\+*^B^JJ^/XZ MY^+Y6M_B"TU1/WXV.CA)QAT&+M<)RO5=,,@RR_@OM(9M'CFC'_GJ ;@TXL MV$'+[[PR&A[)-BNCPR$HHX-GHZ>'[;&>O9K(:ZO6@!HNI/4*Z?ZNT7T*N%O= M$B\!O01\,'1% %XO 7?1)#]_]6K_U?EGN$=BI7\"!0Z.1J>]1!C,]-9F)$$# M#'7;:_#9"$&JR@\W_M*GOH4*^:J&4'\S/!*=;J?IO^X)U8]/3L*C@Y/A4>\K M&^+^9'@4\(K%*Y;[IY-7++M)M\='!^'AZ>GPJ/CW8D? M^?D"8U[=W\>I?V72:*AD8)7^=6OLD\/PV>&M/4%_11[X%?'ZP3/_5TL&KQ\> M_?!T/]P_]OKAOLDPH.S@ER[8&[ZK]\IV==U_RO"3:_4>]JT92C1JFTJ3KUS M#8-4[;#O)Y'K0=L)AX>'X<'M"X;N2.QM+_3\Y?(JZ>LCA5=)#X!47B5M&=H\ M\.IHD(39D>ZSI*BQQ_MP]/5H)VQ 2_.X5 B4@L 96W?R#ZAUX^LEWU #J3=O MO6@1[ZNT/FY= O6YX^%?AI0/VC(Y/'@6GAS=?W?-MA+SJ[IX@VM%]/IL:(+0 MZS.OS[P^:VC[/#QZ]MQKL\VDX>,WI__%<&/7N-JW T$EL+1>*#5:W\UA^'KV M>X/=$=K>;PR5$C2-FVC$_/)[A):'VZ]*\*@19W9D0/JXR*B<[%XI"YB MJ;-BC'=,50Y[R7@N>S*'+^@*]W9IP,P)D=: ELJL@S:Z+:^TN,3G9"MQ%J$S M+#@J$48SPXF'$T24'2_IK/?PFWOX+]DM89L""^W1UU.F/Z W !_H>7R8'CG383 2Q"W^(+"( M7\\3BB8ML/;6>@4U/;J*RB18@!+Z?"C3V[/FK?D0?HU#EG""X^MQ)D#FK!_/ MX012$3D[?-6 D4L5S"(PF<8*P>8+%*^J),QPL3,$S3UV3J-P3J.H*PUL3YP$ MWAY &\/Q^KTKQF?X4WUV)'636P2ML^8MY7P=?PYTSO MH!A8'3AS'ZMX/9GL_?9\Y,]\7,"30<2.0="$B118#DHJ\'+VHRU+]6TSHS\8L7Z M[N7Y#:=&#(E)@S3YVZ.+]R]_^>/HCW_\=O;K^XOW9^\O_OD2?_C9_/O%Q;OS MGU^_^^W1#Q?@F 9'H^ ?J+=II,LE#Q'\!TX/E)]?L+2MP4,/SL8@YE%(@RT= MX%2*FZGU87$:6F_L%M#T#& /U()Y9;2*F)L1!@1T5=;-Y)F5#RP*38,X<)H- MST?0;"P6.%L:/T$Q#UB"1N5'=E^47"I4CHX?C\.BL7HC '\;!P*IC^(KR<^@ MRTRP0Q9.UZ6[.=W<'WYD8A4\&*>TGD:WUGI+W0J6 MJPP:D:M#?[=6[#%K<1HBDQ3T\K'*4G6I>*A+FD\R"6BT=FZ.I', X"G6:'?( M/**M#P.V#H9RH$&=IY,T1A,U!9,BKLSP(HX]L1MI0T(\8 4$S.K@"V23-%\K M)JQ0V,Y(6!$3-[ :/EE,//WC_/6O[]^^_OG='V_>OCY_^>*WMR_?B6!X.@K( M]"TRYGKP-6.5H!Q8=^O-'1_LQG]HA-FZO7VJ0%N;7_C2XHTF-\F(Z:39=NQN M>V&WW4RP2A3>%+:W54[?,;<5'RUBKAD#->XQR-_9$$OPTESALYC"NP?/CYX& MC]W?/D&I2?-O4W),,5>4A+PVE$1AH&G.#YQB$HK>QL^+[!&M7J7S9DB-7JB8 MI]^NZ'S<1*/MFW7BW^RJR*W3VL9:Z0!T#:Z)>PJPW"B.ZSG:$.*+HT=<8\2Z MXL,!PD93<<*;^"\>T?DL51-X(ZR U"P8=FFL2O8JZ6^OK'J1OY$Q0\/S%B4. M>0II C . Z+=8Y0!MJU)>H%I$Y7T,DNKA@D^66L/ALG/##_+D.107%<<>S># M+[*[1?20&;93,D<^7H;DW$0['FT9Y^F]^11, 2%2EL()T!!-H?,S2'(<; M0OT3/"W4=139Y A;.X3*OR/6).GN>'T1L1\J0O1T2H?]EJ">/J ]416K7PAO MMMJ'%EP]&GQP]1.G( S$52,?]S]Q>M?'_V MOPXN+G 4ZL'A]Z_?__WEV\#YP"99N3U_W:M??O#'SR]_.ON9G?*7+RY^_CX&>P[3-V614JXT_TQWD6_&"$Y._*#E*FLIV\H@(AM$U((&%,QB:G,CJ* MA7,4P2L*9J$WB DC^*\S,YE* =+\LL@NV3=<^;Z-T8GCV)/*0O%GTEDCT%+H M:&76BJGP'2$(4#/QF(QUDKWP7Q/T:P)0M:W.2=2$:G_05-"JJC*>74LU3"&. MS(9OBEW6V&08O.)!KV!2JRF';!?U. ,[KEKR>.W*3%Z>1>6*+P M9[ MOOQ].?OC[<6[__[CU=GY^]=O[5TY&P7N[.0[BE:[Y1YWZ3#D83L7'8>8JF/=C^:E*CHJY:4X(IN"VTQI#!5!'UR>I')Y'8G'[5"F[D;>>B M;?K'=N)R[$Y<;O2_-K.7V?2%VTPQ)C!]JB)T@^C\9N98C"C3)71CRMU7WT% M6K2EF]#[<5WU,^<)BIAE$=<]<-ZIYY@Q6XTTH8OFRHG0.1H;F0[71)[A=+[% MZ'997%543X+AK(H&HTL@ >O]. 5OGH#R(YW@:/3^N+Z,JV>I!U3&RHR]K"@^ MX-(=8IE,VSQ*5(<')!*&3Q.!.H\^2*FB*V]'01]WRO1Y>'3$4R-CR9FRUV0T;:EB\+M.E;SG*^KKQU0?[:^=7 MPTG:Q_"'V3Q8+N2EW:R'UM2F3,RMZV?#UR MSK/#PY/O'6&UAH,>[-VY1JDVB^FR0O_QM\TKUL7&=F9E!]0Q M@)E?SA!Q3J:ME-$&;WR'55M:C+M6IH6>E MG>#/X8N[.<5U6)T]\&#@P8W4NJ0B(58-O!(O8D34L:;%:O%A]R_BB7 MO)CD)\'_N4HEOYKF'+ZAQ[:JC.2AI@09_@NZ19&0G]05YN'MFG*%X7.N9^): M LQ&7RI\-CE8H'V2&K24CDPA SI@_+4Q=B44DY3TAU=#NWF9O!KR:LBKH6&J M(1:U7,M2C*FB#L6?1-6QHXKRL86X!:K376PJPQ:P4VZ0:74SYRSNL71,E>A3 MF'*<5ENC9!,X6X&J0(^"BPEJ(BFME9:N0-=CT)1<=5PL,/@58EL;/ +VC#'$ MLEA&6;5L^G]MYZ_ZF'+_9=/V2QK0-))IFRJNN4H!MEQ&*>8LFN.(HP7&QCF< MAZ>&&6:;@4$M&/-)&IRZ[FG!*Q)PWRAY 1NE-2O4ZSG5;L"'C3+L<\^\_MO- M6^SUG]=_7O\-4_^AQ"5];2E,[!S)LA4/JUFRU! CTSO:0T2O21E(1U MC+/AE$HLP-4QC]95G9CV'591]D\52G=MB\FX*A._G*1<=0V/XCB<>?@H.,N7 MZ[2.C?Q%R24Y>6F.@!Z=MY&KB&^+9]3H.(DNX>10+9@-8-49JI[N5YON#/31 MQ)GCSD:"/!%UZ;74;MXUKZ6\EO)::H!:ZF5>@B"SH;A242Z*F(ZZLG*DHJV:!6J14)(&]]:"B\$$@8^ ? M7"(A*(RPVQZ7BO$5FSB?8"NNC<@U(%VDTJ2@>A*E&:I<.ETLL["?\IIM-^^G MUVQ>LWG--D#-]@[;A6MM"]VPG@#5 G8"ZY2]$L)LXT94RKQP.7Z=HVJC$4*( M-@#^V K,YJJ^,1F>%(NM&7U!.A5=K8#!/NR2LPY-V-) A(4HB(?81\L%%JU\ M6"\FL$G_8-)H4FOXZWC9BC;6U:P0J =L(J*7;XXRXE+=-OV"%5C== %M^"9Y M<[0![M5N^@1673I<\V41VTTZG^!5_[O)C&%V3_U9=R$$ME^;U[*[*2N\EO5: MUFO9 6K9L^"#6@9*NC5%^A("O9HNT4OL%GP0# S\?0^;JD OI 4ZN=MSH&")^O@PER1R3#F$G[$./+*;3>OJ%=N7KEYY39 MY78NJ;AM7#\!FI.*?!3M21I-\P*^$',$51Z6YDD:&V7W2N*!-)O%:#J"LI/* M$:0BH381<,%*&4D,'B,#)15ENZ:$PHN5PBAEIRN[+UII-7:!?R=7&;$9J#:R M5$:E4@2SILI_HVL=D%?O>CW(.^:UD]=.7CL-4#N9[BGLP:T9RHS]H*8K2_X4 M!@1')D#OK2BB2:DY\RM^RU.>I\*PVXQ[H8)7+\Z<^@[L#T,XP4@0,/@Q=BF" MLP%4R8.L,.K.:X"=Y&.O ;P&\!I@F!J ,U5<;+X@L-Q<(*K<'B9J#Y916Z8A MUT ]A*XC$"*X6HWH1'6I5L)JVS=F$7!2>PWPBW9 KU.9'IMPEB3L'(S.+17' M0P'9?#IXD$VOHX/&&<^:T1%Q<"@B^B\)SQ^^D[;G+R8UK[:DJDK: M+0Y L[4["5@[&=H6X4K7GD6SDJ(=JO%$W)32%+T*IHD,IA84VG;1*'ZWBVS+ MM43&"+.VC>#?,Y*E=X-W4U!X%>M5K%>Q W2#7UZJ' L.-^;H"$R+ZQYE=@R% M-$/\Q[(-)V4_5I3MMNQD4YR4E0(795!Q8K>@@_-H2C09Y=%D=)_-H7G5L)L, M[E6#5PU>-0Q0-0A\1S-*PP[2T"CM:;KM7I;&/'K"(CW)N# 1Z?"76*8(EGB$ MY'G56H5-F4;'S_JVJSEL]<>6J%88ZT-? [&AG#'S=HI9:[4NP)0[FW(!OTJB M>43#9'%")7MH=@O\G$T- ,!1L[9FZP9GO9_SX*ZD5V9>F7EE-D!E]KI!"L2: M=]LZW,A^AA1D!\=H'"R8SZ.\Z5:VZLZ.0FK*RUM*Q6U,LPY-%[S1*04L%EAF M4N>^GWF'>=A+?R_]O?0?H/3O Q@T<+P$B"[3[IV<#HXIS3+%Z1)I95[B/W"\ M-=9D3*B)Z1JHP91'C>@8OF_FCES[9%OM818#'L.X+*(DE/(4PN^@&5BL842O M]& A6H=$@Q+*HI+61%W6E.PJ\(&2E.I$W%HE]:L B]W6[5L7GG@E-K"KZ)68 M5V)>B0U0B5T+)R_.B4RL3\MD3R)V*I[E//.$^G=-)3J*[=ID3:$R=KM4.]J%*V=L*ZP/R):VP_>* M0>&Y) "..:>@'>(G1JP6FXDJ7L7LZ$7Q*L:K&*]BAJMB^L:=1U>Z3K$6 %R7 M*3>T,JBM3,::(+"$2C9X.)(\,+WF]Y/72,/72)(K; M$ZI,& P>%3J>1P-$2_I"K\4]ZDAT_%43U$+'Y,\ZC3^P9]+@ZL$SY_SG5H , ME&$.[HZIT$ZO*:;3L^**8)% /^EHHB@N1T_E(FB"0\)'>2=I1Z^45T9>&7EE-$!E]+YG#&-OI^^_T_E8E2B)HS'I)M9A M55G0H$2KOF2,(KDWJ-SVWKS8.Z!_C0L:44*N%K?+9*6*DJ69\I'T8,)B_4(& MI&*P/,134K9CJ=&>H"9!H<1F(C"IGF8L5J,FW?*\=6B!XQ2#BVE,[\.3]@[0 MCMX(2MC(3VD:.F7Z1AAH%8,JJ)929RWUT8QYKJ(/!A$V MJJ+0*9,#+ZRL%U2)':X9'!+9P8K.IZ\K^D;&.SC]?@VB.RHDT*V84M(8!"3' MRCT^ I^5?)J;GNJ!\HO(W4-]%R,:?-PF1-@T(H$["*JTH(]R!BPO*IJ(PAMJ M:M+AY%(3:Z3!+HNZ,AODXO/F!-V\F(U6DA_KK-OKW=V4'E[O>KWK]>X ]:Z# M,8NZ)%NR)R4SL5 X$XZ?4[R'B3(9!T9(L]1[U)Y0,L5P9,XCD#G59:=>X8.L3E00IY=I1CJZI, >:$ %_XL)M">@>\KT$DLLFOQ7:%JI3"D%3_-" M3<,N'#X\5U."7F]GOYHR>3-X$K_A5<?DJ#E8O M]!3^80)64!YS)CCG&MC1)Y^J7,[#@\/CP^01.&R>;U PU@+N=(D%Q9!]'.,3R))0 "FTP MFQ1U13"<(=>(61:*X0MG<1CAYN[Y*'5>)]!19):CO-"H'K9]FUP1"]2S)!<96>3\5$*-R+!,/FFV:V[YJ"L.=QS<]WCX MX+Z?IL_OYUQ7G8/[60VB__\C^=/C[\WXI6;S:\:Y%\D*%H&_<.R@2L'MAVR M\='@1N\RFR!1#O#5U)UIX&L8M=JF M\#E,) 8S/ITO;.BF,S"DM#=6E%AF]C;76]OW8+X#C%0+?'5?-T-<$*!\ 9@O1%*=/.6)G=2.E8V)O]A35J5ERDZ MB>8A5CXN5QZ$$K0DS+="M"+/[DCU!]P;Y>@EMV/?$\T+2:G;YY"#AKEW\3RE MW\G 6['CG/%'/0YI$<,P.JQV4Z1KL.!/#5)DK=P'<;1% 4F?%GQ,6" M'U_;V_-W,!" I\/@E>73-^:P\5#/HP6&-N%!CO6PLX%4P=>$RTIAD#T.@Z3S M>9T7>R!8N:J+:W@E[QPQF)ARHTHS/K11\+OMQ:00?@)/SK%),E<556@I1(') M8].ZB%/HS,$V/?4V&T#2Q)V'1X]MQ?[EH68H$H8ZM%(4U>"X8;,FQH>>JIR@ M !*)^5TJ?#955YG!JCK*3$VR"RL-?YZDE!OX]!CO/0JLNR5Y@^8PQXGL(*AP M#GL:8ST=FG&7458; 2/=2D:IVZ@Q1@[-B%P*%BA47_YD/[ M#-GDK.-*P0E]_H@C^@J/0&9X\$:[]^I";KQ/2 M]G%$:)5B"2N]ERI'QRD&5>D26N](GFT^18?"-$A6 M)>;F 2=PA>,/,U X\#=3Q8IZ#3SHQT+#)_Q' MPA'NC,9[C_A9'-ZU,!^"H M'(C!OGXMRQV\K)=492J?MC%#73.2JL(XF=$SL8=KK;KS8J\;$<3(/OC(GNX>X?@-X-.= MEIW0?0HZA.#A<>X.2\2MX,;G6LQNU"F"+]2S!'H*S1I:\D.7<,ZZVFL^ZH9W MZ/8WRIS.FC$E*NM7"18K/#@D:J, NE+N9[L]1ZA.3,_LM0=ZY2[ J!.C29P$ MC\M * LP3P6"G1PU5([Q+(7O6'X5M=CR0B)TCY=%C6U1HF/M^T'7P!\PME+G M(K!R@:>@K)%1WJD(H$5FAMV'/&5).Z[%AQQ;B/'G.N=_&V95%@D]6;/FYD0$ M!4H241IN'@&M6_'<^2+*K@C'796P"VZ-%B,3G&_),6ZP'=O]9_T9ZF:'=#)P MKL8W=D6"7&\'_&JS<)\T=9R;Y(\ M2=*-D\I8["B+':C,U(L"?JQ!S(9#DSV5^3X;1K-GB1N&9>+TB@ M0N"YNEH(%TY0]YADQ0X((+-LW#:TXT(W:J!/\42_C-.U&41M4N=\LWDII\&S=F6*!1QBB/0>/$ E8%LLH0_S0:"GA M-6HFQ0C6QU1+4,J=)>O"5 O<6Y.*9KYUCD-8F"L>\-1P5'HS,H&JEQ..7#& M=O>TBI)E5VAB6RXX@0LEVENGLMO&3H)(DQ)#_N[C:+'/F7%8);ES_-S' M@N!/N!O86N83.%.QRO5F!Y&3"P*]1-<+'"W2L-O:3Z)D'"%I/A&:"DD*(H&: MLC4][29FC)F2K.:ABJ[^9L-CO>TS(96WW,KFZ+H\KGFQ*A_LJ3L]:78!(;NX M?=W8F%4KTW%]-P5P]WA=R,GEY,0:3_>;9\^>-DZRX>J0>1M-3J"0S2@V^@I- M4%,>- ;9HRXES$6\@]^U(5WK#S= T.Z=<; GV6MM%[4&\,P,;DME>1J6?Q2Z MX11SI5L)T$[1W9PR!*9RL&V%MAL??!,B!S M<\*6I6E-X.PJZI&.C7$=N+_;?9&4];0I @E;=DS+-7 "2/AR)XDKZ>W__(_C MYRO,X/OK=H*3O0[P.L#K@('J@+RFI!P%KLTHEI5J>8J^J)A&%!?!HBYUK4@B M!UXD[R1C>9'L1;(7R0,5R2R'6T9X.[:U85AB)PAF[>J;2.N'TA-ULGL]45_@ ME5X7#TRB>%WL=;'7Q0/5Q=P*SW6:["F90!FZ13^E!%RE/J+VQ005CH$IN'C8 MG:,)GXBS&M.4=DRR5'H+I A7[$D>I.M]A6ZG"M? FW$QK60V%B7DR@RMY)H, M30$YZC*K3,D>%3?,HM*6;DRS8MR)R&'C-(7ZJ,"?MP3?-TORX;C=O35>WWA] MX_7-\/4-5ZB0]V>KFFPITY6R=5!4U?0^2F=%\*950*.#\V(4!C]7R2AX3!]X M$L!RE?08-CTN1B?9^J?@,:Z%GWEF?OG$JA51>^>MXBG[.>GQY<=/L-V07WK] M-WU(<8XGM)?9 )3:&;D+7'2CJBKISP!]H2KFQ4RN%=5X["L2+Z9UE M-B^FO9CV8GK 8IJM8I;4B)ZD44ZF>D:H3 YHA^F8<7MLJ*UFBZX9&^U9;;SQ MPGV'6=0+=R_SD]4#DM(%&,TSYC?"(#0(' *3P$W"+0.V(]JFC6=QC,TM+@7Y%@)Z"4 M28J5CP9WVH6X:\"H"2)L@=.(5G"/?&S^X7*UUP=>'WA],$!]L+[ZG22>"?YR4MB+XF])!ZP)%X1Q"NXQ1M! U-J55INR(..;MK>O$, M@+_;&=33.H)O5$IP^J1G3*;7P&D8F#Z9W9H1\*V#V6=Q+W%0)@>G$"-?+2H# M=%J[T:I1<(:8OFT06(1"Q7<9APL13^%P5$4\TXMX$!LE-HB4<]1[\ MIP7WQ/6H^(1F=&HD:/!M)\T%.6Z#G6\#'ML'YMJ#X"KG(@XA,IK$[ZX, G(+ MVO4:_-;KAPT7#?SA*NPE'V\O#"?-RK@&F38,#*%Z4&OQQ!GK.$FSVG8L=G"/ MPTW@M6VP^!*VGL,O],SDL.1Y;KTP5QNOH]0#FN*#4N^%G7Z'Y'^Q&A*XZ)S$ M&U/L\04&][3%] W.Z692"_F41QD+Q'.U,X MO0#NH!JL<[*1M3FI>\8P3M:7-!5YQOH\K[*E^WD1').TU!7-FL9YY_)M0B&T M@Q,0>AFD$#\A T9CZ%L9\I=BOGTN&..H@:JHF13^ZL49/0*EF,):VT83Y0IG M7L!%J>S0[(X4[0-D+NP A1A3L J?BI8+"+\#';LB1 M>^FBIDL<)36/7E,$D=LSB 9'QA,4HU.>$#R^^/7%DU'PLIDI(5N5.9[.!E9W MN/H9=Y-RI(B';DZ:$?:35%./H1VE14S% S-2?F9:M@" 0T;3]& &7"D+Y=^#!^ZH\C8K!6,F(!'ZS M&<$%]"\CN*:Z1U&88 =T,O%9A\YV5V?"=[\)O*W97['>M6=SSF%[SSIJ,;1/;W HT-JGA MBHZ \\4X_@18NZ7OZFI6E&(PTY";J.+%&$68:E&3>.<(LF&MU(53; _VZJ)^$2,H/>HU ASOCOYR06\NGO"S52,:%Q<=J?[H7VHX1\?./6!4Q\X'6C@M".$6W5F M'$5E1 V/Q[2[;.0%L!? 7@ /4 [MK:990GL);"7P .4 MP M5SE.M)3FY* N:>8$;T(]R+@E\@/B*R^1O43V$GF $IDJ:!<,++U21*NY M9%,L:I2;_7GHKW&>T*F?)]3S2J]X!R8^O.+UBM\%_M %/B'!AJ[+E5-!?%6F8^Z_:BD!FLL3U7E,7W8%-B'* M2D%0JS^R1]C#CUQ2FDG])X%5S(E@LBDW/V$-Z%PE9-JC#JASTZ=#_L >^P.+:%EX ;[3;.@%N!?@ M7H /4( KPJ)(+Y4T<;'MWMC-**+AXOD2T-WF(B]_O?SU\G> \E>Z7$W ),5Z M(0R+H%QFN DC>]U)-VZF MDO"OHBFCV42)^K-&+(:6I/;B>8>9S(MG+YZ]>-XI\(,-Z4>]%O1?U Q3UC"AF M8<<$+C5&-$S..Y8-3AR"8Q+:'DKR)(VF>0&".@XJD->ZEN9?F Y3FK9G!")U:I7FM$A= 5$<3Q3;Y),VH MK@2Q(PW Y03D8''UM0Q&8.1P@?",XEFJ+E47ZQ(4I%86D#)UU-H<(2)*!I.(MT/'/AHK/)RYH\#>@X V(O/PRTG*HQW@40(%(@_G:1=KB&9!JP5_F8'*NV\C_'"'%YM!L&8# ML#$<$[ "6BP%8O!:^EHA*S:@K@QN% M_0CT=R-!?E03$C4VYK+Z(6ZK[>^E;U8#%\$]LE8A@5!7T0?EX"OC(NR>*-6+E[VNX'<*OVW%PD.X 'V2;+T$N^[T93NL#_KFYP*69LM0Q(D'Y "\@T\ . MM@GGU& .=B4DT]\/ XS-#]MD(NM9H8J>" MT0]W=TF""W7# N=O]=J8 *-,IJ'HM2 M7176--^D1]PF)5+1,GZF F6!,LLIF:=;B%<+W3 Q]NW*B!O.<"L?U#)066MJ MAM0(+?$0>J8VPX[*: _';H!/E1;NFC1/!NH7UTA9O/^\2UA]3A[).K,2=MNB MFS!Q:,F ;WHS@YL6''Q[,%YY'5H/JBI!\8)^BPA(@=6SC+A6J)P&;*#])AK)H9"N/E.@,,/PDRJU1X MR-@?/&MY%%;PU**G0NX&_,4?\US/CA6WBMF M>T:2]9KKT&61'/GL';7)]*$"TM6ADU)RJS#G:GJZ88WR@'=>6)RB15;44 MS7F9XB&MX7=^3EKVV#\\Z1 /1XQ#L_FU9]5!%)"9(ZW)4NZTPK7/T3+.[5H_ M V4 &H;-%^6F3\CT2"P4*/.+=#!]S1%/:Y&CUO//$4[&8DV"X'PUXV/@I;D%B&(8#B MNA[_2W6EL+'7="<^1M/A@&5U/8?K$YJ!3JC;64LW9AF9V(B6JV1$G";K=NRV MLE2@]2J9M=8GR.P'UU]'7)6,4Y^I* -;0BW Q)^G,?Q116")P(.ZE-MQ,+!G MNP<&MN%@[^U6K,VR?=%5L+G,*0")6V LHG_"H.N.%IHOK2N?6]:3,^F8T1=0 MX!H+BFX^VOCV4P]D5B@J504^34UQU6:N*L=I2&K!:8Q=VXK_U*I6"S&6VTRN M;N(H5ERV0X;6<%@)4[U9C1.U97"_W(U:+,#VE:%AA7.>IWW!%PYKXQPT'''* M$4Z)>+F#/$D_4YZ(M;")92V*!9IL9HZFG?X6 <,M=6J,-WX;9F,/3K]'[PK< M-BS'RY-%D=K>4P\+A(B$Q]X67RW.CY< =I&)^,2EP;"ZB$\#%:;6U07B)\ZB,:E:)AUB3GVZ M;%E5?4-"G;"4&_LPWL0,GJXD;I"GET56XQ_):OT1?.&JR/9^62( VSNXI>,Q M6T%J#DX&^$#-9W\!M^A#R(-][1Q;)M[\V+O0/Z%UV^-2S*9^O8GL-ES MG-_.$81F(BJ'HXX:MYN%0BIO?'_QT\5[^TH3\33Z%5ZGW*OKRE"Z G0BEGK1 M):A+,QHU.'M[OG<:.C&Q0[D%#C7=0!VO+2GFERA B;Z/[HJMPQU>+G=F<"\TE@5NWLKW"XJ^4_SX[_\CVNA#(1 M8IKSY0=[-P+#I![_\!9/*YH6>JBC1ZRS'X(69,]Q[([Q0]2G[]]<_Z$?09)"(CVZ 96D9HP<9C=Y'NT95N5+WQU-%OC'EH,KF> MF MIR0J*^AI/&Q8RPWGTQHPP_+6 5Z! VH;1NE%6VNY.2]HW+<>NJ"MR<9SP M-)[A^>M_7H"4>1[@H&ET_&1(+@B'@F4'2BM)/0E55D6R,Y2::S[,<&G@)_@T MQB4:81!5*Z*,>89>S*D4$4F-7C02C$:B-X'VN*2$@F4V*WS")@E%]B+-X*;J M N' 2&NE->-TXD=F*0VG67DQ5J>B\G6^J]%86%#NK>%=YVR<;_-;V.QB7V&K M9'RGSFFGV;"=CP"3VN8;37#4E.=P)I$HU6/67W=L^.TY5B8 ^[0"*4[\Q+&5 MQ8UP["LV-SBDMOIN6J08B6OT\ OK+O6DMYW,>IK;G$4BGJC$,R5 Z;HII2VE M,.Y&_WBDMJXV>F.9T-UMDK).O9HE_BZ'(/N+)=>$+J:%9(N%C3!@&^%*T!;)\P+K M<:RO9YRQ_M'CU]VWL6)B4-U.7% M'1]G_Z*GN+/85!=8Y]KM;)%U8-K$XAD()G M\;O!Z2AB#O=0[)D+%,'AGQ6)6-MSI< X_.F7-R9438Z0;_/>8:;UXMZ+>R_N M!RCNT;UZ]>*,2G*E.; 3/,N#&7B37OKN, ]YZ>NEKY>^ Y2^-KB+M3M4OF%+ M5BCZ@5EVDV>6K+R3=\)"?(J2>>&\PRSFA;,7SEXX#UDXQ[.BT QZ%T09+#GG M%*&M<:9$F.#VZX.%,7>'LA;,7S@,4SHP5!RLLZP7W(11NQR7UI-6+ M179]P;A![_?K\(&P[UK!,TLXU(S@@<#PAW5RT;F>U560 M%%>Y02ZZ3(M,FN!@3=.B2%8*"[%M*5;!8RP6?&)>:]251;+)0.\P5&Y332C M"1/&@*3/QV6A]1ZA]LQM^]TFD-?4=-?V5#MZ_;;#M]3K-Z_?O'X;HGX#_<0H MBMKT#_5*7VG(H^XS;.2B]B,'>TVZNG*%'\8>)?)N"+W-"^X=9C\ON+W@]H)[ MH(+;XI-)) GMYQ)Q_$QIS;14#*1,F!?4Z(FH!7:R0U%.HUPZ@'7P^/SM:\W@ M*GV 1UZ.[S W>CGNY;B7XP.4XS2%?4^FL!NIVX;RR[A6LB*@G5CEFMM#,=2# M*%&-S8V0WJHD"*2>! &-CC ?H.A3#]9:T>"145TE GG$,Y74&0.N@YY(=655 M2@_*70-;2 $F!]V*8TN@9WXZ?_.D-59BV8HD-:&F9D0]1KLZRR<80L'K(00+ M!WO1!=7!WR,J,M8G,<#.33390\'!?3Y\'%QO- Q,]'FCP1L-WFCX9*/A)B3? M3-?M3(H;FQWB%Z*M,89ELG95XZB4V0NZU@B3S#^09KY*<4B"RFF"9C=_):!J M6V>QL*"AG9IJI9AZ;82PF9Z#X$8&3RY7C(,T21$8 S'(-(XS(^ACL\D6IF5G M>$:-$[<(?:TD"$ #/8FF!H<_>;>$J>B>&^'*+0C,3K*"K<$9F8F6>B=ZAV^U MUX=>'WI].$ GVATD?9&SR.?2@K<\FNS'(BH3\#POWOZHL:QA4FMI4Q%H[M H M.4'AK-"YSF46GH7DI^F1O7"V(8,X\B@:NER5;5+"DC&@&.?KR= MT]0>' #ZPJN+G61ZKRZ\NO#J8H#JPA0\I/G:$"0-B2@R'&G3POUN1M^2\H / MKR3+3 "T&7NSM,%2<"_,RQF1&C0"S9)=Q5AO/0;UEN"WXC0-*:9C9Z(HO7[8 M22[W^L'K!Z\?!J@?9(9&7*8&8Y5#6LZTQ.N&:I#"F,$',@Y(P3825C-_UE&) MZ35$]):)V1H5 4A]:LVDX1&"R8^>0%. L3(8P^3U9"Z&G5=!DZ9;L/L$K"*_ MPS%$\DD.A>$"0#FHLEJ9,T O=L=Z7.$T=!X(JNS,C37CW&Z88-LAM/?WI,G_ M/WOOVN6V=:4)_Q6N3/<[]EJHLNPDG4ZG)VO)LN.HQQYI6>+!$-HX)G5 *I4ZE&ME16/' MLI<4I3F6C+D_RM$21GS-".[U4:@8FHK=0A] ==[BA$]J+!7/FZ-K,V,R 4W^ MCFD$> )U>U#\?D33H:DAL946A K+K=T(H@-RZS"=P>[E,#J^)7@KVNV/T?^H K+8<4*9[E%P 83GL F6)TN%_*NB:6#R7PS%DTE!UXX MZYA(,*M&V=J9IDX+AHUM7NE/Z#.40 B1_^?4YCU^S7]]^^M?_[)T-OEJ$\>7 M[L7.;2]UOYRSN[<+?RKHLX)+.-I$$+";"D9"&_CHCJ:,*MG><<.18X".=%HF MSW?YN [TNX>J'7KXALP:F3I>^ID2XQE*/3=^@E1$(GH:F8_/270K\K(SWXTR M^MCXXB&;H-=1 M78PN>==W>I4466'^2O$M3 D]D)L[9? V>7G!HO -+ F".AH39J%M0[8NITY17R:OQ M==7+J4L(<^P<^\<*=1',CD+-\-?E\40/G\2@'VTF](SW0D1)FO/1-D0BKZ<) M/ 3FJ44=SP+!92EE!>#&MRN;I/L$CUK+A2DQO.S#WP:<\H>-[:(Y?]ZV>(=9 M(Q!W7MN@Q083#>OD;, ;RKM9)C&I5B,T%K#"L7%SB[GG2,,S8DHE<78(*<96 MQMC%T::35+KF3,R0K[G,Q3P,8_\!]]K=:!"-F$,/R-0*GA534H.=>!?(+L1S M)[&V)0R93]:I>>DUD99;ORAHL**F +'?@84[2!TE+&KDI^QC70'9[A\LM/)Y MH8JH698C,24\IN"?(SX/#:Y^UGMB'4()[)IN-KC^65>.C7 M80\?8KY'DJ?P]2-]4JX#O*Z&JPR71;E:1V>NR_BJBOQ1R-?IB"6QVE4]7C2/ MO(/1PX-#)MIO%V_@V6C#8?7(GNBTEL&1!Y+'P?Y9P&6=.@#IX4T6Z(#;2+Z, M%<3,; J7JGK7L5@0DS;O$\)3C[B1#_OD75)3]B&-:TC>N,5GV&\ MW$A#7+XC5\]]3$@[7V[>9V:X^*?U*#E]78CKMQ8FY'(/V[L<]I&>;)8D7"IR MEM96ON8=H;? ]GZ/YN370NHJ]O!WE3YI\09);0,LV2???_W=FT_IMO-?D="P M[>->"J@KT2MIN$:U7:.F^^R5=I7'A>Q9@YPPH5-C^V?N%L?D?\$-2\C 416DGM9)S0 ;%T"/])-&H-3( MJ3[K%W@F.A4#QWD-&"4@Q4BCH5 ZB\8VN$[8#"-9+#8:D(K!'?6ABBL7X07$ MYZ^9K6MFZYK9>H*9K9D8!*I,+40MC2,4'31+.@D0H+E64E8T46RKZ+\@@_D591?1?E5E#]!47["QM:4 MSSF5#%PC=8V%7/IIN\KIJYR^RNDG**>II$F*+_L!J:FP/2%@)5ZE2"*H)#+S6XL6L.<;VJ9E]RH$_ZWZ1FEQJUQ$LD M8GKP.4_4.U8;+?Q?<[G56;T@A=1!<9'V+G1E+/F,;2*GJMJ>>)_(ZH2OL>-KAK7$84T?=CV6%GQV61'XT3+ MQT57?WXK=-X!*Z++U;'X@+KW,M\^5] /:_R+[>/MXD_8%?UCB96G!3=7KA?? M#&5S]]-].RR^ 9U7E8LOJ[9?551V6"Q>M+>+3Z;^@"L9L&S^78/T6O#F/Y?= M$EXM'WZ-UQ9,TF&/<^WI0=_NU[>?+A"=7U&OO[KY MG/ZU;-?'Q2=?\D7Y8?C/"@=;MW?8=O#) MB_(()^?3Q?%^I M9TX_#@OSXKYJRMO%#](ITS _?-?6"VQ)4GZT44O U!4K?(MQ)B8H\Z+RT1X; MV]3'Q^^LRPW?]$N-C\8;0:][J%RU<_*ILC_9F?W#9'X)#"T$D1SO"UJYG__N M#]F5/%6V+T?J?5GEDI)X6.QM:ST$>V26(/2R-?;E<2UWP'Z.S=#1)TZLFLUX M S<#1@H2KNPD3\9JEBA2UX&P1K'TWCTKR@DZ62?KFD&2O"VK>VY%_Z;")K[" MM;SA:\*/V"AB4=V*BL^EKP:TJA ;M5K83\U\%ZU4%^\"S+H.NC'<;2\=$U4O M. /)WE6(;GJ#IQ'6KJ*B_:6R^%$'R8%;SQ%"M1]6"$*_&6H6P-QI"*M=Z%-Y MY=>N2:?ZB9#OYG:1&H?WY3LL?WF V6 ''?8@F7#?!FRKK?HM0\:N-)7*UAK1 MZ6+#1Q<[C+7%3F^&A/6QR0R[A>Y2\'DW7_QT5^[HI!5.U0J&Z6'9MB2A:>H!.,3\RXD%5UP(_L9%. MDO]B$("N'\B, M8%L>&R;N02E$HWY;_@A2[J>@7S?X"VMO,?\CGK@*_EG_Q=>*S,0?03-T2ZJO2+5]PPO3BA&73+M&+ MG.B]L;,_7JDC(B^XAA^\?)/]FS0_/!O<"02WH:$UFVM(K!#80 X[-6LQ5 6; M6I71^R6]D@2: *[R/K6Z-C+EY'F&"'2Q@@]D"UM9@F@A)"FIF5XD!D_! HWX M6'")EN!>+>7D;A/^X).*ELU,CDC0NQ,CD[I.$?'\K,.,VQF].Q!BK)T4-MVZ MN\H:]K8I68-MF$$%]+ORBHTFG@U3+(.AT4;==;OH6VI[G?IUXX1CC66O9=_* M9T*W%9UKG7Q)I".J5P<=@M[7I>M9!I\_:>=2>S6):HI%17.(3VA$X6_0G<9/ MD\JB3>P7H>*VX"@8Q4LPF1,[6I_W5,96L-=3F>F7F7U1U\X(>064PE^[#N;' M^*#)*5[5H 3$-<%WR_C+&H[+^FA:%R>ASDA9MV1AIB@ ) L'0>O*0WWP,#%, M3^EL@;,:3U$.YVSX<,9(O&37XM5I"1:-0Y18@4IJWL<_N(<9>;0B-@(8(6/; MU@&T41BY(R9?_+=X]=,O^E/H# <]8_Y0I<>HF.LNGI)'>7SAPF73J\G3?WQD MIVEWW6:?WE$V\T ?X=7C:!J;IQX"2 TE%H*,:WB/"(5F@+'?(+J:HE@G3'Z- ML*D/,:^]9^\_^2 :;ZH8&* NEYATXV@RVT9B?WNH-V)66W-D#T[/"F,Q*S$& MJ>:8EC"-B<"*5HA (S;Q#E$#:[= MPL!*HROX^;IP-7+!$.UN@];+$;&:&_? ME\?TE,.OX'RK^X6+BIE%EH8KMB?@8 ?Q)XK%1!K7BZ!?_1$6!3[9M9(YY(*- ML[[T8-_1 _$.+M^>C\2FJM'X4'"(H,BH;_[[3_;"2-( S@=;?<.CL$J MH'^]YK)S#18*D:N[6[A7%RU>$@\'S>21: @F5V3BF#-#=5Z@S%'MCSX,_ 9+ MB>XQ2@_K15N#&XT6RWFX/70_,<:\8B"17YYMP^?G^,(K"#Z_O J""S!!9^NB_J&C> %7#",ZYP 3:F>GN&=D M*95W3];YWG5IK$+*G8B@X#4"0>87))G50?$GF8\ MV23<1$U*&"_2E)C5'6B$R%]Z,_3X\I]PH'!\)[VH4\" 5EITH8KLQ>3F9FB] MLCWX*<>B)Y[0F01ZF&@T&##8*(1/UE"PGK0^X,/V8>(9/ZF[CU%=-IW-!:,_ MW2[T;(_"G@I4W)G92TZ=1%@5[W38#_$#A1FA+EA*>;:)_P+@A 3DR^D0;?* M@:TSU?"P;;L;F\"F[.\)+'9?R67@1TH.ET 5Q5!@B.F7IKEALTAIT-T)&Q+ MV"-0[;)JR4SHV,L@*"XR:#R $M@SX(4CGGO'&6%G-5!@)B+1XH%%.#0J;M:W M[4/%F4^L].CZ/?Y:$Z2"D'A?[23A =:5A/RC_M?,0KOL0_? R']31-/TX%;\ M"WP<4RKJ6#XCT2+#L9IPC>;#\JTK3M;&52&Q2+X(6R6Z010!CX8:)GK;YC$X M.I^$X5R0,$6J8-:33U:>8Y",(=1&$+#B" O^5O9;-105_ R+6-R.$9[:C@\" M'L0$Y?\QQ%@=)0$.^@*;H[L(K8[!3<-IDF-^- 01/+6U"D -[0L#:HC#G/28.& M5J 0>V3D N4!/_:2:=',"'BI:5*M#4O=HBEC:,:TDI#1R=PO*15,U.9%DK$ P)/C\L]=,K+L#]@L8TK+'95 MKH]5)B_6 UWZ9@!1@@:WL 4Y)%-[\DI((E(&P&*!AX.EVW'GF@R8\<*AEQ\D1 HSQ=H%.BQPDLQN(^:17$'L[L#@]JOI!=ETYNA.! M5]4]+'+%I#E#L=TN7CVFY%6'JSFD^7(.&4NPE_TI,.>WZ-:!QMN!@!)/$D8Q M#Y!.>T?!%WZUGL*@PB^U],03CAOR/E7 -!W8@O*N"R$6W?)^\XV6K,70Q5(@ M8XV(%#@^.JS\1NV8+&PQ"OM;;=R) 0I)3')R-2MX'D,6;Q$CQ7=$%JW* K]= MK:6:8:M%;"!K,+Q"@/-V!XP[)K8_1O=)LM-,9.JGB#LF^N MFN.0)1=;''B#,*@C M<:$[9,"+&\3FVIUS<<#Z1K6F+54KL&B0@ C^...$WH:BD1 _1\&!PEDG:0:Q+I=0>KN=?&CJ2;T P:36C'@[;1LJY.8$U MZDRJ&CL[=6O!^ LV"&=6^Q!+'-N_\])GH=KGW[^X^?P9^Z0J+5DD:HH=KE(2 M'.^["-I<#K%A8>CX'&I%'S1'U% MM)MB?603>EZ#[!CN[I,#-3I,\_UNIXYIWD\*"T2/K'J?.M!0I"/^8#2CM4LE M9"L_845OAYZ,%C*E6;-+8"(.EO0ARV1^^M\&6&EB XGB2*)+,/JV6]/HR6P M.TRRT+#&U:Z6NA0U':ED=G M I(91)4&4B:^1U^CWVG69(=)?U3L2/^#\1[-]-/6KD, H:[K!J/:AA*M39#3 M9+B ZH+S5!+Z]L M@[X=CP?5=E7:"X#%(6X$M*WD?C+#NJ;7I#:+ _EEWV,@X-@.Z49S!\JC&N&$ MG'L9S0^3+?) FST]E/,=.>V2E61+PD(KL[6FS$$!VU>X;DTM#+&5Z&* 6KG! MPK)A&POPZI+SM@'-JR!-YO5DS^/[61L77IKQQ7^_THSW6.D/7=8S2C/^ :/X MGII,OQ=>([A.\,^*A5(#N@A#PJ\Y)%PLOBN; 2,T@Q6MOAA9XG_/VH1?R-R. MEA[+8*6QFLB/)+_F6<+1#W- C\H!+% 4)A:_:&^.HPQ0L6L9$MHB&TEW=+M-" M2-+/&-$=V_'PQAL,L0HB!"=:"RU&ICU>E3LCG$-6^;7**.-LBSBFY?JO8#IN M7:4,8D_PM)A*E^?$<:ZPMMIEO&VZ&AS?2T<6JYSM%+*)$GNL6"T-N]71ID(P&0'4Y>L2P]]%)&G;@\DE&SU2,4#02 MB]R,E7674QI^Q I@)+P'S=!(?0D54410$?&;\1C F:/6SXKN:-<>P::RVBPP MMM DDA9VJIA#[FH0 W?X!H.NP&87>'YH#+P!>Z'W!PP,BI$.1[\)JRBF. MZ*NIU6G?ZA1/W_:(@,(?([LZE3"TKM3 TZ[>X<5?D:<>A0H5,&NTK#4D$_L MQ\OMQSX1,(2ZZRGA& C"4B(%"/@]'46-*^XE\6Y(#E?^MS,4SA7*\0KE>(5R MO)B;\X_AM) T9=J^.V%Z2^9:*T4G$M=959'O/@?=BZH4LS<-Q3^J)J$G'64% M^Y:#,:(A2*V:59::9%(-)MK]"L9^P2?^JBNNNN*J*YZ@KJ@VXX!0SZ6/TUVG ML2&YUP+I6,>09;=S\OC):)&O9(?1B%[0]$#00M7ID -*HG>!%X-*RKV)4[:E"AY\Z(\:NU8]-FSJ_B_A=^=$RPVC.\0R5 M)^]36&RQ+XKK9_7$F#IP^0*8*3QK%9(Z]5-/OZK5"Q8.5[5Z5:M7M?H$U2IX M0YNZTH)1&'L?K,!XZ!/,4DH1EY1XEJ]TX:[LU@Z>*.("$D2-J[QK%:"0JN# M ^N,FW!5613U!%NK9JA4]*FF!=00*&!:>PQV=]ROTIR%A+Q%G>D.%_]JCQ MJ(>W)8E_%?@7>6RO O\J\*\"_VD*?*XGV5$K'";[#RVY,P_5>L#:6ZY++X4H M1B.!#.&Q;,$G8FX !#W!,G1?ID35P]2BG8C_B8*%PE=$@#LB34$_5ENN1?_\ M][<1G0\K2A >11O$K%+"2D)H2K%JY1,M:"!G9UF+_OF4P=6E6SZ&ZZA41E02 M^(58VL-5/U[UXQ/4CR+?.8[E*)(\]E\DR]+" M0(=T4F3H+ S$'D1CUD>-'LI/CW,LQ72@"EPY8:^\/MUU4Q7S735 M3$]0,RW#JD0T.%>GGS0%N+8/C:D5&$^S!E!C%.)V!R92VA,"-6+FP,32 I3W MYIR^*!"$#M4CM;UF,&7&83D#I2G-V8Q^) N>U.E,P+!HLRK"[27ODQ*6'E:\ MYYI/#,&NR@YA*X:] -@0O5/)&;KUL!=<%^4AVH:P7Q@OY1H.1XWM6N,2%PNU M*L>45+(0*K'U9U0-DB#TA#!(_3/0 MX%!2)W8LQ;6.86JR8:!UNXGQ+"#0HI0]C=$^_" .UJ7Y+B&"-L M70Y6>>(4*R[;U&EV]5FC03W61$C0 A4U/%N\IT* >^W[%VJVF _H0\3SJFN' MO+D4P$FR*QV;V?(X!288$9>UYDV@(R5,-77H;Q=O8 $IK +O*%R%V(OO7R%A MDLX^05DP+$>"FTQ9 11L=$S& M.0!%!E%@J$W49Q;N$+?!8P)AFQJ1IN$R+BAF5G9K6726 MJ[%Y&)^-6\5_W M);B)+!02@$RB@H8_RV5YJPD6.%%B+[YIVW6_>+Y&S#:% MQWI/N#B"U#B#),V#EB<,*=]//U<612Y)OK+PZXY 7X@# 6TQ;8+[B08T_TEQD''U,+BJV^^>YU"G6# MG;<.<-B+A00"D.36^#KV>VYG_XPP#$&R[R>@:ASN#,/*H"R8P-L4M,Z/@=+C M+8')$B(%:%(D4]D'884RO/_,KQ&HA4Y8#FLC%:X-003%HTP!!EIT/!L.]\&@D5 H;D#B99V?NS9%1!S M1_D23CF?K2*60:708Z MG]BF;X^C##2?W @ -S&GPKGE29 'TPP(44?6?::E3]X8W;PIXX2(1O!H.[,= M85I[N6J9HZ1,172/<+)ZGU@,'L&.YX%Q-3F+6B4_/ MS\Z^#_5&O_[7T.ZP:OXG!+KD@\F9M+0[S:#1NO!7V5LI=Y\T,O'.P,785GM/ MW*1 ?V?MQ-%5JT^\G0>9$VSE?!D?# G[U'5MPEXQI9,,KIC.9WK5.(-)D@I% M N= -3B:""3CO$-$O*.Q.*_#N MW;"3'QV"!-*JQ"R!P,+N.8CV-RS (R%WP4(HB[&S-O [ __R,3MQS$;9I3,/Z)$OFQ-"QY(LB0M@8N9G_/@K%CP]9>#20=I+I M54Y8PB*T21JJDG=5YQ$)>=XI1F\U B[:#3VBV5WI$%?+T5CHTN3AX]GWDOPB M?BL*$#T0*!8&_>'Q(,W8Z^(K4X4N+B>J^CX$5ON4OB 3E]DQ0'1W"7):1,E+ M#"Z2"3\,_UDMOJR8P1&.L\A\<0^&6O$^6[B,STE@LZE]WZ%FPQ(3[J_' M@3N*\F+O8RUT<#T* P:_'J_[[\ZN;SWV.G1PTS7W55 M7TF:T ?:9_8ZRL54_VN^4&'C^G>+A+'/;G0_H&]"@,WIA7R,6B^V.N)IEE-: M+)1,U3V,@@.*A,RDS4R%(-(R-4I).Q9F]K''5%9C)W2R7U&4Z47+W,3P0TFI M%ASN1UL+J22WZ3"K:?1!-,4@XF=,H>)YS4H,8J=81H;Z9SK:7;#N486D;MMZ0"6F#B9![=JXL2Z*QZ(1Z+QO_@C7^.LES9"%N-X/) M_)A$#Z-%24G4+$9XAV*PR:Z?1/:"9=5!1,!;$H2H#NM*UHMW(>Q80X@'5V$6 M=LMXYI+]B62&L"AJ2O3'?H_HZSZOB'XT(WCCD_23IRPC&9_\X!<45_%V\;IM M.WM^A!ZIB!=7)XEUB=IX($YN_!@#7>U+#.4T0B-(A0M4CT#9-$>^*DUF2LO> MDOD>N>H>Y]=S1A@BIJ]8LB!51>5I6D0QD_8TDJ#)DTVG160I7KK(5+)N5T/< M*(HD,?L7'5T4"U\AB>USYQM_\G^^>OXIOM!TV.);@:E-/O;EM_@Q8M#%.!TH MW!(SS12-(38 BRJ*@VUPK9A"7'P;S:O7"N"?)SSSV/A4VM/2>M1.:!:=2^ZI MV<57]_VS7 Q9'^]<#^H,#(+QM?.O%RLZN0::^D[X/7E#R30?;>FN[ F"M LW M%I%W\Q*9D@PNB\PD*]H3,*@03N!H)@+^C]9H1*M:K]S8Y5&.KW;#,J/450S4 MB^,+38JY. M;NPK'#*/>$]+NI\KKI;P5C(?-7V^%3D50J A^9=IKE^*-9:[4NLT.& G:1AF MCHW%B^4(CDJ#YXZ'N8BOG""!A7=3(-"QD.;$HVQ_4IW7R-O@8/.N+E?!PTFE M9T%CH<(3/R(3-Q\*GDM8)5SQ2652UBIF^Q,!?6.&P VACQR-*S3/)4D35O=2 MFOBNJME0H]\Q(;NO>TG\G3,X=X>F^AN#H'@N=5$H(*GO2%WZ%?$86K3IEKXX M6F*$) L'_:<&[/(DGG*;Q-AB QM(Q4W@[R E-+4JZ-Z3_:GVE^!M2HY579J1 M:T3C2&;0FF*1?*ZRRQI8?*0@2;Z(P8:.VBQ:]5/'TSAW"[2,952ZQ*1]8\,Z MRWQIC;#_+IA22*YN60LL$$YFH.2Y?:Y(HW4:.U54\IF2U6(O"6..V67FRZE8 M>TO)GT,U-XU*0U?+ATPG'/Q'5FCRFVNAR4=5:)+<+=843;C30&8I)=8Y"#"W MH9VJR3.#GS/ZQ-@*%P7^LAS6=T&PXXE6TXD>L_Y=:0MS"@>M\TZ-OZSFC11J M_[A.C77"1VL]>$2F>=#'U*WK%!9_ J^R^RNZK['Z"LIM+VRAO M@.5R>S;,8\C<-6X4'+K \D?\U$0%4O%H"NXJQ"_X*%Z%^%6(7X7X$Q3BVG/ MO<1)IIYJF2IK(]?&;8-M:+NDRH*Q(938J<1MC,L0ZE+G":"T\FOT[IDMC MW[?OJ%\>9XIKKH+]@H_G5;!?!?M5L#]!P9Y"G2 S/=:;9$7GU%:">$6+9;E? MW3]>+7]%W[SP4W>5UU=Y?9773U!>5[[BM]W$"FPJE,38^8@(YW3)'I:,IHE6 M:E]V32?K !-=QT88;310K"JJ%I00T&QAX$<,X5FHMS/M&04$!;/25"WS3=J> MM844>T) S0;$]TA=IS,PS]*VME%/[A1ZCZ/&8Q["SR9FXJ-Z!DA 7>QS6(YB M/7S44 7G;3LW'H9Q';/K8JQAEN%].A'I]$@[CH<12%!NZA);&WY@$(%^9YBJ MIVBPC.,QXO8>SC[=.DL]R\Z]=W-S8Z$""?2A=G11SMBCE1,8^$R')IVZ'.Z MZKCSOFTY4G].@ :E3^!%"-@_$1"2M-7Y@EK8=\.VA(&70H@&O_RI!1TP8/KYPT6BCLABNQL]<%03;&Q&4YGCA&H4K+J^R%X;E9A M&C51[/%+#:9Q?I'H')PIZ8GDYSW;\L^1]1G3:7$*$()S/$AZ-_W&"9AF 8RH M&NUL* 1.:=P8EO2OUN70<#<^%_XKH='\F[!#@EL9Q:W0;]O>(G#K?Z9I;"AW>L*VT+&3PQ!YK$T&U#?3LHG7Q\W[^LI#FP#)M M@W'U*"GM F&YL GD;EQ+:!9U%QRF.P?B! YXP@;%6_SX44GT;$P29T.CGJC*N4 M(C? 3\>(W:"/9=F.'8$,OL>)"<8L]VB&]F22%MS!]IA=I7V/V/\5I!F0IL1U M_S0\'CYUC->HA";D:9PMJG3P;*VG*.8C5!]M_\J@ MOY==M;Z;LM0%302Q/O?6V@NWC/!^VO&PBZC=1^8)X?/S*,]M":9UC3AM>4?) M^0XL-V4)S-R"W)DA7++T?SNV!PS/180,G(,?#2Q\UC!G(,EFA>R!6/6L38W< MY^X #W+,RODGQJ&;DAH/ MXMPBE- %J[?O4N$;H7W(K^-V)MC.W(\L%@3@#V(R.3$>HH!@%?O QD4#MY8Y MM+2K51PVD*/K&J&7J$"3PN^WBZ\15:EN]U(-9/@:.CQ&(J"JGCOLO&U9^ZH9 M2D3.ZR#6:K\'67NWOR]B+_ENZ%1A[%J8PPI,E)F%T.DD_9^](UD0*E'I'<=' M8B!R76HW^1XE+;QPU_9BR/;M[A[+FQB"R;07 I!0"ZZ':5 \ ]=MBKK6P#1 MT=7$!@J:O[(^TN.!<86;>1P$7T*U 2U(6"K@!P;^%[A3[\H[^B=2FZ(%0T._ MKW8[M?3S,1(2BP)WI:8A[J7TV$7N.$G[,%K)KJUJ> MB1N&9$O5*E&S@U"OU<%LGG-^4 CP\5'[RV2)@LN3>C>))M,B MB;BM5EV[)(#3AZIC9X85N\&^R'9VV#+>*VZ8PJNZY#/HJ"*&1U MV]N1C3#%3$- LQ$TVRA1%21Z&]9'M0/B."= IZ:I6*S=<<*I>AM%AEY N6)= MQ3!-8&ZO24 3> ZA=2J"#GPR*)0$/ ?[P\YNI/*JT!4#R [0)* S;&*I>*X M+*(5]9"Z-5PS")[B#:<+<-%:( E=,!(#==F#M3QN/F==P!&&K ;G<8PL^I;M M2H'TP^A7XCL1Y9R0S!X0C@-WA&X7\N7@;L"*;WMC52 L%PVB%/8;,#AIWYCY MA&ZO&@TZC*[QBDT;"FN4# M*%R' =:5!^\!?@W&*QJY&'!D-(^)>,29X525&4QD$"T9A9X)JE7XK$*U'X<_76Z!4I?LU;JR%@7.C+)J,B3I MK ,I>J''Q6^).\_Y4+(0Q@N7QGYUV-,#GI'%*>:?19A&C 13@2B#5CZH.\10 MDC%XRG\XCSFO:[E\><[( 3 0ZBE+.V;;=K ME1).M+4[OBCHQ?Q':T.\7?9/'1KM SB$'IDWV=';Q3<5VC,FP9)*"HK>3*%*J3<$(W]^V!;W0J7;W@G,SBJQR-$R*@.9FPX/8YY/SA))# M4-DB.+.^%L-F-@>-LK&.C7?VM*Z]:/&<.Z=S=QDI;+I*,BD9^.W/$D$HAH=E M7?7W'#(RH\U@PC%^U$ZI9L0@I]@D#2*.>EOR*]'N7L%=P?\JY"&]2W#=6"K= M+OZ$4) _EAAI91C&<@7OV3)A))R1@?$R!9*+GDAJOJW>HX2*Z/^CU M.Z(=6ZL$S&>+90LLR2@>RX&L4=4)CHEK;*8TY9@<*^.'FY!94*/AFJTT\?E0":0A1Z'1K8ZD +D^S,1W(D?2R?AC M0#'T*+&7Q[F$2E)/=[MX/B6['I%7Y\NAW,['[[RG[+D ^]P)C%.48H42]47! M42Q )ZV9MS6Y,+&81V[.I/-HG^),&_+14=$&;E^CCB2K%EAY O]VU43>"($I MWN1A+^+OP )4]%5A&-"V-\7K$M^X, FR#^R+\0:(9L'"?"Z8R%#+*0O]OBT^J3SF@AW&8NCSH68KPIJW2_PE& M\YGQF7B*^=OT;'JY3S1V 4OSE*2]&T)AX-Y2-K(:2!4F9OHGE8XZC?\ZDF[X MB'YF$^ 62 Z)R+&48X0T$1D&7?50KC#J'%:4(BKD2-$00"#"L)CX0!0B \S+ MT MVO&!A*)07IY2B3D:+GE^_P@,]N>*2__M+0V:%,&SS4+JV9'*13ZH'F=[T MPIY:RV318S G(8_LA..=ZG'4@U70,W#A3:6G),\"M$!.'F;BX?V4M+N!(5QHN3B%N5+;)F M,<6'YWG VFPD.B#L>'I,>9K'F&X!@48Y$'\I8.%".CTWY.FR[8V'X0Y!HO?$ M$RN WY2H3RC^<&;KL %%(*$!AHHGOQLXP5%D./GI5OVWH<;\P1BZB+ZF M]UR-;!: 8%VRCYG3%40VK[S0:QXGL]Y7&+C 4.N2P=53_#;;&Y3D@2]V+=6# MM"_CC@4&\6%2.7$SU1M.J_WV[1T]L9CB1S#1Q6T!276]-,#Y1(X4!'B$9L'8 MST":K^C,3[&;\MJ'?.U#OO8A/\$^Y,Q:F47MR>T8C0"S"=@0357:WP#J5NHN MA_ZDGB.0B2N^Q$6>SJMT7N7\51'$#\AAK]A?7M^X;A+JC>[6UAZ3$!V]SU,;:6 AIM!RYVQKEG:E5PC$A4WC]!WN[#JAFHO MBI^F7:[#WP@,F"O>Z!C&>M^IB>S@4VW3A)KK8KDBD]Q&[@;U.,43+5(>.'%4 MFT@US;XXL0_= P)C)%#R@MJGF(3PZTVU=_V!TD.1?9J['*BVGGOFN%FN;@^T M>*46EQY"%S)\_)[JN^& D<=+M;5:BZB;;K6_MQ=<-HK=4:WVB+F^,ZFV28'_ MIVHID\5Z%&-D I'O_;I@#=20+%IX[00 Q:G]^!@JGIEHP0%Q/KKLT@*8A6:P MY2"V+EIW!B5TYAV&%%@F8FQQ8;YKC;%:=.^)4&0I-G?(6\:PSDE!MV&C4+F_ MMG 2JNC[VW6_^N/MXY@CEW!MG^"&8C=)7NK!G=A4"*((7R1)M;/'>HBU>2[E MD\AP0J59J:?S@#6#KHM/WQ2U&4D,:NM2B!_I2!VY8J:L(1E!H=EZ+.[,J*Z_K1 M^H!?K4KI$J)/4Q^:'(D'LD?TFR0)!!_0=\ .P-;]AR<2T$V MQ]C.8 .,D!P)<66;3:W&U_2Z@R,=YB!7CMP#=XZX,NP'^3 !8\*88;SPA=O% M*SM9XW.4G%DY+F1AK6 _.X185+!=Q/@HY:3C8;@'N1,Z[E54R-<<$7 )A=@C5:]=I2Y7ZP1S[MG+.K8W0\W$ZVV7MF?8QKB=O'<<+5;.L#W@CM@R34'1)U MW(XX^[Z#X/GD)$<@&M8$%8MJEJ!?Y29>LE7X?3)U.^'2H\9IJ*T@R/N^0^R% M;3>,;F%ZQ'M@LS!U<$YZ41CQ8[8=K)GN"!]&GXL "E.:*&*PCZ\1?(3^VY'[ M[9N'U"<2TT/5TJJ]D>^(UM*<&MJ=> ,,Q.Y(M^QV\5H_<+AOR?78P6!6('40 MO)VR9^S$J4**B3B^K%47#=G>UK;J[#GDD+DL'R.;"XY)!+[RBR+H5[(2W-3: M,>"4T;>3<,ID KUCUJLC7$]<+59CN@8E- M&6C:*$DF@$$("=QHJM%%B6^(=R>YT_:.T=M7J >%\\')>Y]>E9[0"+P2^^8L M"(^[U!/&,S?.-@Q8&X'\21FUYP4OI#=-C@D!E1W*CI!.J>\V9FP+888@%"B! MRJT'&AGBZ'*/^[8D. $IJ(VQ"3EFKL"V#G=57S/:MP$>7[ \>Y4"SS^N7=X? M/?.#/-M4DIXDV1'0@/^6WO!I=@<7H'/6;\%:GS&S49@LW<M.(3PH".+K^)CDN";Z/@MI"\7H!T0? M\* ZMEO8"D'4\H(=4L^(*>\?$93V_HJG[-_:PI ME0$8!8T^AZ5JA!WQ[W5&9A)ZFIG&Y(,S6L*,L166/@=2F3T=,R\@6&IYCNP? MW[NJD4T%%V!3SB8,_J&C M>'Y*F"01$^:QH^P;AI\BS6 ?J922J."F7(6(]X@)U18&(OE.)Z?/@5Y_ZI8I MDLU\:31/KRG^],)-'6702R&N@A^?,^/=%\^>_7[QR9>O7[Q\_ND"/68"?X)/ M+Y<=43 Y.84!GWLD0<1-B80V+GE (6_07/!'Q2Y%(=BQH&3OF0+P)%CA->"< MW,#)PN SFCO$([@*$P^_!6M:(ZPT6J)BE]@S38CC8N[-GB?5XM%+\%GV$2D1 M4P.@Y"IT;D&<'D.)2@!40B116EM(GJ-I.D8+[)<8 .O AK>)1,\KT_R1#8)% M^&/CI9!XK$=P^0P>]/Z 27<=MD9N:<089['DR#FCOEU\Q6B!!(3&3[[!)SL6 MI? CZ.R>$-)P_1TY1<,6"-SAJ*T,:1H>BMZ^BU2-!U1M;&YB0&#^C)3?E]\^ MMQ!A?*(%G=M&S0"**6')BD.'92;KD))D&<(A)_8T$,861UW?*,K;!%\E@<>! MZT#V?9 P%OI54S1L!/G'Q*I\B/&2UN4A9R:L>EFY93"#" :]E_ @)I3(Z,C. MUG-<(G82BHCH)O9=R #6'@F]*/VFP^A48@J+\T_<^8MVYO]?A44_H:Z0\)O. M1+M]*$'_\"^Z*4'4JUW*!K?4/$4_:NH;E5]B,J:E*DTD9HRIK8:N4[X2V9'' M[6R"7AR_5W)2)=V?_I[. E&^;8XQXO[8-;]=_+D]!$J%&B=.F=#.PB_D ML?5)^*D5\):%H.Q739YD3KQCD+64S%KW5(^4 _(K%,QXC METNBSR0+&FD4"KG*F'Y:AM!(NI%=3V1$"BM*UE:Z-CZ1C9\E7CSR4OG=7OUD M&3O'$0IO,%A("P$W5CHPL=Q4FXF& @=Q^X4S!@AU63:.TC5@L]D;5(\CP//4 M16*>%ZKJ8#RD"%3'.F=7ERN-89O7)AAVT3QA62N7]S$(Z)]CP[^'6/O@]"3A MC7XOF5^!>7W9W'S+:IW%%1_'-Z2RT$A^'E'<_R[B^Y=P&P3Z6B0F5M10DH^< M \H P#%4V]+#UK-4-)^B7(DW'ND""-=83D=2/J%@TRD"HP:"'DF+:-Q!\?0Q M"+2L#?+5"@B2TK#>9'*4AB\ M1]F5A*KJ8K7^#TR+E+*FV$&QH&!OMR79#EHP%;K,]J#D]6X[?7AK71$R.28: MW7Y+:*G7_.GC;&4>"S]"5>-G04,:EUPZ"DWR^S>3#.!0<<58IA*LJG1X,>*8_<9"5O)-B]1 M">PCQ=-9-]/T][I"?B!)1>-?S?N8F%!)'C3Z'2?I/PSVU2H-U^41[M?-&BM0 M["BH5)D*7)(A,YH(OG5"+#(UD8;6QW5DT;OE2G**:J:8^C#_!DV-1T66I6KY MF4I*0M:-<5>1& L=\='RKV4$1B8X,0NB7=$OK7,X9&T$F)+M6H=/.+E8P^V* M"J5R@[VOC 6%BU)0 K/OACDBSJJ:?<[0RTLAUN6]44]-5 /!R<-ZMBO69Q2V M0J&L-PFE1R:RM6"U"@.MLK.Q46#CFU$?^/#3;>=KI M5#.>GR2"AU_ ]3?7AWIY;K8M'+RA/J&[:/E^@T\9O2)W!6(OU=/'#]](-HYI8RB_THM 2:I[)%8]XP^P9? M"JS#N0,I3U$*JLFAY U"M'.(SKW+Q)*>>B9.K;4'!.L]T0_$W)LUSA(G4:%U MJ/7%)^FSF-NL^:>;-2WSZ& ;LQN',B7,YGMZ3(F$'Z626?2IH\ C)E9_V:QN MM1]Z3*TC"3W/T(: ;:L4I+B9'$T.V\W(]H[KNQT>ON5G[.+.\HA&K%33WY+CHWM MGRJ)<@G[A'??4Z]MTCMC%J0^8D- Z"Z9A^.':%'Z+/TR M-&%3\1HPGR&YZA],X(Z.G^X/#C3B_>KMJ!FFR"1<:=XJ1@*)L=VI)6#G?\S_>C/\]" M$:=+3,5%>"P[X;D[92C*7)QXZ%@.AAQ(X+Y:I:,)$6EDBT*'V)5\<(68[Z18 M2OF8X.YHRSI6R?7=L/-[_I&5QOSK99;&3$NJ7W AQ\4PO\PXDH@K199Z=WC/ MBS%5295R0W7]&&FL%2AW M\B!YRJ%#T)\UB Q6VWTOU7MW;;LFZ6I6.*,#WL-YE3F3+[/&(F(0VRI/I8O2 ME>9J&6M/5;R;2(P,"DM%BK0X7,H("@C6?;43 M.?\N'*EY&'1(UR<1L(X+?H<>+J- 84R^1/.YT@Q#'*YV*ED]'Y#;$]YI[7 ) M=()@;^!(C$AP]FU9E<,(;R,:#Z,MSUB=7>@V,;:4BQ37:"YB.&'J&7ET&G!^ MS&=(PM7;&'&>"U!K=0V>)K8_G'LK!;_(>0Q"H$YH[S"C?CJG\S%4O?T@^7 P M(V3+-/:"!DCA:KE*M^5>QK06L>,X'=Y[#S+JX%;00L)$RZ()>)]7F,@G.^>O M<&G@#S#Q_$0([=J]&/WF)M#7:N+MR:Q(\JNCD9C%4&,01"CB7B2'_'D,B&": MAX*;ZN?)%\*/: 5B9IC?.XT6.E6#10(9%'CK\QK85$Q]?(@.A1=&(*3.[W]7M,GV" MZA1'A\K /'R+A0Q4RVZRSB#7/F#)Y-W^!AGJQ>'GI@Z>NZ@9!)KO-8+5[X2$ MDTL?N!@ E3&,FZ3R&H^H4,B_W.C4K-5&#T5Z)ARFDZRD-*V7A*";EL.SKD'- MU?)R3V2S>"U=,PL)1 D,NKHJ31%RF2_WH+*43DR;^>#4:1PLCN"6-BS8_MAR M</M_K")=C8-H7%OL*]4 U1=< %KB>*(Z[._[]KA[C[:U$(D2(DC<"ZW M.[Y4"%Z7G;BDQ/6](DI,^CV5I0?YW_H[XV5I6>/9-YEX7L +Q=5EIR3>3@0W M3\KN1\*#./ &R2LPO:DO0H.^D!>8LK\PVA."C*0)A9(.9"U M@'EE!-CLS<24/DN*L0RN>FN*69R+HS2>K(A+:6!;OTS=T*=#S#T.3#>.CBH3Y=%&7"2>)W8E1!#OZV#P*AL&AQ&G<+C)T#RYO*6%JH/,JBL+%H@#NF,K9 MQZW"NI 6><.Y:^Y 6 \[,8I09_2]3S'Z5EJ+3DXXTIV?H<&N M0.]7H/:38N\PQ=I>]5^EZE[Q.5O@1% M6=VWW,YKB ,?B(=\E=,7?-JN!>\3%;RQDA\$K\'A[X^3Q7^Q(PBK M.R*DAG5#4TBD@L+"*.[FZ1[[GYD[;:N[=@_&U5#%/?!=:'+,%.STB M,-KW62V@,7]5#1=YP*^JX:H:KJKA":J&JED/O?*W2%3;%?<90]_MF9+W4JNT M?5EB9(TT'&.J7V\80?'<9FLNZA4H79BH\2<:NE/>4>*+7J5V\G ?&-Z2P*BR MXDK#_*6:X')/P%+5@U0!4TMR(^6S0X0%GQF_E0P+8#':!/NNHE[MB$ W@?Q! M_5E4WBQ .&T"5-C$%L^T/X8'YLOA';7+;5J7GH!V&7^1HVI.(=>HGV8U<*]@ M#B_6":@)83*G!(VQ[O0C0YWX_15UXN^RD$\%=4*PPZU;R@,22AUXC>@'BQUV M5H$!-3!#Z%1# 5?\"2.;] ZNW56(-]1(!W*2,L46$"M>NRQ#M.1I?,9U?,Q@ M J8[T>*%SALY&^%JKT&&EGU%_,43<&FC5KRTT5\[EE)0KA-MGZ?2!^/&SP_J M[DQC9'__[L[8:3([CP]K_RRRS,O?H1MT?A3:W/0SWI_UBOI6G7&KZ-^Y(_14 MK^<_OBU3&C+/@9=XXOV3V$TCG:#IH3=\8[-HED0R;M$+PBW<0+9/-[2#]F6!,!C MYYHF^P%1'QBG[EKCA'Y> 9@O]'!R*97]MG$A*>>1O3B MNQ?)L>]#]U"MPI@@ZC2?WZ::XRR;P75_[$C@3R6%C5'I,\C@-(6.]/G=5\N) M6RS]JX6!\ XR0)1>5.UAXB03-1D624(K-+J&?#DF-NDDYB(.W('!C_ -?@YV M\4?$?O/2P^:^5MCCD*7[9'("/G7V-=^&8<#NX?XQTI^ A95WY"=K: M&!4H@3Y8CA'2ILAS+\B.0HM5^\>YC9O$H_CN96>8YV[%I@X4\IBQ-VF;VXRA MJYQ%&XG4WQM.-D>D9K !!=B5(>CF[> =>X2FV;6"] ?FR@;F@D4?/&C'"MK/ M#[NDDVE@63+0!LRH&D%CB?%#F=63**S1B%5;-/.<+1=E\;V2YC$D -X*4"K( M?7WM)W^JB9%K2O&:4KRF%)]B2M$AN;"(%SN^[X> \=JP5JTVH0&N%8 7?+*N M,ODJDZ\R^0G*Y,0Y=%Z"IHY8#J.$1L/\*J.O,OJIK<]51E]E],#DLBZC\])7H-"A%1SYH,N M;7=MZ?D8COQ565R5Q559/&%ET7:4PTFQ>TG^;RH,PI3'GDNI<,TY:]LM5E6W M&K8/2CTG*H1[>J[B^H(/W55<7\7U55P_?7$M-C63UBU=!K=GRY_*%X6)5S/J M5%O-Y/,/Q,"T/#KI+44B<[$:^.-G;7>5ZA=Y-J]2_2K5KU+]"4OUG&N*N!O0 MUD96XSMKW"C7(-@KJDJ44LT5? %Y&I@@!!9C%414(P5$4%9I;Y\K;9+0E" 0 M5GU<)"-ADL2V#Q]ST^8K4IN*\<6+%XN*>BQNX[X2(M$8-0P6"7]=UFI1U<%J M+L-JP(Y"VEVEV:+MZ2L&XYW0N05WWTAMEFRH[J\.T+I S\N+%]1#@@PA?WBY9X0&+"3<]?V?<5,ZU)03-ZAD))QD=Y&8XST8+4\ MI+[7ZKW*M./&BE67 0&)D9"RPI/<+FKB2VU3T\:EG6X7SVM$?[B[S]AA8<-O ML)BK9I)P81K9\"!+*H#+*>?-Y[UON:&FY&HZ1G-[WRFUPWXW4 $S_E&*JY7T MMH#!=#MNSTUZX+!>ZBB)=#3[!+''E-1N(^]NN[NRD7IP_X&$XY=^ MC\M<4LM)N7ZH>NVZ,Z:7Z/H77+*\$8H?3^:S9'(9_H-;1>:MIC4//.]L7\N) MXX@[C==D+1VU8(O^-;3PNC4'AO,B3RP.G#@&%URY>9K)U@?QI5]!*3^G O;K MJF-2[#/J+S_+V\RC*N!F];#V)U] Q/]R^^9V\5I>#3O^MBO7 ;O"%J^P^C:U[9Q].JX@LF6=_V'45ZM%N7] O/O\#/ MW2MC!2,"5E'VH M\-EPPM=IAUXIK-S4?_$.%TX*3KM0AP>L#<6:6WZ--+/2#SAZWU=#6TN]*#*5 M\5F^[([QWSR[=HQ_5!WC;PGX0*KH[1[A>1:#DOL64):5!_R7V2="14YW8>HZ MBZS0E&5'K.]DU" G6?PR1:#I>V8,N2>5R7-N%U\CQY^T-:C)M&[/-I;&9'8. MC,H-IA@-I1,I1'JMW?B>7U:,"VK@P/IW&=8RH%QORJYK#SCG&&RG1KW[@/U; MC;VG#EEK6XA3/4KSB T6'F<6K4RW[?:;MJY:,UU!DO]M@ ^!_4=M5.N1&&=Z_7Y=H/3]H,8=30,NEAV*":4/QT^:G"&S^]G6BJPKV^LT2^^ ]RQ M7IIG$T\[7HH;)I#4]1.TGZH!TQYM,&(X!^4&=V'O#8,5W%,IH",L@JIS=(6> MF5*DD0@-7(%1SU)^UOQYE$9]W_ITZ6:RG/"[H81O[(-H%G>D9*S6<(- M._:!.L=1HBF[J&RJ>B'P -M=V=$B;83+E1/?U&3_QD^(6$.<+T5J'?16"YP7 MH1T>PNC&'@162(<(=XW9/#$\ 0?@.'5,*,H@CD'B7CW2!L5$H[T[VRWE%BQ$ MHF.VML$)R4Y$.PEL,O""16BBY7K;\M%C?3E@4_6 M 7P!U!AT60Q@E.-).$3[T$9M)V0OTZ_S82.GMCQ!(@,=NKHB(EG M$BT!+1&L!)1RH"O'HFA2_(A0]3+25HU/8M*IJ6:DRU--BL@)T2M-=Q;.3+X7 M%W-BUJ0'V3AD- HKH+,K0FO(JS[R4S.IH*Z>+[Z;T:+^0AZB'HZO_5G[,:,: MYFT1G!W&]O!<^O >^]1C%9<+OY\UK+,TUA.W(%YZ-O SH($$_4"0KJ*!X4QK M\Z3F,(,ZNC/QUVU3'PDXSX0W_#PT+O8K %?<9Z6GB6F\V<9E]("0]+FRH"(\ M*DD;*!;+ 9G,Q4R1&'*,II"+@9W<%9Z1R^ZW_A,!6, [*;J#_SV84TS,Y1WO MLY'8QUTDG\)M?.IB32$T=>_E1;RY)V^&+0L_%CES=M ( ^\MX#U"">Q!NAY-I330%C)\1T?7@>+]9;@"J9ZW--YZK;XB:YHP=]B#]Q2F7<*E:?K4VFQO2B$=\ZD-7M4,_!>[!T7G#[[ADL'QN !BZ@?$*P;(Q5W;*![,[C9( (9H^?,Q $DHZF2TRX3!U^M@#WF MSGR]B^%(33Y;]\KYXH:6:GG!@D5 1!$E"_M,;^T]K_<%"TW&QX55*>^<3T4! M&0?TDUFRDG?@&$1A=G'V*8$@X4@RJ+@*!T/R0#'DX0T])K\0**?<8J@"AS!] MGMQFB[FVK%HGPLG;2@$Q!?]84F?KJ [HO(MT;0NVPS7X1"9FD<5Y!">(3@\N M89TD^!GF7@!RYZ_"5$ L"BL8((45>URA/+Y9]B"1]G;OML[M+>] F/8$D&21 M4\+K%Z!$P?4\-;(,%DVBQ1PI1B87\83M_,IB@_J+>&Q6VJ,[.R:KN >-X(^@SY2QZLV">'U"1X" M>*JDOOI/52Z0L4^NVQ?/OO@U;3W\XS>LBMP7/%2PP#I5WD)$>4(.FER$)/QG M$=(8^N:?_0O@E \[BA%'O# L-R!-:W%@.9X5 0PA^FM%R*V1_U=)@]'Q_ZE" M4+)05]MR&9-9:=0C&P8YMTUN[@J0Z3"%I0G/2-[3=G/&LJEM,J'@I5$X\^\G MS8CW,B 8>.F 4H/"H[@*YKC%"U%$0+4XQ2V(?T(*B[[LO/WC(3:WX*2VZWX1 M*K;[&,A/W^?" ,X;37*-T1&VF&_Z!8*MX6P"?BI)(IRJ8%ECZK*"2_L:H=1( MZ-@1%&MW76%N=ZCWV\G,+AF1+GT,@AB#*'*, Q.D(D>\N%DFA)3\%4S/#+%"#)\WN1N%W]V M8$L39]>9_C9%@]Q\1"9XD: )1)4+^?/UH2Z3M Q4@60Z*Q:WW%4/6M;B8=%B MK1'I@'*;M4%&!$E<\ R*/CUP>(3K2NG=P4MO&#=K76[+NRP0#D.J@_Z%C58P M&[LF''LY[(M-P+*-\14A=8;!,@99PB_DA?PR9 MF$UY]K;X#O4H!L15,Q\J^D^IWW4*5?'V(RO"^/QC*L)X.NOZ5&HR#C-)2+BH6W!W5JS[I'X.AVW+FES[A+CG9&>6 .2^8./6# MSZD=*I2=<#@\+YCWMZT.-W.YU\C/R_8/_54D&E=6J6" _2CE+?AW5VG))5U- M *'_'+2&V$XH^=@E4O<'/D=V\]K&;,B6:-^T[T)6-HGA('Z$K-38GQH%/[SY M5[E=2@( M#::KH0/+Q@KI%I3K:EE(I=VB9"2$X,,$6(GIII34U"3>5Q(/-=>KB+$*7H45 M^02#-^+-C)0]XWJ?6JK!XZ+]_2>JU9'K2(&YI[[@NEV!0/HT$71R4Z& _V3SJJ;" M_4I!FVE($XC/MXLW/#ZT[<5E('%HOE1Z*1]Y@P M<7YH1\7VO(-PK[?CI\T,$2'0^V$7*.X@RDCI'6E8O&C--/!;\G5%SWLOP725)#;EY M9'C%0:14$J]TY1YK]GU]F(\5D0@,H4_;#7#\5@LL?D*Z56%#TPB0P;S?A[+C M8L!M:T08T7#KJFT21VX3#'P.@V!E22>L.E0WQ=8?^V!H/:KA(T).W[ZG<6JR MW_G!?,W-TS+5$40"-EH8SVRR/?AAH8]+NX6#CZIN]>YV\1UL?IM!*X, P74\ MML,BZ4D:\>&8O(R\LZ&'=ZR"U'%RBUS'+!U!DY/Q'/!]VQ]W&.O'"'39$Q6% MT!E(@XO5W<*I(-6R3B1)24%%12F7 %D_KN248A9"](Z'&S/MAK/T\\S;>#C9 M8.;;07,7XV$T*NO*B]X^5F3WQ M/.F7J7@32BNARXIDRTEZ((^ <1V9UD:[EM#Y2FI1K]'2<;"N5,I8Z=\K(S\=5;'*G5I,:,VU>MUVB^W<#3[#?V[ MFW+]UZ'?$W5>3Z]:FOV1-+XJ0R@5-F(<=.7+ ;$M\QX>K0@4FA\-/5-0(#66 MD^ [*IY@X@F2Y.#8K4/'L)6S8"5^2$4^@,U1M M=VPEH0_ 5D$%BZ'>B'514V5*>"<*G-8.P[2T\5B"H8_%S[7U\&C%ZA,7)59R MD=#HL(]GKE_2E&H-HKQLW%3'*\\]I6TGBS_7\T917J!Q MT9+E!S741GG4^!+T)MNA:XD(Z%*]X7DLW7EP*%*G3A"9;%_:),SR_]OA# ML+=WO?=EB2K7=U,CES.I#K*QQN=%4SMV9"1L$/-!D]4TGLK##:]8O&O:P\U] M>R#O,9W;1CN)>*6K;G%HP5E$^VOH74R1PA'SBT^*8(T^DDZ"30MM9];4SP8K MJ[GAB@6$>>DL&_!7(!_ 3I'B$T=8I:[O02NN>UP),+.J-:P#[W=Q8L.+B1W' MH3VRZS.KRH7>V;:GNW[95_ > \>R_Z*_@[?H45_4#\$;-K@C&OP(<\9Y,:[W M\CU[4U:YV=0E;ATS:+/U%2UR\K*8?FQC-9A^2%1R/8KQL@^+NGD0/(*IF(!& MH#A9LP' M=Q1%-S:X]S_=)'@SL>:=12M=30.4]#(JPUI(>R:7/DW%Z+JP&_8BI+(((KYY MBFR2+ ARVSG;//CX58;G$)H[+(>C@(1SU@R@ >405AA%P4OWUV$YD/R*_;?. M26L><B?^K(+V%^[M!!L?J.W M&T.M<)CIWWQH"CD.-25^K %)4VXD:3U@#BI$+/]^I&)Z:D4CRZ:*+R[XL\0? MT7WC?9XK^M":@M-]RQEX1,4CCE1FBL(R4<"$XHUJ8B0M@(8R\8'1$D22N740 MB3OQ+HKR2B1[U ?$(L]WS44&4_;FP!* A>R/X,RQN1*Y8&4"!<]\-5!"P/X> MZV_\1\5NVY0/VM7(T0(E*_>X@*<TS94 T\JJ,UJ9YEF.O+ ?F2U M%U]\3+47UV*+/Z8U1.\(K\J*(,4I27*T:57$)DEM)H5O>)79,/>R!"[N UR. MI.G66T2BH9B.'1SR+,1Z^O+'8K 7]Z#PZ9*_!'E>%FQ"X'B&NL?*8+9F*&-1 M'K#&'@L >3%B?O^ '5\2=:"Y@)Q8QY28[SW*(@&4OV-84AO=(1C3)W\3#2)\ M.HV-TL=AS8FNBLO4TFH'K4EK.['RQ?^.#],.[6R<:VVR;V5B5MV+L#EO9L2NSMV0+ MAM7G1Q.%- T%EH;Z<45$%]H6UPMHQ(]BZI']7?+HM."!3Q:62, IP3X.&(4F M(T.3MY)L\X0F^WU$6W720^T<]H'_T-DDQAK1Y2G1E[)9-9Q MR1N9X UOP@XL\B4\[XMGGW].W_TVE/?'FS=;/*O/08;"<0!%]T"W^SEL#;45 M3?SA4VJ81AD6040W [T,$^=>6,N*P7<(J\\)J++GYAQJV<+D M]%N)3W*2BWHS>LZM4C0H0FZ!>3J9@RHI.R/@IFL\5N /8@%1! 83_%-LV.!L M3K 4KZ[E#3N:5-A)"K G,\K7K6+<9!)WR\G+?#ZE=D'YSE^X%-NJ[Q56T(:I M[AB"%VIE1@2:-,P-;NRTWFU*DJ\Y@-9B+KY[R$[A-@(53A #[2&,S9J[U?_9'N!$DP&)LH7/TR^^U=]<#WQ;T5; UT M2!;?$; H'.-?%V+HS1S48N)>D3BG%6*3JEQLJH[2@_@U[B&CBE]V8;G>LT*? M'@LZME:]&NL;>WCP0.UI4LZS-2-O&V0,,^^8!!U5L"LTN_9B^#F10?OLZB>Y MY[*F9H+--*8(W=D 2>F5%B,QB0)8Q'H:/:S0B,^'UXD44P''4_%)*XF\:*/FK4*JIHH6 M]7HWU-QAV^-)06$C5;J8,,^U?J'JD:N)=<]S^"K'V!D;)-$"T @2$?I@=D.B MV(< 'FZCCXM]]M[?Z_T3+/,.^_)5L$J&1M.C6KWCX61?M,U=1V? ?J7MWE$F MZ[FTID?0:#=2IRM-NMB6ENIS"9BA"8#?ESY7&L =)@@:'[@4# ?2G_BLH1$8 M(5HE9D BKT;P-7!E]3[PJ7TAB8/]7/=;HH%+D(M23\5 MXS*VI.[;H"!\-,34.2O.ID7+#CI*JCY>9F];MSMXNLZ%M.>\)H32PQ-I;X7 U4Z M<[H )D!IYF$"B,.UG.3539[M(AUXVXWPG@39PH&@1:5+(G&PP?01GSX6L#&* M6)I9Q2_:[>+J78XJ5EM>R\E&+VQPB.7+IG&(\#-FCX;&_:)0(@]07+=S>SE^!*=4B^H)0"\7KR J@2*L;Y83B.?+?N?XZ MDB-@ 9W0C#@WFP+^&2T%2K=E+5)(6P<17I?AL+"@P:43.: D%=S:DF+EKE7G MAD,S(?^UR0_MQ)US]VUBDFYF+*3$Y9Z:S71\.)NC:F>J9'UL5ET=>,@'I^=EL)+@==Q66*B4P =N47>3) M4XK ^E/(=LC*5UQM:2'IGL<&O,^Y1V)GAIY$U_U(UX?]V'CHT#OI=]5>>UD, MFNT,WI-9UI,\-9?H]FA%3-B:\Q LAA3IV[HJL4#H /# <(&_MB)NK=^V]ELJ M5:\IGEP?77%AKM0HLIB8Y8AMJX*Q.(,+B<(VVAO:IUY4EILD8]+0Q6G3_0&8 M"-EV6/[0,URYE%\,C?[@K7R_O%1VYU#\4IU+H!YL!(&CR#7-O.B2.8QUT)0W MH'R6PM%&11QK-])L8? 564T;>WACJ4K8IKV[90ZHGY"3M/+2H%#T9T_/E92V M/W]FLR;#HQ[1A1=T_/HR"SJ>>&1@EGKQ%X2I'->2:Q(B;;('I71?48Z; V+T M0UKH\4CUU,?0IOMHOTE:J,LM)TZO3\F92GLD%%"=^XS> \"3&JP:VRBNGKW1 M'QFGSP%=-Z4AB>'WXP935F JF8#.0RP.CVF$GH+D M21*H1K^G((^8IC&U/)8;B'W.:\,F\(TXWK$*D]B?^[ M$G1E'9J10PR'1[2.M-Y:WFN5]-H\D34I[,HC?FP"JT#:,]! QA(7R3FN]^DM.=).Z$ MF3B]Y+R , IR!]9D99KWU"?-3MFN69& _I+'QXAH$>C%7'1HZW520B,E_5H> MN1XZB7]\0T$$0#&5[<<(<8^^]E?L[I%BN)J#F@7 X$?Q7;:BY1VTQ MCBC$DNL2*%T!4T#O]AY<5$U290>I9'RTM6QEQ!!#@#V>.\-3ZCI,R75>O A"B"A^@,$4A(WX6W M =ZS1X<;S0>%7':;P,"Z\L8DI3MRGEW1 :'*8(UG)APUD;8\N(4^,(AZQ M0%G!@0N+(\Y\5X@GD.R*UT=?I=B=L4,K35/'_+34X-#2(P30.JOKRA9GW09. ME/ 8M*(#W?GX>"O&0&@EE+T,M4.C5>Q-_UG%4453@J:.I^I;M(QB]AB14MH[ M[!Z?'%C">9J6@#Z@FCQ4:U+S)370UNFSIXOGMEBYMZNCG@PSH+)GFY<00V'5:E2*1?;1&8SH$3E,TN.L MC^CA\_WFZ%_DRWT\4F],ZZ;4T-FAH&8FA*YQZ37I\U56'I(J;OX]QY? 7VD8 M(9OLQL*?0SF91G<9,6>L1L+@Q02Q?,QM8S5().0(#%Y+W7URAR">) *HR-S3 M;0(1]-M5]L1M*.SQ6F1N#:L@Q09"*1:&[Z,K:_\OLRG>0U%^J%;\ONK?]8OO MA7M#NEF_U(3^JUA.]'?1_+]0M +CL2LY;[NXQ3.TY*MRQ_)$2L4*[R4YUT(! M/2WP*^4U9(#J&;OKV@/2%_BB+S!8NV'')_U,XI*G;ER]=V_)'T-P_B45@ MWJ(X6-]4-:J3%Y$O%"3*\P@.P^A",I97D.\I]Z7R1 GQK MRF(5"9' !N1ZUUM!SCDL.J*2^DF3HR]K5#CN3YQZL< 'K04/B\NR(M>45I^Y MQ=D./>RRG,MU]: GD^/2==A@4!7^).SG= 3^UZ^>_6JQ @>SWY689K&?=^@) MR\_R'/[.X=GWX-_W''U#E[^_AK,*QYC=T]/],N'K7_*]?P:VPQ_"'?W/[ MV]_\\Q_@HNW##;X;S_&A*W>_FHNKT_A/QIO_Y=RK @-ONW_['^6P;\^_-G7 MD,^-K-/[M@[Z:/:_?[9?7\SZ3(DBF?+_S.;\/W_68IZ(EY^6>>NP$LG$+_RR M7+UC/-@;/Y%?:E(2!!]7MY_W>CPX__K%%__R!Q=-GSE '^O-2=9N9GMH1'^ M?__CM[__PR+?,/B_#O\/I2_\%P3T54X_P=-VE=-7.7V5TT]03CL[V/L.VCEN M'7=UPO3)*6V"2]1R9FS&&;B+-*^6W4@[_7SL%SD%T,7\J=U@1B"&.I MQ,FNE[?"8K ;=&UI4Q'&L+# M $QLT)0VE]+HO$!HMS7!R2D4EL)325.7=$G?GBFM+S%.^&HPN.:X4M)R@OV4 M%H ?<< MA&5K\5$S[ ^8TRZL7B(BQ_,FR2JKVIRO78WU,?8Q][)R!*S$UDQ10Y:SW[WD+.)GA M@9)T1-+UE"1&BL0HSE_%JW37PJ&_Y)H:)Y 4 (?%1#\A'1 ]!:[8NW"<@P07 M3O/8X\&(%W@("OUZ$O:9B/5<](5[1>>/:+Z/6@(2N@I)GE#2$2H^H]N""!JZ MAOBSLC[]V\6K=-VUEE\J-@03*.&%RO&$^C@*W<]A-][1DWLC[^G?501\)C?? M9A.I0C)<6KA6V,R!YD#,]>1LKIEY0"_ILW=0-Y;YEDFV4-?B#=@H?^I0Q?2K M=O$E7.?G72@+RE?>446<],?>$_LOB?OCXY!0Z(\>P*,COQ2_4:Z0^(DH=M8Q M=8K%(=5^D"381];"\)O+;&&X8E+.C".!\P*1BT@(2=U9VTV+XVE89!$=7#]# MPF/BRRDHQ6(]!*VAH@;P?CR"TFH28_YYZL%@R2&HQ_P5OEU\%]OTSKGQ1C\G M)3LJ=%U* 4!,0]3:M$E"HL!5IW M[TA,QP^W"!G04RHK9ABI4 TP5^.>%"^<7;!_RCTWKETX4.4/[""(MD\P#ZG8 M,70/U2I2KA%6/W7VO@T=G-KOVS[ ^7M]?_O5;4&]R/@-5J'X^1=@66\67_]( ML%)PDUYAM1##[J\7_S' D?^/\N0#7L/]HHSB11N&%[3*GN&%A!\9+PHR.(U= M0"8@-YSOE>&.$,.YLG<75M2C35659.0)'P$UMJ(885;1NPW1O-N#%+53S3'::,T^ H]0'1.#D9A \VU/")\8<++#97O\7Z'_0*>% MMQYV76CS'/YC-+$7FJN/6/W6/#5V*L@66(::?&7%WX/-6G?#75:5EB24['42 M.R*LLGI6'1^]9^"_?(BL3]1NN &,_[@C+"@ M1YDI6$UTJO%V$H^!;'+C%X4HH)- KA:*_> MU<<41I[E;IMTJ-5B@@I: &_(R1:8_KX]- (2SR9U!2K2XKH]Q)70"/>>%@>ZI^II3O2.BFS)*7R>0LN$8 M^SF#RH OBZZYM+-8ZZ6T[(G!9JD(:B'8"UW[A:.'O1'LCX[5K>YD>3\V&E!A7<(WO N1%5SCTVDM 53X#=3"' MID7C@8+.NSVUO.[+NQ;1IHM%V'<#4A,UI;0CT':1;4T']V6S.NZ#H,HS:>I, M#P+!6C_^2L4UBN]Q942P%YB$[$.MX-_VJ.?_#FIT7![PK[_]YS\L,/=(7^?P M*Y^67_WQBQ*\]6'YQ^_=ZWN!7$B@;3)SQIM S[';^O\%L/C*8O&B[1[00GKQ M9@_G C[V-K0],;27.Q+E;,O\'[A7,"!+>/X7S6XYGMW4Y%[#@0'ULD&%PPCU MQ'\ 9[B^V8(4 KL:;,2O?O=KF#41;+4@7Y]_^2__^JP8[9/A#L^%U9RE@@:/ MH/ Z#FF0AW"E0P*A^?Q=Z-LB7>HO.S3HZYOOB)7T#5@URV7< #Z5A5OI-\?M M[KZ]$S/Z;5>"@/_LY\)5?8 @,3TNQ^ Z4W#L:ZZOO7[X0!99M"MS_NZ[< M3JX?. V&6:&=+3>OO[KY7"=R+!8_51A21=V+JV ]HC4^8'X+$TDD[3=)E[=J M#H]X:J__#/[OV\_=:LY>IND=IG4I%J\WR4WCE_OL3;E]^\?.OV:=UN'[!GF/?I'W3G8.'P)GT)^C"@+)N[<-O= M<(>AI-'*O6PPG8E:8RP&BV27OD.L&UK!-V"8[N$(XF/P<]2?A>N"&(IU6-^% MPNU&TT8E.%XX]3O)FD#^)+N>>0$]O;Y@2 MRV,B3X;]?=M5AJIH;8GHZQ+T.N'!]]AWC1%Y(;!W- !HH4X4(L\N4F7$8K0R MY(C6U3M,/FAO)/JZF%;&O,X23NNFVFM^QY+,(Q=*W6$B3F2;%PUO8?SR68A3 M0[.:IGE['U4T-E#*[2@BW 1(]V6H;8AQ))LLHB7>^"8H@3'-=:\;-:ZE8G0IA=NQ-\_JP]MD1,) YPJ:.J?JH/ MXR%M>4!JFT?*TL4Y(N47S:>XK"GPMBXCC..APN4MS,W+JZ^0%917%-VFHSF, MA(-IV54I2(K;M>N$EQ1C *#'$<)7^*(%K"DA9F"/7/*N.F9MZR^GN7MC?-5Q MUDE)3\)Y_!$"-O[V8ZIV>#KK^E2*'[YSK>4N=A'M\TD;F#"VDD!<-+)0/;R' M_:J.R;31R5R57!X@:6>XZI+"$+,F!P/("Q*L#"%64>TKRG+-8CUD15F(8AU, M;_;[@O$'^HV3,Z.I>4E.QT(4V.%:!DI^9V\48^XA#6 MB "0_?EX2*PLFLOE)5*>TF;&LY@Q(HLQ%I$BT WKNE)H8B4YQ0>7MESC<&'M MRV#>4JXSA4O,T(&E A%;=2.(EVYLK+[QU/-I^9ZKX4BB@>EY0>(?/%M.R'%;2QN\D=;T8CHN$K^'7."Y>I84( =<3LL M0*YI7($2JY0>)S=+DMKS' A1/=1BE+WB^X_F#\M *G:J\0O]Z"V674HODN&: MI"5K>NJC)QRVULQ@"=4I(^@,WIXGGGI\F\&O3M>SP_KZ&!')+\Y8QHPD'!CQ DF0^BA]F MJB^[[N,Y9XB''O'_0%]@#DR@\T>QR"<8=1/\YKF884SWN?C/6LL0^#@5UG.B ME8<^C4AD'A,VB@M92F2N.CV230*VBP"&9GTH/^*8]O4_AB8LOGCVQ3-'7_>G MKYXSDSA.!H1C+20M-C*8P?\.QWTWK,M_[X?==#( (?9N[OD3Q.)MZQV$3Z\7^V%KG$FT7U3& M2;]=;(>]NM @G.$^:/EM7A?2A3P\>6*=\9@C:N+4(LZ5-,B=>3A-:H=#81ED)'"V*Q$IZ/N6I5MGJXI:&Y:U5$B;>>1ZYH M"Y(W+:7LUO ?,TVZX;*=\11,:&@M>%<_@$Q=!7M^6% M$@XV/'[Z,8 [N4J)X%%CO? "I@_$H$SLZG'YNA3*TJQ:8HUC,IE!T6!)(I&; MAL'V5;H1CDJ+VT1;^NA I;)P5>B0\H0B,#]BF)LN!'-MB&W?G$5I)4X4LN5ZR281 MM;BB\QNYWB*+\H'YOP(V_F&$27B:<$XHZ#WOV!P]%4(CH[C59AT"CYR U4^) MT>PT^FDG!:P)%]M+3JKHX=2 ^AJT:=R MK=;AC<2VY(NM%R"A"7=L(]3JYN(OXS4XMDL+C/GL7;\JH*TVB M8=D^6\I&\B94:3-CON#+XZC72BES/]K9*D1^GZ6\Y+6GE)@]$S=*RU0/A0 M&PI^IP4K;0OBH^3 YQ[+EEHL.55-0%%(% %<=R\:-@WCC;0MCPZ)'-!U$C9VZ-')E,-[&Y1*J M5)383B0XN8W(M\+O\>\]]C_1B>P&AE9O3*1MD>2HBYJ0P1NT-6ED0:EKJ+$" MT&-K\%E11YU'X>+AC+GB1 @+&F)7'3IJ&*&:QK29(^UQ9;*H%Z_^[TOP:G^_ M0* ,ZQMG= G8+GJ2D%4U89\S5Z?HRRFAK))]'MKN':==MF"FU<>T4(),@'&C M)YYN4*=8>'*T#G74[!61P^!HP0 MS=7"64M.G[?=5-K6^(_H59A M,JM1O=J%UU[\R[7VXF.NO7C+B ]$H")U4Q@:]B&1+C<+C9+61U/XTC&WFUBZ ME.Q5C821^4BZ*+5FC>,MSJ^KM_G;$[3,!V5" 0D[=(O4X)H+>F09%MHLTH]>R>8+CRS2GCWVZ\%J,F)WG<8U/4QA/5%>N2*FME07G,R*- MED+4GR1#@Y\F*L%<\!MKD&HWWE#STHMY]]([$@DG\VG&TL?C*L5L8.73]U=& MQ?BD.W6$9S+6KC ].G,F/=B-1]> #L3YJSHY>!^$FOJ[8^X<5P'';$>;^9%L M)B+E4V('PH#@ %.),26,:HE_4EB!6:\6F_#_M_?MSVT;2[K_"LJWOO_V:P8 $J8?M")#F5.W& M(D%@,-/S]6.ZOXXH'=\[BPFC;/S7 #&C85SKEGI8:' MS#")E0XKPRS/SUW^P]&\OGM$[Y/4^R,4X: M@$=F?$@&">M[%->Q: >MR;Y9S4: 'L_&C&]KS:\5:U)UY.9,=##!W").[.B M)1JK8*G)G6_JR35%V7B-?$GKQ4$!81!:6U;GD0Y%#/B),/*D09K5'E;@7H!D M6V GN]ST#L0NQ/"5])6RP1P;I'$TK F8JSD*-YLH2&-1-EZ)Z[?76"$5'^38 ME ASEP66^V/Y!'>D1*R?,X\ZM7#E@H42O;L5.V!A6?\&ICBT[HGE)GC8JX0[ M=F/QA^'"*%<;7O(#*F?3M2U+@SH-[[$ ST13=J24^U)&1X2IFKDDD,W@"EM4 MTAR-U)L7)>?Y#1 "!V3LF"E*AO4OA3=N8KS%8 MNL"UM7N]NX\$_== D/+4Q-:.9W/5Y(ND,)E@0FL$!P' .1;@R&E1KI_HK&3V M&((D:H]IVE#3"2Q>;!.@_JS^)PY^E7PS.ET.F?D@12J65 UL#HY+\;R6HX!G M?TYAH#$E;"9;$1S_<;SF:F"Q#3;[GDA+]AD(BK:I4QL= SGQJ(>#3ZI,$IFY MX\*)K]7*V:Q NF$1-I2?".L<;RBTD3@S9L4X:X1I%G68TC9RG/2DFSU_UXI%A4]3E2NO:TV(]<0R@K(-V677&#[7*F\LR>16J$L['.J7 MFM-QH[26;+B1:04KF@GY%;9]7BFJ<=L<.]D*5\?3Z+E21^QTRD(#Q7 MNMB3T/0 5(Z49IC*=-4T5(BDCIZ_F57,U6(%K0Y)FBA/8K@+=T6A_;8H( M6KH;7TGKB380 CLS&]U^MPRN@U_M$.7$*GP7T6L J.\QY'L,^1Y#O=DY/[C' M$/GQH"4SP&Z;%>L:GJP4FO5@5QYXK .\[RW:8QGTZ.W1VZ-W1]$[3MTV9G*2 M%D@G.->Y<%IXC76HJL+R1*)G:@F''4_4@W:/1<^#M@=M#]H=!&WB=*< K&'! M9_2E )644G!@R%!"&UO:;?15JDMNLU>EEDZ$DP'<&)9'\![+H4=PC^ >P3N( MX'4#,NG!&,PQ53\VG"D<4&F$0>HSA+H$5W(UJ$&,R[%!C58\^3V MR-U!Y,;$G)Q.T#%)-L?2^A!+B.@4V)O-]T*$//AZ\/7@VT'P%>I="5H4DB%$ M&"E,*51KA*/T -QC,?( [ '8 W!W 9AK4V@LF,F!*?3($^DQM\>2XS'78Z[' MW"YBKDK/*V0K&*L\QR(R+D/"@GI)!.<. !Y]>RQ#'GT]^GKT[2#ZFF;8#HT: M,?"UD'T$.4X/'=H1I?_:R9U'Z![+F4=HC] >H3N(T$Q:%A>E-LR?=<6?RTV3 MZT1?*"(ZJCD3MP&YA^L>"YV':P_7'JX["-?6*B:&CQ![5G"SZ(#X*28)\E0S M,PL#,.;#>1#NI2AY$/8@[$&X@R#,G%(PPCDVD#51#<,8+K;P15P0I1(SDC#_ MGL.):>GHA!H>*??-'9!T!!L##*^)W/>%(OMY_RBR/2MWZU*^$4$G0ITKF6P< MVK^-U)72(2ENB"$SBNGFV94##7KA2J#L0:KT&CZ0M^.+N M"\+]UF>RLS^U(6QN=G6A3A"+:3:C-E-$PT6T41NG7L,/IW]5ZJLFDM5<.[S- M:TUTUEL-"Y>E81(W5QK2[&4P3Y2P&Q+'7:3A641I9(A[;2\W;(I ?6K,37K/ MCS;5*H+7S>W4S93;RGX""I YV+&!=F0((P[:ZK$ /FFMFHF*5J?=T'FU;=:9TDI.GX2V(+>Q MEFUC&T4XO-?NX$G(;S)1#99%HA=N8Q0>K#4'9JAV!:#/&O)]N S:IJ M2:#.$Z'*\R7<;Z'R2&P%@0[A%U27V)F'B )U8?!&=EZOE93I:T;PDZ/RL)C[+,N&+$B:+;[+Y.!6@=(*$+CHN85' :?TPH)?*]L Y+P)$ VX]&P6L=:NHPMC\:!'N[H^?<+@* .K>72CLGNFT@]R7F+3#_ MX.DR.KB:8F P#=E,,ZMWNL3]7,8);]:*AXP#0FB.L4W:9^;\R:)K]YFQ17YMT*;TK\8*5 M!B\@^*P)S$V,],CDR\R*M,FK.R25-!KVPWD&S[18]?LO]NAF^R_VC68\-8KO MH_2;/L[ %WA\^O'X"5XR>OGBD-J;J1G)$"WU0O.-SS.$9 JO[+[*%MAR$?FO MV6\8T.>C5X9EG_K@PF)H:89Z3BT+ FJ1ND/A547=$O4,KP58)62-;0QIP M'4(!CA472R7+@C8DSB9,C9G1QH3"8ZA-X?NPS%:D!-83M)QAL]\ J@X!?V-3 MMI<46]2;!QG@V8]5;H-="1C3R6TU@>#PX/= 6S9H)BJO ZM(,U8 M)F" 4_1;3$4&,(-O]#BOL'T2[,Q1HT>M+(2 2UP4%1KLQE5C/7Z$T&OUXZAI,/%TGXHL*EOHC&06.#Z?HEB*3 MW3RAI)O9#KIH/Y9-5&X>X^;*G\ITI)R(T&XHZAQ+O>_&J_B31( 9)( MAWE2EK"Y=;/1FUT-W&T+M.:IO^B$/$LT(<1 P,:S50!*#O?NR$PVGPSE-F#T)&>VK^MK8.MH5; M7LL<^9L3S< M1T":#]3-B=D1T>Q3P:TN="U?8:)BTS9XZQMQTPLYKU'DC\4I]C&05@]NZ] - MDCF$'8S]&Q+-O3SA_6+F L$8%]JX656R-;B^(C+0AFWB^PUT]0#>IZ[XU!6? MNM+!U!5J?4QN$38V2NODE::>\LG;/18A#[X>?#WX=A)\340ITC/3V'*K%^9: MW2TFOX?I'@N;AVD/TQZF.PC3%-=8FH/+7,\K.4KCS+8Z%RW5B-C8T%-'L<+X M+)9+9JF'Y1X+EX=E#\L>ECL(RYA5$N5JP:UQFP$+<[#K Q=]%B /O1YZ/?1V M$'HQHS2VL>)&M*+ 9$3;&,OC;Y^ER..OQU^/OQW$7S?H$&9%25E DM.!:2DF M2P7S+,[K6 4 K,X+06T8MSJG]BK29KR@0C6;:Y_K OX3WHQG[[Y4GK_PE>07=103L9CS/X68D9YXI+9T!5%V45+6V,BDYUX1&^TUG/ MAH*[WA64"/JH*/DG)*'#;TRG%J2OA7BD\M'5U %'@*R6>$5A!+;8DYDUDK M>7J)AB=IEF6[,TMELD1S@S&C,)[3+^4"IGO27'1L:0BX.'=U&$B-L;5L5T47 M] /#U=-6C\P%QXUZX%[C--W1L5)U4N MHC5#!A$B6)IJ!=++!WVJ5&Z/+>*7QB\D,8/R-(03@)K/9@Y[;J"1DS"DH\% M"7'68Y=@@DE 8"7BBYAH*\(\QN)!)+V$_X_B_01KMN,+HB.QAY #',-3K'$1 M$L)Y-89I,DRP?'.31-VDKZAYB;C:^P:D@UW'G#_YS)4VE6FP0PW8U1C!/*B'@_;OF&$KBG(LS*=E#)>U7!4:P K6 M[ EQT* R^9P2^=L9#J48!&D%6('$6C)(SI-G:IJ6Q[FD,N87(LLQ2N*,#[#- M./ 6\MH\'CR4!=$$1*$C6?#)#Q98"LH&%"K!(#H2%T>^+QJ'?,2;Y# MC@0[AS#=?2$A?C%T0LZ.(0(B)D-T/S$T48Z4K5 *B6K*QH3++9-(E*A-*NG' M]4I:@B:DE8C+BI]+OV$H@?O+O5=2=W%1GX@,-LG/7%$T4FB8P(CJ2VC?S&+^ MSH.N%=2'+#=4/'23HY"Z"9J/CL*2*?]>'@:/?S_]<'3TQ&'^,ZSC]J[U5'S" M]K%@99T38V1P8DC&\1G'YNWD=_*0O=W=E_B03R?'O\-.>DV\VT)C1"R8*A20 M"^,\K&9XG!0VN#6:@-#@1#8H+*K\(LY0B@)ZI5YC)7'9Z?.X2+C0QH$29!E- MX.\B5'/F:]Z(7);#F0[C]$667,@>7&A#^T?RQQ1:S F*8J\HL^^IP$J_P=PV(*[1P[PTCBB/:\[!@BO:G- Q%ED0R744Z"![ M>0&O3+"5Z9K;@'0 [XSO3L,TE)JMB(M\>W1BP \)-8ICI.$'"5'AU%<"P,+] MIMEBRW.)[;9 ,K$&!M-\PC0%X/)-LQRV55&;588:BI@HV<= S5713HC43"%- M)>X#\QZ.MM26[S)&HDL]F\.-J,TJ722BS)A'J-'@.%YU&O WSF#%HZG]%+)2 M8['J"Q&CVM:I;?0UHM#-&F]A-:I,<)ML#(,S8OT;(XLY$J*"D:#MUN;1,ICB MN0]]YO#)80N6,J>#9ND;(T):7MW ML@';F-OL7NLQ;@O)KGBC[09J@Q#Q:O.';L(6!+(55B6N^3IP6B/UI,)^E. Q MPM>XMSY:N X>GWQ^@J!T^/3P.2CEWYBO-WB-3_A0#[/^Q9,&7L&:_Z&6C&H$ M_-@V@!GB>4]).P$^0(1WR,#K.:]M[0T6>YL:6*%ZO=XL$4-AH9N6DO'AR#"T MXR'PG#/]\.J@,FR6@)O(;930M$T$@2?DG4?@'485X@.K3*%)AB_/,ZR,-?3( MBC:8/*XVT!A9UX=';*_L.#9M?J39=(R@%;3[3)8AWN[JY1VLO;O@+]E4(48= M4%AYG6'3@N\;P^*R28+\PV1@5W,<[K.?+ -NAHUI%EF>1 L2U2I/";6QM01= M"S.R?_CLU=YN 'LT(0'.R@@BP_%-;3 >]< M?/YD=5Y$@O&CGRFD5\4FXR0[<,=,H;!^U0S;7/] M_4+A!1@\CI330\&V*9U&(C61 MKYTG-HA3HCITM#;I97PC-'O!"%U=U+Q*=+^#,!MB:JC'Q9B_6H&UQM=J_N"> M1]C^ .,'WV"PJ=16[##320KY@QNF3C.D);Y_P_9VR*BI5Y&TG"GPGDQPC?&& MHFD'XC)5PE+MM-Q+E@[=Z2H)-;>=PN@+;U3GAD-PV&L*S(5TNQ /.G+5FI1- M6#.0E=\ /'=R 58DJ4UD!M3QAU64TP))>@8Z5D*36!BF J0U4KBJ>.S6F(!X];JZH]^[ W>(@%2&:7$3C;/Q$-L[8 M:@NIA5<+5I6[)-$L2R0Q))$D >9L!L:'Y-PD:*3X6+ILJ(C(99O-J01% MUA>QYY4[+_M7N=,'_;A^G']'/?(VIA?4O.9'!MG:8T[59D-,4 MJP*<(["N#76KQKN^4ALTVD":^$9+(!L_M@=$;B^ZVNS@: ;=@T*-L[E"B5*S M#*-VW!YA"E,I_>KL290U!T6GF9."+/S7,T,>WZ*[KT$9&J[ M88+./C;<1%G+<^QTP<$5?GEY]6D\+]P3>IHC:]N"%3]=%F!MF49Z$L"1$S6S M$>R4\( 'A@*>#%EI R%=5233 X,PJR=MSMN20ZT2:0^$-: M&X)W.&[4JRZ^8#M)[KX;96"RV:/O5+PAK D]!MJ?XF- MITSS53.&>F3UBZW<2);2G'S,T7(' [#B+LCXFN#K\]E7C%$-LE<=;]_(/OA\ MF)1@A\#[&L]2P'>J"J;\ES,/_)<$^$Y+/0M&P^!7V2_.C;>>]#&"J&F" %(&&R=(,B:N+.&<%I LKC7Y]VYFL>F M0[<)E9MV@3J]B/,L-7=V8)?Z],R&P9LU<'!',\XBW!_D9YESWTA.[XHPAXW$ MVX*"0B9^,];E MNX.D^KMQH^IQW]&:*Q([,$#13FSXPY+-MDUJ$V&'AZ*W_! MT"[<=N6%+LO$AO=I1IQGFN-H[+J!P443W5QA[\'H]EASW(#5&-- .$$$ FL\ MM4 ZB;*-2,(R7YHD$>VH[Z-TR7C>>#(:@/4+M!V:\=%AHRT5-[=-K^S^V^,] MN3NKG"" 7M+<.TDRMB2RSTI4Y3L4CL/'UOVQ:T@:N-DF(/5@^TD&Q46L M%W(A+:R!!84G]MDT'I-]U)@1-K@P+C_67%\(HX5'1A3E025KL(<^:!AT;2E MTEG:Y89!XVI06U:\1HWCJCI7R-A8=(!%Z6GG6D<3&LG[0M5GK+M[YQOV#!34O5WY(H<;:QG.WIWVMMMU)39K2DL]#Z25, MU-]D3V781=4B55Q(M%J2IS(*-Z].A(-1/!OP_&5+[JL1YT%]/+(BU 7<="VW MU IM<0.I[7.0^UA:U<;I"N:;+ 76M7SDXWKJ]3%,V'J+>0:#7@X<[[NIF-"% M5\OZ"$4ZD(EYAL?0V+"3?'9I72U=ZEWLVJ[316OQ015N"$>F>ZSMVQ*JV;9# M5#(^7B-@8AI]TA2.P0(=F)B%DZ^(\8(+]A\W9T^:Q6[$2MAAS;AMJ&M3:\_0QZEHW,W5_A[5ZP7A#[^NQ"QP M;$[,PC3?-"WS-I;%U+JU9:QQ8?.,P'JE*!/O ,I%D;@DQR+;DW;(VTD*O<"% M,NN%S58=<2=? @;'G:F)=P">T[[_>,J+^EB>7)@($(WX#":T^#!>O$/#'2G( M&)H1CL-W?X&JE:/AIY3&B8F4].J4/[DIOY\U12.H8'-=T9%!(<0&T&B&AA7& M^R09U5A2L*5!'8M79'[@3(8]F.9$C9GZ%W(T.()K^$XA&UO+K! M5O;_'.FIHUXM0(:[1F\+:XSV7OU6:Y$ZFT.^^[V>^X_T8!,*B=,K8@_;LH&88SQF/Y_1\"1AS%RB:'M(;B)R@B%B9HR>(XX,[ MQ?/8#?9(4J2I?"A1UO$EA\'_LZ*-MZI7AG9%G?_A9@C4T7C*9^1"%+2VK<.X MZA3B$ R' XL)#B.&52%W4H]!8_"%ZI+J.0M T1FOK=1PB>K"M6$1IL,G-[VI MQ1^L%]#=TG7 @B?=78!FX(ZT*"6WV@I8*WTX(L=/L!X_W*S^> >4%9@"TP>Y'I5FLCA4?9D%HN^L5L4O&<4"^@E\C;V-%3;NTOYH-BA(Y^7;M< M.89L*$/8#0--LOH,#(56VXV$-'1V<"V5P&@4H,3QX5&JT2C J@S)(H4=%X'&NEE5P_(8[#DP8[<(WR-.>(<[LR*N,*= MIK3K!2VR>C\WLJ? +45?!":-=BR:&J:VPN;6@-S"/[^FV2+1T3EM/XY=V ?W MV2WD["+,4EO-47/BYNA=.P7%A9IH:4>^?K+KA*-6@R>2#)T[82;:AZ&-YS8R MS,@)G&'K:SI27?, R=;ENG2S]/
S#IC MH#99YS#OVWVYI*SBZ,JKW4VK%X:,8<:I0D4Z-.X7L M"HYQ:&>/T/YR"#Q #9]S@4)2IU"W'2@9S>QN8O;HVS?PGS;TIQ.R)DO>M6 T M?K5ABKKK-"H&ZK1G#@V+QDO^Z9QZK-H+&,-F.Y:,;BE^%+M8HE&;GU?_TAY7 MK@%+_8;C)>8'RU3<'*V%ZJ$NY^"7TI>AUBO,^[5Q:(]#JY4#'BZG+(HL9/N3 M1K!>-5 ;\8W,W[XG%+32]2RR'*-R)CV?TGK2PE39&"H R\M329&L+4SE!'I< M38><)XC8^R*)$7LT%'+Z?!21E!Q"2 :W&%=@X&S M(4I?CB\M1M0@-G F ]V2=CCKL42V46C(MG6=:Q(VC +FE#?6-,--&@MZ^G*H M>1M3SB1*KM^N-7QC8J!QOIXU*OSW4( ?.#1=! MSK)-".J'^5LWD)+;BL1'T'9%\%%J=&'6WB^XOAQF&:L=80.=E5GX]?N(_5UX ME)371:_ 52^6789>CK^I#P;DR&^%4.."(E0)80>3S6% 0DL;(?K1R@4)$H%9'JAEOCU\-M%^-WD*]@CBQ5@-OG37*-HLQ(\.O=8QCPZ>W3V MZ-Q!=#:YVQ0L)ZA.SS,ZGFUAI)>XY>I7-NYL0IS.M1M3?;/<":]0P:]O4]]O M2?48[S'>8WP',=ZI7A!JBG]Q4O\ZUYQ#6TCGGT(DP2FM SE%M^=.,ZU+.7"2 MFQJ>>^>12(H\0^IV.84:+PWU-:<:JV1I$]!T8A+6 'FSQ5KTW>N''DNYUP]> M/WC]T$']4-<>#J1B@.N\J(K+9AQL*:HS:?]"0=S,\K2*H(19F4R/7CUT$'U0 5EAD?>9F7F=2+5 M-4(]-F3D*!1+[N!AN\?"YV';P[:'[0["]DJL!MFT](6M-VD ,1-6B*V-!:T3 M@&5-Y.=IFB'WGX?H'@N:AV@/T1ZB.PC1!EUGAFM8A7]5<1%+"3!5\.MS;&": M,$$;V=(-=BY#=N?4P\$__+'J_9%!C]X>O3UZ=Q"]4V$[(6Z8)W.==YC$SS2!A98A]8X>Y"O721)17VZQ%N+HH$ M49T14UR;WB:K?7J<)C8N'1AW@V7&&*>""3XD#J]X-JO2;"=+<37/ES5QP5!X MY>J;;+^>1^=PC,7L!Z4ITF2F)O%2R!VQ05!.&9>E+==JIUL@SANDDG9&)IUE MYJHH!TV_C <18S=,YV7#1&'3)^:;K!L"2+V6/#'.(GE-FCRAE(-IHSYG"TPL MRH5OCHC*A4F:7M1YEMMO(#;DY(9ANR+JSS4RQX'IAFG)6VU)0=T,DU= FF76 ME<^-GE9">IXTVC!?B^2\X[3S2'*G9EBJ86PZPT:982>(]6:O>,E?ED-!;N%>TLQ*^;\P_\Q93OZ*;+85D]\EB"XVN"O!YFJ,K6R@) M,>B"Y:"V8I]H"2WYX1BYJ+%S![**4K\OZ2OGDMCK&B0\B6%7#1OO$GB7P+L$ M'70))#,[E@[/MOM*G>.-Q/HKQ"S(-[ZM(S-5YG":(-QW+^9L5]DR7?OJ[74^O7+>2B4EE4^&6V4'E4<$2#2[IFTE8' M5?3FZBYTQ>,$_>R4>ZJ8X@-7.>,MJ%>T:UD4X@@F6D4FPE14!=8!2_^>$AL1 MFG8^/)"F*<*^^%KE+REW?WC4RVWC%8Y7.%[A=-]3Q+ X@#)W/+,T#NSK$1;' MU,ZWOQW$/81@DU[<$S6*N&=,*MJ&N=:FCM3EMY?%4SG)-:1IYRX%V+E =D#L@?D M#@(RD1]'<4F'HJ95RB).$I/H'*W3WZ-Y!=+!6KV*\6%PA,RI_-> B2'R6"KRUNO+,=-'"!Y@KG?X7\%8%3'7GJ=9 MB;7@,ZU2^-FD2H;!)^0JH5F0\;4.FE\6O*?,>6/3P$9R3DVSX1;Z *XRI)*% M.%4I'6C;QL)9[A ,3*24D8=.?!3XF%Q?:"3_R-K>^@KV@O8'81\&^@D^#9ZJ M0X77B'.XTEZ9W5*JLXPG4BKO_*+U:JK+O^&HF$:%J1)L*7]-H2C+(*0)+KE& MLAP&9^3F-N@6S)7\NRS$X"?.9+"8XO_33"(RP\%2;8J^B+.J )GD?M+PCZ(D M+I/S*HZ(HZ0Y/\.M6.."1'^Y., ^Q1K5W%;/U)P6V0(K8*?QG&/,2?P5^4B( M3[.^2OA:4+&-GK]R8QYQ"FB!U#CPC'R.8(Z3B^JC6&5F:/T5,V =QH-UVVS4V^* M[ +E&:XQ$D_'0"SVNHXJ2@^>YL.:>\YLH^;KDK8V=T&N7&<4]38FB646)M#A MQ_9S^2B8X72@*B[55T!BPF30+":!RZ%YRF!1"MKK,U'6ZX!D88AO2VJ:IHA> M0^B1)EPX2,9#3EBOV:A3I@H$"0HR)HZI96^.FH'FL&5PJ HN8MC@L+MJJ>XS M^])KF*,%:F[X#ZTU:;K"Y:A7(+^1L))A;VQ2D$C(1&)0:C9YC"Q0]C7*3-NO MQDMXC#$E9R *R".FP8X$02\UI_G!\N6\8MGEDA8(?EW3^="VR?48ZT+G6(%J MQ->0/6^T)GH-]N]I\ZJR*KBW@%VWU7DG[ 5!W\&=1N#@K"@;]?6/?P,9SF%? M'SLW>0N"@'*.#'\PA>H<$)QVDK.-ZCW$.9^TA\9D)DWC<4S;#$9*958Z/5?G M3.[L(,^"U;,@B0\O^O"B#R]V,+RHF("4DUU;G 4I@@!] MM8/Z"E7X.5@[V*8>W093FFSB'*AE7?=WM3<%:")1611WT=C @@QA#+"L=:98 M'X\__.^Q*'LEX)6 5P(=5 (KB+TA;H2AS**HM W63="; F:T;U+U1G%2EQ&-M+(94$ R)LA[(&-5SA>X7B%TU&%HR\![PL\ MQ2%@WZYX*+0/\&R/S)"7'@\6D&\=0#U1DCF^5T.EMO''&@;><#DVD M+T($=YGB-[F>F2.#^KE&OT@8L6AZ-Q0N'&N*T2/>FT'R$*FU1>H=F_NW6[R> M\7K&ZYD.ZAE5'^@@\J9-GX$/BT%?+/(86]D0DSJQ>C#(P[NC"]+R&^JT(T?! M"G-Q;#Y8'B"3$_%_:*Z+<1-0;&K)PZ-@W_,4[%ZO>KWJ]:K7JYZ"G3U R?$B M7BU*!U!MRG,M?PDT;Z@2;*.7I8FT1+OZ;RF\YJN@Q[DJIZ:2,Q0@0J \9,Z,#K'R3@'999H592\ MKP\/_Z.HYNL+_.+@IU=8[K$SY9D=[0%&8K-5[/,AZT-KQ[;9@M)6*0E;OH+_2W?<)/3ZS,_YI:2D MRU\FY9OS.S&M%10)99<,B&P-\P/E0-#-Y[Q=QJ'+G<\E/+;]K%'G)E%3E/B6 M_$278#].*5ZPJLC1Q9:7=0::OH@FH?4U!,(>F;4$?<=PO3&1GLFWYE M5924;9Y0R1X27%#[]Q#57P3_VE90Q>X:>V^Z+F.B&#'X;Z;&C1W*!DE)=-%"Y@7ZV(<\H-)<,*UA;7;(3E MA3G74K24&39M.I(KK&R2\C.N=L$_: M54O@=F+[V3G$++,LP.&HO\,'Q9W,L MMBUY%N*B?CT,Y>A+JHER/H2;QU1U'<-88)*VFH58)+ZL+3+*68,?7_T;*E/A M+#+.(8A7#O>'P>]@)U]0U$?*+[$X'UX& U%MK]/KLNLQ;T+%HQZG-, X2#C=PRCXY+(D;AJHZ(U.&2OY1 M6.4Y"EE;@+&.U]G2LW@VU]'U"P;C]")++@QUA%1"$21P(1<7SQJ2"V=]>.)2 MK%T&[Q3Y*MA9V7C4OJY2;E!DVO]4H9J[!%/FW1G.ETEP:UUI- MV^?:TO>WP0YZV ES"NT3<:Z7&B=(BS3EETKE'8#U=>F.Y"=H\"GO8"70Q?S7R#3%*"O MAV4'812#"(RS&4R9/GX%%D22+353TO06'F\G&69M!/(L"\GWE1-N.9O'%QR= MDI0%QI=0:P*E,=C;E'0G^6AZJA+J:+@TUZNBP% M8U FK3,'J>H6+0W 316#U$996.9QJE=*9T^:!64"2'DOUP:$V3%PT[Y46!.TEVUQ(&@!SG5=(V4/]Q% %:M(ZZ!\0 MF2I@^+EHZ<:A4C'8*FP3'=&,P_Z%MPO-#8W(?4XI:$625S")PUAOE#F0?U%6 MU*H8'2F8Y[*Y *HJF.)5%D=D@KOCD)AK4*FL=HZ8 6'T;,8D#J>9 M*#(>PXJ)S!#7\+:LI^, W#AW18.@;@7@6$9*9$&*"@<';P%\O$(6_FC]5UP] M5N7EY^U*<+?8YR2% G&&Z)! M<[*8>PJM7;A5@O9XH?77#5,F1$]E&:UBFH+&+K=$1:<&8&4 M,,.$;=_%/+@+ ML_%,);SQ'(LM,!W'6CQO.5NA]KZ$D=LM=2JP(IJP7IM0GVY G,8<;KF-K-A9 M++$J@\_ MBM.-]S(=/E#4Z:'B718ZN=!6@39GW'D3F27:.+!>[+/"M=7[?9]1W@/-'W)"8BXOR P8/0C";)_(D M07Q0%U$P@?$E2Z,*F:[/O!"%A_%1K/F<-R8&?>( ,\N'0[,<9:$J[/;!$^D$ MU52!)[))!8M.9I P&/([?*Q@TD?/GMW0Z.JO"W\ZP:5%TDL6H-@2TD=A])6)7^CX+/-1?L&G%)ANXP$ MFBF^ 1)3@/.&5E;M9B&19^YDSR:QXR"V/4;95"4-=J0]2VW%>'2"PS#+A6\7 M7<1S=F?03PU#34=$#0)O,!LP(N263[&":+0#7,-QLIIOBF,3JC H-K1PS^Y21 M72_!@ :BQF !54BDVN+X-I];GT>31B!3V/C#,UT.@U^U#2-QK&[*T3#7U,$% M29*5.Q?T2AJ/*^QR6IQU7\&,=G6P,S#0ZD6/*BKOI=DDFFR_>(Y!XS_984L(%YI 4O2-V6",P:#2; =8JL;Z%)(LU-)CG ,\E,6-H)E0FK,U8Z3UAA1C+&G&6V4 MX=6DX/U2@R.#[*" MZV.6R#+U-^: DQO?L%'H 1;)H'/D!E4X[(GN4A;1WG2Y0T7W"H11C8H;+<$I M()8W/ ( $*L#]CQ@:6HP0*W"V11CW7#!K/ULF=1I84);3M/BI7%#AB6Y>8@J MKJ?' "SW&,BQ2L%S#O?:YMRU;U#3UU_. MCMZ>G'TY^>_/IY_^]\O9R?'GCZ>?P F'R0OVAL'GU(G&V"CI"8=2G#@$SM9G M5O(?^,SRAG-UG0B$,U>'5UO[F[,LW>=PBN]-%^$[8ML[U+[S>0*;$7WRYNCSVT]G7SY_>/\.A.K=Z?N/1K9.3\Y$O/:'P6L]4=1? MY#/&T\YT&L-NK\5JVVQ]DO?!0]UJ)2[ZE"HP?_3-57=RD(LS\WE0OSDTU6A3DV0*=QG\^VGMD"UJD M#-'6GJV5?;RA_[WB!ST?'N[]]$K>QDP4.<_![O#YP;P,C"NY7E'UZM'-)EO^ MQ*H:^KLY^_C!%D/[Q0^TLW\1 ;JQ^'3WC=[12?F&FJ>;B"K% MWML4_'='[-&#%/7O#AI^&J\_C4V0P"EH18AKS?,M8*1YV[,U!2N6>LMJ]1%Y MWL _?H#P?]NJ^=VQ>9Y?#%_ZS?%W;0[,A7V7#?T&Z=$&\>KC;@(A?H/T9(., M1L/=%WZ'_'TZ!/,-7H-K=UMG;A9'4:)O%Z'=N+H_<(>LGMNWQ1"<.-C-7N_@ MV?#PI]Z._OGP^8O^CGZT.]S=Z^_P>S[Y>\.[F7L+55NH]*Z%2=_W1(A.W!KO ML\,?W>$QKJNK]X>C[WB<\F/6_>YGZ1HTC=<[&/F!&^-O3Q?[#Q5,&S M@Y>[HQ>[H[UGSYX_S<.JV-&7^Z,O!\]&PVDYNPX)_:-?CAP2E8^&1.6XR?=Q MZO)]V&QDM8DX\3;.@)?Z[5[NWW4D]IV7I6N%J^ZW,/VAEL'+0; 'AMMU7*_;1(3ZZO?>OX#/ MCQ/>.PH!]?F%[MT"M82)[NA]?.#HEH&C/1\X\H&CNPD<[>WN[AV^.'0#1\^_ M,6ST*S&=^@"1=\&^]XR]V/DO+TL^/N3C0WT3J(< 3CX^Y.-#WS4^M'>( :*] MW1ZX6)V;/U?D1KNP,[^M\><__L$]/[V?]CTVN'?'Q!U[\6)O]^4!>6.CW6>' M!R_W1KNCW9?/=Y^JO='. 7S^9:0O7[Z,OODDGXF6F6#U0P5#08:D(T/6'# 3 MVG^JM,(^%_LC IZ1[6=SA,YA\&N<%6&,56K% ),!AO2,W^)$JR@X:WQS8^?/ MJSYG&MA:NL.*R+N9J[/C8+3_^NE15R3FJMCMY@4D_^G!K=_N[L'.R]UG>_O] M7\ 'N@-?OKRN#]/EQ1,'X<&MWAL]SDE_[['Z]G[#-_L->]_J-XC;\&UW";[K M7;P+XUV8:[@P;>%).@R/;^?19'\SQ. N-62'^)MT33 MJE:U7&#[UP\9]KL[@;D,3H.WR$8.]_R@\C+5 M>3&-Y]XU>0BNR14V0T=7^)[Z&0]D,?S6Z-)J],4)Z%$>5:'T[MJY]DR8U'[A;D$J"$]NL\CTW<\"(NFVG_9%:G8WV MU<[HV6/UA(S3T4$D?[7V^W-;J4GCOV?4^.\HRJAID7O_,\V-;O=W]VQ;\O4> M:? -9G;=W-J]P\/I'R#7=ZZ3K_M.]WH5[MI,]8O@MT)'5N'NS=(^9O#_[5+E MS3>_;V^#GG[.O=EPOQ;!"[XW$GIO)'0B//6]SI*]?7,_PU-[7UY^E_#4&]LN MTX>G.B[77KEZJ_)!+H(7?&]5]MZJ]*$G'WKR6'DOY]P;"1U8!"_XWDCHO9'0 M@=#3WG#T?__/B[V]9]Y N:>QH[T;D3;=.K5I]"+X/#P;'@]ME&>T?[![92CH MY>ZA#P5Y9=>].?=67@<6P0M^=ZV\AVS3;6<-];$?'_OQX'@OY]Q;!1U8!"_X MWBKHHE70]4C/GH_TW.](S]Z7T>[?D";D0SU>M]VG.?=&70<6P0N^-^JZ:-3Y M4$\';*N'OE$].';5*O!3[L6\UW/N;8#;OHX\?9?^=Y=AGH:S_^NFZ<$6VJ/A MZ;LSZV%[2^7>B<+__/KQ;7":%J5*0QV\SL**V#,Q\#<:O0H^3740FV\C\VV4 MP1#3K S4?*Y5#E=0D.84G5P54L;/:U6JX$V9Y#Q%EO6;S!MP#F'(OYMZ ZZ(!YX,X/HASYS/L MP='; ]@RKV8>QN@5S9 9YSWF\1QSHY_]W&<^QO'<>,FG]1EEF:S97!R6>JT MP%2:LW"J9\K&=QXBY'DUXZVI!S#E7LR]-<76E'FJH0*DZ_MA8?DHBX^R>,"\ MOW/N[0(OY@]@SKU=<"]][9N$78Z/WOJPR_T5A2O"+LQNG7,?:H M]4&8;@#B0YES;VQY,7\ <^Z-+1^$Z9D9XS>O!TQO%SR@*?=B[NV"OM@%'?>\ M;Q*$>7WRQ@=A[J\H7!&$>:TG<1K[&(Q70M[6>D!3[L7KO@ 4RY%W-O%_3%+NBXXWV3&,S;HU]]#.;^BL(5,9BW:JP3'W[Q^L>; M60]DRKV8>S.K+V:6#[_X\,N=S[ '3&\7/( I]V+N[8+>VP6=<;MO$H'Y\/'$ M1V >; 3F0ZX+&+2O1?*:R!M<#VG*O9A[@ZOW!I
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Ό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�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

EPRRSWIJ.&(!1-S&)++5M(1-E1WXMIQ4>J+IRP,A(84,07D- M7[1 L'-H:8;LN=[=M2#(BH4@,R3U[K#5$4F>N'4&I8(R9(<&)6>>0X;A!R5= MIO5 L9@*DX%X(5TZ:@ B5Z84@U"Z&JXIA+GTN0R\CWHKX]*AJZK(<2+?(+;! MODU+;AXBCE)R<1FV>IO+I&_0BIQMAJ5TK>> ):6T @ 9O)^FN[P$KUC=" ;I MI&,6(*TJ&<+@TM,B*0X65]67#+[/DS)4N,3YROLP *4K0H=^7!L*.#'4)A5G MUWK+4Y"+H3?9ODM&B/IJ:RELIRJB\556$7P,GWWT5T@=[R_TN2&OC* Y?VH M(PAA7$&*#5'P3(0LG^K3=/OZ(O7M&X@()=/=(M]':+Z)U )W>8N(E(E"L[=?UJDE^%=Q07'$#:^I&7GAUKW-_) MJX6&2/T#&?RYJA"20ZU7>C:N(^G==7&*U 3+,=23C'[TA+PU]R)P4AL*_^M7 MVP]HM,E\(7;:@(#\$Z3P^ 9_PU$!IH#-,N_ED0[_WXZ 1^9[Y;XY;T? M;#S"_,FGZ$]OZ9_RU4W(S_ZXG/$PE_UJ7U56'M&22J1O""\]8[.R3<.!51QK M(- ;SVG(=WY02*68!@)#;%9P>8;*[P?@7*CJ0CV-P6TXK=/#;8LPFB(*35L8 MMYXRWV M*NOZ]7B5,X?U=L,*'L';XIO[_8ZK;0L,'[VS.GCPX3(9,&2^"NZ[6;LQPTU-IE[7UZO>;WGE!W/L-XBQBX$U71$=?(8-2 M[Z2J3ONPS=G,"KQ,EX>T* 0&ZG2S )4&&RC>K0VRL:&N"-6V47!N[4^I"[Y M%_H_SV19__/_ U!+ P04 " !9@J52^=PO8L$_ !^NP( $0 ')C=7,M M97@Q,#)?.3$N:'1M[7U];]M&MO?_%WB^ Z]WN[4!AB%%D:*2;@''<;;IMDF0 M>+>XN+A84-+(9D.)6I*RZ_WTSSEG9LCAFT39_?3VPCAY]OSY+^[%\^>OKU[S+X:6[1A7:;C, MHCQ*EF'\_/GENQ/CY";/5R^>/[^[N[/N7"M)KY]??7Q^DR_BX?,X23)FS?+9 MR??_[[^^P\_H7Q;.\-\\RF,&OZ33=?:,_>;8@W^-'0NN@N^>RR^_>RXO_^]G MSXQW?S,NDN4M2W.6&K>>95L#R[.-9\_P@DDRNX=__^N[E9'E]S'[ZTG.?LN? MA7%TO7R11M3),^3Q0M[57R2)ROZD^Z(EC.VS%_8W[R<)\O\ MV1W#>U],DGC&/\BB_[ 7S@ NIS_GX2**[U]<10N6&>_8G?$Q681+<2D.Y,4R M21=AS!^>(P7G\ %\NF3\JMLPC4)XHR$N//G^\K>;:!+EA@,S_.[YZOOV24UA MF"Q5YT"C:L[R4*;U'7Y>FK-(I-8V /'.,4O]OZXLOYG$WS MZ)89K\.<%>\UCT'TQ#O"(W7+ [OPI09<;2(?K_MK3_!$.,DG2GCQD%ON^W\X\4_/AFOWK[_=/'V\MW%Y2?3>/ONPA)/ M@6<48]OV)#D;V LKL1UZK/856X;*(EM]@4)L G5?X#X9#)M(46/A]6K%TFF8 ML;WOE<<"1FHP8VI$1@Y4CXU,$G3C_;0A3[Y_40&5671K$-'^>A*S>7X"'^7A M)&;&!!B$I7\]L4^,*8OC;!5.H^5U\?>'80&)Z0XH_9L:M>#,LQXE\"+^4(]3=#7#X,WPU$NXN#5T\;UI]"(S?VW61@>%F'4-^ \I^,=E5RA91!J^%F681;(GE-8X@7*W2 MY+=H 6]'6OGFT!\9*9" (#;[]QH%^9RQO(?XD_QC?!#O*M6=NPC4H!#N3?%1 M@,PIRX@"[G@0&!\2X&CC$C:>\4L(9/PAO $U M0!#!*/MMQ46",A&)7/A]M)S&:S#1*O.@K;010QW7](?#=@R%B_D#-N%A3USK M9P;B'#.T7AJ8K"%.0]Q.X[C0$$= 4H>R.P";3MQK:)8UX),:I3.0&F6O?5U_ M['[!3W[31(]'X"(8([9M;\'%76;?UTS9@('=.#SP'2

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